Genetic epidemiology of atopy and asthma by Wan, Yize Isalina
Wan, Yize Isalina (2011) Genetic epidemiology of atopy 
and asthma. PhD thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/12224/1/Print_YWan_ThesisFinal_Oct2011.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
  
 
  
 
 
 
 
 
Genetic Epidemiology of 
Atopy and Asthma 
 
 
By 
Yize I Wan, BMedsci. (Hons) 
 
 
 
 
 
Thesis submitted to the University of Nottingham for the 
degree of Doctor of Philosophy 
 
May 2011 
  
 
 
 
 
 
 
 
 
To my family, 
with all my love 
 
 Contents 
ABSTRACT ..........................................................................................................................I 
ACKNOWLEDGEMENTS ................................................................................................ II 
ABBREVIATIONS ............................................................................................................III 
PUBLICATIONS RELEVANT TO THESIS .................................................................... IV 
 
CHAPTER 1 ........................................................................................................................ 1 
GENERAL INTRODUCTION ............................................................................................ 1 
1.1 ALLERGIC DISEASE ................................................................................................... 1 
1.1.1 Definition ............................................................................................................. 1 
1.1.2 Epidemiology ....................................................................................................... 1 
1.1.3 Pathogenesis ........................................................................................................ 1 
1.1.4 Allergens .............................................................................................................. 4 
1.1.5 Atopy ................................................................................................................... 6 
1.1.6 Clinical Manifestations of Allergic Disease........................................................... 7 
1.1.7 Management ...................................................................................................... 10 
1.1.8 Susceptibility to Disease ..................................................................................... 12 
1.2 GENETICS OF COMPLEX DISEASE ................................................................................ 15 
1.2.1 Statistical Approaches ........................................................................................ 15 
1.2.2 Linkage Analysis ................................................................................................ 16 
1.2.2 Association Analysis ........................................................................................... 17 
1.2.3 Genome-Wide Association (GWA) Studies .......................................................... 18 
1.3 GENETICS OF ALLERGIC DISEASE ................................................................................ 20 
1.3.1 Genetic Studies of Allergic Disease..................................................................... 20 
1.3.2 Genome±Wide Linkage (GWL) Studies ............................................................... 20 
1.3.3 Meta-Analysis of GWL Studies ............................................................................ 24 
1.3.4 Candidate Gene Studies ...................................................................................... 25 
1.3.5 GWA Studies ...................................................................................................... 27 
1.3.6 Gene-Gene Interactions ...................................................................................... 29 
1.3.7 Gene-Environment Interactions .......................................................................... 29 
1.4 THE µ0ISSING HERITABILITY¶ COMPONENT................................................................. 31 
1.4.1 Deficiencies in Previous Studies ......................................................................... 31 
1.4.2 Next-Generation Sequencing (NGS) .................................................................... 33 
1.5 SUMMARY .................................................................................................................. 35 
1.6 PROJECT AIMS ............................................................................................................ 37 
CHAPTER 2 ...................................................................................................................... 38 
MATERIALS AND METHODS ....................................................................................... 38 
2.1 STUDY POPULATIONS AND PHENOTYPING .................................................................... 38 
2.1.1 Atopy Analyses ................................................................................................... 38 
2.1.2 Asthma Analyses ................................................................................................ 43 
2.2 GENOTYPING AND SEQUENCING .................................................................................. 48 
2.2.1 Genome-Wide SNP Genotyping .......................................................................... 48 
2.2.2 Direct SNP Genotyping (Atopy Analyses)............................................................ 52 
2.2.3 Targeted Re-sequencing (Asthma Analyses) ........................................................ 54 
2.2.4 Dye Terminator Sequencing................................................................................ 54 
2.3 BIOINFORMATICS........................................................................................................ 56 
2.3.1 Online Resources ............................................................................................... 56 
2.3.2 Genetics Analysis Software ................................................................................. 57 
2.4 STATISTICAL ANALYSES ............................................................................................. 58 
2.4.1 Principal Components Analysis (PCA) ................................................................ 58 
2.4.2 Association Testing ............................................................................................ 58 
2.4.3 Test Inflation ...................................................................................................... 60 
2.4.4 Statistical Power ................................................................................................ 61 
2.4.5 Meta-Analysis .................................................................................................... 61 
2.4.6 Linkage Disequilibrium (LD) .............................................................................. 61 
2.4.7 Imputation.......................................................................................................... 62 
2.4.8 Significance Testing ........................................................................................... 63 
2.5 CELLULAR AND MOLECULAR TECHNIQUES .................................................................. 64 
2.5.1 Cell Culture ....................................................................................................... 64 
2.5.2 Molecular Biology Methods ................................................................................ 66 
 2.6 INDIVIDUAL CONTRIBUTIONS AND COLLABORATIONS .................................................. 72 
CHAPTER 3 ...................................................................................................................... 73 
GENOME-WIDE ASSOCIATION STUDY TO IDENTIFY NOVEL ATOPY 
SUSCEPTIBILITY LOCI ................................................................................................. 73 
3.1 INTRODUCTION ........................................................................................................... 73 
3.2 AIM ........................................................................................................................... 74 
3.3 METHODS .................................................................................................................. 75 
3.3.1 Study Populations............................................................................................... 75 
3.3.2 Association Testing ............................................................................................ 76 
3.3.3 Statistical Significance Testing ........................................................................... 77 
3.3.4 SNP Selection for Replication Studies ................................................................. 77 
3.3.5 Candidate Gene Expression ................................................................................ 77 
3.3.6 Evaluation of Previously Reported Atopy Genes.................................................. 78 
3.4 RESULTS .................................................................................................................... 79 
3.4.1 Discovery GWA Study ........................................................................................ 79 
3.4.3 In silico Replication ........................................................................................... 83 
3.4.4 Replication Genotyping ...................................................................................... 83 
3.4.5 Total IgE Analyses ............................................................................................. 83 
3.4.6 Combined Analyses ............................................................................................ 83 
3.4.7 Meta-Analysis .................................................................................................... 87 
3.4.8 Candidate Gene Expression ................................................................................ 88 
3.4.9 Candidate Gene Look-up .................................................................................... 92 
3.5 DISCUSSION ............................................................................................................... 94 
CHAPTER 4 .................................................................................................................... 100 
ASSESSING ATOPY SUSCEPTIBILITY WITHIN PREVIOUSLY IDENTIFIED 
LINKAGE LOCI ON CHROMOSOMES 3 AND 17 ...................................................... 100 
4.1 INTRODUCTION ......................................................................................................... 100 
4.2 AIM ......................................................................................................................... 102 
4.3 METHODS ................................................................................................................ 103 
4.3.1 Study Populations............................................................................................. 103 
4.3.2 Association Testing .......................................................................................... 103 
4.3.3 Statistical Significance Testing within GSMA Bins ............................................ 104 
4.3.4 Fine Mapping of Identified Loci ........................................................................ 105 
4.3.5 SNP Selection for Replication Studies ............................................................... 105 
4.3.6 Candidate Gene Expression .............................................................................. 105 
4.4 RESULTS .................................................................................................................. 107 
4.4.1 Association Testing of GSMA Bins in the British 1958 Birth Cohort .................. 107 
4.4.2 Fine Mapping of Identified Loci ........................................................................ 109 
4.4.3 In silico Replication ......................................................................................... 111 
4.4.4 Replication Genotyping .................................................................................... 111 
4.4.5 Total IgE Analyses ........................................................................................... 111 
4.4.6 Combined Analyses .......................................................................................... 112 
4.4.7 Candidate Gene Expression .............................................................................. 113 
4.5 DISCUSSION ............................................................................................................. 114 
CHAPTER 5 .................................................................................................................... 118 
GENOME-WIDE ASSOCIATION STUDY TO IDENTIFY GENETIC 
DETERMINANTS OF SEVERE ASTHMA ................................................................... 118 
5.1 INTRODUCTION ......................................................................................................... 118 
5.2 AIM ......................................................................................................................... 119 
5.3 METHODS ................................................................................................................ 120 
5.3.1 Study Populations............................................................................................. 120 
5.3.2 Genotyping Quality Control ............................................................................. 120 
5.3.3 Genome-wide Association (GWA) Testing ......................................................... 124 
5.3.4 Post-Association Quality Control ..................................................................... 124 
5.3.5 Statistical Significance Testing ......................................................................... 124 
5.3.6 Imputation Using the 1000 Genomes Project .................................................... 125 
5.3.7 Replication and Meta-Analysis ......................................................................... 125 
5.3.8 Evaluation of GABRIEL loci ............................................................................. 126 
5.4 RESULTS .................................................................................................................. 127 
5.4.1 Loci Identified by GWA Testing ........................................................................ 127 
5.4.3 Imputation Using the 1000 Genomes Project .................................................... 134 
5.4.4 Replication In Silico ......................................................................................... 140 
 5.4.6 Evaluation of GABRIEL Loci ............................................................................ 142 
5.5 DISCUSSION ............................................................................................................. 150 
CHAPTER 6 .................................................................................................................... 156 
EVALUATION OF THE RELATIVE CONTRIBUTION OF PREVIOUSLY 
REPORTED CANDIDATE LOCI IN SEVERE ASTHMA ........................................... 156 
6.1 INTRODUCTION ......................................................................................................... 156 
6.2 AIM ......................................................................................................................... 157 
6.3 METHODS ................................................................................................................ 158 
6.3.1 Literature Search ............................................................................................. 158 
6.3.2 Defining Loci Co-ordinates .............................................................................. 158 
6.3.3 Region Evaluation ............................................................................................ 159 
6.3.4 Region and SNP Analyses ................................................................................. 160 
6.4 RESULTS .................................................................................................................. 161 
6.4.1 Systematic Literature Review ............................................................................ 161 
6.4.2 Identified Genes ............................................................................................... 162 
6.4.3 Loci Evaluation Results .................................................................................... 163 
6.4.4 Examination for Region Support ....................................................................... 167 
6.4.5 Previously Reported SNPs within the 2q12 Locus.............................................. 168 
6.4 DISCUSSION ............................................................................................................. 170 
CHAPTER 7 .................................................................................................................... 176 
MOLECULAR CHARACTERISATION OF THE GENE PROMOTER REGIONS OF 
IL1RL1 AND IL33 ............................................................................................................ 176 
7.1 INTRODUCTION ......................................................................................................... 176 
7.2 AIM ......................................................................................................................... 178 
7.3 METHODS ................................................................................................................ 179 
7.3.1 Real-Time Quantitative PCR ............................................................................ 179 
5DSLG$PSOLILFDWLRQRI¶F'1$(QGV¶5$&( ............................................... 180 
7.3.3 Sequence Data Analysis .................................................................................... 189 
7.4 RESULTS .................................................................................................................. 190 
7.4.1 Defining Genomic Arrangements ...................................................................... 190 
7.4.2 Quantitative Gene Expression........................................................................... 193 
,/5/DQG,/7UDQVFULSWV'HWHFWHG8VLQJ¶5$&(..................................... 194 
7.4.4 IL1RL1 Open Reading Frame Analysis ............................................................. 200 
7.4.5 Promoter Binding Sites ..................................................................................... 201 
7.5 DISCUSSION ............................................................................................................. 202 
CHAPTER 8 .................................................................................................................... 206 
RE-SEQUENCING TO IDENTIFY RARE VARIANTS WITHIN THE 
CHROMOSOME 2Q12 AND 9P24.1 LOCI .................................................................... 206 
8.1 INTRODUCTION ......................................................................................................... 206 
8.2 AIM ......................................................................................................................... 208 
8.3 METHODS ................................................................................................................ 209 
8.3.1 Study Populations............................................................................................. 209 
8.3.2 Region Selection ............................................................................................... 209 
8.3.3 The 1000 Genomes Project ............................................................................... 209 
8.3.4 Re-sequencing Design ...................................................................................... 210 
8.4 RESULTS .................................................................................................................. 213 
8.4.1 Region Selection ............................................................................................... 213 
8.4.2 Results from the 1000 Genomes Project ............................................................ 215 
8.4.3 Bait Design for Target Enrichment ................................................................... 217 
8.4.4 Variants Identified by Re-sequencing ................................................................ 219 
8.5 DISCUSSION ............................................................................................................. 222 
CHAPTER 9 .................................................................................................................... 226 
GENERAL DISCUSSION ............................................................................................... 226 
9.1 GENETIC DETERMINANTS OF ATOPY ......................................................................... 227 
9.2 GENETIC DETERMINANTS OF SEVERE ASTHMA .......................................................... 229 
9.3 CHROMOSOMES 2Q12 AND 9P24 AS ASTHMA SUSCEPTIBILITY LOCI ............................ 231 
9.4 STRENGTHS AND WEAKNESSES IN STUDY DESIGN ..................................................... 233 
9.5 FUTURE WORK.......................................................................................................... 236 
APPENDICES .................................................................................................................. 238 
BIBLIOGRAPHY ............................................................................................................ 272 
i 
Abstract 
The evidence for genetic contributions to the development of asthma and atopy has been well 
established. Refining the major genetic factors underlying these contributions will lead to a 
greater understanding of the pathophysiology of these conditions and potentially identify novel 
therapeutic targets. 
 
This thesis describes a series of studies designed primarily using genome-wide association 
(GWA) approaches to examine common single nucleotide polymorphisms (SNPs) contributing 
to these phenotypes in the Caucasian population. Susceptibility to atopy was assessed using 
both non-parametric association tests of SNPs across the genome and focused analysis of two 
regions on chromosomes 3p22.1-q22.1 and 17p12-q24.3 previously identified through a meta-
analysis of genome-wide linkage studies (GSMA). The discovery cohort consisted of 1,083 
cases and 2,770 controls, replication analyses were undertaken in four independent population 
cohorts. A GWA study of severe asthma was carried out in 933 cases and 3,346 controls with 
replication in a further 231 cases and 1,345 controls. The contribution of SNPs within all 
previously reported asthma susceptibility loci identified using a comprehensive literature 
search was also evaluated. 
 
Overall, there is evidence for a large number of loci influencing both atopy and severe asthma, 
each harbouring modest effects. A number of potentially novel loci meeting nominal 
significance in both GWA studies have been identified requiring further work. Strong evidence 
was found to support the IL1RL1-IL33 signalling pathway in asthma pathogenesis. Molecular 
characterisation RI WKH ¶ XQWUDQVODWHG UHJLRQV of IL1RL1 and IL33 suggest a complex 
regulatory role of identified common variants involving multiple promoters for IL1RL1. A 
number of asthma specific variants within the chromosome 2q12 and 9p24.1 regions were 
detected using next generation re-sequencing in homogenised pools of cases and controls 
warranting further analyses. 
 
This work has identified a potentially important pathway in which to focus the development of 
effective asthma therapies. Future directions will include functional analysis of replicated 
variants and tests of interactions between the multiple genetic and environmental factors likely 
to be involved in disease. 
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Chapter 1 
General Introduction 
 
1.1 Allergic Disease 
 
1.1.1 Definition 
Allergy is a hypersensitivity reaction initiated by immunological mechanisms resulting from 
antigen-induced changes in reactivity (Von Pirquet 1946). Allergic diseases such as asthma, 
allergic rhinitis, and atopic dermatitis are characterised by inflammatory responses mediated by 
immunoglobulin E (IgE) to environmental allergens resulting in both acute and chronic 
responses in a range of end organs and tissues (Johansson et al. 2004). 
 
1.1.2 Epidemiology 
Over recent decades, the global prevalence of allergic disorders has increased substantially 
(Bajekal and Prescott 2003). This has been associated with increasing allergic sensitisation in 
the developed world (Masoli et al. 2004). Although this trend appears now to be stabilising, 
allergic diseases remain extremely common and continue to represent an important source of 
patient morbidity and healthcare utilisation (Gupta et al. 2007). In the UK, 39% of children and 
30% of adults have been diagnosed with one or more atopic disorder. Furthermore, 
approximately 10% of primary care prescribing costs is utilised on treatment for these 
conditions and direct NHS costs for managing allergic problems are estimated at over £1 
billion per year (Gupta et al. 2004). 
 
1.1.3 Pathogenesis 
Allergic diseases result from an augmented response of the immune system to external 
substances. An acute reaction in response to allergen exposure is known as a type I 
hypersensitivity reaction and is characterised by the excessive activation of leukocytes by IgE 
antibodies resulting in the induction of an extreme inflammatory response. Type 1 immediate 
2 
hypersensitivity results from two temporally distinct processes when an allergen is inhaled, 
ingested or injected into a susceptible individual [Figure 1.1]. 
 
The primary sensitisation stage occurs when the allergen is presented to the immune system 
inducing IgE production. Allergen uptake and presentation by dendritic cells activate T-helper 
(Th) lymphocytes leading to the release of cytokines such as interleukin 4 (IL4), interleukin 
(IL5), and interleukin 13 (IL13). This activates B lymphocytes resulting in the secretion of 
specific IgE antibodies. These antibodies then bind to mast cell membranes via the high 
affinity IgE receptor (Fc epsilon R1). During subsequent provocation upon re-exposure to the 
allergen and internalisation at a later date, the allergen binds to membrane bound IgE 
molecules on the surface of immune cells such as eosinophils, mast cells, and basophils. This 
induces degranulation of pre-formed mediators and new vasoactive mediator synthesis, 
triggering the release of various inflammatory mediators including histamine, prostaglandins, 
and leukotrienes leading to the clinical symptoms of allergy ranging from rash to anaphylaxis 
[Table 1.1] (Holgate and Church 1993). 
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Figure 1.1 - Immunological mechanisms involved in allergic disease. Primary sensitisation following antigen exposure induces secretion of specific IgE antibodies. 
Subsequent provocation by the same allergen triggers inflammatory mediator release. Adapted from (Holgate and Church 1993). 
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Table 1.1 - Products of mast cell degranulation. 
Mediator Biological effect 
Preformed and stored within granules  
Histamine Vasodilatation, chemotaxis, broncho-constriction, mucus 
secretion, increased capillary permeability 
Tryptase Activates complement factor 3 in innate immunity 
Eosinophil Chemotactic factor Eosinophil chemotaxis 
Neutrophil Chemotactic factor Neutrophil chemotaxis 
Newly synthesised 
Leukotrienes e.g. LTA4, LTB4, LTC4, 
LTD4, LTE4, and LTF4 
Increased vascular permeability, chemokines and mucus 
secretion, smooth muscle contraction 
Prostaglandins e.g. PGI2, PGE2, and 
PGFĮ 
Broncho-constriction, platelet aggregation, vasodilatation 
Thromboxanes Broncho-constriction 
Platalet-activating factor Broncho-constriction, eosinophil and neutrophil chemotaxis 
 
The type 1 or early-phase reaction is often followed by a late-phase reaction in many 
individuals developing 2 to 6 hours post allergen exposure and peaking at 6 to 9 hours. 
Although this typically resolves within 2 days, symptoms in the skin involve pain, oedema, and 
erythema, and in the lungs are characterised by airway narrowing and mucus hypersecretion. 
The late-phase reaction results from local recruitment and activation of leukocytes such as Th2 
cells, eosinophils and basophils as well as the sustained production of mediators from IgE 
activated mast cells and allergen primed T cells (Kay 2001). 
 
Prolonged or repetitive allergen exposure to specific allergens can result in chronic 
inflammation with significant leukocyte recruitment, extracellular matrix alteration, and 
structural cell modification at the affected site (Galli et al. 2008). 
 
1.1.4 Allergens 
A range of allergens are recognised as being able to induce hypersensitivity reactions in 
susceptible individuals. Properties which make a substance an allergen may facilitate access to 
the immune system in a susceptible host dependent on a number of factors such as its 
molecular complexity, biochemical characteristics, as well as the genetic predisposition of the 
host (Aas 1978). 
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1.1.4.1 Sources of Allergens 
Environmental allergens can be classified into two main types, the first involving the induction 
of IgE production by sensitising the subject and subsequently causing an allergic reaction upon 
re-exposure. Common such allergens include house dust mite faecal particles, grass pollen, 
animal dander, and certain medicines. Most allergens are proteins or haptens and many 
inhalant allergens such house dust mite serine proteases, Dermatophagoides pteronyssinus 1 
(Der p 1) and 9 (Der p 9) exhibit enzymatic activity in hypersensitivity (Robinson et al. 1997). 
The second type of allergen is classified as inducing an adaptive immune response to 
exogenous antigens such as bacteria or toxins, and endogenous antigens produced by viruses 
replicating within a host cell. Responses to these allergens cause local inflammation 
independent of IgE production (Janeway et al. 2001). 
 
1.1.4.2 Allergen Sensitisation Testing 
A number of techniques have been developed to assess IgE-mediated hypersensitivity to 
allergens. The most widely used allergy test is the skin prick test (SPT) using aqueous 
solutions of a variety of allergens. The skin test lancet is injected through drops of solution to 
prick the superficial epidermal layer of the skin. Introduction of the antigen and a positive test 
results in raised red lesions. The size and flare of these wheals are measured 15 to 20 minutes 
post-application and tKHQXPEHURISRVLWLYHUHDFWLRQVFRPPRQO\GHILQHGDVZKHDOVPPLQ
diameter, summated as an index of skin test positivity. Both negative antigen-free and positive 
histamine controls are required, for example, 50% glycerol and 1mg/ml histamine 
hydrochloride respectively (Ten et al. 1995). 
 
Serum or plasma levels of IgE production, either total levels or specific to different allergens 
after allergen exposure can be measured in vitro. The radioallergosorbent test (RAST) uses an 
immobilised test antigen bound to an insoluble matrix such as paper or agarose beads. When 
patient serum is added, allergen specific IgE antibodies bind to the allergen complex. 
Subsequent addition of radioactively labelled anti-IgE allows the estimation of specific IgE 
production in an individual (Ortolani et al. 1989). A positive allergen result is typically defined 
by leYHOVRIVSHFLILF,J(0.35KUA/L (Boyano Martinez et al. 2001). Non-radioactive versions 
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of this technique include the allergosorbent test (CAP-RAST) and enzyme linked 
immunosorbent assay (ELISA) using fluorescence and enzyme substrates (Luczynska et al. 
1989; Darsow et al. 1995). These methods can be more specific and less likely to be influenced 
by concurrent drug treatment but tend to be more expensive and time consuming. 
 
The above techniques used in allergen sensitisation testing have been shown to be significantly 
associated although the quantitative correlation remains weak, particularly in individuals with 
low levels of sensitivity (Stenius et al. 1971; Norman et al. 1973; Bryant et al. 1975). Reasons 
for this may include the use of non-standardised allergenic extracts or patient-dependent factors 
such as differing abilities in mast cell release (Witteman et al. 1996). Furthermore, previous 
studies have also shown that total IgE levels raised due to helminth parasite infections can 
cause mast cell Fc epsilon R1 saturation resulting in lower detected specific IgE antibody 
responses against given allergens (Godfrey and Gradidge 1976). 
 
1.1.5 Atopy 
Atopy is the predisposition to an IgE isotype production and the development of immediate 
hypersensitivity in response to exposure to common environmental allergens (Jackola et al. 
2002). The presence of atopy can be defined by elevated levels of serum total IgE, specific IgE, 
positive SPT to common allergens or a combination of these markers. 
 
The heritable tendency to produce allergen-specific IgE is one of the strongest risk factors for 
the development of allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis 
(Coca and Cooke 1923; Burrows et al. 1989). The prevalence of asthma increases with 
increasing serum IgE concentrations (Sunyer et al. 1995). In addition, 60% of asthma subjects 
show immediate hypersensitivity to defined environmental agents such as nitrogen dioxide and 
ozone as well as commonly suffer from other atopic diseases such as allergic rhinitis and atopic 
dermatitis (Valacer 2000).  
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1.1.6 Clinical Manifestations of Allergic Disease 
Allergic hypersensitivity to environmental allergens can affect many tissue types in the human 
body such as the lungs, the nasal tract or the skin resulting in a wide range of end-organ 
manifestations of disease. 
 
1.1.6.1 Asthma 
Asthma is a chronic inflammatory condition of the airways characterised by recurrent episodes 
of reversible airway obstruction and increased bronchial hyper-responsiveness (BHR) 
(Dantzker et al. 1987). According to WHO estimates, approximately 300 million people suffer 
from asthma worldwide with an additional 100 million predicted to be diagnosed by 2025, as a 
result of increasing urbanisation (Masoli et al. 2004). Symptoms of asthma include cough, 
wheeze, chest tightness, and dyspnoea particularly at night and during the early morning; these 
may be severe and potentially life-threatening during acute exacerbations which can occur 
episodically and vary in onset. Many well characterised sub-types of asthma have been 
identified such as atopic, aspirin-induced, and occupational asthma. The immediate asthmatic 
response is mediated by IgE dependent mast cell release of mediators such as histamine and 
leukotrienes. The late reaction is a manifestation of eosinophilic airway inflammation 
associated with the development of airway hyper-responsiveness. 
 
In asthma, repeated allergen exposure and inflammatory responses can cause epithelial damage 
exposing deeper airway structures. Inflammatory and structural cell production of growth 
factors and pro-fibronogenic cytokines lead to angiogenesis, smooth muscle proliferation, and 
basement membrane thickening. Along with cellular infiltration of eosinophils and 
mononuclear cells, this pathological remodelling leads to fibrosis and chronic BHR [Figure 
1.2] (Hogg 1997). 
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Figure 1.2 ± Inflammatory and structural changes in asthma. Haematoxylin and Eosin 
stained micrographs showing terminal bronchioles from a normal subject (left) and a subject 
who died during an asthma attack (right), taken from (Saetta and Turato 2001; Junqueira and 
Carneiro 2009). In comparison, the asthma subject sample displays smooth muscle 
hypertrophy, thickening of the basement membrane, and a marked inflammatory process in the 
airway wall mainly characterised by eosinophils (Roche 1998; Holgate 2000). 
 
Clinical care is complicated due to heterogeneity in disease expression and severity resulting in 
variability of clinical symptoms, as well as a range of physiological and pathological 
abnormalities in individuals (Wenzel et al. 1999).  Currently utilised guidelines for treatment 
are based on four to six steps describing clinical characteristics including frequency of 
symptoms, lung function, as well as requirement for preventer and relief medication (National 
Asthma Education and Prevention Program 2007; Global Initiative for Asthma 2008) 
(described in more detail in Section 1.1.7). Patients with severe or difficult-to-treat asthma 
constitute approximately 5% to 8% of the total asthma population (Holgate et al. 2011). This 
sub-group of patients disproportionately consume healthcare resources related to asthma and 
contribute the largest proportion of morbidity and mortality (The ENFUMOSA Study Group 
2003). Multiple distinct subgroups of asthma phenotypes have been identified using cluster 
analysis (Haldar et al. 2008; Moore et al. 2010). Within the overall asthma population, patients 
were found to fall mainly into two groups consisting of early-onset atopic individuals and 
obese individuals with non-eosinophilic airway inflammation (Haldar et al. 2008). Multiple 
subgroups were identified within severe asthmatics; these clusters differed mainly in lung 
function, age of onset, and atopic status [Figure 1.3] (Haldar et al. 2008; Moore et al. 2010). 
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Figure 1.3 ± Cluster analysis showing 5 distinct, severe asthma phenotypes ranging from 
milder asthma (Cluster 1) to more severe disease (Clusters 4 to 5). 80% of 726 subjects 
from the Severe Asthma Research Program (SARP) were successfully clustered, the size of 
coloured figures are proportional to frequency of individuals. Adapted from (Moore et al. 
2010). 
 
1.1.6.2 Allergic Rhinitis 
Allergic rhinitis is an inflammatory disease of the nasal mucosa characterised by pruritis, 
irritation, and excessive mucus production in response to specific environmental allergens such 
as seasonal plants, airborne chemicals, and dust particles (Skoner 2001). Although frequently 
under diagnosed, Allergic rhinitis is the most common manifestation of allergic disease with a 
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high prevalence ranging from 21% to 26% in Europe (Bauchau and Durham 2004). It is a 
major healthcare burden as well as having an important impact in determiniQJDQLQGLYLGXDO¶V
quality of life. Allergic rhinitis is an important co-morbidity in asthma with 20% to 30% of 
clinically diagnosed patients also having asthma (Bousquet et al. 2008). Conversely, up to 80% 
of asthma patients have also been shown to exhibit symptoms of allergic rhinitis (Shaaban et 
al. 2008). 
 
1.1.6.3 Atopic Dermatitis 
Atopic dermatitis is a chronically relapsing, inflammatory skin disease resulting in symptoms 
such as pruritis and eczematous lesions typically presenting in early childhood (Leung et al. 
2003). The skin of an affected individual reacts easily and abnormally to irritants, food, and 
environmental allergens increasing vulnerability to bacterial infections. The prevalence of 
atopic dermatitis is approximately 15% in industrialised countries but has been difficult to 
establish since no standardised diagnostic criteria exist (Williams et al. 1999). There is 
increasing evidence for a genetic component in determining atopic dermatitis through 
breakdown of the dermal barrier as well as support for LWVUROHLQWKHµDWRSLFPDUFK¶(Hanifin 
2009). This hypothesis describes the phenomenon whereby some children with atopic 
dermatitis also go on to develop asthma and/or allergic rhinitis in later life (Spergel 2010). 
 
1.1.7 Management 
Management for allergic diseases is primarily based on control of symptoms. A number of 
non-pharmacological methods have been proposed such as minimising allergen exposure in 
sensitised individuals in order to reduce both the frequency and severity of immediate 
hypersensitivity responses (Ownby et al. 2002; Simpson and Custovic 2004; Lucas et al. 
2005). However, this strategy can be ineffective particularly for air-borne allergens such as 
grass pollens. Furthermore, more studies are required in this area as there is currently 
insufficient evidence to support the effectiveness of these strategies. 
 
A range of specific pharmacotherapy agents targeting the immunologic response are currently 
available with differing value dependent on the type and severity of the allergic disorder. In 
11 
mild disease, allergic rhinitis is predominantly managed using anti-histamines targeting the 
histamine H1 receptor such as diphenhydramine (Scadding et al. 2008). Emollients form the 
basis for atopic dermatitis management. Additionally, topical steroids are commonly used in 
both diseases with increasing severity of symptoms. Asthma management requires the use of a 
ȕ2-DGUHQHUJLFUHFHSWRUDJRQLVWȕ2-agonist) such as salbutamol to induce bronchodilation and an 
inhaled gluco-corticosteroid (ICS) such as beclamethasone to reduce inflammation (Barnes and 
Barnes 2006; Holgate et al. 2008). Some patients are prescribed cysteinyl leukotriene 
modifiers either in the form of receptor antagonists or synthesis inhibitors and others with more 
severe forms of asthma can require the use of IgE targeting monoclonal antibodies such as 
omalizumab (Holgate et al. 2005). 
 
As mentioned in Section 1.1.6.1, asthma severity can be classified on the basis of the intensity 
of treatment required to achieve good asthma control. Mild asthma can be well-controlled with 
low-intensity treatment such as low-dose ICS, leukotriene modifiers or cromones. Partly-
controlled asthma is based on having any of the following characteristics in a week: daytime 
symptoms, limited activity, nocturnal symptoms, need for reliever medication, <80% predicted 
lung function based on forced expiratory volume in the 1st second (FEV1) or peak expiratory 
flow (PEF), and exacerbations occurring one or more times per year. Symptoms are 
uncontrolled if three or more features of partly-controlled asthma are present in a given week 
or if exacerbations occur weekly. According to the Global Initiative for Asthma (GINA) 
guidelines for the management of asthma, five treatment steps have been defined with 
increasing disease severity [Table 1.2] (Bateman et al. 2008). 
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Table 1.2 ± GINA defined management approach based on control. Adapted from 
(Bateman et al. 2008). 
Treatment steps 
Step 1 Step 2 Step 3 Step 4 Step 5 
Asthma education, environmental control 
As needed rapid-
acting ȕ2-agonist 
As needed rapid-DFWLQJȕ2-adrenergic receptor agonists 
Controller 
options (ICS, 
long-DFWLQJȕ2-
agonist) 
Select one Select one To Step 3, select 
one or more 
To step 4, add 
either 
Low-dose ICS Low-dose ICS 
plus long-acting 
ȕ2-agonist 
Medium or high-
dose ICS plus long-
DFWLQJȕ2-agonist 
Oral gluco-
corticosteroid 
(lowest dose) 
Leukotriene 
modifier 
Medium or high-
dose ICS; 
Low-dose ICS 
plus leukotriene 
modifier 
Leukotriene 
modifier;  
Sustained release 
theophylline 
Anti-IgE 
treatment 
 Low-dose ICS 
plus sustained 
release 
theophylline 
  
 
Variability in asthma control is to an extent due to heterogeneity in drug treatment responses in 
allergic diseases. Widespread differences even in patients with seemingly identical clinical 
phenotypes have been investigated using pharmacogenetic approaches (Hall and Sayers 2007). 
Part of this variability could be due to differences in the genetics of individual patients, for 
example, pol\PRUSKLVPVLQWKHJHQHVHQFRGLQJWKHȕ2-adrenergic receptor and 5-lipoxygenase 
enzyme family KDYH EHHQ VKRZQ WR LQIOXHQFH UHVSRQVH WR ȕ2-agonist and anti-leukotriene 
therapies respectively (Drazen et al. 2000). 
 
1.1.8 Susceptibility to Disease 
Atopic disorders are complex multi-factorial diseases and do not follow classic Mendelian 
inheritance patterns. A large number of interacting genetic and environmental factors are 
involved in determining disease expression (Sibbald and Turner-Warwick 1979; Barnes 1999). 
 
1.1.8.1 Environmental Factors 
Environmental factors such as exposure to house dust mite, tobacco smoke, and viral infections 
are important determinants of asthma and atopic disease such as allergic rhinitis (Carlsen et al. 
1984; Skoner 2001). Although debated, one theory termed the hygiene hypothesis suggests that 
childhood exposure to lower levels of bacterial or parasite antigens may in turn result in a 
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tendency for T lymphocytes to polarise towards a Th2 rather than a Th1 cytokine profile and so 
increase risk of allergic disease in later life (Wills-Karp et al. 2004). Common precipitants to 
asthma exacerbations include exercise particularly in cold weather, exposure to airborne 
allergens or pollutants and viral upper respiratory tract infections (Lemanske et al. 2003). For 
example, 60% of asthma subjects exhibit immediate hypersensitivity to defined environmental 
allergens such as nitrogen dioxide and ozone (Carlsen et al. 1984; Valacer 2000). 
 
In addition to complex interactions of genes within multiple pathways, environmental factors 
are also important in the expression of genetic predisposition. Most current hypotheses propose 
that changes in environmental factors favour the manifestation of allergic disease in those who 
are genetically susceptible and it is the interaction between these that leads to clinical disease 
(Ober and Vercelli 2011). 
 
1.1.8.2 Disease Heritability 
A genetic predisposition to the development of allergic diseases such as asthma, allergic 
rhinitis, and atopic dermatitis has been recognised since the early 1900s. In 1916, Cooke and 
Van der Veer reported that almost 50% of patients with allergic rhinitis and asthma had a 
positive family history of similar illness (Cooke and Veer 1916). Since then, the genetic 
component of susceptibility to atopy has been confirmed by numerous epidemiological studies 
showing familial clustering of disease and concordance rates amongst twins (Meyers et al. 
1995). 
 
The heritability of asthma has been reported at as high as 75% and with each additional atopic 
first degree family member, the 3% risk of developing atopic dermatitis in the general 
population increases by two-fold (Duffy et al. 1990; Kuster et al. 1990). Correlation rates 
between twins for intradermal skin testing were significantly lower in dizygotic pairs (r2=0.46) 
compared to in monozygotic twin pairs (r2=0.82) (Hopp et al. 1984). This was similarly 
demonstrated for allergic rhinitis where a 45% to 60% concordance rate reduces to 25% and 
for atopic dermatitis, a rate of 72% to 86% falls to 21% to 23% in monozygotic compared to in 
dizygotic twins (Schultz Larsen and Holm 1985; Larsen et al. 1986; Feijen et al. 2000). 
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Although a genetic contribution to atopic traits has been well established, heritability estimates 
of various atopic phenotypes vary, ranging from 34% to 74% (Koppelman et al. 2002). 
Numerous studies have been carried out to identify the inheritance pattern of these allergic 
diseases including using segregation analyses resulting in many different genetic models being 
proposed (Los et al. 1999). 
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1.2 Genetics of Complex Disease 
 
1.2.1 Statistical Approaches 
Identifying the genetic determinants of complex, multifactorial diseases has been more difficult 
than that of single gene traits. Generally, three main approaches have been used to detect loci 
and genes that are implicated in disease transmission: linkage and association in populations 
presumed to be ancestrally homogenous, as well as admixture mapping using multiple 
genetically diverse populations [Figure 1.4]. Admixture mapping involves combining known 
SRSXODWLRQKLVWRU\ZLWKLQIRUPDWLRQIURPVXEMHFWV¶PHDVXUHGgenotypes using known ancestry-
informative markers within admixed populations. This thesis will focus on linkage and 
association approaches. 
 
Linkage analysis tests for co-segregation of genetic markers with the disease phenotype using 
family-based cohorts such as multiplex extended pedigrees and nuclear families with affected 
sib-pairs (Risch 1990). This approach tests genetic variation across the genome using linkage 
markers based on a positional map of genetic markers relative to each other in terms of 
recombination frequency. The greater the frequency of segregation during crossover of 
homologous chromosomes occurring between two genetic markers, the further apart they are 
assumed to be. 
 
Association studies examine the co-occurrence of a marker and disease between cases and 
controls to determine if the marker occurs more frequently in people with the disease compared 
to those without. This approach can be carried out using both family-based and unrelated 
subjects commonly using single nucleotide polymorphism (SNP) markers based on a map of 
their physical distances along each chromosome. Over 12 million SNPs have been deposited in 
NCBI GeneBank, approximately one million of which have been validated with identified 
SNPs across the genome occuring approximately every 500 base pairs (bp) (Sachidanandam et 
al. 2001; 1000 Genomes Project Consortium et al. 2010). 
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Figure 1.4 - Approaches to complex disease gene discovery. 
 
1.2.2 Linkage Analysis 
Genetic linkage is the deviation of loci from independent assortment during meiosis resulting 
in a tendency for certain loci or alleles located close in chromosomal position to be inherited 
together. Linkage analysis uses the assumption that a genetic marker and the disease causing 
variant are in physical proximity and therefore results in transmission from parent to offspring 
more often than expected XQGHULQGHSHQGHQWLQKHULWDQFH0HQGHO¶VVHFRQGODZ7KHEDVLVIRU
using this approach comes from the evidence for genetic heritability of a trait found using 
family studies. Maximum likelihood of disease ratio methods are used to assess the likelihood 
that a trait co-segregates with a genetic marker, expressed as an LOD score measure of the 
log10 ratio of the odds of two loci being linked compared to the odds of observing the data by 
chance (Morton 1955). In genome-wide linkage studies using more than 300 markers, a value 
of +3.6 is taken as significance evidence for linkage (Feijen et al. 2000). Once loci have been 
located, fine mapping can be carried out to locate candidate disease susceptibility genes and 
subsequent association analyses termed positional cloning are often used to provide additional 
evidence for genes in determining disease [Figure 1.4]. 
 
Studies based on linkage approaches are hypothesis-free thereby offering the potential to 
identify novel susceptibility genes, particularly those in pathways not obviously implicated in 
allergic disease. Linkage is able to identify multiple regions simultaneously and is particularly 
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useful in detecting genes of modest to large effects usually with an odds ratios (OR) greater 
than 5 (Ober and Hoffjan 2006). The use of this approach has successfully identified genes 
such as breast cancer 1, early onset (BRCA1) in determining breast cancer through mapping the 
linkage signal (LOD 5.98) on chromosome 17q21 by positional cloning (Hall et al. 1990). 
However, the genetic component for the majority of complex diseases is likely to be composed 
of multiple genes with only modest effects. Evidence provided by linkage studies can have 
limited statistical power and methods in following up linked regions such as high-throughput 
sequencing can be costly and labour intensive, in particular when large numbers of broad 
linkage regions are identified (Wills-Karp et al. 2004). 
 
1.2.2 Association Analysis 
The aim of an association study is to determine whether affected individuals are more likely to 
have a particular allele of a marker or gene than the unaffected individuals in the same 
population. This is based on the common disease, common variant hypothesis which states that 
genetic variants in the population affecting risk of common diseases may be polymorphisms 
that are common in the whole population with a minor allele frequency (MAF) greater than 5% 
(Risch and Merikangas 1996). It is assumed that these variants have not been eliminated 
through natural selection due to low effect sizes, genetic drift given small effective human 
population sizes, and different selection pressures in modern society. Furthermore, adaptation 
to environmental changes such as levels of pathogen exposure may have resulted in the 
selection for alleles that confer increased protection against infections but predispose to 
autoimmunity, for example, in interleukin 18 receptor accessory protein (IL18RAP) (Sironi and 
Clerici 2010). Each of these common genetic variants will contribute a small, additive or 
multiplicative effect resulting in part, in the evolutionarily neutral state of these common 
diseases. 
 
The candidate gene approach utilises association analysis to assess the contribution of 
polymorphisms in genes with hypothesised biological functions in determining disease [Figure 
1.3]. Association is determined when differences in allele frequencies are found to be 
statistically significant between a disease affected case population and an unaffected control 
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population (Cardon and Bell 2001). This approach has been used to identify common disease 
variants such as the apolipoprotein E (APOE) İ DOOHOHLQ$O]KHLPHU¶VGLVHDVHSUHVHQWLQWKH
general population at approximately 30% (Corder et al. 1994). Association between markers 
and disease can implicate candidate genes and be used to determine true causation suggesting 
that the markers or genes are involved in disease risk. However, association can also result 
from the marker being in linkage disequilibrium (LD) with another disease causing allele or 
gene. The subsequent non-random association of these alleles mean that they are not 
transmitted independently thus increasing the rate of false-positive association results (Baron 
2001). False-positive results in association studies can also be attributed to the potential for 
population stratification and the value of results depends on the selection of candidate genes 
with the greatest involvement in disease pathophysiology (Hirschhorn et al. 2005). 
 
1.2.3 Genome-Wide Association (GWA) Studies 
A genome-wide association (GWA) study is a powerful, recent approach that rapidly scans 
thousands of SNP markers across complete sets of deoxyribonucleic acid (DNA) or genomes 
of case-control cohorts in order to find genetic variations associated with a particular disease 
(Hirschhorn et al. 2005). This approach was made possible following the completion of the 
Human Genome Project in 2003 and the International HapMap Project in 2005 through 
providing computerised databases that contain the reference human genome sequence, a map 
of human genetic variation and new technologies that can quickly and accurately analyse 
whole-genome samples (Sachidanandam et al. 2001; Venter et al. 2001; The International 
HapMap 2003). Of the over 10 million common SNPs believed to be present in the human 
genome, these variants have been demonstrated to cluster into haplotypes groups. This allows 
for a large proportion of SNPs across the genome to be accurately sampled using fewer, 
carefully chosen SNPs (Gabriel et al. 2002). GWA studies have the ability to identify novel 
disease genes and pathways simultaneously including those with small effect sizes (Hirschhorn 
et al. 2005). As a result, they have been used extensively to study common diseases including 
FRURQDU\ DUWHU\ GLVHDVH &URKQ¶V GLVHDVH UKHXPDWRLG DUWKULWLV DV ZHOO DV W\SH  DQG W\SH 
diabetes (Smyth et al. 2006; Petretto et al. 2007; Wellcome Trust Case Control Consortium 
2007). 
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Since almost the entire genome is analysed for the genetic associations of a particular disease, 
this technique allows the genetic factors of a disease to be investigated in a non-hypothesis 
driven manner and represents a promising way to study complex, common diseases in which 
many genetic variations contribute to disease risk. Despite the advantages of using GWA to 
study complex traits, this approach has a strong potential for false-positives due to the large 
number of permutations generated requiring stringent statistical criteria in analysis such as the 
Bonferroni correction (Miller 1981). Similarly for all association studies, GWA is subject to 
influences from factors such as population stratification and phenotype misclassification 
between cases and controls (Baron 2001). Large sample sizes are required to detect genetic 
variants of modest effects with power calculations indicating that 2,000 individuals are needed 
WR GHWHFW DQ 25  (Risch and Merikangas 1996). In addition, genome coverage from SNP 
chips used in GWA has recently been demonstrated to be limited at about 60% rather than 
previously reported levels of 80% to 90%, particularly for low-frequency and rare variants 
(Hao et al. 2008). 
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1.3 Genetics of Allergic Disease 
 
1.3.1 Genetic Studies of Allergic Disease 
Different approaches have been used to study genetic determinants in the development of 
allergic disease with increasing numbers of candidate loci and genes being implicated for 
disease susceptibility. Genetic studies indicate that many genes may be involved in the 
pathogenesis of allergic disease in addition to other disease specific genes which regulate the 
development of different types of allergic conditions (Barnes 2000). For example in atopy 
development, the production of total IgE and specific IgE have been shown to have influences 
from different genetic loci in additional to common loci controlling both traits (Dold et al. 
1992; Marsh 1996). However, the majority of studies have been limited in both statistical 
power and experimental design resulting in problems encountered such as type I error. This has 
in turn led to difficulty in reproducing findings across studies and the inability to reliably 
confirm levels of contribution from multiple genetic factors (discussed in detail in Section 
1.4.1). 
 
1.3.2 Genome±Wide Linkage (GWL) Studies 
Several genome-wide screens have linked atopy and related atopic diseases to loci across the 
genome containing genes coding for proteins involved in host immune responses. The first 
locus linked to atopy defined by IgE responses was identified on chromosome 11q13 in a study 
of seven families to the marker D11S97 with a maximum LOD score of 5.58 (Cookson et al. 
1989). Subsequently, DJHQHFRGLQJIRUWKHȕVXEXQLWRIFc epsilon R1: membrane-spanning 4-
domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I, receptor for; beta 
polypeptide) (MS4A2) was identified in this region (Dizier et al. 1999). However, linkage of 
atopy to the 11q13 region has not been reproduced consistently across several studies using a 
variety of genetic markers and phenotypes in populations with differing ethnic backgrounds 
(Moffatt and Cookson 1997). Other linked loci that have been replicated for statistical 
significance in more than one genome-wide screen for asthma include regions 2q33, 5q23-31, 
6p24-21, 11q21-13, 12q24-12, and 13q14-12 (Wills-Karp et al. 2004).  
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Genome-wide searches for allergic rhinitis have been carried out in six populations identifying 
linkage regions on chromosomes 3q and 4q as common to atopy (serum total and specific IgE), 
atopic asthma, allergic rhinitis, and atopic dermatitis (Haagerup et al. 2004). Other regions may 
contain trait-specific genetic factors such as 3q13.31 for allergic rhinitis. A study testing dense 
markers in this region using a total of 236 allergic Danish families found that the signal 
intensified using 125 sib-pairs with rhinitis alone (LOD 5.55 compared to 3.71 for increased 
specific IgE) (Brasch-Andersen et al. 2006). To date, GWL scans have been conducted for 
atopic dermatitis in four different populations. Regions on chromosomes 3p, 3q, 17q, and 18q 
have been linked in at least two independent studies (Hoffjan et al. 2005). 
 
Linkage results for atopy and related traits with regions replicated in at least two studies are 
summarised in Table 1.3. The independent identification with which these regions have been 
detected indicates that they might indeed contain disease susceptibility genes. 
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Table 1.3 ± References to studies showing loci replicated for linkaJHLQGHSHQGHQWVWXGLHV 
LINKAGE 
Loci Atopy (total IgE, specific IgE, SPT) Asthma Allergic rhinitis Atopic dermatitis 
2q12-q33   Dizier et al. 1999; Haagerup et al. 2001  
3p6-24    Bradley et al. 2002; Haagerup et al. 2004 
3q13   Haagerup et al. 2001; Brasch-Andersen et 
al. 2006; Bu et al. 2006 
 
3q14-21    Lee et al. 2000; Bradley et al. 2002 
5q23-q33 Marsh et al. 1994; Hizawa et al. 1995; 
Meyers et al. 1995; Noguchi et al. 1997; 
Hizawa et al. 1998; Palmer et al. 1998 
Postma et al. 1995; CSGA 1997; Noguchi et 
al. 1997; Ober et al. 1998 
  
6p21.1-p23 Caraballo and Hernandez 1990; Daniels 
et al. 1996; Hizawa et al. 1998; Wjst et 
al. 1999 
CSGA 1997; Wjst et al.1999   
6p22-24   Haagerup et al. 2001; Bu et al. 2006  
11q13 Cookson et al. 1989; Young et al. 1992; 
Shirakawa et al. 1994; Shirakawa et al. 
1994; Hizawa et al. 1995; Daniels et al. 
1996; Doull et al. 1996; Palmer et al. 
1998 
Van Herwerden et al. 1995; Daniels et al. 
1996; Doull et al. 1996 
  
12q14-q24.33 Barnes et al. 1996; Nickel et al. 1997; 
Wjst et al. 1999 
Barnes et al. 1996; Ottman 1996; Ober et al. 
1998; Barnes et al. 1999; Wjst et al. 1999 
  
13q14.3-qter Daniels et al. 1996; Hizawa et al. 1998 CSGA 1997; Kimura et al. 1999   
14q11.2-q13 Moffatt et al. 1994; Mansur et al. 1999    
17q21- 25    Cookson et al. 2001; Bradley et al. 2002 
18q11-21    Bradley et al. 2002; Haagerup et al. 2004 
19q13  CSGA 1997; Kimura et al.1999   
21q21  CSGA 1997; Kimura et al.1999   
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Positional cloned genes for asthma and related traits are listed in Table 1.4, six genes have 
been identified and positively replicated using this approach for asthma including at the level 
of a SNP. Currently, no genes have been identified veritably for both allergic rhinitis and 
atopic dermatitis by positional cloning. Studies identifying linkage to regions containing 
susceptibility genes for another inflammatory skin condition, psoriasis including to 
chromosome 17q containing the psoriasis susceptibility 2 (PSORS2) and psoriasis 
susceptibility 5 (PSORS5) genes suggest an important role for dermal expressed genes in atopic 
dermatitis in addition to general atopic genes (Cookson et al. 2001). 
 
Table 1.4 ± Genes identified by positional cloning in determining susceptibility to atopy 
and related traits. * Genes replicated in  independent studies. 
POSITIONAL CLONING 
Loci Genes Phenotype Putative function 1st positional cloning study 
Population Reference 
2q14 DPP10 Asthma* Controls bronchial reactivity via 
voltage-gated potassium 
channels 
239 UK and 
Australian 
families 
Allen et al. 
2003 IgE 
6p21 HLA-G Asthma* Alters the Th1/Th2 cell balance 129 US 
Caucasian 
families 
Nicolae et al. 
2005 Allergy 
7p14 NPSR1 Asthma* Controls smooth muscle 
contractibility 
1,972 German 
children 
Kormann et 
al. 2005 IgE 
Atopy 
12q24 SFSWAP Asthma* Involved in T cell activation via 
CD45 antigen 
236 Danish 
families 
Brasch-
Andersen et 
al. 2006 
13q14 PHF11 Asthma* Promotes Th1-type cytokine 
gene expression through 
interaction with NFkB protein 
202 
Australian 
families 
Ferreira et al. 
2005 IgE 
Atopic 
dermatitis 
20p13 ADAM33 Asthma* Involvement in epithelial repair 460 US 
Caucasian 
families 
Van 
Eerdewegh et 
al. 2002 
IgE 
DPP10: dipeptidyl-peptidase 10 (non-functional); HLA-G: major histocompatibility complex, class I, G; 
NPSR1: neuropeptide S receptor 1; SFSWAP: splicing factor, suppressor of white-apricot homolog 
(Drosophila); PHF11: PHD finger protein 11; ADAM33: ADAM metallopeptidase domain 33. 
 
More than 20 distinct chromosomal regions have been identified for linkage with atopy and 
related phenotypes such as serum total IgE, specific IgE, SPT, and asthma in more than 17 
distinct populations (Ferreira et al. 2005). A large amount of heterogeneity remains with few 
replicated findings and reported linkages meeting the accepted criteria for significant genome-
wide linkage i.e. a LOD score of 3.6. The results of these linkage analyses suggest that 
multiple genomic regions contain genes influencing atopic phenotypes [Figure 1.5]. 
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Figure 1.5 ± Results of 16 genome-wide scans for asthma or asthma-related intermediate 
phenotypes. Specific chromosomal regions have been highlighted for importance (green) and 
particular importance (red) based on consistency of results. Locations of key positionally 
cloned genes studied detailed in Table 1.4 are shown. Adapted from (Carroll 2005). 
 
1.3.3 Meta-Analysis of GWL Studies 
Previous work performed in Nottingham combined data from 11 GWL studies for asthma and 
related traits in order to investigate the consistency of linkage results across studies in 
Caucasian populations using asthma enriched families (1,093 pedigrees, n=4,746) (Denham et 
al. 2008). The genome-wide scan meta-analysis (GSMA) study yielded supporting evidence 
for overlap of susceptibility loci for atopy, BHR, and total IgE including chromosome 5q23.2-
q34 containing candidate genes IL4, IL13, IL5, IL12B, and the major histocompatibility 
complex (MHC) or human leukocyte antigen (HLA) locus on chromosome 6p22.3-p21.1 
implicating potentially pleiotropic effects for these genes. Significant evidence for linkage was 
shown for chromosomal regions 3p22.1-q22.1 and 17p12-q24.3 as containing susceptibility 
loci for positive SPT (1,093 pedigrees, n=4,746). For asthma (1,267 pedigrees, n=5,832), no 
single chromosomal region at genome-wide statistical significance could be found to be clearly 
linked. This may have been due to the heterogeneity in disease diagnosis across the multiple 
studies used (Denham et al. 2008). 
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1.3.4 Candidate Gene Studies 
Findings of candidate genes for atopy and related traits are summarised in Table 1.5. Most 
commonly, the candidate gene approach has been used to examine the cytokine gene cluster on 
chromosome 5q23-31 and HLA group of genes on chromosome 6p21-22. A review carried out 
in 2006 of nearly 500 disease association papers showed that 118 asthma candidate genes have 
been identified by candidate gene association, of which 79 have been associated with an 
asthma or atopy-related phenotype in two or more independent studies (Ober and Hoffjan 
2006). As of 2011, there are now over 1,000 published studies examining association of SNPs 
in asthma and allergy candidate genes (Postma et al. 2011). Several of the most investigated 
genes include the HLA-DR genes, interleukin 4 receptor (IL4R), and interleukin 13 (IL13), 
which have been replicated over 10 times in various studies although this may have been 
subject to publication bias. 
 
HLA-DR genes, for example, were chosen due to the involvement of these molecules in the 
immune response by binding to antigen derived peptides prior to T lymphocyte presentation. 
As a result, a number of association studies have been carried out looking at their potential 
roles in determining genetic susceptibility to atopy (Marsh et al. 1982; Aron et al. 1996; 
Nicolae et al. 2005). Although a number of association studies produced varying consistency 
of results, evidence for this region was supported by a linkage analysis study identifying a 
number of allele polymorphisms in HLA-DR genes associated with specific IgE responses to a 
number of allergens (Young et al. 1994; Holloway et al. 1996). 
 
In some studies, candidate genes have been selected based on positional properties within loci 
identified for linkage. The gene encoding filaggrin, a protein involved in terminal 
differentiation of the epidermis and formation of the skin barrier was identified and replicated 
on chromosome 1q21, a region showing strong linkage to atopic dermatitis (Palmer et al. 2006; 
Sandilands et al. 2007). Following multiple replication studies, two losses of function genetic 
variants within this gene have shown significant association with the expression of atopic 
dermatitis (Weidinger et al. 2006). 
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Table 1.5 ± 6XPPDU\RIFDQGLGDWHJHQHVUHSOLFDWHGLQGHSHQGHQWVWXGLHVIRUDWRS\DQGDVWKPDIRUDWRSLFGHUPDWLWLV$'DQGIRUDllergic rhinitis (AR).  
CANDIDATE GENE 
Loci Genes Phenotype Putative function Selected references 
1q21 Filaggrin AD Involvement in protective dermal barrier function by encoding the 
Filaggrin protein which bind to keratin fibers in epithelial cells. 
Seguchi et al. 1996; Palmer et al. 2006; Weidinger et al. 2006; Sandilands et al. 2007 
5q31 IL4, IL13, 
CD14 
Atopy Th2 cytokines: inducing differentiation of naive Th cells into Th2 cells 
(IL4); IgE isotype switching following release from Th2 cells (IL13). 
Pattern recognition receptor in the innate immune response expressed 
predominantly by macrophages (CD14). 
Baldini et al. 1999; Gao et al. 1999; Ober et al. 2000; Cardaba et al. 2001; Koppelman 
et al. 2001; Bourgain et al. 2003 
Asthma Ober et al. 2000; Takabayashi et al. 2000; Zhu et al. 2000; Noguchi et al. 2001 
AD Heinzmann et al. 2000; Liu et al. 2000; Tsunemi et al. 2002; Hummelshoj et al. 2003 
5q31-
33 
SPINK5 AD Role in skin and hair morphogenesis, anti-inflammatory and/or 
antimicrobial protection of mucous epithelia. Mutations in the SPINK5 
SURWHLQ PD\ UHVXOW LQ 1HWKHUWRQ¶V V\QGURPH HOHYDWHG ,J( ZLWK DWRSLF
manifestations). 
Walley et al. 2001; Tsunemi et al. 2002; Kato et al. 2003; Nishio et al. 2003; Kabesch 
et al. 2004; Kusunoki et al. 2005 
5q32-
34 
ADRB2 Asthma Targeted site for ȕ2-agonists as a membrane-bound G-protein-coupled 
receptor involved in smooth muscle relaxation and vasodilatation. 
Reihsaus et al. 1993; Turki et al. 1995; Hopes et al. 1998; Ober et al. 2000; 
Hakonarson et al. 2001; Bourgain et al. 2003 
6p21 TNF Asthma Mediates the inflammatory response in the acute phase response by 
promoting neutrophil migration through expression of endothelial adhesion 
molecules (TN)Į YDVFXODU HQGRWKHOLDO DQG SKDJRF\WLF FHOO ELQGLQJ
(LTA). 
Moffatt and Cookson 1997; Tan et al. 1997; Chagani et al. 1999; Moffatt et al. 1999; 
Trabetti et al. 1999; Lin et al. 2002; Witte et al. 2002; Di Somma et al. 2003 
LTA Asthma Moffatt and Cookson 1997; Tan et al. 1997; Moffatt et al. 1999; Cardaba et al. 2001; 
Immervoll et al. 2001; Lin et al. 2002; Witte et al. 2002 
6p21.
3 
HLA-DR 
genes 
Atopy Antigen presentation to T lymphocytpes to stimulate Th cell production. Marsh et al. 1982; Freidhoff et al. 1986; Marsh et al. 1987; Ansari et al. 1989; Young 
et al. 1994 
11q13 MS4A2 Atopy Expressed on antigen-presenting cells to form antigen-IgE complexes 
leading to degranulation of basophils and mast cells to release 
inflammatory mediators. 
Shirakawa et al. 1994; Hill and Cookson 1996; Nagata et al. 2001 
Asthma Li and Hopkin 1997; Cox et al. 1998; Green et al. 1998; Hijazi et al. 1998; Palmer et 
al. 1999; van Hage-Hamsten et al. 2002 
AD Cox et al. 1998 
11q22 IL18 AR Pro-inflammatory cytokine working in combination with IL12. Kruse et al. 2003; Lee et al. 2006; Sebelova et al. 2007 
14q11 CMA1 AD Mast cell serine protease conferring pro-inflammatory effects. Mao et al. 1996; Mao et al. 1998; Soderhall et al. 2001; Weidinger et al. 2005 
16p12 IL4R AD Encodes an alpha-chain for both the IL4 and IL13 cytokine receptors. Hershey et al. 1997; Oiso et al. 2000; Callard et al. 2002; Novak et al. 2002; Hosomi 
et al. 2004 
17q23 EPO AR Eosinophil activation in the Th2 response. Nakamura et al. 2003; Nakamura et al. 2004 
IL4: interleukin 4; IL13: interleukin 13; CD14: CD14 molecule; SPINK5: serine peptidase inhibitor, Kazal type 5; ADRB2: adrenergic, beta-2-, receptor, surface; TNF: tumor necrosis factor; 
LTA: lymphotoxin alpha (TNF superfamily, member 1); MS4A2: membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I, receptor for; beta polypeptide); 
IL18: interleukin 18; CMA1: chymase 1, mast cell; IL4R: interleukin 4 receptor; EPO: erythropoietin. 
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1.3.5 GWA Studies 
Rapid advances in genotyping technologies have resulted in increasing numbers of GWA 
studies in allergic disease identifying for example in asthma, a widely replicated locus on 
chromosome 17q12-21 containing genes ORM1-like protein 3 (ORMDL3), chemokine (C-C 
motif) ligand 11 (CCL11) and gasdermin B (GSDML) as well as additional genes including 
chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1), interleukin 1 receptor-like 1 (IL1RL1), 
and WD repeat domain 36 (WDR36) on chromosomes 1q31, 2q12, and 5q22 respectively 
[Table 1.6] (Moffatt et al. 2007; Ober et al. 2008; Gudbjartsson et al. 2009). Recently, the 
biggest collaborative effort thus far investigating the genetic determinants of asthma was 
published by the Multidisciplinary Study to Identify the Genetic and Environmental Causes of 
Asthma in the European Community (GABRIEL) Consortium. This study consisted of 10,365 
case subjects and 16,110 controls and observed genome-wide significance between asthma and 
SNPs within previously reported loci and genes including interleukin 18 receptor 1 (IL18R1) 
(p=3x10(-9)), the HLA-DQ group of genes (p=7x10(-14)), and interleukin 33 (IL33) (p=9x10(-10)) 
as well as the chromosome 17q12-21 locus (p=6x10(-23)) specific to childhood-onset disease 
(Moffatt et al. 2010). 
 
Importantly, association studies to date have mostly focused on mild-to-moderate disease and 
genetic risk factors for severe asthma remain unclear. In 2009, a relatively small GWA study 
was conducted on a population of patients with severe or difficult to treat asthma (473 cases, 
1,892 controls) carried out by The Epidemiology and Natural History of Asthma: Outcomes 
and Treatment Regimes (TENOR) study (Li et al. 2010). This study identified association with 
multiple SNPs in the DNA repair protein RAD50-interleukin 13 (RAD50-IL13) (p=3x10(-7)) 
and HLA-DR/DQ (p=9x10(-6)) regions although no loci met conventional genome-wide 
significance criteria (p<5x10(-8)) (McCarthy et al. 2008). 
 
Additional potential disease susceptibility genes for atopy, asthma, and atopic dermatitis 
identified by GWA studies are listed in Table 1.6. Many of these findings have been supported 
by functional analyses. No study has yet been conducted for allergic rhinitis using this 
approach. 
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Table 1.6 ± Susceptibility genes identified using GWAS. 
GWA STUDIES 
Loci Genes Phenotype Putative function Population Genotyping 
platform 
p value Replication Reference 
1p31 DENND1B Asthma (children) Cytokine release and regulation US Caucasian (793 cases, 1,988 controls) Illumina 300K 9x10(-9) Yes Sleiman et al. 2010 
1q23 )FH5Į Atopy (total IgE) &RGHV IRU WKH Į FKDLQ RI KLJK DIILQLW\ ,J(
receptor 
European (1,530 individuals) Affymetrix 
500K 
2×10í Yes Weidinger et al 2008 
2q12 IL18R1 Asthma Promotes Th1 response European (10,365 cases, 16,110 controls) Illumina 610K 3x10(-9) No Moffatt et al. 2010 
2q12.3-
14.2 
DPP10 Asthma Controls bronchial reactivity African-American (464 cases, 471 
controls) 
Illumina 650K <10(-5) in all 
subjects 
Yes Mathias et al. 2010 
5q12.1 PDE4D Asthma Modulates airway relaxation US Caucasian (259 cases, 846 controls) Illumina 650K 9x10(-7) Yes Himes et al. 2009 
5q31.1 RAD50 Asthma (severe) Role in apoptosis US Caucasian (453 cases, 1,892 controls Illumina 500K 3x10(-7) No Li et al. 2010 
5q33 ADRB1 Asthma &RGHVIRUDĮ-adrenergic receptor subtype African-American (464 cases, 471 
controls) 
Illumina 650K <10(-5) in all 
subjects 
Yes Mathias et al. 2010 
6p21.3 HLA-
DR/DQ 
genes 
Asthma (severe) Antigen presentation US Caucasian (453 cases, 1,892 controls Illumina 300K 1x10(-5) No Li et al. 2010 
Asthma European (10,365 cases, 16,110 controls) Illumina 610K 7x10(-14) No Moffatt et al. 2010 
9q21.31 TLE4 Asthma (childhood-onset) Promote inflammatory processes Mexican (482 trios) Illumina 550K 7x10(-4) Yes Hancock et al. 2009 
9q24 IL33 Asthma Drives production of Th2-associated cytokines European (10,365 cases, 16,110 controls) Illumina 610k 9x10(-10) No Moffatt et al. 2010 
10q21.3 CTNNA3 Asthma (Occupational 
TDI) 
Recruitment of E-cadherin and formation of 
cell-cell adhesion 
Korean (84 cases, 265 controls) Affymetrix 
500K 
6x10(-6) No Kim et al. 2009 
11q13 LRRC32, 
C11orf30 
Atopic dermatitis Unknown European (939 cases, 975 controls) Affymetrix 
500K 
7.64x10(-10) in 
all subjects 
Yes Esparza-Gordillo 2009 
15q22.33 SMAD3 Asthma Transcriptional modulator of regulatory T cells European (10,365 cases, 16,110 controls) Illumina 610K 4x10(-9) No Moffatt et al. 2010 
17q12-21 GSDMB 
/GSDMA 
Asthma (childhood-onset) Unknown European (10,365 cases, 16,110 controls) Illumina 610K 6x10(-23) No Moffatt et al. 2010 
17q12-21 ORMDL3 Asthma (childhood-onset) Unknown European (944 cases, 1,243 controls) Illumina 300K 9x10(-11) Yes Moffatt et al. 2010 
17q24.3 GNA13 Asthma G-protein coupled receptor molecule African-American (464 cases, 471 
controls) 
Illumina 650K <10(-5) in all 
subjects 
Yes Mathias et al. 2010 
20pter-
p12 
PRNP Asthma Immune cell activation, signal transduction, 
cell adhesion, antioxidant activity 
African-American (464 cases, 471 
controls) 
Illumina 650K <10(-5) in all 
subjects 
Yes Mathias et al. 2010 
22q13 IL2RB Asthma Regulate homeostasis of effector T-cell 
subgroups 
European (10,365 cases, 16,110 controls) Illumina 610K 1x10(-8) No Moffatt et al. 2010 
DENND1B: DENN/MADD domain containing 1B; IL18R1: interleukin 18 receptor 1; DPP10: dipeptidyl-peptidase 10 (non-functional); PDE4D: phosphodiesterase 4D, cAMP-specific; RAD50: DNA repair protein 
RAD50; ADRB1: adrenergic, beta-1-, receptor; TLE4: transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila); IL33: interleukin 33; CTNNA3: catenin (cadherin-associated protein), alpha 3; LRRC32: leucine 
rich repeat containing 32; C11orf30: chromosome 11 open reading frame 30; SMAD3: SMAD family member 3;  GSDMB/A: gasdermin B/A; ORMDL3: ORM1-like protein 3; GNA13: guanine nucleotide binding 
protein (G protein); PRNP: prion protein; IL2RB: interleukin 2 receptor, beta. 
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1.3.6 Gene-Gene Interactions 
Genes identified using the above methods have tended to be analysed individually. Interactions 
of multiple genes and pathways are likely to be involved in the genetic basis of complex 
disease highlighting the need to examine the effects of gene-gene interaction or epistasis in 
determining the genetic susceptibility of atopy and related traits (Martinez 2007). For asthma, 
carrying the risk genotypes for both IL4R and IL13 has been shown to increase risk of 
developing disease five-fold relative to carrying risk genotypes for only one or equally none of 
these genes (Howard et al. 2002). Although not extensively investigated, the importance of 
epistasis for other atopic traits has also been demonstrated. For example, interaction between 
genes coding for IL4R and the thromboxane A2 receptor (TBXA2R) on determining serum IgE 
has been reported (Tanaka et al. 2002). To date, few studies have adequately addressed 
epistatic gene-gene interactions in allergic disease. 
 
1.3.7 Gene-Environment Interactions 
Similarly, gene-environment interactions remain to be determined. As the environmental 
components in these complex diseases are diverse, the interaction between gene expression and 
environmental influences need also to be taken into consideration (Martinez 2005). 
Environmental factors such as exposure to house dust mite, viral infection, and cigarette smoke 
may influence sensitisation following allergen exposure through alteration of normal 
homeostatic defence mechanisms by increasing allergen access via epithelial permeability 
(D'Amato et al. 2005). 
 
A number of studies have shown differential phenotypic effects of the same genetic 
polymorphisms as a result of environmental factors, in particular, between variants in CD14, 
toll-like receptor 2 (TLR2), and chromosome 5q with farming exposure (Eder et al. 2004; Eder 
et al. 2005; Bieli et al. 2007; Leynaert et al. 2008), pet microbes (Williams et al. 2008), 
household dust mite (Zambelli-Weiner et al. 2005), and tobacco smoke (Meyers et al. 2005) 
respectively. Linkage of hyper-responsiveness to the 5q locus was stronger in families with 
environmental tobacco smoke exposure during pregnancy or early childhood (Meyers et al. 
2005). The risk allele for the development of asthma and elevated IgE of the CD14 -159 SNP, 
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rs2569190 has been shown to differ in communities with varying endotoxin exposures 
(Simpson et al. 2006). In a number of studies, homozygotes for the T allele polymorphisms in 
CD14 have increased likelihood of developing asthma and elevated IgE when exposed to high 
levels of endotoxin but the same genotype was shown to be protective against atopy and 
asthma when exposures were low (Eder et al. 2005; Zambelli-Weiner et al. 2005). Interaction 
of ORMDL3 variants with smoke exposure in asthma has also been shown in both early and 
late-onset individuals (Flory et al. 2009). The differential association of flexural atopic 
dermatitis with IL4R dependent upon previous history of bacterial infection has also been 
reported (Gern et al. 2004). 
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1.4.1 Deficiencies in Previous Studies 
Current GWA studies are only sufficiently powered to detect common casual variants. 
Assuming that some identified polymorphisms are truly associated with disease, lack of 
replicated and inconsistent findings may have resulted from a number of different factors. The 
main difficulties arise from phenotype definition and population ascertainment (Holloway et 
al. 1999). Studies have been carried out using a range of population cohorts with varying 
ancestry and differences in defining affected individuals with disease. This not only has 
detrimental impact on the ability to detect common variants but also reduces accuracy in 
estimating disease heritability. Identified markers linked to or associated with disease may 
have variable linkage correlation across populations reducing the effectiveness in tagging 
candidate genes or other disease causative polymorphisms. There may be individual and 
population specific genetic effects which may be independent of other genetic variants and 
environmental exposures, or result from epistasis and gene-environment interactions. 
 
The proportions of phenotypic variation attributed to additive genetic factors, described by 
heritability estimates, have tended to be calculated from family studies (Visscher et al. 2008). 
Although theoretical models and data have proposed that the genetic effects are most likely to 
be additive in complex diseases, the accuracy of subsequently estimations has been challenged 
by not accounting for additional non-additive genetic factors, shared environmental exposures 
as well as interactions (Stunkard et al. 1990; Hill et al. 2008; Manolio et al. 2009). 
Furthermore, larger sample sizes and improved phenotyping are required to yield adequate 
statistical power and reduce error in detecting polymorphisms with lower allele frequencies and 
modest genetic effects. 
 
Given the low effect sizes seen (typically with OR 1.2 to 1.5), even in results from large-scale 
studies such as that carried out by the GABRIEL Consortium, it is unlikely that identified 
common variants will explain all of the disease variability identified in allergic disease (Park et 
al. 2010). Currently, reported common variants have only been able to determine less than 10% 
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RI WKLV YDULDELOLW\ 7KH VRXUFH RI WKLV µPLVVLQJKHULWDELOLW\¶ KDV EHHQ ZLGHO\ GHEDWHG (Maher 
2008). Other forms of structural variation warranting further study include insertion/deletion 
polymorphisms (indels) and copy number variants (CNVs), for example, a deletion up to 50% 
of glutathione S-transferase mu 1 (GSTM1) in determining asthma with an OR of 1.59 to 1.89 
has been identified (Ivaschenko et al. 2002; Brasch-Andersen et al. 2004). A deletion of two 
genes in the late cornified envelope (LCE) gene cluster, LCE3C and LCE3B has also been 
shown to confer susceptibility to psoriasis and has recently been replicated (de Cid et al. 2009; 
Hüffmeier et al. 2010). 
 
Recent interest in the contribution of rare polymorphisms has focused on identifying variants 
not previously studied using GWA approaches: low-frequency SNPs with MAF of 0.3% to 5% 
and rare SNPs with MAFs of less than 0.3%. The common disease, rare variant hypothesis is 
based on the assumption that low frequency causative SNPs are likely to be non-synonymous 
and increase disease risk by having a deleterious effect on the protein function (Goldstein 
2009). The effects of these SNPs may not be strong enough to be selected out of the population 
and may persist due to genetic drift or founder effects. Re-sequencing of two genes, potassium 
inwardly-rectifying channel, subfamily J, member 11 (KCNJ110) and hematopoietically 
expressed homeobox (HHEX) associated with diabetes in 13,715 individuals discovered an 
abundance of rare variants (Coventry et al. 2010). This study suggested that short, recent gene 
genealogical branches may have arisen as consequence of recent accelerating population 
growth. Therefore, selection would only have had sufficient time to influence the frequencies 
of only the most severely harmful variants. 
 
Low-frequency and rare SNPs are thought to occur frequently in the genome with 
approximately 138,700 validated SNPs currently deposited online (dbSNP 134), most recently 
by the 1000 Genomes Project (Gorlov et al. 2008; 1000 Genomes Project Consortium et al. 
2010). Rare variants are likely to have larger effect sizes with an OR between 2 and 5 filling 
the effect gap of detected heritable variants between linkage and association studies (Bodmer 
and Bonilla 2008). Recent evidence suggests that rare variants may be responsible for 
previously seen association signals attributed to common SNPs through synthetic association 
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demonstrating that 30% of synthetic associations were caused by the presence of rare causative 
variants and furthermore, the strength of the association with common variants increased with 
increasing numbers of rare causative variants (Dickson et al. 2010). However, there is evidence 
to challenge this hypothesis demonstrated by results from pathway analyses implying 
functional roles of GWA identified variants. Furthermore, less overlap between GWA signals 
and well-powered linkage studies, in addition to lower frequencies of rare variants in re-
sequenced regions identified through GWA has been shown, than would be expected if 
synthetic associations were widespread (Anderson et al. 2011). 
 
1.4.2 Next-Generation Sequencing (NGS) 
Over the past few years, developments in next-generation sequencing (NGS) platforms have 
enabled the sequencing of several individual genomes (Venter et al. 2001; Levy et al. 2007; 
Bentley et al. 2008; Wang et al. 2008; Wheeler et al. 2008). These findings have emphasised 
the highly polymorphic nature of the human genome and the fact that compared to common 
variants, the catalogue of rare variant information remains highly incomplete. Sequencing of 
large numbers of individuals is required to identify rare polymorphisms across the genome. 
However, this is currently unfeasible in hundreds of individuals. Recent advances in NGS have 
made re-sequencing candidate genes to a greater depth of coverage more affordable to identify 
rare variants within hypothesised or previously identified loci (Stratton 2008). Methods to 
multiplex larger sample sizes have also been incorporated into NGS platforms and can now be 
carried out requiring fewer runs to sequence mupltiple individuals in pools (Dahl et al. 1998; 
Craig et al. 2008; Harismendy and Frazer 2009). Use of this approach has generated support 
for the contribution of rare variants in common, complex diseases and phenotypes such as 
colorectal adenomas, low plasma levels of high density lipoprotein (HDL) cholesterol 
hypertriglyceridemia, and blood pressure (Cohen et al. 2004; Fearnhead et al. 2004; Ji et al. 
2008). Re-sequencing technology has been used in combination with GWA giving evidence of 
overlap in rare and common variant signals, patients with high plasma triglyceride levels were 
found to carry twice as many rare, coding genetic variants within four candidate genes 
identified through GWA (Johansen et al. 2010). 
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A number of different strategies in identifying rare variants have been proposed varying in the 
extent of the genome covered, whether to target loci identified through GWA, the whole exome 
or the whole genome (Shendure and Ji 2008). Selecting populations for sequencing has also 
been debated, whether or not to focus on extreme phenotypes and to specifically incorporate 
family based designs. The current challenges faced by NGS approaches include both technical 
limitations such as low accuracy genotyping in regions with larger numbers of rare variants 
and in interpretation such as whether effects detected are disease causative or due to population 
stratification or cryptic relatedness within study samples (Day-Williams and Zeggini 2011). 
 
The 1000 Genomes Project has undertaken a combination of low-coverage whole-genome 
sequencing of 179 individuals from four populations with an average of 3.7x coverage, high-
coverage sequencing of two parent-child trios and exon-targeted sequencing of 697 individuals 
from seven populations (1000 Genomes Project Consortium et al. 2010). Data released from 
the August 2010 pilot has generated a catalogue of 8 million previously unknown SNPs and 
around one million structural variants due to small indels. This project has shown the 
feasibility of the use of pooled DNA in multiplexing for the identification of rare variants in 
candidate genes and provided further support for the common disease, rare variant hypothesis. 
Further efforts in high coverage sequencing are currently been carried out across the scientific 
community to catalogue reference databases of low-frequency and rare variants including the 
UK10K Project (http://www.uk10k.org/) aimed at sequencing the exomes of 4,000 individuals 
to 6x sequencing depth. 
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1.5 Summary 
 
Numerous chromosomal regions such as 2q, 5q, and 11q have shown strong evidence of 
linkage to atopy and allergic diseases including asthma, allergic rhinitis, and atopic dermatitis 
and have been predicted to contain disease susceptibility genes. The use of positional cloning 
has identified novel susceptibility genes including DPP10, HLA-DR/DQ genes, and ADAM33 
for asthma. Polymorphisms within several candidate genes including IL4, IL4R, IL13, HLA-
DRB1, and MS4A2 have shown reproducible association with atopy, asthma, and related 
phenotypes. GWA approaches have also been used, identifying confident association with 
genes such as ORMDL3 with childhood-onset asthma and FCER1A with serum total IgE. 
 
Due to the heterogeneity of these traits, disease expression and severity are influenced by 
numerous genetic pathways interacting with environmental components such as epistasis 
between IL4R and TBXA2R in serum IgE as well as influences of house dust mite endotoxin on 
CD14 polymorphisms in asthma and elevated IgE. The total numbers of genetic loci implicated 
are extensive and the proportion of effect from individual genes remains unclear. Furthermore, 
it seems unlikely that all of the genes underlying these complex disorders have been identified. 
 
Lack of replicated results and inconsistent findings result from a number of different factors in 
study design, implementation, and interpretation. Other sources of genetic variation may be 
responsible for the missing component in disease heritability including phenocopies, CNVs, 
and differential gene expression (Moffatt et al. 2007; Emilsson et al. 2008). Furthermore, the 
interaction between these factors and with the environment needs also to be addressed, for 
example, the importance of epigenetic causes such as DNA methylation. Genetic variability 
resulting from CpG islands, for example, has been described in influencing ADAM33 
expression in epithelial cells of asthma patients (Yang et al. 1999). 
 
As focus on treatments for allergic diseases turn towards total prevention and better therapeutic 
interventions, information about specific genetic susceptibility in individuals will become 
increasingly valuable. Determining the genetic basis in the development and outcome of these 
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diseases could help to identify prior risk and prevent disease onset as well as predict variations 
in clinical responses to treatment. Genetic factors have also been shown to be responsible for 
up to 80% of the variability in treatment responses in Caucasian asthmatic patients (Drazen et 
al. 2000). Studies in genetics can also help to question the underlying biological mechanisms 
behind these conditions by identifying new pathways not previously indicated in disease 
pathogenesis, which can in turn form the basis for novel therapies. 
 
Although genetic determinants of allergic disease have been widely studied, two areas which 
remain least understood are the specific IgE and severe asthma phenotypes. No study has yet 
used GWA approaches to identify genetic factors contributing to the development of atopy 
defined by elevated specific IgE and only a single small study has been published for severe 
asthma in 473 cases and 1,892 controls (Li et al. 2010). 
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1.6 Project Aims 
 
The overall objective of this project was to obtain a greater insight into the genetic 
determinants of two of the least understood aspects of allergic disease. Two main phenotypes 
were investigated, firstly, type I hypersensitivity in response to common environmental 
allergens i.e. atopy defined by elevated specific IgE 0.35KUA/L or positive SPT, and 
secondly, severe asthma based on GINA criteria for poor control with steps 3 or above. 
 
The aims of individual results chapters within this thesis were to: 
Chapter 3: Conduct a GWA study to attempt to identify novel atopy susceptibility genes. 
Chapter 4: Further define atopy susceptibility loci within chromosomal loci 3p22.1-q22.1 and 
17p12-q24.3 showing significance linkage for SPT response identified by the GSMA. 
Chapter 5: Use GWA to attempt to identify common variants determining susceptibility to 
severe asthma. 
Chapter 6: Evaluate the contribution within severe asthma of previously identified candidate 
genes for mild-to-moderate disease. 
Chapter 7: &KDUDFWHULVH WKH ¶ XQWUDQVOated region (UTR), establish transcription start sites 
and identify putative promoter locations for the IL1RL1 and IL33 genes. 
Chapter 8: Use re-sequencing to identify if the relative abundance of variation within the 
GWA identified loci on chromosome 2q12 and 9p24.1 determine susceptibility to severe 
asthma. 
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Chapter 2 
Materials and Methods 
 
2.1 Study Populations and Phenotyping 
 
2.1.1 Atopy Analyses 
Studies of atopy in Chapters 3 and 4 involved conducting a primary genome-wide association 
(GWA) study in the British 1958 Birth Cohort. Replication of loci identified for association 
was performed using both in silico replication (utilising directly genotyped or imputed SNPs) 
in the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort and by prospective 
genotyping in the Nottingham Gedling and Southampton cohorts. In Chapter 4, in silico 
replication was also carried out in the deCODE Icelandic cohort. Demographic data for these 
population cohorts are summarised in Table 2.1 and key details summarised in the following 
text. 
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Table 2.1 Study populations used in atopy analyses. 
Discovery  
Study cohort N total N 
male 
N 
female 
Mean age, 
years (SD) 
Median total IgE, 
kUA/L (Range) 
Atopy marker N 
case 
N 
control 
SNP Array 
British 1958 Birth 
Cohort D1 
1,428 Data unavailable Elevated specific IgE 
N8A/L 
388 1,040 Illumina HumanHap500, 
Affymetrix Human Mapping 500K 
British 1958 Birth 
Cohort D2 
3,853 1,889 1,964 45.2 (0.4) 27 (0-1281) Elevated specific IgE 
N8A/L 
1,083 2,770 Illumina HumanHap500 
Replication in silico 
Study cohort N total N 
male 
N 
female 
Mean age, 
years 
Median total IgE, 
kUA/L (Range) 
Atopy marker N 
case 
N 
control 
SNP Array 
ALSPAC 1,324 642 682 7.5 22 (0.7-99.8) 3RVLWLYH637PP 282 1,042 Illumina HumanHap300 
deCODE 28,058 Data unavailable Positive S37PPRU
of histamine-positive control 
908 27,150 Illumina HumanHap300 
Replication genotyping 
Study cohort N total N 
male 
N 
female 
Mean age, 
years, (SD) 
Median total IgE, 
kUA/L (Range) 
Atopy marker N 
case 
N 
control 
SNP Array 
Nottingham Gedling 1,268 635 633 56.2 (12.3) 22.9 (0-2000) 3RVLWLYH637PP 394 831 KBiosciences 
Southampton 682 339 343 42.3 9.7 (0-39893.5) Elevated specific IgE 
>0.35kUA/L 
295 381 KBiosciences 
Positive SPT >3mm 382 294 
Total n available for pooled analyses 
Phenotype N total  N 
case 
N 
control 
 
Elevated specific IgE 4,529  1,378 3,151  
Positive SPT 31,283  1,966 29,317  
Serum total IgE levels 7,276  
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2.1.1.1 The British 1958 Birth Cohort 
The British 1958 Birth Cohort is a longitudinal study of 18,558 individuals born during one 
week in March 1958 across the UK. Follow up at ages 7, 11, 16, 23, 33, and 42 years were 
conducted using parental interviews, school medical examinations, and individual interviews 
(Power et al. 2006). Protocols for the 2002 to 2004 biomedical examination were approved by 
the South East MultiCentre Research Ethics Committee. Written consent to participate in 
genetic association studies was given by all participants. DNA was obtained from 7,703 
singletons of Caucasian ethnicity during 2002 to 2004. Phenotype data at age 44 to 45 years 
were collected for specific immunoglobulin E (IgE) levels in response to house dust mite, 
mixed grass or cat fur measured with Hytec enzyme immunoassay as well as serum total IgE 
levels (Hycor Biomedical, Irvine, CA, USA). Analyses included 1,083 cases defined by 
HOHYDWHGVSHFLILF,J(N8A/L to one or more allergens and 2,770 controls. Serum total IgE 
level (loge transformed) analyses were carried out in 3,873 individuals. 
 
2.1.1.2 The ALSPAC Cohort 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective birth cohort 
study of 14,000 infants born between 1st April 1991 and 31st December 1992 from mothers 
residing within the three Bristol-based health districts to study determinants of health, 
behaviour and development. Ethics approval was granted from the ALSPAC Law and Ethics 
Committee and Local Research Ethics Committees. Informed consent was obtained from all 
study participants (Roberts et al. 2005). DNA was extracted from approximately 70% of 
children using a number of commercial extraction methods. Skin prick testing at the age of 7.5 
years was carried out using a panel of six allergens: house dust mite, mixed grass, cat fur, 
mixed nuts, peanut, and milk. Atopy was defined by a positive skin prick test (SPT) with a 
mean whHDOGLDPHWHURIPPWRRQHRUPRUHRIKRXVHGXVWPLWH, mixed grass, and cat fur. A 
total of 282 cases and 1,042 controls with genotype data were included in analyses. Serum IgE 
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2.1.1.3 The deCODE Icelandic Population 
The deCODE Icelandic cohort was compiled by cross-matching patient records between 1977 
to 2001 from the Department of Allergy and Pulmonary Medicine, National University 
Hospital of Iceland with a genealogy database of the entire Icelandic nation. Informed consent 
was obtained from all patients, and ethics approval granted by the Icelandic Data protection 
Commision and the National Bioethics Committee of Iceland (Hakonarson et al. 2001). A 
biobank of 100,000 genetic samples was created for participation in GWA studies of various 
disease projects at deCODE Genetics. Atopic individuals related to at least one other patient 
within and including six meiotic events were selected as cases. Atopy was defined by positive 
SPT measured by a wheal diameter PPRURIWKHKLVWDPLQH-positive control response 
to 12 aeroallergens: birch, grass, Rumex crispus, cat, dog, horse, Cladosporium, Mucor, 
Alternaria, house dust mite (Der p 1), house dust mite (Der f 1), and Lepidoglyphus destructor 
(Greer Laboratories, Lenoir, NC, USA) identifying 908 cases. A sub-group of 239 non-
asthmatic, atopic case individuals were identified. The 27,150 general population controls used 
in this study consisted of individuals from other ongoing GWA studies at deCODE. 
 
2.1.1.4 The Nottingham Gedling Cohort 
The Nottingham Gedling cohort was collected in January 1991 from the general population, 
through a systematic sample of 2,633 adults (age 18 to 70 years) living in Nottingham, UK for 
participation in a cross-sectional study of the relationship between diet, asthma, and chronic 
obstructive pulmonary disease. Ethical approval was granted by the Nottingham City Hospital 
and Nottingham University Ethics Committee boards, and written consent was obtained from 
all subjects (McKeever et al. 2002). DNA was extracted using a Genomic DNA Maxi-Prep kit 
(Qiagen, Crawley, UK). Skin prick testing to the three common allergens: house dust mite, 
grass pollen, and cat fur was performed, with concomitant saline and histamine controls 
(Bencard, Brentford, UK). The response to each allergen was measured as the mean of two 
perpendicular diameters of the wheal, excluding flares and pseudopods. Analyses were carried 
out in 1,286 individuals for whom blood samples for DNA extraction were available. Atopy 
ZDVGHILQHGDVDPHDQZKHDOGLDPHWHUPPWKDQWKHVDOLQHFRQWUROUHVXOWLQJLQFDVHVDQG
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822 controls. Serum total IgE levels were measured by enzyme linked immunosorbent assay 
(ELISA) in 1,293 individuals. 
 
2.1.1.5 The Southampton Cohort 
The Southampton cohort consists of a subset of non-related adult individuals (parents only) 
from the Southampton Asthma Families cohort. The Southampton Asthma Families cohort 
comprises 341 Caucasian families recruited from the Southampton area with at least two 
biological siblings (ages 5 to 21 years) with a current physician diagnosis of asthma taking 
regular asthma medication. Ethics approval was obtained from the Southampton and South 
West Hampshire joint ethics committee, written consent was obtained from all subjects (Sayers 
et al. 2003). DNA was extracted from whole blood using a Genomic DNA Maxi-Prep kit 
(Qiagen, Crawley, UK). Serum specific IgE level and total IgE level data were determined by 
radio allergosorbent test (RAST) to response to house dust mite, grass, cat, dog, Alternaria, 
and tree allergens. Skin prick testing was also completed for the same common allergens. 
Analyses were carried out using data from 757 non-related adult individuals (parents only) 
classified into 295 cases and 381 controls using atopy defined by elevated specific IgE levels 
>0.35kUA/L or 382 cases and 294 controls using atopy defined by positive SPT with >3mm 
wheal diameter to one or more allergens. Serum total IgE levels were measured by ELISA in 
675 individuals. 
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2.1.2 Asthma Analyses 
Studies of severe asthma in Chapters 5, 6, and 8 involved conducting a primary GWA study as 
part of the Asthma UK Genetics of Severe Asthma (AUGOSA) study. In Chapter 5, 
subsequent in silico replication was carried out for SNPs of interest in the Australian Asthma 
Genetics Consortium (AAGC) study. Demographic data for these population cohorts are 
summarised in Table 2.2. A subset of individuals from the Nottingham Gedling cohort was 
also used for targeted re-sequencing in Chapter 8, described previously in Section 2.1.1.4. 
 
Table 2.2 ± Study populations used for severe asthma analyses. * Sex was unspecified for 
one individual within AUGOSA and six within GABRIEL Severe. 
Discovery 
Study cohort N total N 
male 
N 
female 
Mean age, 
years, (SD) 
SNP Array 
Cases 
AUGOSA 682* 226 455 46 (13.9) Illumina HumanHap610-Quad, 
Illumina HumanHap660w-Quad 
GABRIEL Severe 344* 133 205 43 (17.8) Illumina HumanHap660w-Quad 
Controls 
Busselton 576 245 331 58 (15.7) Illumina HumanHap550 
WTCCC2 1,483 753 730 45 (0.4) Illumina Human1M-duo v3 
T1DGC 1,313 640 673 45 (0.3) Illumina HumanHap660w-Quad 
Total n available for analysis 
Cases 1,026 
Controls 3,372 
Replication in silico 
Study N total N 
male 
N 
female 
Mean age, 
years, (SD) 
SNP Array 
AAGC Cases 231 90 141 51 (16.3) Illumina HumanHap610-Quad 
Controls 1,345 530 815 32 (15.0) Illumina HumanHap610-Quad 
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2.1.2.1 The Asthma UK Genetics of Severe Asthma (AUGOSA) Study 
 
Severe Asthma Cases 
The Asthma UK Genetics of Severe Asthma (AUGOSA) study consisted of 682 cases with 
severe asthma collected from eight centres across the UK by the AUGOSA Consortium and an 
additional 344 cases collected by the Multidisciplinary Study to Identify the Genetic and 
Environmental Causes of Asthma in the European Community (GABRIEL) Consortium. 
 
Cases recruited by the AUGOSA Consortium were 682 individuals of European ancestry with 
severe asthma classified as steps 3 or above based on the Global Initiative for Asthma (GINA) 
criteria, recruited across eight UK-based centres: Nottingham QMC, Nottingham City Hospital, 
Belfast, Birmingham, Glasgow, Leicester, Manchester, and Southampton. Written consent was 
obtained and ethics approval granted by the Nottingham QMC Hospital, City Hospital and 
Nottingham University Ethics Committee boards. DNA extraction was carried out by phenol 
extraction at Centre National de Génotypage (Paris, France). Using GINA criteria, individuals 
were classified with step 3 severe asthma if they suffered from daily asthma attacks affecting 
activity or nocturnal symptoms more than once a week. Individuals were classified with step 4 
severe asthma if they suffered from continuous symptoms limiting physical activity or frequent 
symptoms at night (Bateman et al. 2008). FEV1 or PEF is 60% to 80% predicted for patients in 
step 3 and less than 60% in step 4, FEV1 or PEF variability is greater than 30% for both 
groups. Patients in GINA step 5 were prescribed maintenance oral gluco-corticosteroids. 
 
The GABRIEL Consortium is a collection of over 40,000 European cases and population-
matched controls obtained from 23 different studies aimed to identify determinants of asthma. 
All participants or their parents provided signed informed consent to participate in the study, 
and ethics approval obtained by corresponding local committees (Moffatt et al. 2010). DNA 
extraction was carried out by each individual centre. Asthma was determined using physician 
diagnosis and sub-group analyses carried out for (i) age-of-onset at 16 years or older, (ii) cases 
with unknown age of onset, (iii) occupational asthma or (iv) severe asthma. Individuals with 
severe asthma were recruited from three specialist asthma clinics; adult and childhood clinics 
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based at the Royal Brompton Hospital, London and an adult clinic at the Glenfield Hospital, 
Leicester. A total of 344 subjects were included in analyses defined using combinations of 
ATS and ERS criteria, as well as specialised protocols involving parameters of airway 
inflammation, airway physiology, quality of life, and control of symptoms (Bacharier et al. 
2008; Stanojevic et al. 2008). ATS definitions are based on reduced peak flows and responses 
to corticosteroids, chronic airflow limitation, and rapidly progressive loss of lung function 
(ATS 2000). ERS definitions are based on poor symptomatic control, episodic exacerbations, 
persistent and variable airways obstruction in addition to requirement for ȕ2-agonists and oral 
gluco-corticosteroids (Chung et al. 1999). For clarity, these subjects will be referred to as 
GABRIEL Severe cases in order to distinguish them from the complete case population used in 
the published GABRIEL study totalling 10,365 individuals (Moffatt et al. 2010). 
 
General Population Controls  
A total of 3,353 control subjects without history of asthma or wheeze were collected from the 
UK and Western Australia, all of whom were of European ancestry. This consisted of 564 
individuals collected by the Busselton Health Study, 1,483 individuals collected by the 
Wellcome Trust Case-Control Consortium Phase 2 (WTCCC2), and 1,299 individuals 
collected by the Type 1 Diabetes Genetics Consortium (T1DGC). 
 
The Busselton Health Study consists of residents from the town of Busselton in the south-west 
of Western Australia who have been involved in a series of cross-sectional, whole-population 
health surveys since 1966 for studies of common diseases, primarily cardiovascular and 
respiratory and their relationships to risk factors, lifestyle, and environmental variables. 
Informed written consent for participation and subsequent use of data was obtained from 
participants at the time of the survey. Ethics approval was obtained from the University of 
Western Australia Human Research Ethics Committee (James et al. 2010). DNA from each 
subject was extracted using phenol/chloroform extraction and ethanol precipitation. Controls 
wHUHGHILQHGDVWKRVHZKRKDYHFRQVLVWHQWO\DQVZHUHGµ1R¶WRµ+DV\RXUGRFWRUHYHUWROG\RX
WKDW\RXKDGDVWKPD"¶DWDOOSUHYLRXVVXUYH\VWKDWWKH\KDYHDWWHQGHGIURPWR
non-asthmatic, non-wheeze individuals were included in analyses. 
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The WTCCC2 involved 15 WTCCC collaborative studies and 12 independent studies totalling 
approximately 120,000 samples established in April 2008 with the aim of performing GWA 
studies in 13 disease conditions. Both patients and family members gave written consent for 
the use of their DNA for research within the laboratory. Ethics approval was granted by the 
Multi-Centre Research Ethics Committee (MREC) (Wellcome Trust Case Control Consortium 
2007). DNA was extracted from EDTA-venous blood samples using conventional salt lysis 
methodologies. Control subjects consisted of 6,000 common controls from WTCCC, an 
additional 3,000 from the British 1958 Birth Cohort, and 3,000 from the UK Blood Service 
Collection, of which, 1,483 non-asthmatic, non-wheeze control individuals were included in 
analyses. 
 
The T1DGC is an international, multicenter program organised to promote research to identify 
genes and alleles determining risk of susceptibility to Type 1 Diabetes. Written informed 
consent was obtained for all individuals involved in the study and ethics approval granted by 
HDFKLQVWLWXWLRQ¶V,QWHUQDO5HYLHZ%RDUG,5%RU(WKLFV&RPPLttee at each clinic (Barrett et 
al. 2009). DNA extraction was carried out using variations of the salting out and chloroform 
methods. Cases and trio families (one child with diabetes and both biological parents) were 
collected across multiple ethnicities. Controls were defined as individuals without type 1 
diabetes and recruited from matched populations. A total of 1,313 non-asthmatic, non-wheeze 
control individuals of Caucasian ethnicity were identified for inclusion in analyses. 
 
2.1.2.2 The Australian Asthma Genetics Consortium (AAGC) Study 
The Australian Asthma Genetics Consortium (AAGC) was established in 2009 with the aim of 
identifying genetic causes underlying asthma through analysis of whole-genome genetic data 
from 7,197 unrelated individuals of European ancestry. Study subjects were recruited from 
eight independent cohorts by six participating institutions across Australia. Ethics approval and 
informed consent were obtained by individual centres. DNA extraction was carried out using 
variations of the salting out and chloroform methods (Ferreira et al. 2011). Case individuals 
with severe asthma were recruited by the Lung Institute of Western Australia (LIWA) and 
defined as those with a physician diagnosis of asthma receiving medication inclusive of inhaled 
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gluco-corticosteroids ,&6 µg in combination with a long-acting ȕ2-agonist. Non-
asthmatic control subjects were recruited through the LIWA (n=35) and the Queensland 
Institute of Medical Research (QIMR) studies (n=1,310). In the replication study, a total of 231 
cases and 1,345 controls were included in analyses. 
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2.2 Genotyping and Sequencing 
 
2.2.1 Genome-Wide SNP Genotyping 
Analysis of genotype data from individuals included in study cohorts were generated primarily 
using DNA microarray technology through genome-wide genotyping. Single nucleotide 
polymorphisms (SNPs) were tested across the whole genome from each DNA sample using 
fluorescence based allele calling and probes covalently bound to a chemical matrix (Gruber et 
al. 2002). Assays with varying density of SNP coverage used in analyses were designed by the 
Illumina (San Diego, USA) and Affymetrix (Santa Clara, USA) genotyping laboratories.  
 
Illumina utilise single-base extension with labelled bases on 50-mer oligonucleotide probes 
(one per SNP) designed almost entirely on the International HapMap Project tagging SNPs on 
coded microscopic beads (BeadArrary). Affymetrix employ differential hybridisation with 25-
mer oligonucleotide probes (4 to 5 replicates per allele) designed using 50% HapMap tagging 
SNPs in combination with unbiased SNPs covering the whole genome on spatially arranged 
solid glass or silicon surfaces (GeneChip). Features of genome-wide SNP platforms used in 
genotyping of cohorts used in this thesis are detailed in Table 2.3. Genotype calls were made 
using the Illuminus and Bayesian Robust Linear Model with Mahalanobis distance classifier 
(BRLMM) calling algorithms for the Illumina and Affymetrix platforms respectively. 
49 
Table 2.3 ± SNP Genotyping Arrays designed by Illumina and Affymetrix used in analyses. CEU denotes European ancestry in Utah, MHC denotes major 
histocompatibility complex, CNVs denotes copy number variants. 
Genotyping 
laboratory 
Array name Number of SNPs tested Average coverage 
Illumina HumanHap300 >317,000 HapMap Phase 1 tag SNPs 
7,300 non-synonymous SNPs 
Additional tag SNPs in the MHC region, regions with CNVs, mitochondrial SNPs 
1 SNP per 9kb across 
the genome (CEU) 
Illumina HumanHap550 ~550,000 HapMap release 20 tag SNPs 
7,800 non-synonymous SNPs 
Additional tag SNPs in the MHC region, regions with CNVs, mitochondrial SNPs 
1 SNP per 5.5kb across 
the genome (CEU) 
Illumina HumanHap610-Quad 620,901 SNPs HapMap release 23 tag SNPs 
7,577 non-synonymous SNPs 
Additional tag SNPs in the MHC region, regions with CNVs, mitochondrial SNPs 
1 SNP per 4.7kb across 
the genome 
Illumina HumanHap660w-Quad 657,366 SNPs HapMap release 24 tag SNPs 
10,051 non-synonymous SNPs 
Additional tag SNPs in the MHC region, regions with CNVs, mitochondrial SNPs  
1 SNP per 4.4kb across 
the genome (CEU) 
Illumina Human1M-duo v3 1,199,187 SNPs HapMap release 23 tag SNPs 
21,877 non-synonymous SNPs 
Additional tag SNPs in the MHC region, regions with CNVs, mitochondrial SNPs 
1 SNP per 2.4kb across 
the genome (CEU) 
Affymetrix Human Mapping 500K ~262,200 (Nsp I restriction enzyme) 
~238,000 (Sty I restriction enzyme) 
1 SNP per 5.8kb across 
the genome 
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2.2.1.1 Atopy Analyses 
Genome-wide genotyping of the British 1958 Birth Cohort, the ALSPAC cohort, and the 
deCODE Icelandic population cohort used in atopy analyses were undertaken independently by 
collaborating study centres. Genotyping procedures and quality control measures carried out 
prior to association testing are summarised and described below. 
 
The British 1958 Birth Cohort 
Individuals from the British 1958 Birth Cohort were genotyped using the Illumina Infinium 
HumanHap550 SNP BeadChip. SNPs with minor allele frequency (MAF) <1% or p<10(-7) 
following tests for Hardy-Weinberg equilibrium (HWE) as well as individuals of non-
European ancestry or displaying high levels of missing genotypes or heterozygosity were 
excluded from further analyses. A total of 459,334 autosomal SNPs passed all quality control 
measures. Analyses included 3,853 individuals with results of association testing with specific 
IgE data and 3,873 individuals with results of association testing with serum total IgE level 
data. In addition, the Affymetrix GeneChip Human Mapping 500K Array was also used to 
genotype a subset of 1,468 individuals with the same quality control measures applied as 
above. 
 
The ALSPAC Cohort 
Individuals from the ALSPAC Cohort were genotyped using the Illumina HumanHap300 SNP 
chip. SNPs with MAF <1%, >5% missing genotypes or failed an exact test of HWE with 
p<5x10(-7) were excluded from further analyses. After quality control, 315,807 autosomal SNPs 
were left in analyses. Individuals of non-European ancestry or who displayed high levels of 
missing genotypes or heterozygosity were also excluded. Analyses were carried out in 1,324 
individuals with results of association testing with SPT data and 1,423 individuals with results 
of association testing with serum total IgE level data. 
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The deCODE Icelandic Population 
Individuals from the deCODE Icelandic Population were genotyped using the Illumina 
HumanHap300 SNP chip. Exclusion of SNPs with MAF <1% or deviated from HWE with 
p<10(-10) and individuals with non-European ancestry or who displayed high levels of missing 
genotypes or heterozygosity was carried out. A total of 312,179 autosomal SNPs were tested 
following quality control. Analyses included 28,140 individuals with results of association 
testing using SPT data. 
 
2.2.1.2 Asthma Analyses 
Genotyping of severe asthma cases recruited by both the AUGOSA study and the GABRIEL 
Consortium were carried out by Centre National de Génotypage (Paris, France). Controls had 
previously been genotyped independently by the relevant centres. Genotype data for all 
individuals in the AUGOSA study were combined prior to applying quality control measures. 
This work was carried out as part of this thesis; details of methods used for quality control are 
described in detail in Chapter 5. Procedures for genome-wide genotyping undertaken by the 
AAGC study and quality control measures carried out prior to association testing are described 
below. 
 
The AUGOSA Study 
Case subjects recruited by the AUGOSA Consortium were genotyped using the Illumina 
HumanHap610-Quad SNP BeadChip for 121 individuals and the Illumina HumanHap660w 
SNP BeadChip for 561 individuals. All 344 subjects recruited by the GABRIEL Consortium 
were genotyped using the Illumina HumanHap660w SNP BeadChip. Controls subjects were 
genotyped using the Illumina HumanHap610-Quad SNP BeadChip for all 576 individuals from 
the Busselton Health Study, the Illumina Human1M-duo SNP Beadship for all 1,483 
individuals from the WTCCC2, and the Illumina HumanHap550 SNP BeadChip for all 1,313 
individuals from the T1DGC. This resulted in six groups of individuals for genotyping. 
Individuals with <90% of SNPs called were excluded and SNPs were excluded if they had low 
call rates (proportion of genotypes called <90%), were not in HWE (p<10(-4)), had a low MAF 
<1% or with differential missingness between cases and controls (p<10-6)). Any SNPs not 
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present in all genotyping platforms used were excluded resulting in a total of 490,303 
autosomal SNPs. This led to 9,414 SNPs being excluded leaving 480,889 SNPs in the analysis 
carried out in 1,026 cases and 3,372 controls remaining after genotyping quality control. An 
additional 119 individuals were excluded following principal components analysis (PCA) for 
underlying population structure leaving 933 cases and 3,346 controls (see Chapter 5 for 
details). 
 
The AGGC Study 
Individuals from the AGGC study cohort were genotyped using the Illumina HumanHap610-
Quad SNP BeadChip. Quality control measures were carried out to remove SNPs with MAF 
<1%, >5% missing genotypes or failed an exact test of HWE with p<10(-6). Replication 
analyses were carried out in 231 severe asthma cases and 1,345 controls. 
 
2.2.2 Direct SNP Genotyping (Atopy Analyses) 
Prospective genotyping of selected SNPs in Chapters 3 and 4 atopy analyses was carried out in 
the Nottingham Gedling (1,286 individuals) and Southampton cohorts (757 individuals) by 
KBioscience (Hoddesdon, UK). The KBioscience Competitive Allele-Specific Polymerase 
Chain Reaction (KASP) genotyping system uses two allele-specific primers with interacting 
ROLJRV ODEHOOHG DW WKH ¶ HQG ZLWK )$0 RU &$/ )OXRU 2UDQJH  IRU DOWHUQDWH DOOHOHV
&RPSOHPHQWDU\ ROLJRV ZLWK ¶ TXHQFKHUV SUHYHQW IOXRUHVFHQFH VLJQDO JHQHUDWLRQ XQWLO WKH
corresponding fluor-labelled oligo corresponding to the amplified allele gets incorporated into 
the template. This occurs during polymerase chain reaction (PCR) when the allele-specific 
primer becomes incorporated into the template. 
 
Direct SNP Genotyping Quality Control 
Genotyping quality control measures were carried out including positive and negative control 
samples. Individuals with <90% of SNPs called were excluded as well as SNPs based on low 
FDOO UDWHV  JHQRW\SHV FDOOHG ORZ 0$)  RU QRW LQ +:( S *HQRW\SH
calling was carried out using software SNPviewer2 [Figure 2.1]. 
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Figure 2.1 - Genotyping calling using SNPviewer2 for genotyped SNPs in atopy analyses. The x and y axis represent scales of the intensity of fluorescence detected. 
Example screenshots: A) rs10164255 showing clear clustering into TT (red), TG (green) and GG (blue). The non-template control (black) is also identified; one anomaly 
(pink) can be seen. B) rs6561505 show greater variation of data within each cluster and four anomalies. Only genotypes classed as homozygotes (red or green) and 
heterozygotes (blue) were included in analyses. 
A B 
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2.2.3 Targeted Re-sequencing (Asthma Analyses) 
Two identified loci in severe asthma analyses were re-sequenced in a subset of cases from the 
AUGOSA study (200 individuals) and a subset of controls from the Nottingham Gedling 
cohort (200 non-asthmatic, non-wheeze, non-atopic individuals) by SourceBioscience 
(Nottingham, UK). Individual DNA samples were sheared and target sequence enrichment 
carried out using 120bp oligos. Cases and controls were then each split into three indexed 
pools consisting of 66, 66, and 68 individuals. Paired-end sequencing using 100bp reads for 
cases and controls was run on two separate lanes using the Illumina HiSeq 2000 Systems by 
fluorescence-based reversible terminator technology. Principles and methodology used are 
described in detail in Chapter 8. 
 
2.2.4 Dye Terminator Sequencing 
Dye terminator sequencing was carried out to verify products of candidate gene expression in 
&KDSWHUVDQGDVZHOODVWRVHTXHQFHLQVHUWUHJLRQVRI'1$SODVPLGVSURGXFHGE\¶UDSLG
DPSOLILFDWLRQRIF'1$HQGV ¶5$&( LQ&KDSWHU7KH%Lg Dye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, Cat. No. 4337456) was used containing enzymes and 
dNTPs labelled with fluorescent markers allowing fragments ending at every base pair of the 
sequence to be produced by the PCR reaction. DNA sequencing is a form of PCR with DNA 
synthesis in the presence of dNTPs and dideoxynucleoside triphosphates (ddNTPs) in a ratio of 
([WHQVLRQRI WKH'1$SRO\PHUDVHGXULQJ'1$V\QWKHVLV UHTXLUHVD¶K\GUR[\O8VLQJ
the Sanger chain termination method, fluorophore labelled ddNTPs lacking hydroxyl groups 
were added to terminate DNA synthesis during the reaction. At the end of the reaction, 
polyacrylamide gel electrophoresis was used to separate each terminated strand and the DNA 
sequence to be read by the position of bands in the gel. Automated sequencing was carried out 
in the School of Biomedical Sciences, University of Nottingham.  
 
Thermal Cycle Sequencing 
Samples were prepared by setting up reactions as follows and amplified using a heated lid PCR 
machine (25 cycles: 96°C for 30 seconds, 50°C for 15 seconds, 60°C for 4 minutes; 4°C 
pause): 
55 
DNA samples   3ȝl 
Primer (10pM/ȝl)  1ȝl 
2x Sequencing Buffer  ȝO 
Big Dye version 3.1  ȝO 
DEPC Water   WRȝO 
 
Ethanol Precipitation 
Samples were precipitated at URRPWHPSHUDWXUHIRUPLQXWHVE\WKHDGGLWLRQRIȝO
(WKDQRO ȝO 6RGLXP $FHWDWH, DQG ȝO ZDWHU EHIRUH FHQWULIXJDWLRQ DW USP IRU 
VHFRQGV7KHVXSHUQDWDQWZDV UHPRYHGDQGUHVXOWLQJSHOOHWZDVKHG ZLWKȝO(WKDQRO
before centrifugation for 10 minutes. The ethanol was then removed and pellet dried at 72°C 
by placing the tubes with lids open in a PCR machine. 
 
Sequencing Reaction and Analysis 
Sequence data produced by laser radiation were recorded using an ABI PRISM® 310 Genetic 
Analyser (Applied Biosystems). Samples were run in the sequencing machines on a sequencing 
gel or column. Isolated DNA fragments were separated according to size by capillary gel 
electrophoresis.  Each fluorescent peak detected corresponded to a particular base in the 
sequence. Data in the form of sequence chromatogram files and sequence data files were 
analysed with Chromas Lite 2.01 software (www.technelysium.com/auy/chromas_lite.html) 
(see Chapters 3, 4, and 7 for details). 
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2.3 Bioinformatics 
 
A range of bioinformatics techniques have been used to carry out in silico work using online 
sequence databases, search engines, and genetic analysis software. URLs for online resources 
are listed in Appendix 1. 
 
2.3.1 Online Resources 
Genome sequence and polymorphism information were obtained from NCBI (dbSNP, 
Nucleotide, Gene), the UCSC Genome Browser, Ensembl, and the 1000 Genomes Project. 
Data from both genome releases NCBI Build 36.1 (release date March 2006) and Genome 
Reference Consortium GRCh37 (release date February 2009) were used. 
 
Haplotype data for the CEU (Utah residents with ancestry from northern and western Europe) 
population panel was obtained from the International HapMap Project using HapMap3 
Genome Browser release #2 (Phase 3 - genotypes, frequencies & LD). Searches based on the 
genomic regions of interest were carried out to generate phased haplotype display images (see 
Chapter 4 for details). The SNAP pairwise LD program (Broad Institute) was used to process 
HapMap3 data for individual SNPs throughout this thesis; search options were based on 
distance limits of 500bp and no limits for the r2 threshold. 
 
3&5VXLWDELOLW\RISULPHUVGHVLJQHGIRUJHQHH[SUHVVLRQDQG¶5$&(ZHUHDVVHVVHGXVLQJthe 
web-based tool PCR Primer Stats by detecting the presence of undesirable internal secondary 
structures such as palindromes, self-annealing bases, and hair-pins. Pass/fail/warning values 
were generated based on single base runs, dinucleotide base runs, % GC, melting temperature, 
GC clamp, self-annealing, and hairpin formation. PCR products were compared to reference 
sequences using search tool BLAST (NCBI) (see Chapters 3, 4, and 7 for details). 
 
Transcription factor analyses were carried out using four search tools: WWW Signal Scan 
TFD, WWW Signal Scan TRANSFAC, Transcription Element Search System (TESS), and 
TFSEARCH. Protein information for IL1RL1 and IL33 was obtained using protein sequence 
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database UniProtKB/Swiss-Prot. Protein prediction was carried out using analysis tool 
EMBOSS Transeq (EMBL-(%,E\HQWHULQJQXFOHRWLGHVHTXHQFHVRILQWHUHVWGHWHFWHGXVLQJ¶
UDSLGDPSOLILFDWLRQRIF'1$HQGV¶5$&( (Rice et al. 2000). Procedures for transcription 
factor and protein sequence analyses are described in detail in Chapter 7. 
 
 2.3.2 Genetics Analysis Software 
A number of open-source command line programs were downloaded and run using the UNIX 
operating system. Principal components analysis (PCA) was carried out using EIGENSOFT 
3.0 (Patterson et al. 2006). Haplotype phasing was carried out using MACH 1.0 (Li and 
Abecasis 2006) and subsequent imputation using minimac 
(http://genome.sph.umich.edu/wiki/Minimac). Genome-wide association analysis quality 
control and association testing for genotype data was carried out using PLINK 1.07 (Purcell et 
al. 2007). Association testing for imputed data was carried out using ProbABEL 0.1-3 
(Aulchenko et al. 2010). Detailed methods for PCA, imputation, and association testing are 
described in Chapter 5. MeffLi variables were calculated using SNPSpD 
(http://gump.qimr.edu.au/general/daleN/SNPSpD/) (see Chapter 6 for details). 
 
Power calculations were estimated using CaTS 0.0.2; estimation parameters used were based 
on the sample sizes and disease prevalence of tested population cohorts under an allele additive 
model, detailed in the relevant results chapters (Skol et al. 2006). Region plots were generated 
using the online graphical tool LocusZoom.1.1 (Pruim et al.). General statistical analyses were 
carried out using R version 2.12.1, Microsoft Excel 2007, SPSS 15.0 for Windows, and 
STATA/SE 10.1 for Windows. Manhattan and Quantile-quantile (Q-Q) plots were also 
generated using scripts written in R version 2.12.1. 
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2.4 Statistical Analyses 
 
A range of statistical methods have been used to analyse genotype data in the stages of quality 
control, association testing, and analysis of results. The principles behind these analyses are 
explained below. Procedural details are given in the relevant results chapters. 
 
2.4.1 Principal Components Analysis (PCA) 
Principal components analysis (PCA) of study populations was carried out to correct for 
population substructure in severe asthma analyses based on the covariance of effect allele 
loadings (0, 1, 2) using EIGENSOFT 3.0 (Price et al. 2006). PCA converts the set of 
observations of potentially correlated variables into a set of values of uncorrelated variables 
called principal components, less than or equal to the number of the original variables. The first 
principal component is defined to maximise variance between individuals, subsequent 
components in turn maximise remaining variance under the constraint of being orthogonal i.e. 
uncorrelated with the preceding components. Individuals with very different locations on a 
principal component may have very different ancestry proportions; outliers were defined with 
varianceV!ı 
 
2.4.2 Association Testing 
SNP association testing was carried out using an allele additive model to carry out per-allele 
tests given no presumptions about the underlying disease mechanisms. A number of statistical 
tests based on a range of probability distributions were used in analyses. 
 
2.4.2.1 Degrees of Freedom 
The degrees of freedom of each test describe the number of components that need to be known 
before the vector is fully determined. In general, this is equal to the number of independent 
scores included in the estimate of a parameter minus the number of parameters estimated as 
intermediate steps. 
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2.4.2.2 3HDUVRQ¶V&KL-VTXDUHGȤ2) Test 
7KH 3HDUVRQ¶V &KL-VTXDUHG Ȥ2) test carried out in MS Excel 2007 was used to compare 
elevated specific IgE and positive SPT case control status between alleles by comparing 
observed versus expected frequencies computed under the null hypothesis of independence. 
Quality control tests of SNP MAF and HWE in atopy analyses were also carried out using this 
test. The test statistic X2 Ȉ2-E)2/E) was calculated by the sum of the squared differences 
between the observed and expected frequencies [Table 2.5]. 
 
Table 2.5 ± Cross-tabulation of allele frequencies in case control analyses 
Frequencies Observed (O) Expected (E) 
Case Control Case Control 
Minor allele a b (a+b)(a+c)/(a+b+c+d) (a+b)(b+d)/(a+b+c+d) 
Major allele c d (c+d)(a+c)/(a+b+c+d) (c+d)(b+d)/(a+b+c+d) 
 
The p value and standard deviation (SD) were calculated by comparing X2 to a Ȥ2 distribution 
with one GHJUHHRI IUHHGRP7KHȤ2 distribution is based on the sum of the squared values of 
the N(0,1) distribution observations. It has a positive skew with a mean equal to the number of 
degrees of freedom; as this increases, WKH Ȥ2 curve approaches a normal distribution. Odds 
ratios (OR) with 95% confidence intervals (CI) were calculated for case control analyses of 
elevated specific IgE and positive SPT using OR=(a/b)/(c/d) and 95% CI=OR±1.96SD. 
 
)LVKHU¶V(xact Test 
)LVKHU¶VH[DFt test using PLINK 1.07 was carried out for quality control tests of SNP MAF, 
HWE, and differential missingness in severe asthma analyses by assuming fixed row and 
column totals and using the hypergeometric distribution to compute probabilities of possible 
tables conditional on these values. P values were determined by 
p=[(a+b)!(c+d)!(a+c)!(b+d)!]/(a!b!c!d!n!). This test does not rely on using approximate 
theoretical distributions and is therefore more accurate in evaluating the significance level of 
the test, especially with small numbers of observations or imbalances between cases and 
controls. 
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2.4.2.4 Linear Regression 
Linear regression using STATA/SE 10.1 was used to test association of serum total IgE with 
alleles by calculating the best-fitting regression line for the observed data through minimising 
the sum of the squares of the vertical deviations from each data point to the line. Serum total 
IgE data were loge transformed to result in a normal distribution. The equation of the straight 
line given by \ Įȕ[with constant (Į) and beta coefficient (ȕ) is used to estimate the effect 
size for trend increases per effect allele with standard error (SE). The p value was calculated by 
DVVHVVLQJ WKHWHVW VWDWLVWLF W ȕ6(ZLWKQ-2 degrees of freedom using the t distribution. The t 
distribution is similar to the N(0,1) distribution but altered by the number of degrees of 
freedom. The t distribution has a mean equal to 0; with infinite numbers of degrees of freedom, 
the distribution becomes normal. 
 
2.4.2.5 Logistic Regression 
Logistic regression using PLINK 1.07 was used to test association of severe asthma case 
control status with alleles using genotype data. ProbABEL 0.1-3 was used to test association 
using imputed data with effect allele dose on a continuous scale between 0 and 2 to reflect 
imputation uncertainty. This model is a variation of linear regression for dichotomous variables 
which fits observed data to a logit function logistic curve. The logistic function is given by 
f(z)=1/(1+e-z) with output f(z) and input z ranging from negative to positive infinity. The logit 
z Įȕ[LVWKHPHDVXUHRIWKHFRQWULEXWLRQRIWKHLQGHSHQGHQWYDULDEOH7KHOLNHOLKRRGUDWLRWHVW
was used to compare the fit of the null and the alternative models by assessing how many times 
more likely the data are using one model than the other. The test statistic D=-2ln(likelihood for 
QXOOPRGHOOLNHOLKRRG IRUDOWHUQDWLYHPRGHO ZDVDSSUR[LPDWHGXVLQJ WKHȤ2 distribution with 
one degree of freedom to calculate the p value. OR with 95% CI were calculated using 
25 (;3ȕDQG&, 256( 
 
2.4.3 Test Inflation 
7HVW LQIODWLRQ VWDWLVWLFV Ȝ ZHUH FDOFXODWHG LQ 5 YHUVLRQ  XVLQJ
Ȝ >PHGLDQȕ6(2]/[median(qchisq(0.5,1)] where qchisq(0.5,1) is the Ȥ2 distribution with one 
degree of freedom. This is equal to one under the null hypothesis. 
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2.4.4 Statistical Power 
Retrospective power analyses for GWA analyses were carried out using CaTS 0.0.2 at the 5% 
significance level to give estimates of the minimum effect sizes of polymorphisms likely to be 
detected in analyses using the available sample sizes. The power of a statistical test is given by 
one minus the false negative rate or type II error. Power increases with increasing sample size 
and decreasing study variance. 
 
2.4.5 Meta-Analysis 
Meta-analysis was used to combine results from individual studies in order to identify a 
common measure of effect size. This aimed to provide greater power in estimating the true 
effect size for this phenotype as opposed to those derived from a single study under a single set 
of assumptions and conditions. A fixed effects model with weights inversely proportionate to 
individual study variances was used based on the assumption that the true effect sizH ș LV
QRUPDOO\GLVWULEXWHGZLWKȃșıș), ZKHUHıș2 is the within study variance of the effect size. 
 
In atopy analyses, this was carried out using the metan function in STATA/SE 10.1. As all 
studies have the same expected fixed effect size using this function, between study differences 
are not considered. Therefore, tests for heterogeneity in effects across studies were carried out 
using test statistics which measured the weighted sum of the differences between k individual 
study effects and the overall estiPDWHXQGHUDȤ2 distribution with k-1 degrees of freedom. 
 
In severe asthma analyses, weights for each study (W1..n for primary AUGOSA, W2..n for 
UHSOLFDWLRQ $$*& ZHUH FDOFXODWHG LQ 06 ([FHO XVLQJ WKH HIIHFW VL]H HVWLPDWHV ȕ1..n) and 
variances (SE1..n) per SNP1..n given by 1/( SE1..n2). The results from meta-analysis were 
calculated for example for SNP1 XVLQJ ȕ1PHWD ȕ1W1ȕ2W2)/(W1+W2) and 
SE1PHWD ¥>:1+W2)]. 
 
2.4.6 Linkage Disequilibrium (LD) 
Linkage disequilibrium (LD) occurs when some combinations of alleles occur more frequently 
in a population than would be expected from a random formation of haplotypes based on the 
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frequencies of each relevant allele i.e. the non-random association of alleles at two or more 
loci. Levels of LD are influenced by factors including linkage, selection, recombination rate, 
genetic drift, non-random mating, and population structure. For a two locus, bi-allele haplotype 
model A1B1, A1B2, A2B1, A2B2 with relative frequencies x11, x12, x21, x22 respectively, allele 
frequencies are calculated using p1=x11+x12 (A1), p2=x21+x22 (A2), q1=x11+x21 (B1), q2=x12+x22 
(B2). Hence the frequency of A1B1 is given by x11=p1q1. Parameter D=x11-p1q1 constrained by 
allele frequencies measures the difference between observed and expected haplotype 
frequencies. A value of 0 denotes independence under linkage equilibrium (LE) (Lewontin 
1964). Two pairwise meaVXUHVRI/'DUHJHQHUDOO\XVHGEDVHGRQWKH'SDUDPHWHU'¶LVJLYHQ
by D/Dmax, r2 is given by D2/(p1p2q1q2DQGDGMXVWHGIRUSRSXODWLRQVL]H%RWK'¶DQGU2 give an 
indication of recombination history and range from 0 to 1 i.e. complete LE to LD, r2 can also 
be used to predict the frequency of one polymorphism given the other. 
 
2.4.7 Imputation 
Genotypes for untyped SNPs in the ALSPAC cohort, the AUGOSA study, and the AAGC 
study were inferred using imputation to allow comparison of GWA data across the multiple 
population cohorts genotyped using different platforms. This approach relies on the assumption 
that apparently unrelated individuals can share haplotypes inherited from distant common 
ancestors. Reference sample haplotypes were downloaded from the International HapMap 
Project and the 1000 Genomes Project. Selected SNPs were imputed in atopy analyses to allow 
comparison of genotypes across the platforms used. Imputation of genotyped SNPs to over 6 
million SNPs were carried out in severe asthma analyses. Imputation carried out using MACH 
1.0 Markov Chain based haplotyper for phasing and minimac for imputation. The implemented 
method uses genotyped SNPs as proxies to randomly generate a pair of haplotypes compatible 
with observed genotypes for each sample individual. These initial estimates are then refined by 
carrying out a series of 20 to 100 iterations, during which a Hidden Markov Model (HMM) 
generates a new haplotype pair for each individual and describes the haplotype pair as an 
imperfect mosaic of the other haplotypes. The probability of change in the mosaic pattern 
between every pair of consecutive markers and the probability of observing an imperfection in 
the mosaic at each specific point is measured in order to construct a consensus haplotype 
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sampled in each round. Quality measures based on r2 were calculated by estimating the squared 
correlation between imputed and true genotypes. A cut-off of r2<0.3 was used to identify the 
majority of poorly imputed SNPs whilst only excluding <1% of well imputed SNPs. 
 
2.4.8 Significance Testing 
Incorrect rejection of the null hypothesis is more likely to occur when a set of statistical 
inferences are considered simultaneously such as when testing a group of SNPs. Corrections 
for multiple testing generally require a stronger level of evidence to be observed in order for an 
individual comparison to be deemed significant, so as to compensate for the number of 
inferences being made. In addition to the use of nominal significance and evaluation for SNP 
clustering to assess statistical significance, two additional approaches were used to correct for 
multiple testing at the 5% significance level described below. 
 
2.4.8.1 Bonferroni Correction 
The Bonferroni correction is derived by observing Boole's inequality (Miller 1981). If n tests 
are performed, eaFKVLJQLILFDQWZLWKSUREDELOLW\ȕZKHUHȕLVXQNQRZQWKHQWKHSUREDELOLW\
that at least one of them comes out signiILFDQWLVQȕ,IWKHUHTXLUHGsignificance level for the 
entire VHULHVRIWHVWVLVHTXDOWRĮ by VROYLQJIRUȕȕ ĮQ7KLVFRUUHFWLRQGoes not require tests 
to be independent. 
 
2.4.8.2 MeffLi Correction 
A large number of SNPs tested exhibit linkage disequilibrium (LD) not accounted for by the 
Bonferroni correction. SNP spectral decomposition (SNP SpD) was used to calculate the 
effective number of independent variables, given by Meff=1+(M-1)(1-VarȜREV/M), to allow for 
pairwise SNP correlation (Nyholt 2004). The variance of the Eigenvalues of the correlation 
matrix of SNP alleles (VarȜREV) estimated using reference genotypes obtained from Busselton 
controls will vary from M (the total number of SNPs) when they are perfectly correlated to 0 
when there is no correlation. The resulting significance threshold was calculated using 
S Į0eff JLYHQWKHUHTXLUHGVLJQLILFDQFHOHYHOIRUWKHHQWLUHVHULHVRIWHVWVLVHTXDOWRĮ 
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2.5 Cellular and Molecular Techniques 
 
A range of techniques were used to analyse RNA and DNA for testing expression and 
sequencing of candidate genes in Chapters 3, 4, and 7. 
 
2.5.1 Cell Culture 
Sub-culture of cells sourced from consented individuals without history of allergic or 
respiratory disease was carried out and detailed in the following text. These cells were 
cryopreserved in liquid nitrogen (-179°C) using 10% dimethyl sulphoxide (DSMO, diluted 
with FCS) and routinely maintained in the Division of Therapeutics & Molecular Medicine. 
All cultured cells were incubated at 37°C in 5% CO2. Reagents for cell culture were obtained 
from Sigma-Aldrich (Dorset, UK) unless otherwise stated. All cell culture plastics were 
obtained from Corning life sciences from Fisher Scientific (Loughborough, UK). 
 
2.5.1.1 Human Airway Smooth Muscle (HASM) Cells 
Adherent, primary human airway smooth muscle (HASM) cells were obtained by colleagues 
from thoracotomy surgery and bronchial biopsies from three donors (D0501, D0401, D0502) 
(Daykin et al. 1993)&HOOVZHUHFXOWXUHGLQ'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXP'0(0
containing 2mM glutamine from Sigma-Aldrich (Dorset, UK), supplemented with 10% FCS. 
Cells were utilised between passages 3 and 5. 
 
2.5.1.2 Human Bronchial Epithelial Cells (HBECs) 
Adherent, undifferentiated human bronchial epithelial cells (HBECs) sourced from 3 donors 
(5F0750, 4F0507, 7F3158) were purchased from Clonetics-%LRZKLWWDNHU0'86$&HOOV
were cultured in bronchial epithelial cell basal medium (BEGM) from Lonza (Berkshire, UK) 
VXSSOHPHQWHGZLWKȝJPOERYLQHSLWXLWDU\H[WUDFW%3(ȝJPOK\GURFRUWLVRQHȝJPO
human recombinant EGF K(*) QJPO HSLQHSKULQH ȝJPO LQVXOLQ QJPO
WULLRGRWK\URQLQHȝJPOWUDQVIHUULQȝJPOJentamicin, and ȝJPODPSKRWHULFLQ-B. Cells 
were utilised at passage 3 until 80% to 90% confluency. 
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2.5.1.3 Dermal Fibroblast Cells 
Flasks of confluent dermal fibroblast cells from two donors (6C193 at passage 8, C240209 at 
passage 5) were provided by Dr. Christine Pullar, University of Leicester. RNA extraction was 
carried out without further cell culture. 
 
2.5.1.4 Bronchial Epithelial Cell Line (BEAS-2B)  
Adherent cells, obtained from the American Type Culture Collection (ATCC) via LGC 
Promochem (Middlesex, UK), were cultured from an immortalized human bronchial epithelial 
cell line (BEAS-2B) originally isolated from the normal human bronchial epithelium of a non-
cancerous donor for lung transplantation (Reddel et al. 1988). Cells were cultured in 
'XOEHFFR¶V 0RGLILHG (DJOH¶V 0HGLXP '0(0 FRQWDLQLQJ P0 JOXWDPLQH IURP 6LJPD-
Aldrich (Dorset, UK), supplemented with 10% FCS. Cells were utilised up to passage 13. 
 
2.5.1.5 Human Mast Cell Line (HMC-1) 
Non-adherent cells, obtained from the ATCC via LGC Promochem (Middlesex, UK),  were 
sub-cultured from a human mast cell line originally derived from a patient with mast cell 
leukaemia (Butterfield et al. 1988). &HOOV ZHUH FXOWXUHG LQ *,%&2 ,VFRYH¶V 0RGLILHG
'XOEHFFR¶V0HGLXP,0'0FRQWDLQLQJ*OXWD0$;,PHGLXPDQGP0+(3(6EXIIHUIURP
Invitrogen-GIBCO (Paisley, UK), supplemented with 10% FCS. Cells were utilised at passage 
3. 
 
2.5.1.6 Human Acute Monocytic Leukaemia Cell Line (THP-1) 
Non-adherent cells, obtained from the ATCC via LGC Promochem (Middlesex, UK), were 
sub-cultured from a human acute monocytic leukaemia cell line (THP-1) originally isolated 
from the peripheral blood of a 1 year old male with acute monocytic leukaemia (Tsuchiya et al. 
1980). These were cultured in RPMI-1640 medium from LGC Promochem (Middlesex, UK). 
Cells were utilised up to passage 14. 
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2.5.2 Molecular Biology Methods 
 
2.5.2.1 Total RNA Extraction 
$ SDQHO RI WRWDO 51$ VDPSOHV ZHUH FROOHFWHG IRU XVH LQ JHQH H[SUHVVLRQ SURILOLQJ DQG ¶
RACE. Commercial total RNA was obtained for peripheral blood mononuclear cells (PBMCs) 
from two donors (RNA051206, RNA051206) from 3H Biomedical (Uppsala, Sweden); lung 
tissue from two donors (07020236, 1002004), brain tissue from two donors (073P010203017A, 
030503013), kidney tissues from two donors (08010041, 0811001), and placenta tissue from 
two donors (114P020303015A, 03070032) all from Applied Biosystems/Ambion (Warrington, 
UK). Total RNA was isolated from cultured HASM, HBEC, dermal fibroblast, BEAS-2B, and 
THP-1 cells using the RNeasy mini Kit (Qiagen. Cat. No. 74104) and the RNAase-free DNase 
set (Qiagen. Cat No. 79254). This method of spin-column technology allows isolation of all 
RNA molecules >200 nucleotides in length. Prior to all RNA preparations, procedures were 
undertaken to minimise contamination using RNase Away (Invitrogen). 
 
Cell density following sub-culture was ascertained using a haemocytometer to estimate cell 
FRXQWV XVLQJ ȝO DOLTXRWV 7RWDO 51$ ZDV H[WUDFWHG IURP FRQIOXHQW FHOOV &RQIOXHQW FHOOV
were trypsinised, washed with PBS, and pelleted before re-VXVSHQVLRQLQȝORI%XIIHU5/7
ZLWK DGGHG ȕ-0HUFDSWRHWKDQRO ȝO ȕ-ME/ml Buffer RLT). The lysate was pipetted onto a 
Qiashredder column for centrifugation at maximum speed for 2 minutes to homogenise the 
PL[WXUH2QHYROXPHȝORIHWKDQROZDVDGGHGDQGPL[HGZHOOE\SLSHWWLQJ8S WR
ȝO RI WKH VDPSOH ZLWK UHVXOWLQJ precipitate was loaded onto an RNeasy column with 
collection tube centrifuged at 10,000rpm for 15 seconds discarding the flow-through. Surplus 
volumes were aliquoted onto the column successively. 
 
Subsequent on-column DNase treatment was carried out. Solid DNaseI supplied with the 
51DVHIUHH'1DVHVHW4,$*(1ZDVJHQWO\GLVVROYHGLQȝO'1DVHIUHHZDWHUDQGVWRUHG
at -Û&ȝORI%XIIHU5:ZDVSLSHWWHGRQWRWKH51HDV\FROXPQDQGFHQWULIXJHGIRU
VHFRQGV DW USP GLVFDUGLQJ WKH IORZ WKURXJK ȝl of the DNaseI stock solution was 
DGGHGWRȝO%XIIHU5''DQGPL[HGE\JHQWOHLQYHUVLRQ7KLV'1DVH,PL[ZDVWKHQDGGHGWR
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the spin column membrane and incubated at room temperature for 15 minutes to degrade the 
'1$%XIIHU5:ȝOZDVDGGHGWRZDVK the column and centrifuged for 15 seconds at 
10,000rpm discarding the flow-WKURXJK7KLVSURFHGXUHZDVUHSHDWHGWZLFHXVLQJȝO53(
Buffer with added ethanol (RNeasy mini kit) centrifuging for 15 seconds and 2 minutes 
respectively. A clean collection tube was added to the column and centrifuged at maximum 
speed for 1 minute to remove all residual wash solution before transferring to a 1.5ml RNase 
IUHH PLFURIXJH WXEH ȝO 51$VH IUHH ZDWHU ZDV DGGHG GLUHFWO\ RQWR Whe membrane and 
centrifuged at 10,000rpm for 1 minute to elute the RNA. Samples were stored at -Û& 
 
Quality control for RNA integrity was checked by analysing ȝOof each sample by 1% agarose 
gel electrophoresis to check the 28s and 18S rRNA bands in total RNA seen at 4.5kb and 1.9kb 
respectively (see Section 2.5.2.5). UVLQJ ȝO RI WKH VDPSOH, the Nanodrop ND-1000 
spectrophotometer (NanoDrop Technologies) was used to measure the RNA concentration and 
assess RNA purity indicated by a 260/280 10mm absorbance ratio between 1.9 and 2.1. 
 
2.5.2.2 cDNA Synthesis 
Reverse transcription of single stranded RNA to synthesise complementary cDNA was carried 
RXWXVLQJWKH6XSHU6FULSW)LUVW-Strand Synthesis System for RT-PCR (Invitrogen. Cat. No. 
11904-018). The first-VWUDQGF'1$V\QWKHVLVUHDFWLRQLVFDWDO\VHGE\6XSHU6FULSW,,5HYHUVH
Transcriptase (RT) and primed using random hexamers to produce cDNA of different lengths 
representing the whole RNA sequence. PCR sensitivity was increased by removal of the RNA 
template from the cDNA:RNA hybrid molecule by digestion with RNase H after first-strand 
synthesis. RT negative samples were prepared alongside each cDNA synthesis reaction to act 
as negative controls for genomic DNA contamination. The final cDNA samples were diluted 
using DEPC water in the ratios of 1:5 for use in PCR and 1:25 for use in Taqman® analysis. 
 
The protocol used for first strand cDNA synthesis is detailed as follows. RNA/primer mixtures 
were prepared in sterile 0.5ml tubes and incubated at 65°C for 5 minutes followed by standing 
on ice for at least 1 minute: 
Total RNA    600ng 
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5DQGRPKH[DPHUVQJȝO   ȝO 
10mM dNTP mix    ȝO 
DEPC-treated water   WRȝO 
 
Subsequently, ȝO [ 57 %XIIHU P0 0J&O2, 0.1M DTT, and ȝO 51DVH287
Recombinant Ribonuclease Inhibitor were added to each reaction. The reaction was mixed 
gently and collected by brief centrifugation before incubation at 25°C for 2 minutes. To test 
UHDFWLRQV ȝO  XQLWV RI 6XSHU6FULSW ,, 57 ZDV DGGHG DQG LQFXEDWHG DW & IRU 
minutes, 42°C for 50 minutes and 70°C for 15 minutes before chilling on ice. The reactions 
ZHUH FROOHFWHG E\ EULHI FHQWULIXJDWLRQ DQG ȝO RI 51DVH + DGGHG WR HDFK WXEH prior to 
incubation for 20 minutes at 37°C. 
 
2.5.2.3 Polymerase Chain Reaction (PCR) 
Polymerase chain reaction (PCR) is a sensitive technique designed to indirectly detect levels of 
mRNA expression using cDNA for PCR amplification using gene-specific primer pairs and a 
Taq DNA polymerase enzyme. The PCR reaction involves three consecutive steps which can 
be repeated up to 30 to 35 cycles, with exponential amplification of the DNA product. 
Denaturation separates the double stranded DNA molecule followed by annealing of primers to 
their target sites and then extension to amplify the primer defined sequence. Typically 25 to 30 
cycles of reaction occurs, yielding more than 107 copies of the amplified sequence. Efficiency 
of the reaction reduces after 40 cycles. 
 
Primer Design for Gene Expression 
Forward and reverse primers for annealing to opposing strands of the DNA duplex chain were 
designed by hand, crossing intron and exon boundaries where possible to ensure cDNA 
specificity. Suitability for primer use was examined using the following rules: 
Primer length 18bp to 25bp  
3ULPHUVZLWKFRQWLJXRXVEDVHV 
  Avoiding repetitive sequences 
40% to 60% G/C content 
Amplified sequence length 300bp to 1,000bp 
0DWFKHGSULPHU7PÛ&GLIIHUHQFHLH at which 50% of the sequence is annealed 
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*&DWWKH¶HQGRIWKHSULPHU EXW 
Primer integrity was assessed using the web-based tool PCR Primer Stats (see Section 2.3.1). 
All primers used in analyses in expression of different genes are listed in Appendix 2. 
 
PCR Assay Conditions for Gene Expression 
Samples were prepared by setting up reactions as follows and amplified using a heated lid PCR 
machine (40 cycles: 94°C for 45 seconds, variable annealing temperatures for 30 seconds, 
72°C for 1.5 minutes; 72°C for 10 minutes; 4°C pause): 
10x PCR Buffer      2.5µl 
Magnesium Chloride (50mM)    3mM 
dNTP mixture (10mM dATP/dTTP/dGTP/dCTP)  200µM 
Taq DNA polymerase (2.5U/µl)    0.025U/µl 
Forward primer (10µM)     0.2µM 
Reverse primer (10µM)     0.2µM 
DNA template      2-10ng 
Sterile distilled water     to 25µl 
 
Optimisation was carried out by varying annealing temperatures and Magnesium ion (Mg2+) 
concentrations between 1.5mM and 3mM. Positive control housekeeping gene, Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and negative controls were included in each experiment. 
Specific conditions following assay optimisation for testing expression of different genes are 
detailed in Appendix 2. 
 
Real-Time Quantitative PCR (Taqman®) 
Real-time quantitative PCR based on Taqman® methodology was used to measure levels of 
IL1RL1 and IL33 relative mRNA expression. This procedure follows the general principle of 
PCR but detects amplified DNA as the reaction progresses in real-time. Principles behind this 
technique and the protocols followed are detailed in Chapter 7. 
 
2.5.2.4 Rapid Amplification of cDNA Ends (RACE) 
Rapid Amplification of cDNA Ends (RACE) was used to obtain the RNA transcript sequences 
of the IL1RL1 and IL33 genes found within tested mRNA templates from a small known 
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sequence within each transcript to the 5' end (5' RACE). This technique results in the 
production of a cDNA copy of the RNA sequence of interest using reverse transcription, 
followed by PCR amplification of the cDNA copies, which are then sequenced.  Detailed 
principles and protocols used are detailed in Chapter 7. 
 
2.5.2.5 Agarose Gel Electrophoresis 
Nucleic acids such as PCR products can be analysed using agarose gel electrophoresis. 
Applying a current through the electrophoresis chamber causes negative DNA fragments to 
migrate from the negative electrode at the top of the gel to the positive electrode at the bottom 
with fragments moving at a slower rate with increasing size. The DNA fragments are stained 
by ethidium bromide which intercalates between the bases and fluoresces under ultraviolet 
(UV) light. Accurate visualisation of separated PCR products can then be carried out under an 
UV transilluminator (Anachem, UK) using a DNA ladder to estimate the size and 
concentration of fragments. Different percentage agarose gels were used to run PCR products 
depending on the resolution of separation required. Smaller PCR products migrate at a faster 
rate across the electrophoresis gel requiring higher percentage agarose gels. 
 
Agarose (Invitrogen, electrophoresis grade. Cat. No. 540-5510UB) at the required 
concentration was added to 1x TAE Buffer (0.4M Tris Base, 0.2M acetic acid and 0.01M 
ethylendiaminetetraacetic acid), e.g. for 1% gels, a mixture of 1g agarose per 100ml 1x TAE 
Buffer was used. The mixture was microwave heated to dissolve and 5µl 10mg/ml ethidium 
bromide (Sigma, UK catalogue number: E-1510) was added per 100ml of solution. When 
FRROHGWRÛ&WKHPL[WXUHZDVSRXUHGLQWRDJHOWUD\ZLWKZHOOFRPEVDQGOHIWWRVHWDWURRP
temperature. The set gel was placed into the electrophoresis chamber (Bio-Rad) and 1x TAE 
buffer was added to cover the gel to a depth of 3mm above the gel surface. Loading dye (6x 
orange G loading dye: 0.25% orange G dye, 30% glycerol) was added to each PCR product 
(2µl loading dye per 10µl PCR product) to increase density. A 1kb or 100bp DNA ladder (10% 
'1$ ODGGHU  %OXH-XLFH ,QYLWURJHQ ZDV Dlso run. Gels were run at approximately 
80mA to 100mA for 35 minutes for small SciPlas/Fisher Scientific (Leicestershire, UK) gel 
tanks and 125-155mA for 1 hour for large Biometra Agagel Maxi (Glasgow, UK) gel tanks 
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until the dye front had migrated sufficiently. DNA bands were subsequently visualised under 
UV light in a GeneGenius Gel Doc system and photographed using Syngene software. 
 
2.5.2.5 Gel Extraction and Purification 
Extraction of gel-fractionated DNA from agarose gels was carried out using the StrDWD3UHS
DNA Gel extraction kits (Stratagene, Cat. No. 400766, 400768). DNA extraction eliminates 
the need for manipulation of resins, toxic phenol-chloroform extractions, and time consuming 
ethanol precipitations. Buffers were used to wash away unwanted constituents and DNA eluted 
to result in a purified product for restriction digestion, ligation, and probe labelling. An 80% 
recovery rate is expected from DNA that is 250bp to 9kb in length; a 50% recovery is expected 
for longer DNA up to 23kb. 
 
300µl of BXIIHU4*ZDVDGGHGWRWKHJHOVOLFHVLQDQHSSHQGRUIWXEHDQGLQFXEDWHGDWÛ&WR
allow the gel slice to dissolve. The sample was then applied to the spin column in 2ml 
collection tubes and centrifuged for 1 minute at 13,000rpm allowing for DNA to bind to the 
columns discarding any flow-through. 0.75ml of Buffer PE was added and unwanted 
contaminants washed off by further centrifugation for 1 minute. This step was repeated to 
ensure purification of the DNA. Then, 50µl of Buffer EB was added and tubes centrifuged for 
1 minute to elute the DNA. The purified DNA was checked using agarose gel electrophoresis 
DQGVWRUHGDWÛ&XQWLOUHTXLUHG 
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2.6 Individual Contributions and Collaborations 
 
The work described in this thesis has resulted through a combination of individual and 
collaborative efforts. A number of established population cohorts have been used in analyses, 
in which genotyping using genome-wide SNP platforms was previously carried out by 
individual study centres. 
 
Studies of atopy within multiple populations was possible due to provision of summary results 
after quality control and association testing of genotype data through collaboration with Prof. 
'DYLG 3 6WUDFKDQ 6W *HRUJHV¶ 8QLYHUVLW\ 8. 'U -RKQ+HQGHUVRQ 8QLYHUVLW\ RI %ULVWRO
UK), Dr. Tricia McKeever (University of Nottingham, UK), Dr. John W Holloway (University 
of Southampton, UK), and Dr. Eva Halapi (deCODE Genetics, Iceland). 
 
In studies of severe asthma, processing of genotyped and sequencing data including quality 
control and association testing was carried out in collaboration with Dr. Nick R G Shrine 
(University of Leicester, UK). Summary results for SNPs studied in the follow-up replication 
cohort were provided by Dr. Manuel A R Ferreira (Queensland Institute of Medical Research, 
Australia). 
 
Descriptions of all population cohorts used including details on the set up of each study, 
participant recruitment and phenotyping are given in Section 2.1. Genotyping procedures, 
quality control measures, and association testing undertaken, were either summarised by 
collaborators where stated or carried out by myself as described in Section 2.2. 
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Chapter 3 
Genome-Wide Association Study to Identify Novel 
Atopy Susceptibility Loci 
 
3.1 Introduction 
 
As discussed in Chapter 1, there is extensive evidence supporting a genetic contribution to the 
risk of developing atopy. This was first established through familial clustering of disease and 
concordance rates amongst both monozygotic and dizygotic twins. Efforts to identify causative 
genetic loci and genes have been made through studies using linkage, candidate gene 
association, and more recently, genome-wide association (GWA). In recent years, GWA 
approaches have been used extensively to study a range of allergic diseases and associated 
traits. To date, a total of eight GWA studies have been published for asthma, one for atopic 
dermatitis, and one for serum total IgE levels by studying these phenotypes as the primary 
outcome (see Chapter 1: Section 1.3). 
 
Results presented from these studies have supported association of previously reported 
candidate genes such as IL13 and HLA-DRB1 as well as identifying novel loci including 1q31 
and 9q21.31 for asthma and 11q13 for atopic dermatitis (Ober et al. 2008; Moffatt et al. 2010). 
This methodology has allowed identification of genes including ORMDL3 for childhood 
asthma susceptibility and FCER1A for determining serum total IgE levels (Moffatt et al. 2007; 
Weidinger et al. 2008). However, no study utilising a GWA approach has yet examined 
predisposition to atopy using measures of specific IgE. 
 
The majority of novel loci identified by GWA studies in allergic diseases appear to be trait 
dependent; for example, different genotype and allele distributions in TGFB1 polymorphisms 
have been shown in atopic compared to non-atopic asthmatics as well as in patients with more 
severe airflow obstruction (Mak et al. 2006). An exception to this has been the Th2 cytokine 
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cluster on chromosome 5q31-33 where association with genetic variants across this region is 
evident across multiple atopy phenotypes (Palmer et al. 2000). Published literature suggests 
that IgE is a distinct sub-phenotype involved in atopic disease development and therefore may 
be controlled by independent genetic factors (Weinmayr et al. 2007; Moffatt et al. 2010). 
 
Considering the extent of phenotypic variability in defining complex diseases such as asthma, 
using related traits for genetic studies such as serum IgE levels and skin prick test (SPT) 
responses to common allergens may help to determine disease severity and characterise 
different forms of disease, for example, atopic and non-atopic asthma (Sandford et al. 1998). 
Furthermore, the use of more quantifiable and objective measures such as specific IgE 
responses, serum eosinophil counts, and bronchial hyperresponsiveness (BHR), which are 
closely associated with atopy and asthma could prove to be useful surrogate markers for atopic 
diseases in genetic studies. These measures can increase study power by improving 
phenotyping as they are less likely to underestimate disease prevalence compared to physician 
diagnosis or questionnaire-based self-reporting, particularly in asymptomatic individuals 
(Kauffmann et al. 2002). 
 
3.2 Aim 
 
The aim of this chapter was to identify susceptibility loci for atopy defined by elevated specific 
IgE or positive SPT using a non-parametric based GWA study. 
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3.3 Methods 
 
3.3.1 Study Populations 
The primary GWA study was carried out using the British 1958 Birth Cohort consisting of 
1,083 cases and 2,770 controls genotyped using the Illumina HumanHap550 SNP platform. 
Statistically significant SNPs were assessed for replication in silico in 1,324 individuals from 
the ALSPAC cohort genotyped on the Illumina HumanHap300 SNP platform as well as being 
prospectively genotyped in 1,286 individuals from the Nottingham Gedling cohort and 757 
individuals from the Southampton cohort. Details of study recruitment and phenotyping are 
described in Chapter 2: Section 2.1.1. Genotyping and quality control procedures undertaken 
are summarised in Chapter 2: Section 2.2.1.1. 
 
Atopy was GHILQHGXVLQJHOHYDWHGVSHFLILF,J(N8A/L in the British 1958 Birth Cohort, 
SRVLWLYH VNLQ SULFN WHVW 637 ZLWK D PHDQ ZKHDO GLDPHWHU PP in the ALSPAC cohort, 
positive 637 PP LQ WKH 1RWWLQJKDP *HGOLQJ FRKRUW, and measures of both specific IgE 
35kUA/L and SPT >3mm were taken in the Southampton cohort. Analysis of SNP 
association with serum total IgE levels was also undertaken in 3,873 individuals from the 
British 1958 Birth Cohort, 1,423 individuals from the ALSPAC, 1,293 individuals from the 
Nottingham Gedling cohort, and 675 individuals from the Southampton cohort. Adjustments 
for serum total IgE level data in the British 1958 Birth Cohort had been taken for potential 
confounders: sex, date & time of collection, postal delay, laboratory batch and nurse. 
 
Power estimates calculated using CaTS 0.02 for each study dataset used in elevated specific 
IgE and positive SPT analyses are listed in Table 3.1. Each individual cohort had low power to 
detect modest effects, which was improved through combined analyses. 
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Table 3.1 ± Study power for datasets used in atopy analyses. Values for the minimum 
detectable OR for a SNP with a given MAF are presented at 80% power. 
 
 
 
 
 
 
 
3.3.2 Association Testing 
Summary data in the form of allele counts following GWA testing of 459,334 autosomal SNPs 
genotyped in the British 1958 Birth Cohort passing quality control was provided for analysis. 
Allele counts for SNPs undergoing replication analyses were provided from a previous GWA 
study in the ALSPAC cohort. All tests of association for elevated specific IgE and positive 
SPT in these populations were FDUULHGRXWXVLQJ3HDUVRQ¶VChi-VTXDUHGȤ2) per-allele tests with 
one degree of freedom (df) comparing allele frequencies between cases and controls. Linear 
regression was used to test association of serum total IgE in the British 1958 Birth Cohort (see 
Chapter 2: Section 2.4.2). 
 
During analyses, odds ratios (ORs) with 95% confidence intervals (CI) were calculated to 
assess minor allele effect sizes using provided allele counts. Following prospective genotyping 
of SNPs in the Nottingham Gedling cohort and the Southampton cohort, 3HDUVRQ¶VChi-squared 
Ȥ2) per-allele tests with 1df were carried out to test association with elevated specific IgE and 
positive SPT. All serum total IgE level data were loge transformed and SNP association tested 
XVLQJ OLQHDU UHJUHVVLRQ DQG EHWD WUHQG ȕ FRHIILFLHQWV ZLWK % CI were calculated for the 
minor allele. All association testing of data from prospective genotyping and calculations of 
effect sizes were carried out in STATA/SE 10.1. 
 
Pooled analyses for each phenotype used to define atopy were performed using all available 
count data. This included the British 1958 Birth Cohort and the Southampton cohort for 
Study Minimum detectable OR with MAF 
10% 25% 40% 
Discovery 
British 1958 Birth Cohort 1.19 1.13 1.11 
Replication in silico 
ALSPAC 1.39 1.27 1.24 
Replication genotyping 
Nottingham Gedling 1.30 1.21 1.19 
Southampton Elevated specific IgE 1.30 1.21 1.19 
Positive SPT 1.22 1.16 1.15 
Combined 
Elevated specific IgE 1.16 1.11 1.10 
Positive SPT 1.18 1.12 1.11 
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elevated specific IgE; the ALSPAC, Nottingham Gedling and Southampton cohorts for 
positive SPT; the Nottingham Gedling and Southampton cohorts for serum total IgE levels. 
Forest plots were generated using Microsoft Excel 2007 by plotting the minor allele effect size 
HVWLPDWHV 25 DQG ȕ with 95% CI) per study cohort for each SNP. Weighted meta-analysis 
using a fixed effects model of individual per-allele effect sizes for serum total IgE levels was 
carried out in order to include data across all four study populations carried out in STATA/SE 
10.1. 
 
3.3.3 Statistical Significance Testing 
Genome-wide statistical significance in the British 1958 Birth Cohort GWA study was defined 
XVLQJS[(-7) as determined by the Bonferroni correction at the 5% significance level for 
a total of 459,334 SNPs. In consideration of the fact that this may be over-conservative 
particularly in regions with poor SNP coverage, two additional less stringent thresholds were 
XVHGQRPLQDOO\GHILQHGS(-5) IRUDQ\VLQJOH613DQGFOXVWHULQJRI613VZLWKS(-4) 
within a 100kb region. Loci were selected for replication analyses by setting limits of 300kb 
flanking all identified SNPs. Distinct loci with no overlap were taken forward for replication 
analyses. 
 
3.3.4 SNP Selection for Replication Studies 
Replication of SNPs showing the highest statistical significance within each locus passing 
quality control with minor allele frequency (MAF) >5% and in Hardy-Weinberg equilibrium 
(HWE p>0.05) was tested. Positive replication was assessed at the 5% significance level. Non-
genotyped SNPs in the ALSPAC cohort were imputed.  
 
3.3.5 Candidate Gene Expression 
Expression profiling of possible candidate genes identified by statistically significant SNP 
associations was carried out using polymerase chain reaction (PCR) in two independent cDNA 
panels with two repeats each. Assays were designed to detect all published gene transcripts 
documented online using NCBI. PCR products were sequence verified (see Chapter 2: Section 
2.5). 
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3.3.6 Evaluation of Previously Reported Atopy Genes 
Association of SNPs within atopy candidate genes previously reported in a smaller dataset of 
the British 1958 Birth Cohort was also analysed (Maier et al. 2006). 
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3.4 Results 
 
3.4.1 Discovery GWA Study 
The Quantile-Quantile (Q-Q) plot shows observed versus expected -log10 p values for all tested 
SNPs in the British 1958 Birth Cohort showing a small number of SNPs with extreme p values 
and additional SNPs with more modest effects [Figure 3.1]. The Manhattan plot shows -log10 p 
values for all tested SNPs ordered by chromosomal position showing the highest significance 
SNPs lying on chromosomes 8 and 13 [Figure 3.2]. 
 
 
Figure 3.2 ± Q-Q plot showing results of the discovery GWA study. The straight line shows 
the distribution of 459,334 SNPs analysed in 1,083 cases and 2,770 controls under the null 
hypothesis. 
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Figure 3.3 ± Manhattan plot showing results of the discovery GWA study for 459,334 SNPs analysed in 1,083 cases and 2,770. The arrows indicate the position of the 
seven loci taken forward for replication studies based on both genome-ZLGHVLJQLILFDQFHS[(-7)QRPLQDOVLJQLILFDQFHSDQGFOXVWHULQJRI613VZLWKS(-4) 
within a 100kb region. 
81 
A single SNP, rs6561505 on chromosome 13q14 reached genome-wide significance 
(p=2.15x10(-9)). A further four 613V ZHUH LGHQWLILHG XVLQJ WKH ORZHU WKUHVKROG RI S(-5): 
rs7835153 (p=4.50x10(-7)), rs7835920 (p=5.54x10(-7)), rs17202769 (p=1.39x10(-6)), and 
rs11244450 (p=6.50x10(-6)), on chromosomes 8q22, 8q12 (2 SNPs), and 10q26 respectively. 
An additional 11 SNPs were identified based on the pre-defined criteria for clustering with 
S(-4) 613VZLWKLQNb) on chromosomes 8q12 (2 SNPs), 11q24 (3 SNPs), 18q22 (3 
SNPs), and 20p13 (3 SNPs). 
 
The total of 16 SNPs was grouped into seven distinct loci. The SNPs with the highest statistical 
significance in each locus were rs7835920 (8q12), rs7835153 (8q22), rs11244450 (10q26), 
rs4936003 (11q24), rs6561505 (13q14), rs10514054 (18q22), and rs6082335 (20p13). All 
seven SNPs were taken into replication studies following quality control checks. MAFs of 
identified SNPs were similar between cohorts for all SNPs apart from rs10514054 and 
rs6082335 [Table 3.2]. All SNPs apart from rs7835153 showed a risk effect for the minor 
allele [Table 3.3]. 
 
Table 3.2 ± Minor allele frequencies for seven identified SNPs taken into replication 
studies. * r2 quality metrics for imputed SNPs using MACH 1.0 were 0.86 (rs11244450), 0.96 
(rs4936003), 0.97 (rs6561505), 0.99 (rs6082335). 
 
SNP Allele 
(Major/Minor) 
British 1958 
Birth Cohort 
(n=3,853) 
ALSPAC 
(n=1,324) 
Nottingham 
Gedling 
(n=1,286) 
Southampton 
 (n=757) 
rs7835920 A/C 0.25 0.27 0.25 0.25 
rs7835153 A/G 0.42 0.42 0.43 0.43 
rs11244450 G/A 0.09 0.08* 0.10 0.09 
rs4936003 A/G 0.24 0.24* 0.23 0.26 
rs6561505 G/A 0.08 0.08* 0.12 0.12 
rs10514054 C/A 0.12 0.12 0.39 0.36 
rs6082335 G/A 0.38 0.37* 0.25 0.25 
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Table 3.3 - Association with atopy phenotypes for studied SNPs: elevated specific IgE, positive SPT, and loge serum total IgE levels. Results shown for studied SNPs 
identified in the discovery GWA study cohort: British 1958 Birth Cohort (B58C) and replication cohorts: ALSPAC, Nottingham Gedling, and Southampton (Soton).  Pooled p 
values and effect sizes were FDOFXODWHGXVLQJDYDLODEOHFRXQWGDWD6LJQLILFDQWSYDOXHVSDUHVKRZQLQEROG+ 5LVNPLQRUDOOHOHØ3URWHFWLYHPLQRUDOOHOH 
ANKRD46: ankyrin repeat domain 46; KIRREL3: kin of irregular chiasm-like 3; FNDC3A: fibronectin type III domain containing protein; NETO1: neuropilin tolloid-like 1. 
 
Chr SNP 
(minor allele), 
Gene 
Elevated specific IgE Positive SPT Loge serum total IgE levels Combined 
British 
1958 Birth 
Cohort 
Soton ALSPAC Nottingham 
Gedling 
Soton British 
1958 Birth 
Cohort 
ALSPAC Nottingham 
Gedling 
Soton Elevated 
specific IgE 
Positive 
SPT 
Loge 
serum 
total IgE 
levels 
8q12 rs7835920 (C), 
intergenic 
5.54x10(-7) + 0.30 0.35 0.06+ 0.49 5.79x10(-4) + 0.55 0.13 0.12 8.20x10(-7) + 0.11 0.24 
8q22 rs7835153 (G), 
ANKRD46 
4.50x10(-7) Ø 0.17 0.13 0.82 0.17 3.47x10(-5) Ø 0.45 0.82 0.38 7.00x10(-5) Ø 0.82 0.72 
10q26 rs11244450 (A), 
intergenic 
6.50x10(-6) + 0.33 0.045 Ø 0.73 0.12 2.14x10(-4) + 0.89 0.13 0.87 2.08x10(-4) + 0.14 0.49 
11q24 rs4936003 (G), 
KIRREL3 
4.20x10(-5) + 0.33 7.33x10(-4) + 0.32 0.69 0.054 Ø 0.48 0.86 0.63 4.36x10(-4) + 0.052 + 0.23 
13q14 rs6561505 (A), 
FNDC3A 
2.15x10(-9) + 0.44 0.73 0.16 0.27 7.75x10(-5) + 0.87 0.84 0.86 5.45x10(-7) + 0.31 0.34 
18q22 rs10514054 (A), 
NETO1 
2.54x10(-5) + 0.17 0.06 + 0.38 0.60 6.52x10(-3) + 0.13 0.19 0.03Ø 1.32x10(-3) + 0.90 0.48 
20p13 rs6082335 (A), 
intergenic 
5.00x10(-5) + 0.10 0.80 0.97 0.31 0.04 + 0.96 0.34 0.43 2.78x10(-5) + 0.71 0.83 
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3.4.3 In silico Replication 
All seven identified SNPs were studied in the ALSPAC cohort, only three of which were 
genotyped in ALSPAC (rs7835920, rs7835153, rs10514054). None of these SNPs showed 
replicated association with SPT positivity [Table 3.3]. Imputed data were provided for the 
remaining four non-genotyped SNPs with r2 quality metrics 0.86 (rs11244450), 0.96 
(rs4936003), 0.97 (rs6561505), 0.99 (rs6082335). Association was seen with rs4936003 
(p=9.93x10(-4)) showing the same direction of effect for the minor allele and marginally with 
rs11244450 (p=0.045) where the opposing allele conferred risk in ALSPAC [Table 3.3]. 
 
3.4.4 Replication Genotyping 
All seven identified SNPs were prospectively genotyped in the Nottingham Gedling and 
Southampton cohorts. None of the SNPs showed evidence of association with elevated specific 
IgE or with positive SPT in either cohort [Table 3.3]. 
 
3.4.5 Total IgE Analyses 
Six studied SNPs also showed association with serum total IgE levels in the British 1958 Birth 
Cohort: rs7835920 (p=5.79x10(-4)), rs7835153 (p=3.47x10(-5)), rs11244450 (p=2.14x10(-4)), 
rs6561505 (p=7.75x10(-5)), rs10514054 (p=6.52x10(-3)), and rs6082335 (p=4.37x10(-2)) [Table 
3.3]. A single SNP, rs10514054 replicated association with serum total IgE levels in the 
Southampton cohort (p=0.03) but showed opposing directions of effect for the minor allele: the 
British 1958 Birth Cohort (OR 1.14, 95% CI 1.04-1.26), the Southampton cohort (OR 0.53, 
95% CI 0.30-0.94). 
 
3.4.6 Combined Analyses 
Combined analyses of count data for elevated specific IgE and positive SPT across cohorts 
were conducted to estimate pooled p values and effect sizes [Table 3.3]. Forest plots of the per-
allele effect sizes for each of the SNPs are presented [Figures 3.3 and 3.4]. Results tables for 
all SNPs are listed in Appendix 3. 
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Pooled data showed significant associations with elevated specific IgE for all seven SNPs 
although these effects were driven by the initial British 1958 Birth Cohort dataset. No SNP 
showed significant association with positive SPT [Table 3.3]. Pooled analysis of serum total 
IgE levels was carried out for the Nottingham Gedling and Southampton cohorts. No SNP met 
statistical significance in this analysis [Table 3.3]. 
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Figure 3.4 - Forest plots of studied SNPs 1 to 4: (A) rs7835920 (8q12), (B) rs7835153 
(8q22), (C) rs11244450 (10q26), (D) rs4936003 (11q24). Per-allele summary effect sizes for 
the minor allele are shown for atopy phenotypes: elevated specific IgE (OR), positive SPT 
25 DQG VHUXP WRWDO ,J( OHYHOV ȕ (DFK URZ UHSUHVHQWV RQH VWXG\ UHODWLYH VL]HV RI GDWD
points are proportional to the cohort sample size, horizontal lines represent 95% confidence 
intervals. Diamonds represent the meta-DQDO\VHV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Figure 3.4 - Forest plots of studied SNPs 5 to 7: (A) rs6561505 (13q14), (B) rs10514054 
(18q22), (C) rs6082335 (20p13). Per-allele summary effect sizes for the minor allele are 
shown for atopy phenotypes: elevated specific IgE (OR), positive SPT (OR), and serum total 
IgE levels (ȕ). Each row represents one study, relative sizes of data points are proportional to 
the cohort sample size, horizontal lines represent 95% confidence intervals. Diamonds 
represent the meta-DQDO\VHVGHQRWHVVWDWLVWLFDOVLJQLILFDQFHS 
B A 
 
C 
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3.4.7 Meta-Analysis 
Four datasets were available with serum total IgE levels data in addition to combined analysis 
on count data available only from the Nottingham Gedling and Southampton cohorts. 
Therefore, a meta-analysis of the per-allele effect size estimates for each individual study was 
carried out. Three SNPs met statistical significance as determined by the Bonferroni correction 
at the 5% significance level for seven SNPs (p0.007), but these p values were driven by the 
British 1958 Birth Cohort, which formed the largest contribution [Table 3.4]. This analysis also 
confirmed high levels of between-study heterogeneity of effect sizes. 
 
Table 3.4 ± Meta-analysis of individual per-allele study effect sizes of studied SNPs for 
serum total IgE weighted inversely proportionally to study variance. A meta-analysis of 
individual per-allele effect sizes across all studies for total IgE was carried out using STATA 
10.1 with weights inversely proportional to study variance. Significant p values (S07) are 
shown in bold. Effect sizes presented for the minor allele. 
SNP Allele 
(Major/
Minor) 
Study 
heterogeneity 
(p value) 
Effect (95% CI) p value 
rs7835920 A/C 0.166 1.09 (1.04-1.15) 6.67x10(-4) 
rs7835153 A/G 0.005 0.95 (0.91-0.99) 0.017 
rs11244450 G/A 0.010 1.09 (1.01-1.18) 0.028 
rs4936003 A/G 0.638 1.05 (0.99-1.10) 0.092 
rs6561505 G/A 0.036 1.11 (1.03-1.21) 0.007 
rs10514054 C/A 0.071 1.11 (1.04-1.19) 0.003 
rs6082335 G/A 0.144 1.05 (1.01-1.10) 0.023 
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3.4.8 Candidate Gene Expression 
Four identified SNPs are positioned within intronic regions of the following genes: rs7835153 
within ankyrin repeat domain 46 (ANKRD46) on 8q22, rs4936003 within kin of irregular 
chiasm-like 3 (KIRREL3) on 11q24; rs6561505 within fibronectin type III domain containing 
protein (FNDC3A) on 13q14; and rs10514054 within neuropilin tolloid-like 1 (NETO1) on 
18q22. Using NCBI to assess published transcript variants, three transcripts were published for 
ANKRD46 (NM_198401), a single transcript for KIRREL3 (NM_032531), four for FNDC3A 
(NM_001079673), and five for NETO1 (NM_138999). 
 
Expression profiling of these genes was carried out in two independent panels consisting of 
cDNA samples from human airway smooth muscle (HASM), human bronchial epithelial cells 
(HBEC), lung, dermal fibroblasts, human mast cell line (HMC-1), peripheral blood 
mononuclear cells (PBMC), brain, kidney, and placenta. Primers were designed to detect all 
published transcripts and are listed in Appendix 2. In the tested panels, ANKRD46 and 
FNDC3A were expressed ubiquitously; KIRREL3 was expressed in brain only; NETO1 was not 
shown to be expressed [Figure 3.4]. Expression of NETO1 was tested using two primer sets to 
ensure validity of expression assays. PCR products were sequenced and verified against 
published gene transcripts using NCBI blast and an example for FNDC3A is shown in Figure 
3.9. 
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Figure 3.5 ± Gel electrophoresis using 1.5% agarose under UV illumination showing 
ubiquitous expression of ANKRD46 (8q22). Primers were designed to detect all three 
published transcripts (NM_198401). This is a representative gel from two experiments 
showing similar results. A product of 302bp was seen in all cell types examined. HASM 
denotes human airway smooth muscle, HBEC denotes human bronchial epithelial cell, HMC-1 
denotes human mast cell line, and PBMC denotes peripheral blood mononuclear cells. 1kb 
DNA ladders are shown on the left and right extremes, RT -ve and water controls are shown in 
the second row. 
 
Figure 3.6 ± Gel electrophoresis using 1.5% agarose under UV illumination showing 
expression in brain of KIRREL3 (11q24). Primers were designed to detect the single 
published transcript (NM_032531). This is a representative gel from two experiments showing 
similar results. A product of 300bp was seen in brain. HASM denotes human airway smooth 
muscle, HBEC denotes human bronchial epithelial cell, HMC-1 denotes human mast cell line, 
and PBMC denotes peripheral blood mononuclear cells. 1kb DNA ladders are shown on the 
left and right extremes, RT -ve and water controls are shown in the second row. 
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Figure 3.7 ± Gel electrophoresis using 1.5% agarose under UV illumination showing 
ubiquitous expression of FNDC3A (13q14). Primers were designed to detect all four 
published transcripts (NM_001079673). This is a representative gel from two experiments 
showing similar results. A product of 563bp was seen in all cell types examined. HASM 
denotes human airway smooth muscle, HBEC denotes human bronchial epithelial cell, HMC-1 
denotes human mast cell line, and PBMC denotes peripheral blood mononuclear cells. 1kb 
DNA ladders are shown on the left and right extremes, RT -ve and water controls are shown in 
the second row. 
 
 
Figure 3.8 ± Gel electrophoresis using 1.5% agarose under UV illumination showing 
absence of expression of NETO1 (18q22). Primers were designed to detect all five published 
transcripts (NM_001079673). Expression of NETO1 was tested using two primer sets to ensure 
validity of expression assays. This is a representative gel from two experiments showing 
similar results. Products of 366bp (assay 1) and 203bp (assay 2) were not seen in any cell types 
examined. HASM denotes human airway smooth muscle, HBEC denotes human bronchial 
epithelial cell, HMC-1 denotes human mast cell line, and PBMC denotes peripheral blood 
mononuclear cells. 1kb DNA ladders are shown on the left and right extremes, RT -ve and 
water controls are shown in the second row. 
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Figure 3.9 ± Example of sequencing results for a 563bp standard PCR product for FNDC3A in human airway smooth muscle (HASM) obtained from excision from 
the gel shown in Figure 3.7. All products seen in cell types examined were excised and purified for sequencing. Matching sequence to FNDC3A (NM_001079673) using 
BLAST (NCBI). 
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3.4.9 Candidate Gene Look-up 
Candidate genes previously identified in a smaller dataset of the British 1958 Birth Cohort 
were identified and association results for SNPs within a list of widely replicated candidate 
genes from the literature were evaluated in the studied British 1958 Birth Cohort [Table 3.5]. 
Association with elevated specific IgE was seen with SNPs within previously identified atopy 
genes including FCER1A (5 SNPs, lowest p=0.002), IL13 (2 SNPs, lowest p=0.02), and signal 
transducer and activator of transcription 6, interleukin-4 induced (STAT6) (6 SNPs, lowest 
p=0.003). No SNPs within CD14 (5q31.1) and HLA-DRB1 (6p21) were genotyped in the 
current studied British 1958 Birth Cohort dataset. Therefore, these genes could not be formally 
evaluated. 
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Table 3.5 ± Evaluation within the British 1958 Birth Cohort of previously reported atopy candidate genes. *Note no SNPs were able to be tested within CD14 and 
HLA-DRB1. 
Chromosome Gene Number of 
SNPs tested 
within gene 
Highest significance SNP 
SNP Function Elevated specific IgE Serum total IgE levels 
p value OR (95% CI) p value OR (95% CI) 
1q23 FCER1A 5 rs2251746 Intronic 2.14x10(-3) 0.84 (0.75-0.94) 1.04x10(-8) 0.82 (0.76-0.88) 
1q31-q32 NOS1 45 rs9658535 Intronic 0.19 1.77 (0.76-4.16) 0.31 1.36 (0.75-2.44) 
1q31-q32 IL10 8 rs1800896 ¶875 0.27 0.95 (0.86-1.04) 0.46 0.98 (0.92-1.04) 
2q33 CD28 9 rs10490573 Intronic 0.058 1.13 (1.00-1.28) 0.24 1.05 (0.97-1.14) 
2q33 CTLA4 1 rs733618 ¶875 0.61 1.05 (0.84-1.26) 0.99 1.00 (0.89-1.13) 
5q31 IL13 2 rs20541 Q [Gln] ֜ R [Arg] 0.020 1.16 (1.02-1.32) 5.97x10(-6) 1.21 (1.11-1.31) 
5q31.1 IL4 3 rs2243248 ¶875 0.020 0.78 (0.63-0.96) 0.49 0.96 (0.84-1.08) 
5q31.1 CD14 *0 - - - - - - 
5q32 SPINK5 16 rs2303064 D [Asp] ֜ N [Asn] 0.23 1.10 (0.94-1.28) 0.29 1.05 (0.95-1.17) 
6p21 HLA-DQB1 1 rs1063355 ¶875 0.57 0.97 (0.88-1.08) 0.63 0.98 (0.92-1.05) 
6p21 HLA-DRB1 *0 - - - - - - 
11q13 MS4A6E 4 rs2165832 Intronic 0.029 0.89 (0.80-0.99) 0.81 0.99 (0.93-1.06) 
11q13 MS4A2 1 rs10750935 ¶875 0.59 1.03 (0.93-1.14) 0.68 0.99 (0.92-1.05) 
12q13 STAT6 6 rs1059513 ¶875 0.003 0.78 (0.66-0.92) 1.95x10(-6) 0.79 (0.71-0.87) 
16p12.1-p12.2 IL4R 18 rs1805011 E [Glu] ֜ A [Ala] 0.035 0.84 (0.72-0.99) 7.63x10(-3) 0.88 (0.80-0.97) 
FCER1A: Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide; NOS1: nitric oxide synthase 1 (neuronal); IL10: interleukin 10; CD28: CD28 molecule; CTLA4: cytotoxic T-
lymphocyte-associated protein 4; IL13: interleukin 13; IL4: interleukin 4; CD14: CD14 molecule; SPINK5: serine peptidase inhibitor, Kazal type 5; MS4A6E: membrane-spanning 4-domains, 
subfamily A, member 6E;  MS4A2: membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I, receptor for; beta polypeptide); STAT6: signal transducer and 
activator of transcription 6, interleukin-4 induced; IL4R: interleukin 4 receptor. 
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3.5 Discussion 
 
Results presented in this Chapter describe a large-scale population based GWA study for 
elevated specific IgE to three common allergens in 3,853 subjects from the British 1958 Birth 
Cohort with follow-up investigations in 7,423 individuals from three additional cohorts using 
atopy defined by elevated specific IgE and/or positive SPT. Overall, no replicated evidence for 
any of the atopy susceptibility loci identified in the discovery cohort using elevated specific 
IgE to define atopy was found. 
 
The Q-Q plot for all SNPs in the British 1958 Birth Cohort specific IgE dataset gives an 
indication of the likelihood of identifying susceptibility loci. Deviation of plotted results from 
the predicted distribution of p values in the absence of genetic effects is seen for a small 
number of SNPs predominantly at the extreme p values. However, in addition there was also a 
large number of SNPs with small effect sizes above the line, indicating probable existence of 
numerous regions containing SNPs with small effects. This suggests that genetic influences on 
atopy defined using elevated specific IgE do not come from a single or even a few major genes 
with large effect sizes but rather a larger number of loci with modest effects. 
 
Seven potential loci were identified in the initial GWA scan for susceptibility to atopy, all of 
which are in regions that have previously reported linkage to IgE levels and the development of 
various atopic traits: 8q12 (Gusareva et al. 2009), 8q22 (Dizier et al. 2000; Ciullo et al. 2006), 
10q26 (Tremblay et al. 2008), 11q24 (Anderson et al. 2002), 13q14 (Chen et al. 2006), 18q22 
(Van Eerdewegh et al. 2002), and 20p13 (Jang et al. 2005; Lesueur et al. 2007). Chromosome 
13q14 is a region supported by both previous linkage and association results in which a number 
of studies have been conducted to examine candidate genes including plant homeodomain 
finger protein 11 (PHF11) and cysteinyl leukotriene type 2 receptor (CYSLTR2) with 
potentially functional roles in both atopy and asthma (Fukai et al. 2004; Sanak et al. 2007). 
 
Identified SNPs on 8q22, 11q24, 13q14, and 18q22 are intronic in ANKRD46, KIRREL3, 
FNDC3A, and NETO1 respectively. Few studies have been published regarding these genes 
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and their functions remain unclear, but some suggestions have been proposed for their 
functional roles. ANKRD46 has been proposed to participate in phosphorylation during 
glycolysis (Shin et al. 2007). KIRREL3 has been shown to have a functional role in PDZ 
domain binding, a domain found in diverse signalling proteins (Bhalla et al. 2008). FNDC3A 
has been proposed to be involved in extracellular matrix (ECM)-receptor interactions (Obholz 
et al. 2006). NETO1 encodes a predicted transmembrane protein which contains a specific 
intracellular motif, shown in other proteins to be a strong promoter of endocytosis (Stöhr et al. 
2002). 
 
The pivotal SNP on 13q14 (rs6561505, p=2.15x10(-9)) reached genome-wide significance for 
increased risk of atopy (OR 1.67, 95% CI 1.41-1.98) and is located in FNDC3A, a gene not 
previously implicated in atopy or related traits, approximately 300kb in distance from both 
CYSLTR2 upstream and PHF11 downstream. In order to replicate these findings from the 
GWA study, a combination of in silico replication, prospective genotyping, and combined 
analyses was used. This SNP was not associated with atopy defined by elevated specific IgE or 
positive SPT in the additional three cohorts (1,007 cases and 2,153 controls in total). The 
minor allele for this SNP also increased the risk of raised serum total IgE in the British 1958 
Birth Cohort but not in the additional cohorts. Pooled results for elevated specific IgE showed 
a significant combined effect of OR 1.49 (95% CI 1.28-1.75) for the risk allele. 
 
Whilst this study focused on the identification of signals reaching conventional GWA 
significance, a more inclusive region-based strategy was also implemented involving 
prospective genotyping of an additional six SNPs within loci showing at least some evidence 
of association. For the majority of SNPs genotyped, there was no evidence for association in 
the additional cohorts. Despite significant associations for elevated specific IgE for rs7835153 
(8q22), rs11244450 (10q26), and rs10514054 (18q22) in the British 1958 Birth Cohort, there 
was little evidence of consistent association in the additional cohorts for these SNPs. Overall it 
seems unlikely that these three loci confer markedly increased susceptibility to atopy in these 
populations. 
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A single SNP, rs4936003 (11q24) showed replicated association with positive SPT in the 
ALSPAC cohort (p=7.33x10(-4)) with the same direction of effect for the minor allele (OR 1.43, 
95% CI 1.16-1.76) as in the British 1958 Birth Cohort (OR 1.27, 95% CI 1.13-1.43). This is 
the only SNP which showed association with atopy across two independent cohorts, using 
subjects of different ages and definitions of atopy. As this SNP, intronic of the KIRREL3 gene, 
did not show evidence of association with total IgE, this indicates that it may play a role in 
sensitisation to allergens different from influencing IgE production per se. In the limited 
profiling panel used, expression of this gene was only detected in the brain template. 
Interestingly, one study has shown the involvement of the gene product mKirre in the support 
of hematopoietic stem cells by stromal cells (Ueno et al. 2003).  
 
In addition, some suggestive evidence for association has been identified for two intergenic 
SNPs, rs7835920 (8q12) and rs6082335 (20p13). For these SNPs, although not all replication 
results are statistically significant, a consistent effect can be seen for the risk allele throughout. 
The results for these two SNPs suggest that there may be genes underlying atopy susceptibility 
in these regions. Combined analyses for elevated specific IgE showed effect sizes of OR 1.17, 
95% CI 1.29-1.43 (p=8.20x10(-7)) and OR 1.22, 95% CI 1.11-1.34 (p=2.78x10(-5)) respectively 
although these were likely to have been driven by the initial signal in the British 1958 Birth 
Cohort. 
 
Since four datasets were available with total IgE measures, a meta-analysis of the individual 
study per-allele effect estimates was conducted in addition to combined analysis on available 
raw data from the Nottingham Gedling and Southampton cohorts only. Three SNPs met 
QRPLQDOVLJQLILFDQFHSUVTS [(-4)), rs6561505 (13q14, p=0.007), 
and rs10514054 (18q22, p=0.003) although as anticipated, these p values were driven by the 
British 1958 Birth Cohort which formed the largest contribution. Significant levels of study 
heterogeneity of effect sizes were identified for three SNPs S. This indicates 
that difficulty in replicating significant results for these SNPs may have been influenced by 
differences in the way each study was conducted. 
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Potential association for SNPs in candidate genes previously identified in a smaller dataset of 
the British 1958 Birth Cohort were also examined (Maier et al. 2006). In the British 1958 Birth 
cohort, association with elevated specific IgE was seen with SNPs within previously identified 
atopy genes including FCER1A (five SNPs: lowest p=0.002, OR 0.84), IL13 (two SNPs: lowest 
p=0.02, OR 1.16), and STAT6 (six SNPs: lowest p=0.003, OR 0.78) (Heinzmann et al. 2000; 
Schedel et al. 2004; Sanak et al. 2007). Whilst there was some evidence of association for both 
specific IgE and total IgE in the current study, none of these signals met conventional GWAS 
significance criteria in the larger dataset. Genes around the HLA locus was unable to be 
formally examined due to limitations in SNP coverage on the Illumina HumanHap550 Array. 
This cohort has demonstrated replication of previously identified atopy genes with more 
modest p values and effect sizes.  
 
A number of factors may have contributed to difficulty in repOLFDWLRQ)LUVWO\µZLQQHU¶VFXUVH
ELDV¶ PD\ KDYH UHVXOWHG LQ LQIODWHG HIIHFW VL]H HVWLPDWHV REWDLQHG IURP WKH GLVFRYHU\ FRKRUW
requiring much larger replication studies in order to have sufficient power to detect unbiased 
effect sizes. Numbers of study subjects used in this study may have been unlikely to yield 
enough statistical power to detect variants with modest effects particularly in the presence of 
substantial allelic heterogeneity (Wright et al. 1999). Despite efforts to increase total sample 
sizes through combined analyses, there was still inadequate power overall, which was further 
reduced as a result of study heterogeneity. Using a two-stage replication design, a total of more 
than 16,000 individuals was required in replication cohorts in order to have 80% power to 
detect risk allele odds ratios of greater than 1.2.  
 
Secondly, heterogeneity across study populations in both phenotype definitions and variable 
coverage of SNPs across the genome in genotyping arrays used may have complicated 
analyses. Not all of the key SNPs studied were genotyped in the ALSPAC cohort requiring the 
use of imputed data. Although the r2 quality metrics for these SNPs were relatively high 
ranging from 0.86 (rs11244450) up to 0.99 (rs6082335), this was a further limitation during 
replication. 
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Many SNPs showing association with elevated specific IgE in the discovery GWA study were 
also associated with serum total IgE levels in the British 1958 Birth cohort. In addition, 
measured elevated specific IgE and positive SPT results for the same subjects in the 
Southampton cohort corrHODWHG ZHOO 3HDUVRQ¶V U2=0.73, p<0.001). However, the relationship 
between these phenotypes is unclear and it is likely that the use of different atopy markers 
across cohorts may have contributed to difficulty in replication due to different genetic 
contributions to these related phenotypes. Despite some overlap in SNP association, loci 
identified for atopy defined using specific IgE and positive SPT in this study appear to be 
unique compared to those for increased serum total IgE levels suggesting that the processes 
controlling sensitisation may differ from those controlling level of IgE production. Carrying 
out a GWA study of total IgE within the British 1958 Birth Cohort using this dataset may have 
helped to provide further insight into this question, but this was not possible as related analyses 
were already included as part of the GABRIEL study (Moffatt et al. 2010). 
 
Previous research using subjects from the ALSPAC cohort has shown that 70% of all atopic 
children were identified from their reactions to the three common allergens alone i.e. house 
dust mite (Der p 1), mixed grass pollen and cat fur (Perkin et al. 2006). However, there is still 
some risk of phenotype misclassification in which atopic individuals will be considered as 
controls in the absence of a more extensive panel. In addition, variations in the antigen panels 
used across cohorts may have complicated replication as well as differences in population 
demographics. The British 1958 Birth Cohort, Nottingham Gedling, and Southampton cohorts 
are adult populations whereas subjects in the ALSPAC cohort had a mean age of 7.5 years at 
the time of atopy data collection. 
 
The main conclusion that can be drawn from this GWA study is that overall there is evidence 
for a large number of genetic factors influencing atopy risk, each with a small contribution. 
Therefore, the detection of further susceptibility loci will require GWA studies with more 
complete genome SNP coverage and using larger sample sizes together with the combination 
of results across multiple studies. These results have significant implications for the design of 
reliable studies to identify genes regulating elevated specific IgE and contributing to atopy. 
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The results from this Chapter have highlighted the importance for well designed and large 
GWA studies to address these issues. 
100 
 Chapter 4  
Assessing Atopy Susceptibility within Previously 
Identified Linkage Loci on Chromosomes 3 and 17 
 
4.1 Introduction 
 
Prior to the discovery and widespread use of genome-wide association (GWA) approaches, 
considerable efforts had been made to map the chromosomal locations of susceptibility genes 
for asthma and atopy through the use of linkage in families. Over the past decade, numerous 
genome-wide linkage (GWL) scans in multiple populations have identified more than 20 
distinct susceptibility regions including chromosomes 2q, 5q, 6p, 11q, and 13q as well as 
positionally cloned genes such as ADAM33, GRPA, PHF11, DPP10, and HLA-G (Ober 05, 
Bouzigon 10) (see Chapter 1, Section 1.3.2). 
 
However, inconsistency in study designs including phenotype definitions, family ascertainment 
schemes, and analytical methods have resulted in a lack of replication and consistent evidence 
for individual loci. Previous work performed by colleagues in Nottingham completed a meta-
analysis of data from GWL studies of asthma and related traits: bronchial hyper-responsiveness 
(BHR), allergen positive skin prick test (SPT), and serum total Immunoglobulin E (IgE) 
(Denham et al. 2008) (see Chapter 1: Section 1.3.3). This study aimed to increase statistical 
power and reduce the potential for type 1 and type 2 errors in identifying novel candidate genes 
as well as infer reasons for the inconsistency and lack of reproducibility of findings. 
 
The rank based genome-scan meta-analysis (GSMA) method was used to combine linkage data 
from nine Caucasian asthma proband populations. The close inter-relation between asthma and 
atopy suggested by co-occurence of these phenotypes has allowed the study of atopic 
phenotypes in families ascertained through a proband with asthma. Significant evidence for 
linkage was shown for chromosomal regions 3p22.1-q22.1 and 17p12-q24.3 suggesting that 
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they may contain susceptibility loci for positive SPT at least in asthma enriched families (1,093 
pedigrees, n=4,746) [Figure 4.1]. Results from this study supported the contribution of regions 
that contain previously identified asthma susceptibility genes to the risk of developing allergen 
SPT responses and by inference atopy. 
 
 
Figure 4.1 - Weighted GSMA results for positive SPT response. This plot taken from the 
GSMA shows significant evidence for linkage to positive SPT response on chromosomes 
3p22.1-q22.1 and 17p12-q24.3. Taken from (Denham et al. 2008). 
 
The identified regions were large, spanning 70.3Mb and 28.5Mb on chromosomes 3p22.1-
q22.1 and 17p12-q24.3 respectively, each harbouring a large number of potential candidate 
genes. The genotype data generated from the GWA study described in Chapter 3 were able to 
be used to test association of SNPs within these regions in order to carry out fine mapping to 
try and localise causative loci and variants within genes responsible for the possible linkage 
signals seen. 
 
Although these regions were not identified for significant association and did not feature in the 
work derived in Chapter 3, this provides an alternative, complimentary approach to identifying 
susceptibility genes. The results from the GWA study indicate that there are likely to be 
multiple loci with modest effects in determining susceptibility to asthma. This focused 
approach may yield more statistical power as it limits the regions studied and thus the level of 
stringency needed when correcting for multiple testing. 
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4.2 Aim 
 
The aim of this Chapter was to further define previously identified atopy susceptibility loci on 
chromosomes 3 and 17 using data from a GWA study in the British 1958 Birth Cohort. 
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4.3 Methods 
 
4.3.1 Study Populations 
As in Chapter 3, primary analyses in Chapter 4 were carried out in the British 1958 Birth 
Cohort (1,083 cases and 2,770 controls), identified SNPs of interests were assessed using in 
silico replication in the ALSPAC cohort (1,324 individuals) as well as prospective genotyping 
in the Nottingham Gedling (1,286 individuals) and Southampton cohorts (757 individuals) (see 
Chapter 3: Section 3.1.1 for details). 
 
The work presented in Chapter 4 was commenced using data from a subset of 388 cases and 
1,040 controls from the British 1958 Birth Cohort prior to the complete dataset becoming 
available. This subset of individuals was also genotyped using the Affymetrix Human Mapping 
500K SNP platform. In addition, the deCODE Icelandic cohort was used in Chapter 4 during in 
silico replication. This cohort consisted of 908 cases and 27,150 general population controls 
genotyped using the Illumina HumanHap300 SNP platform. Details of study recruitment and 
phenotyping in all cohorts are described in Chapter 2: Section 2.1.1. Genotyping and quality 
control procedures undertaken are summarised in Chapter 2: Section 2.2.1.1. 
 
$WRS\ZDVGHILQHGXVLQJSRVLWLYH637PPRURIWKHKLVWDPLQHFRQWUROLQWKHGH&2'(
Icelandic cohort. A sub-group of 239 non-asthmatic, atopic cases were also identified. No 
serum total IgE level data was available for analysis in this cohort.  
 
4.3.2 Association Testing 
Details of summary data generation in the British 1958 Birth Cohort and the ALSPAC cohort, 
methods for association testing following prospective genotyping in the Nottingham Gedling 
and Southampton cohorts as well as in pooled analyses are described in Chapter 3: Section 
3.3.2. In Chapter 4, the subset dataset analysed in the British 1958 Birth Cohort (1,468 
LQGLYLGXDOV ZLOO EH UHIHUUHG WR DV µ%& VSHFLILF ,J( '¶ WKH FRPSOHWH GDWDVHW 
LQGLYLGXDOVZLOOEHUHIHUUHGWRDVµ%&VSHFLILF,J('¶$OOHOHFRXQWVIRU613VXQGHUJRLQJ
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replication analyses were provided from a previous GWA study in the deCODE Icelandic 
cohort. Association tests for positive SPT in total cases and the sub-group of non-asthmatic 
cases against general popuODWLRQ FRQWUROV ZHUH FDUULHG RXW XVLQJ 3HDUVRQ¶V Chi-VTXDUHG Ȥ2) 
per-allele tests with one degree of freedom (df) comparing allele frequencies (see Chapter 2: 
Section 2.4.2). The flow of analyses carried out is summarised in Figure 4.2. 
 
 
Figure 4.2 ± Summary flow diagram of analyses to assess atopy susceptibility within 
previously identified linkage loci on Chromosomes 3 and 17. * Note: individuals included 
in B58C specific IgE D2 encompasses those in B58C specific IgE D1. 
 
4.3.3 Statistical Significance Testing within GSMA Bins 
Results of GWA testing using B58C specific IgE D1 (1,468 individuals) were provided for 
SNPs within GSMA reported susceptibility bins: 3p22.1-q22.1 (38,845kb to 134,474kb), 
17p12-q24 (11,325kb to 66,600kb). These were grouped according to the genotyping platform 
used (Illumina HumanHap550 or Affymetrix Human Mapping 500K). Statistical significance 
ZDVDVVHVVHGXVLQJQRPLQDOO\GHILQHGSDVZHOODV%RQIHUURQLFRUUHFWHGSYDOXHVDWWKH
 VLJQLILFDQFH OHYHO S[(-6) for 15,640 SNPs on 3p22.1-q22.1 and p[(-6) for 
8,543 SNPs on 17p12-TWHVWHGRQWKH,OOXPLQDSODWIRUPS[(-6) for 14,083 SNPs on 
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3p22.1-q22.1 and p[(-6) for 7,146 SNPs on 17p12-q24 tested on the Affymetrix 
platform. 
 
Susceptibility loci were identified based on clustering of statistically significant SNPs, 
consistency of results across genotyping platforms, the surrounding linkage disequilibrium 
(LD), and relationship with potential candidate genes in the same region. Intervals shown to be 
kb apart were combined and distinct loci taken forward for fine mapping. 
 
4.3.4 Fine Mapping of Identified Loci 
Subsequently, summary data from the complete GWA dataset in the British 1958 Birth Cohort 
i.e. B58C specific IgE D2 (3,853 individuals) and the deCODE Icelandic cohort became 
available. Distinct loci identified using the method described above using B58C specific IgE 
'ZHUHQRORQJHUSXUVXHGLIWKH\GLGQRWFRQWDLQDQ\DVVRFLDWHG613VSZLWKLQERWK
the B58C specific IgE D2 and deCODE Icelandic cohort datasets. In order to identify potential 
atopy-VSHFLILF ORFL 613V ZLWKLQ UHPDLQLQJ ORFL ZHUH WHVWHG IRU DVVRFLDWLRQ S ZLWK
serum total IgE levels in the British 1958 Birth Cohort within the complete dataset (3,853 
individuals) and non-asthmatic, atopic cases (239 individuals) in the deCODE Icelandic cohort. 
All SNPs meeting p value thresholds were assessed to ensure that the same direction of effect 
was shown across cohorts. Atopy-specific loci were taken forward for replication analyses. 
 
4.3.5 SNP Selection for Replication Studies 
Replication was tested for SNPs showing the highest statistical significance within each atopy 
specific locus as well as consistent association in both datasets from the British 1958 Birth 
Cohort. Quality control was assessed for minor allele frequency (MAF) >5% and in Hardy-
Weinberg equilibrium (HWE p>0.05). Positive replication was assessed at the 5% significance 
level. 
 
4.3.6 Candidate Gene Expression 
Expression profiling of possible candidate genes identified by statistically significant SNP 
associations was carried out using polymerase chain reaction (PCR) in two independent cDNA 
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panels with two repeats each. Assays were designed to detect all published gene transcripts 
documented online using NCBI. PCR products were sequence verified (see Chapter 2: Section 
2.5). 
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4.4 Results 
 
4.4.1 Association Testing of GSMA Bins in the British 1958 Birth Cohort 
No SNPs met Bonferroni corrected threshold for significance [Figure 4.3]. A total of 40 SNPs 
on 3p22.1-q22.1 and 22 SNPs on 17p12-q24 met criteria for nominal significance (p
All SNPs were plotted on positional maps showing LD blocks and all candidate genes in the 
region (Appendix 4). A total of 14 groups of SNPs were identified on chromosome 3 and 9 on 
chromosome 17, FRPELQLQJ LQWHUYDO UHJLRQV Nb apart resulted in 11 distinct loci on 
chromosome 3 and 8 distinct loci on chromosome 17 [Table 4.1]. 
 
Table 4.1 ± Loci identified for fine mapping by results of all SNPs tested for association in 
the B58C specific IgE D1 within GSMA identified susceptibility bins on chromosomes 
3p22.1-q22.1 and 17p12-q24.3. Loci identified for fine mapping are labelled A to K (11 loci 
and 8 candidate genes) on chromosome 3 and A to H (8 loci and 6 candidate genes) on 
chromosome 17 [Figure 4.3]. 
Chromosome Loci (kb) Size (kb) Gene(s) 
3 A 45405-45580 175 LARS2 
B 54560-54600 40 CACNA2D3 
C 56930-57050 120 - 
D 61415-61510 95 PTPRG 
E 64115-64710 595 - 
F 66390-66910 520 SLC25A26, LRIG1 
G 87070-87355 285 - 
H 97725-98160 435 EPHA6 
I 114230-114550 320 WDR52 
J 118625-118725 100 - 
K 120090-120210 120 IGSF11 
17 A 13080-13105 25 - 
B 13913-14060 147 COX10 
C 39025-39080 55 - 
D 39990-40415 425 ADAM11, EFTUD2, LOC146909 
E 47965-48050 85 - 
F 50100-50145 45 - 
G 53200-53220 20 - 
H 54650-55280 630 GDPD1, VMP1 
LARS2: leucyl-tRNA synthetase 2, mitochondrial; CACNA2D3: calcium channel, voltage-dependent, 
alpha 2/delta subunit 3; PTPRG: protein tyrosine phosphatase, receptor type, G; SLC25A26: solute carrier 
family 25, member 26; LRIG1: leucine-rich repeats and immunoglobulin-like domains 1; EPHA6: EPH 
receptor A6; WDR52: WD repeat domain 52; IGSF11: immunoglobulin superfamily, member 11; 
COX10: COX10 homolog, cytochrome c oxidase assembly protein, heme A: farnesyltransferase (yeast); 
ADAM11: ADAM metallopeptidase domain 11; EFTUD2: elongation factor Tu GTP binding domain 
containing 2; GDPD1: glycerophosphodiester phosphodiesterase domain containing 1; VMP1: vacuole 
membrane protein 1. 
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Figure 4.3 ± Results of all SNPs tested for association in the B58C specific IgE D1 within 
GSMA identified susceptibility bins on chromosomes 3p22.1-q22.1 and 17p12-q24.3. 
SNPs genotyped using the Illumina 550K and Affymetrix 500K platforms are shown in blue 
and orange respectively. The Bonferroni (chromosome and platform specific) and nominal 
significance thresholds (p=0.001) are marked. Loci identified for fine mapping are labelled A) 
A to K on chromosome 3 and B) A to H on chromosome 17 [Table 4.1]. 
 
A 
B 
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4.4.2 Fine Mapping of Identified Loci 
The complete dataset from the British 1958 Birth Cohort became available. Therefore, SNP 
results within the original GSMA set susceptibility bins were assessed using B58C specific IgE 
D2. Results indicate that the physical positions of identified susceptibility loci had shifted 
following the inclusion of more individuals in analyses [Figure 4.4]. Four loci (D, E, F, G) on 
chromosome 3 and five loci on chromosome 17 (B, C, D, G, H) identified using the subset 
B58C specific IgE D1 dataset remained significant within the complete B58C specific IgE D2 
dataset. Summary data from association tests with atopy in the deCODE Icelandic cohort were 
provided for SNPs within these loci. Only three loci (D, F, G) on chromosome 3 and a single 
locus (D) on chromosome 17 contained SNPs associated with positive SPT in the deCODE 
Icelandic cohort. On chromosome 3, these were rs2886524 (p=6.60x10(-4)) within locus D, 
rs7628307 (p=0.008) and rs9845175 (p=0.002) within locus F, rs1002765 (p=0.002) and 
rs6768771 (p=0.003) within locus G. On chromosome 17, a single SNP was identified within 
locus D: rs1126642 (p=0.007).  
 
Only locus D on chromosome 17 contained SNPs showing association with both serum total 
IgE levels in the British 1958 Birth Cohort (eight out of 78 tested SNPs: SDQG
non-asthmatic atopy in the deCODE Icelandic Population cohort (one out of three tested SNPs: 
p=0.018 for rs1002765). The highest significance SNP, rs7212001 within this atopy specific 
region showing consistent association in both British 1958 Birth Cohort datasets (p=4.31x10(-5) 
for specific IgE in D1, p=0.016 for specific IgE in D2, p=0.024 for total IgE) was taken 
forward for replication analyses. 
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Figure 4.4 ± Results of all SNPs tested for association in the B58C specific IgE D2 within 
GSMA identified susceptibility bins on chromosomes 3p22.1-q22.1 and 17p12-q24.3. 
SNPs were genotyped using the Illumina 550K platform only, shown in blue. The Bonferroni 
(chromosome and platform specific) and nominal significance thresholds (p=0.001) are 
marked. Loci identified for fine mapping are labelled A) A to K on chromosome 3 and B) A to 
H on chromosome 17 [Table 4.1]. 
A 
B 
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4.4.3 In silico Replication 
The single locus (D) identified on 17q21.3 was studied in the ALSPAC cohort by analysis of 
rs7212001, but this SNP did not show replicated association with SPT positivity, p=0.316 
[Table 4.2]. 
 
4.4.4 Replication Genotyping 
The identified SNP, rs7212001 was genotyped in the Nottingham Gedling and Southampton 
cohorts and did not show statistically significant evidence of association for either specific IgE 
or positive SPT. However, all results showed the same direction of effect for the minor allele 
[Table 4.2]. 
 
4.4.5 Total IgE Analyses 
Association with serum total IgE levels in the British 1958 Birth Cohort was seen for 
rs7212001 (p=0.024) showing the same direction of effect for specific IgE (OR 0.88, 95% CI 
0.79-0.97) and serum total IgE (OR 0.93, 95% CI 0.87-0.99). This was not replicated in any of 
the other cohorts. 
 
Table 4.2 - Association results for rs7212001 (17q21.31) in individual cohorts and 
combined analyses. P values and effect sizes for the minor (2nd) allele measured using OR for 
elevated specific Ig(DQGSRVLWLYH637ȕ for serum total IgE. 
SNP Phenotype Cohort N Effect (95% CI) p value 
Case Control 
rs7212001 Elevated 
specific IgE 
B58C 1,083 2,768 0.88 (0.79-0.97) 0.011 
µ7&¶ Southampton 281 370 0.91 (0.73-1.13) 0.394 
 Positive 
SPT 
ALSPAC 282 1,040 0.92 (0.76-1.11) 0.384 
 deCODE 966 27,129 1.04 (0.95-1.14) 0.316 
 Gedling 395 847 0.95 (0.80-1.13) 0.585 
 Southampton 367 283 0.90 (0.72-1.12) 0.341 
 Serum total 
IgE 
B58C 3,873 0.93 (0.87-0.99) 0.024 
 ALSPAC 1,423 1.01 (0.95-1.08) 0.753 
 Gedling 1,167 1.00 (0.88-1.15) 0.951 
 Southampton 654 0.84 (0.59-1.19) 0.319 
 Combined Specific IgE 1,364 3,138 0.88 (0.81-0.97) 7.87x10(-3) 
 Positive SPT 2,010 29,299 0.96 (0.89-1.02) 0.167 
 Total IgE 1,821 0.93 (0.67-1.17) 0.547 
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4.4.6 Combined Analyses 
Combined analyses of allele count data for elevated specific IgE and positive SPT across 
cohorts were conducted to estimate pooled p values and effect sizes [Table 4.2 and Figure 4.5]. 
A significant association with elevated specific IgE was seen for this SNP although these 
effects were driven by the British 1958 Birth Cohort dataset. No SNP showed significant 
association with positive SPT. Pooled analysis of serum total IgE levels was carried out for the 
Nottingham Gedling and Southampton cohorts and no SNP met statistical significance. 
 
 
Figure 4.5 - Forest plot for rs7212001 (17q21.31). Per-allele summary effect sizes for the 
minor allele are shown for atopy phenotypes: elevated specific IgE (OR), positive SPT (OR), 
and serum total IgE levels (ȕ(DFKURZUHSUHVHQWVRQHVWXG\UHODWLYHVL]HVRIGDWDSRLQWVDUH
proportional to the cohort sample size, horizontal lines represent 95% confidence intervals. 
Diamonds represent the meta-DQDO\VHVGHQRWHVVWDWLVWLFDOVLJQLILFDQFHS 
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4.4.7 Candidate Gene Expression 
The identified SNP rs7212001 is within an intronic region of Kinesin family member 18B 
(KIF18B). Two published transcript variants were documented on NCBI for KIF18B 
(NM_001080443). Expression profiling of this gene was carried out in two independent panels 
consisting of cDNA samples from human airway smooth muscle (HASM), human bronchial 
epithelial cells (HBEC), lung, dermal fibroblasts, human mast cell line (HMC-1), peripheral 
blood mononuclear cells (PBMC), brain, kidney, and placenta. Primers were designed to detect 
all published transcripts and are listed in Appendix 2. In the tested panels, KIF18B expression 
was observed in dermal fibroblast only [Figure 4.6]. PCR products were sequenced and 
verified against published gene transcripts using NCBI blast. 
 
 
Figure 4.6 ± Gel electrophoresis under UV illumination showing expression in dermal 
fibroblast of KIF18B. Primers were designed to detect all two published transcripts 
(NM_001080443). This is a representative gel from two experiments showing similar results. 
A product of 331bp was seen in all cell types examined. HASM denotes human airway smooth 
muscle, HBEC denotes human bronchial epithelial cell, HMC-1 denotes human mast cell line, 
PBMC denotes peripheral blood mononuclear cells. 1kb DNA ladders are shown on the left 
and right extremes, RT -ve and water controls are shown in the second row. 
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4.5 Discussion 
 
This Chapter describes results from assessment of previously reported linkage loci for atopy on 
chromosomes 3 and 17 to identify potential susceptibility polymorphisms; these loci were 
identified through a meta-analysis of nine GWL scans carried out in Caucasian asthma 
families. Three adjacent bins implicating chromosomal region 3p22.1-q22.1 and two adjacent 
bins implicating 17p12-q24.3 showed significant evidence for linkage to atopy defined by 
positive SPT responses in the meta-analysis. Testing SNPs within these regions for association 
with elevated specific IgE in 1,428 subjects from the British 1958 Birth Cohort was carried out. 
Fine mapping was subsequently undertaken using a more complete dataset from the same 
cohort (inclusive of an additional 2,425 subjects) as well as  28,140 individuals from the 
deCODE Icelandic cohort. Follow-up investigations in 7,423 individuals from three additional 
cohorts were carried out using atopy defined by elevated specific IgE and/or positive SPT. 
Overall, no causative loci could be determined. 
 
Within the British 1958 Birth Cohort specific IgE D1 dataset, consistency of genotyping results 
was demonstrated between the Illumina and Affymetrix SNP platforms. However, there were 
11.1% and 19.5% increased SNP coverage on chromosomes 3 and 17 respectively using the 
Illumina platform for genotyping. No SNPs on either platform met Bonferroni corrected 
threshold for significance. A second less stringent nominal significance level (p ZDV
used identifying a further 40 SNPs on chromosome 3 and 22 SNPs on chromosome 17. 
 
Following analysis for clustering of significant SNPs, extent of LD, and positions of candidate 
genes in the region, a total of 11 independent susceptibility loci were identified on 
chromosome 3 and eight loci on chromosome 17. Four loci on chromosome 3 and five loci on 
chromosome 17 identified using the British 1958 Birth Cohort specific IgE D1 remained 
significant within the larger dataset, the British 1958 Birth Cohort specific IgE D2 which 
became available during analyses, in which there was a nearly three-fold increase in the 
number of individuals genotyped. 
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Three loci on chromosome 3 and one on chromosome 17 replicated association with positive 
SPT in the deCODE Icelandic cohort. Further analysis for association with both total IgE in the 
British 1958 Birth Cohort and non-asthmatic atopy in the deCODE Icelandic Population cohort 
S VXJJHVWHG WKDW WKH VLQJOH locus on chromosome 17q21.3 contained SNPs showing 
atopy specific association. This identified a single candidate gene, KIF18B which encodes a 
motor protein which may be involved in adenosine triphosphate (ATP) binding and 
microtubule-based movement (Lee et al. 2010). The top hit SNP in this region, rs7212001 was 
studied for replication in silico and by prospective genotyping. There was little evidence of 
consistent association in the additional cohorts for this SNP and therefore, it seems unlikely to 
confer increased susceptibility to atopy in these populations. 
 
The GSMA assessed GWL scans carried out in family cohorts ascertained using asthma 
probands. Analyses detailed in this Chapter were carried out in general population cohorts, 
therefore identified loci in the GSMA may be more important in determining susceptibility to 
asthma rather than atopy. Efforts had been made to standardise asthma diagnosis and criteria 
for positive SPT in order to reduce between-study heterogeneity. However, varying phenotype 
definitions were used and allergens tested differed across studies. This is likely to have 
influenced the production of allergen-specific IgE and therefore confounded the use of elevated 
specific IgE as a marker of atopy for association testing in this study. Furthermore, although 
asthma and atopy are intrinsically linked, increasing evidence in particular from genetic studies 
to support the existence of trait specific loci suggest that the methodology used in this study 
was perhaps unlikely to identify atopy susceptibility but rather more pleiotropic genes (Palmer 
et al. 2000). 
 
Results from previous Chapter 3 describing the GWA study from which SNP data for fine 
mapping was generated suggest that a large number of genes are likely to be involved in the 
development of atopy, each conferring a modest effect. Given this, the power to find 
association produced by a single or few gene(s) in specific chromosomal regions may be low. 
Estimations of study power for individual cohorts used in analyses (detailed in Chapter 3) 
show that there is overall low statistical power to detect small effects. In addition, the 
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significant signals seen may be due to several genes in combination in close proximity within 
the entire region and therefore fine mapping for individual genes may not be appropriate. 
 
In the past year, a second GSMA has been completed in 20 GWL scans in multiple ethnicities 
showing consistency of findings (n=3,024 families). This study identified novel loci for asthma 
and atopy susceptibility as well as provided further genome-wide significant support for 
3p25.3-q24 and 17q12-q24 for SPT response in individuals of European ancestry (Bouzigon et 
al. 2010). Convincing evidence for these two regions has been reported by numerous studies 
demonstrating both linkage and association for asthma and atopy phenotypes (Ober et al. 1999; 
Bradley et al. 2002). These results suggest that 3p22.1-q22.1 and 17p12-q24.3 may harbour 
several susceptibility genes, including some pleiotropic effects on correlated phenotypes 
including toll-like receptor 9 (TLR9), chemokine (C-C motif) receptor 3 (CCR3), chemokine 
(C-C motif) receptor 5 (CCR5) on chromosome 3, and interestingly, ORMDL3 on chromosome 
17 (Bradley et al. 2002; Moffatt et al. 2007). 
 
Shifts in the positions of significant peaks seen between the two British 1958 Birth Cohort 
datasets indicate that differences in sample sizes used in genetic association studies have a 
considerable influence on the accuracy and ability in localising causative variants. These 
results indicate that the initial findings may have been modest and less robust to type II errors. 
Using the smaller cohort to select distinct loci for further analysis may have prematurely 
eliminated regions harbouring the true causative variants. Due to practical limitations, sub-
group genotyping in two phases was carried out in the British 1958 Birth Cohort, but this is 
likely WR KDYH LQWURGXFHG µEDWFK HIIHFWV¶ RU WHFKQLFDO ELDV OHDGLQJ WR QRQ-biological 
experimental variation in the two datasets used.  
 
Similarly to Chapter 3, there are problems in heterogeneity across the fine mapping and 
replication study populations in demographics, phenotype definitions, and variable SNP 
coverage across genotyping platforms. For example, within locus D on chromosome 17, a total 
of 78 genotyped SNPs were tested in the British 1958 Birth Cohort compared to three SNPs in 
the deCODE Icelandic cohort. In addition, less robust phenotyping in the deCODE Icelandic 
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cohort through defining control subjects as all individuals in the general population may have 
resulted in misclassified subjects who could have been considered cases using elevated specific 
IgE as the marker of atopy or alternatively have asthma symptoms. For this reason, study 
power estimations were not carried out for this cohort. Furthermore, variation in environmental 
exposures in particular in the deCODE Icelandic cohort are likely to have influenced the ability 
to detect consistent signals. 
 
Subtle, underlying population stratification due to varying ancestry may have led to potential 
differences between the deCODE Icelandic cohort and other British cohorts used in this study. 
This variation in linkage disequilibrium patterns in combination with a poor overlap of 
genotyped SNPs within these chromosomal regions may have precipitated the lack of 
replicated loci to carry forward for fine mapping. 
 
The results presented in this Chapter have not been able to identify atopy susceptibility loci 
through fine mapping of two susceptibility regions for SPT positivity on chromosomes 3p22.1-
q22.1 and 17p12-q24.3 identified through a previous meta-analysis of nine GWL scans. This 
further supports conclusions drawn from the GWA study described in Chapter 3 indicating 
evidence for multiple loci harbouring modest effects. 
 
This fine mapping approach reduces the number of regions studies and therefore increases 
statistical power and previous research suggest that signals generated by linkage are likely to 
be driven by variants with larger effect sizes. However, due to the large number of individuals 
used in the discovery cohort compared to much smaller replication samples, effect sizes were 
most likely overestimated. In combination to the other phenotyping and genotyping problems 
elucidated earlier, this would limit an ability to find variants determining disease susceptibility 
with small effects. Current methodologies to reliably identify causative genes require greater 
refinement in both study power and design. 
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Chapter 5 
Genome-Wide Association Study to Identify Genetic 
Determinants of Severe Asthma 
 
5.1 Introduction 
 
From the studies performed to date, it is clear that the total number of genetic loci implicated in 
asthma susceptibility is large and the proportion of effect from individual genetic variants both 
independently and in combination remains unclear. Importantly, association studies to date 
have predominantly focused on mild-to-moderate disease and genetic risk factors for severe 
asthma remain especially unclear (see Chapter 1: Sections 1.3.4 and 1.3.5). 
 
Previous studies of severe asthma have mostly used related traits such as measures of lung 
function defined using FEV1 or medication requirements such as steroid use. These have 
reported association between polymorphisms in previously reported asthma genes with 
increased declines in lung function and near fatal events including IL4 and IL4R (Burchard et 
al. 1999; Rosa-Rosa et al. 1999; Sandford et al. 2000), TGFB1 and chemokine (C-C motif) 
ligand 2 (CCL2) (Pulleyn et al. 2001; Szalai et al. 2001), and ADAM33 (Jongepier et al. 2004) 
as well as ADRB2 with worsened treatment response (Israel et al. 2001). Furthermore, a SNP 
near the ORMDL3 locus was reported to be associated with asthma severity in a group of early-
onset asthma cases (p=0.0012) (Halapi et al. 2010). In 2009, a relatively small genome-wide 
association (GWA) study was conducted on a population of patients with severe or difficult to 
treat asthma from the TENOR study (473 cases, 1,892 asthma-free controls) and identified 
association with multiple SNPs in the RAD50-IL13 and HLA-DR/DQ regions although no 
signal met conventional genome-wide significance (Li et al. 2010). 
 
The Asthma UK Genetics of Severe Asthma (AUGOSA) study has established the largest 
genotype database of severe asthma patients to date consisting of 1,026 individuals of 
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European ancestry recruited across UK-based centres. Participants from this study contributed 
to the group of cases used in the recent GABRIEL consortium GWA study. Furthermore, some 
overlap in controls also occurred with individuals collected by Busselton and the WTCCC2.  In 
addition to identifying determinants of asthma per se, GABRIEL also reported analyses for 
severe asthma (927 individuals after tests of quality control) of identified loci for all asthma 
subjects but did not identify any significant associations (Moffatt et al. 2010). 
 
The AUGOSA study presented the opportunity to use the GWA approach with the potential to 
identify novel loci to address two key questions: firstly to determine whether the genetic 
susceptibility to severe asthma differs from that of asthma per se, and secondly to evaluate the 
contribution of polymorphisms in recently reported asthma susceptibility genes identified 
through GWA in a more extreme phenotype. 
 
5.2 Aim 
 
The aim of this Chapter was to use GWA to identify common genetic variants influencing 
susceptibility to the development of severe asthma. 
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5.3 Methods 
 
5.3.1 Study Populations 
The primary GWA study was carried out using the Asthma UK Genetics of Severe Asthma 
(AUGOSA) study consisting of 1,026 cases and 3,372 individuals genotyped using the 
Illumina HumanHap550, HumanHap610-Quad, HumanHap660w-Quad, and Human1M-duo 
v3 SNP platforms. Power estimations calculated using CaTS 0.0.2 indicate that this dataset had 
80% power Į  WR GHWHFW DQ RGGV UDWLR 25 RI DSSUR[LPDWHO\  IRU D 613 ZLWK D
minor allele frequency (MAF) of 10%; 1.14 for a SNP with a MAF of 25%; and 1.12 for a SNP 
with a MAF of 40%. Replication of SNPs of interest was undertaken in the Australian Asthma 
Genetics Consortium (AAGC) study consisting of 231 cases and 1,345 controls genotyped 
using the Illumina HumanHap610-Quad SNP platform. This replication cohort dataset had 
80% power to detect an OR of 1.46 (MAF=10%), 1.31 (MAF=25%), and 1.28 (MAF=40%). 
Details of study recruitment and phenotyping for these population cohorts are described in 
Chapter 2: Section 2.1.2. 
 
Genotyping quality control measures undertaken in the AAGC study are described in Chapter 
2: Section 2.2.1.2. Remaining autosomal SNPs were then imputed up to 7.8 million SNPs 
against reference panel data from the March 2010 release of the 1000 Genomes Project and the 
February 2009 release of the HapMap3 Genome Browser release #2 using Impute2 (Howie et 
al. 2009). Post-imputation exclusion of SNPs with r2imp<0.3, MAF<1%, and Hardy-Weinberg 
equilibrium (HWE) p<10(-6) were carried out. Genotype data for a subsequent total of 5.7 
million SNPs were tested for association using a standard case-control allelic test with a 
genomic inflation factor of 1.02. 
 
5.3.2 Genotyping Quality Control 
Results of genotyping in all case subjects from the AUGOSA study were returned from Centre 
National de Génotypage (Paris, France) in .txt files detailing genotyping success (report.txt), 
summary of results per SNP (success_mark.txt), summary of results per individual 
(success_sample.txt), and the raw genotype calls for all SNPs genotyped in each individual 
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(data.txt). Results files containing raw genotype calls for all control subjects were provided by 
collaborators. 
 
Initial Filtering 
Initial filtering of supplied genotyped data was carried out in PLINK 1.07. Only autosomal 
SNPs were retained for analyses. Relevant data columns were extracted using R version 2.12.1 
to create .ped and .map PLINK input files. The .ped file contained the results per individual 
created using the data.txt file; the first 6 columns of this file contained the following 
information: Family ID (0=unknown), Individual ID, Paternal ID (0=unknown), Maternal ID 
(0=unknown), Sex (1=male, 2=female, 0=unknown), Affection status (1=unaffected, 
2=affected). Each line of the .map file described a single SNP containing three columns 
extracted from the success_mark.txt file: Chromosome (1 to 22, X, Y or 0 if unplaced), rs# or 
snp identifier, Base-pair position (bp units). 
 
The following command line was run in UNIX to remove individuals with <90% SNPs 
genotyped (--mind 0.1), SNPs with <90% of individuals genotyped (--geno 0.1), SNPs with 
MAF <1% (--maf 0.01), SNPs not meeting HWE p<10(-4) (--hwe 0.0001): 
 plink --file augosa --map3 --maf 0.01 --mind 0.1 --geno 0.1 --hwe 0.0001 --recode 
No individuals were removed during this filtering; the numbers of SNPs excluded are listed in 
Table 5.1. A subset of 490,303 SNPs present in all six cohorts was then taken. 
 
Table 5.1 ± Number of samples remaining and number of SNPs excluded after initial 
filtering. AUG610 and AUG660 denote results of cases recruited by the AUGOSA 
Consortium genotyped on the Illumina HumanHap610-Quad and 660w-Quad platforms 
respectively, BHS denotes the Busselton Health Study. 
Filter AUG610 AUG660 GABRIEL 
Severe 
BHS WTCCC2 T1DGC 
Sex Chromosomes 15303 13392 15303 15303 42558 13845 
MAF <1% 29485 23970 26832 31118 666 23615 
<90% samples genotyped 3115 1770 1994 2169 0 1260 
HWE p<10(-4) 259 948 902 1035 2109 3238 
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Tests of Differential Missingness 
The proportion of missing genotypes between cases and controls for each SNP was compared 
XVLQJ)LVKHU¶VH[DFWWHVWXVLQJWKHfollowing command line in UNIX: 
plink --file augosa --test-missing  
A total of 9,414 SNPs were excluded with p<10(-4) under the null hypothesis of equal 
proportions of missing data in cases and controls, leaving 480,889 SNPs for testing. 
 
Principal components analysis (PCA) 
Correction for underlying population structure in the data was undertaken by Dr. Nick R G 
Shrine using principal components analysis (PCA) (see Chapter 2: Section 2.4.1) based on the 
covariance of effect allele loadings (0, 1, 2) between SNPs and samples as implemented in 
EIGENSOFT 3.0. PCA can show components that are influenced by the linkage disequilibrium 
(LD) structure if SNPs in strong LD are used. Therefore, a subset of 57,213 uncorrelated SNPs 
for the PCA was identified by removing SNPs correlated by r2>0.1 within a window of 50 
adjacent SNPs in PLINK 1.07. The PCA results are shown in Figure 5.1 indicating generally 
homogenous populations. A total of 119 outliers were identified with variances >ı IRU
exclusion leaving 933 cases and 3,346 controls in the analysis [Table 5.2]. The first 10 
principal components was stored in a PCA.txt file with columns: Family ID, Individual ID, 
PCA1..10. 
 
Table 5.2 ± Number of samples remaining after Principal components analysis (PCA). 
AUG610 and AUG660 denote results of cases recruited by the AUGOSA Consortium 
genotyped on the Illumina HumanHap610-Quad and 660w-Quad platforms respectively, BHS 
denotes the Busselton Health Study. 
Filter AUG610 AUG660 GABRIEL 
Severe 
BHS WTCCC2 T1DGC 
Total 121 561 344 576 1483 1313 
PCA outliers 8 31 54 11 2 13 
Remaining 113 530 290 565 1481 1300 
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Figure 5.5 - Example plots showing the first two principal components. AUG610 and 
AUG660 denote results of cases recruited by the AUGOSA Consortium genotyped on the 
Illumina HumanHap610-Quad and 660w-Quad platforms respectively. A) No clear separation 
of clusters for each cohort (three case cohorts: AUG610, AUG660, GAB and three control 
cohorts: BUSSELTON, WTCCC2, T1DGC) suggests homogeneous populations. B) The PCA 
analysiV LGHQWLILHG  RXWOLHUV ZLWK YDULDQFHV !ı WKHVH ZHUH H[FOXGHG IURP VXEVHTXHQW
analyses. 
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5.3.3 Genome-wide Association (GWA) Testing 
Association testing was carried out using logistic regression models with one degree of 
freedom (df) (see Chapter 2: Section 2.4.2) comparing allele frequencies between cases and 
controls using PLINK 1.07. Identified principal components were used as covariates in the 
association analysis (--covar). Modified results files after quality control measures were 
analysed using the following command line in UNIX: 
plink --bfile augosa_QC --logistic --beta --ci 0.95 --covar PCA.txt 
The .assoc.logistic file produced contained regression coefficients (--beta) with 95% 
confidence intervals (--ci 0.95) and p values for association for the default minor allele per 
SNP.  
 
5.3.4 Post-Association Quality Control 
Control-control comparisons using the three control cohorts were run by appointing the status 
of each cohort in turn as cases in an association test with the others. This identified 21 SNPs 
with p<10(-6) in a given test for exclusion, leaving 480,868 SNPs in the analysis. The test 
inflation VWDWLVWLFȜVHH&KDSWHU6HFWLRQZDVFDOFXODWHGXVLQJWKHFRPPDQGOLQHLQ5
version 2.12.1 for data frame (results) with regression coefficients (BETA) and standard errors 
(SE): 
lambda<-median((results$BETA/results$SE)^2,na.r=T)/qchisq(0.5,1) 
Manhattan and Quantile-Quantile (Q-Q) plots were generated to visualise SNP results (see 
Chapter 2: Section 2.3.2). 
 
5.3.5 Statistical Significance Testing 
Genome-ZLGH VLJQLILFDQFH ZDV GHILQHG XVLQJ S[(-7) as determined by the Bonferroni 
correction at the 5% significance level (see Chapter 2: Section 2.4.8). Suggestive regions of 
interest were identified as those with a sentinel SNP showing association with asthma (at a 
threshold of p<5x10(-5)) with at least one additional SNP within 500kb also reaching a 
threshold of p<5x10(-5). 
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5.3.6 Imputation Using the 1000 Genomes Project 
Imputation using the 1000 Genomes Project (1000G) reference panel (see Chapter 2: Section 
2.4.7) was used to improve the resolution of regions identified for association from genotyped 
data carried out by Dr. Nick R G Shrine in two stages. Genotyped data were imputed to 
6,858,242 SNPs and GWA testing of imputed data was carried out. However, analyses were 
limited to regions identified from genotyped data. Genotypes were compared across the quality 
controlled 4,279 cases and controls to phase haplotypes, and then compared to haplotype 
blocks in the August 2010 release of the 1000G data. The European (CEU) panel was used 
consisting of 120 individuals genotyped at 6,858,242 SNPs downloaded from the MaCH 
website. The phasing step requires all alleles to be defined on the positive strand. Strand 
assignments of our samples were checked against UCSC and dbSNP. The phasing was 
performed using MaCH 1.0 and the imputation using minimac. Post imputation quality control 
was carried out to exclude SNPs with MAF <1% and imputation quality threshold r2imp<0.3. 
Association testing of remaining SNPs were performed using ProbABEL 0.1-3 using a logistic 
model with the dose of the effect allele (on a continuous scale between 0 and 2 to reflect 
imputation uncertainty) as the independent variable and 10 ancestry principal components 
derived from genotyped SNPs as covariates. Post association filters were applied to remove 
SNPs showing significant association in control-control comparisons (p<10(-6)) leaving 
6,103,628 SNPs. 
 
5.3.7 Replication and Meta-Analysis 
Replication analyses were carried out for a selected number of SNPs using the AAGC study. 
This was based on the following four criteria: genotyped SNPs identified through the primary 
GWA study, imputed SNPs with lower p values than genotyped SNPs in regions containing the 
genotyped SNPs of interest, imputed SNPs with p>10(-5) responsible for secondary peaks in 
regions with known asthma genes, as well as SNPs in new regions identified through analysis 
using imputed data with p<10(-5) and r2imp>0.7. Statistical significance for replication was 
assessed using a 5% significance threshold and results of inverse-variance weighted meta-
analysis assessed using conventional criteria for genome-wide significance (p=5x10(-8)) 
(McCarthy et al. 2008). 
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5.3.8 Evaluation of GABRIEL loci 
The contributions of risk polymorphisms identified for mild-to-moderate asthma by the 
GABRIEL Consortium were assessed in the AUGOSA severe asthma population. Regions 
±500kb of SNPs reported to be associated with asthma in the GABRIEL study were examined, 
including both regions reported to have reached genome-wide significance i.e. S[(-8) and 
those providing suggestive evidence of association i.e. S[(-7) in GABRIEL. 
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5.4 Results 
 
5.4.1 Loci Identified by GWA Testing 
The primary analysis involved 480,868 SNPs in 933 cases and 3,346 controls, resulting in a 
modest test inflation statistic Ȝ The Q-Q plot shows observed versus expected -log10 p 
values for all tested SNPs showing a small number of SNPs with extreme p values and 
additional SNPs with more modest effects [Figure 5.2]. The Manhattan plot shows -log10 p 
values for all tested SNPs ordered by chromosomal position showing the highest significance 
SNPs lying on chromosomes 2, 5, 6, 7, 13, and 17 [Figure 5.3]. 
 
 
Figure 5.2 ± Quantile-Quantile (Q-Q) plot showing GWA results for genotyped SNPs. The 
straight line shows the distribution of 480,868 SNPs analysed in 933 cases and 3,346 controls 
under the null hypothesis. 
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Figure 5.3 - Manhattan plot showing GWA results for 480,868 genotyped SNPs analysed in 933 cases and 3,346 controls under analysis. * Note: the signal on 
chromosome 13q31.1 was intergenic. 
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No SNPs met genome-wide significance for association with severe asthma using a cut-off 
defined by the Bonferroni correction: p=1.02x10(-7). Using a second criterion to evaluate other 
potential loci below this threshold, eight SNPs were identified with p<5x10(-5), with at least one 
other SNP within 500kb with p<5x10(-5) [Table 5.3]. Further assessment of supporting evidence 
within the region for these SNPs suggests that six of these loci may contain susceptibility genes 
for severe asthma [Figures 5.4 to 5.6]. Region plots showing low supporting evidence for the 
two eliminated SNPs are shown in Appendix 5. Sentinal SNPs for the six suggestive loci were 
rs11745587 within chromosome 5 open reading frame 56 (C5orf56) on 5q31.1 (p=2.09x10(-6)), 
rs9382963 upstream of CD83 molecule (CD83) on 6p23 (p=5.61x10(-6)), rs2496764 within an 
intergenic region on 13q31.1 (p=7.86x10(-6)), rs12699949 within phosphoribosyl 
pyrophosphate synthetase 1-like 1 (PRPS1L1) on 7p21.1 (p=1.19x10(-5)), rs1810132 within v-
erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2) on 17q12-21     
(p=1.73x10(-5)), and rs3771166 within interleukin 18 receptor 1 (IL18R1) on 2q12.1 
(p=1.93x10(-5)). 
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Figure 5.4 - Region plots for suggestive loci 1 to 2 (rs3771166 and rs11745587) using 
genotyped data identified by GWA testing. Statistical significance of each SNP on the          
±log10 scale is shown as a function of chromosome position (NCBI build 36). The sentinel SNP 
is shown in blue and the correlation (r2) of each of the surrounding SNPs shown by their colour 
(see key). Fine scale recombination rate is plotted in blue. 
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Figure 5.5 - Region plots for suggestive loci 3 to 4 (rs9382936 and rs12699949) using 
genotyped data identified by GWA testing. Statistical significance of each SNP on the          
±log10 scale is shown as a function of chromosome position (NCBI build 36). The sentinel SNP 
is shown in blue and the correlation (r2) of each of the surrounding SNPs shown by their colour 
(see key). Fine scale recombination rate is plotted in blue. 
 132 
 
Figure 5.6 - Region plots for suggestive loci 5 to 6 (rs2496764 and rs1810132) using 
genotyped data identified by GWA testing. Note rs2496764 is intergenic. Statistical 
significance of each SNP on the ±log10 scale is shown as a function of chromosome position 
(NCBI build 36). The sentinel SNP is shown in blue and the correlation (r2) of each of the 
surrounding SNPs shown by their colour (see key). Fine scale recombination rate is plotted in 
blue. 
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Table 5.3 ± Genotyped SNPs meeting significance criteria for association with severe asthma. Ref denotes reference allele; effect refers to the minor allele. SNPs with 
low supporting evidence in the region were not taken into additional analyses. 
 
 
 
 
 
 
IL18R1: interleukin 18 receptor 1; C5orf56: chromosome 5 open reading frame 56; CD83: CD83 molecule; PRPS1L1: phosphoribosyl pyrophosphate synthetase 1-like 1; ERBB2: v-erb-b2 
erythroblastic leukemia viral oncogene homolog 2; TRIM5: tripartite motif containing 5.  
 
Table 5.4 ± Top imputed SNP in suggestive regions identified by GWA testing using genotyped data. Ref denotes reference allele, effect refers to the minor allele. r2imp: 
Imputation quality. r2LD: Linkage disequilibrium with corresponding genotyped SNPs in Table 5.3 based on 1000G June 2010. 
 
 
 
IL18R1: interleukin 18 receptor 1; PRPS1L1: phosphoribosyl pyrophosphate synthetase 1-like 1; STARD3: StAR-related lipid transfer (START) domain containing 3. 
Chromosome Gene SNP Position Ref Effect MAF OR (95% CI) p value 
Suggestive loci meeting significance criteria 
2q12.1 IL18R1 rs3771166 102352654 G A 0.38 0.79 (0.71-0.88) 1.93x10(-5) 
5q31.1 C5orf56 rs11745587 131824821 G A 0.36 1.30 (1.17-1.45) 2.09x10(-6) 
6p23 CD83 rs9382936 14173097 G A 0.25 1.31 (1.17-1.48) 5.61x10(-6) 
7p21.1 PRPS1L1 rs12699949 18010787 G A 0.32 0.77 (0.69-0.87) 1.19x10(-5) 
13q31.1 Intergenic rs2496764 84477159 G A 0.20 1.34 (1.18-1.52) 7.86x10(-6) 
17q12-21 ERBB2 rs1810132 35119531 T C 0.31 1.28 (1.14-1.43) 1.73x10(-5) 
Eliminated loci due to low region support 
6p12.1 AL591034.2 rs9395865 53415653 G A 0.29 0.76 (0.67-0.85) 5.27x10(-6) 
11p15.4 TRIM5 rs10500656 5879658 G A 0.15 1.36 (1.18-1.56) 1.87x10(-5) 
Chromosome Gene SNP Position Ref Effect MAF r2imp r2LD OR (95% CI) p value 
2q12.1 IL18R1 rs9807989 102337632 T C 0.33 0.91 0.84 0.76 (0.67-0.85) 5.20x10(-6) 
7p21.1 PRPS1L1 rs12699948 18044210 C G 0.28 0.92 0.75 0.75 (0.66-0.85) 4.84x10(-6) 
13q31.1 Intergenic rs9547037 84476839 G T 0.19 0.90 0.83 1.38 (1.20-1.58) 6.60x10(-6) 
17q12-21 STARD3 rs9972882 35061224 C A 0.25 0.98 0.52 1.32 (1.17-1.49) 5.17x10(-6) 
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5.4.3 Imputation Using the 1000 Genomes Project 
Imputation was used to refine association signals within the six suggestive loci [Figures 5.7 to 
5.9]. The test inflation statistic for GWA testing was unchanged folORZLQJLPSXWDWLRQȜ 
This analysis identified a further four SNPs with a lower p value than the original genotyped 
SNP in the same region: rs9807989 within IL18R1 on 2q12.1 (p=5.20x10(-6)), rs12699948 
within PRPS1L1 on 7p21.1 (p=4.84x10(-6)), rs9547037 intergenic on 13q31.1 (p=6.60x10(-6)), 
and rs9972882 within StAR-related lipid transfer (START) domain containing 3 (STARD3) on 
17q12-21 (p=5.17x10(-6)) [Table 5.4]. 
 
Two imputed SNPs produced secondary peaks in other regions with known asthma associated 
genes: rs13035227 within interleukin 1 receptor-like 1 (IL1RL1) on 2q12.1 (p=8.91x10(-5)), and 
rs847 within IL13 on 5q31 (p=4.05x10(-5)) [Figure 5.6]. An additional 12 SNPs with p<10(-5) 
and r2imp=0.7 produced signals in new regions (1.19x10(-5)S[(-7)) following analyses of 
imputed data. Two of these SNPs, rs9897185 and rs4794820 produced secondary peaks in the 
previously identified 17q12-21 locus. All SNP results are detailed in Table 5.5, region plots for 
the secondary peaks produced by rs13035227 (2q12.1), rs847 (5q31), and rs9897185     
(17q12-21) are shown in Figures 5.10 and 5.11. Region plots for the secondary peak produced 
by rs4794820 (17q12-21) and all other new regions identified through imputation are shown in 
Appendix 5. 
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Figure 5.7 - Region plots using imputed data for suggestive loci 1 and 2 (rs3771166 and 
rs11745587) identified by GWA testing. Statistical significance of each SNP on the ±log10 
scale is shown as a function of chromosome position (NCBI build 36). The sentinel SNP is 
shown in blue and the correlation (r2) of each of the surrounding SNPs shown by their colour 
(see key). Fine scale recombination rate is plotted in blue. 
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Figure 5.8 - Region plots using imputed data for suggestive loci 3 and 4 (rs9382936 and 
rs12699949) identified by GWA testing. Statistical significance of each SNP on the ±log10 
scale is shown as a function of chromosome position (NCBI build 36). The sentinel SNP is 
shown in blue and the correlation (r2) of each of the surrounding SNPs shown by their colour 
(see key). Fine scale recombination rate is plotted in blue. 
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Figure 5.9 - Region plots using imputed data for suggestive loci 5 and 6 (rs2496764 and 
rs1810132) identified by GWA testing. Note rs9547037 is intergenic. Statistical significance 
of each SNP on the ±log10 scale is shown as a function of chromosome position (NCBI build 
36). The sentinel SNP is shown in blue and the correlation (r2) of each of the surrounding SNPs 
shown by their colour (see key). Fine scale recombination rate is plotted in blue. 
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Figure 5.10 - Region plots for identified regions with secondary peaks following 
imputation. Statistical significance of each SNP on the ±log10 scale is shown as a function of 
chromosome position (NCBI build 36). The sentinel SNP is shown in blue and the correlation 
(r2) of each of the surrounding SNPs shown by their colour (see key). Fine scale recombination 
rate is plotted in blue. 
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Figure 5.11 - Region plot for an identified region with a secondary peak following 
imputation. Statistical significance of each SNP on the ±log10 scale is shown as a function of 
chromosome position (NCBI build 36). The sentinel SNP is shown in blue and the correlation 
(r2) of each of the surrounding SNPs shown by their colour (see key). Fine scale recombination 
rate is plotted in blue. 
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5.4.4 Replication In Silico 
A total of 24 SNPs were followed up using in silico replication in the AAGC study [Table 5.5]. 
This consisted of the six genotyped SNPs identified by the primary GWA study, four imputed 
SNPs with lower p values than genotyped SNPs in the same six regions of interest, two 
imputed SNPs responsible for secondary peaks in regions with known asthma associated genes, 
and 12 SNPs in new regions identified through imputation. 
 
Two loci were replicated in the AAGC study cohort. The first of these was on 17q12-21 by 
rs4797820 within ORMDL3 (p=0.002). The second was on 2q12.1 by a cluster of 3 SNPs: 
rs3771166 (p=0.001), rs9807989 (p=0.003) both within IL18R1, and rs13035227 within IL1R1 
(p=0.002). In non-replicated regions, a consistent direction of effect for the minor allele was 
seen across studies for 12 out of the 20 remaining SNPs. Following meta-analysis, the signal 
on ORMDL3 met conventional genome-wide significance (p=1.03x10(-8)) and the signal on 
IL18R1 approached this threshold (p=5.59x10(-8)) [Table 5.5]. 
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Table 5.5 ± Results for follow-up SNPs of in silico replication and meta-analysis. *(12GHQRWHVJHQRW\SHG6136LJQLILFDQWSYDOXHVSLQUHSOLFDWLRQS[(-8) in 
meta-analysis are shown in bold. 
 AUGOSA (933 cases, 3,346 controls) AAGC (231 cases, 1,345 controls) Meta-analysis 
6 Genotyped SNPs from regions identified in genotype analysis 
Chromosome Gene SNP Position r2imp OR (95% CI) p value r2imp OR (95% CI) p value OR (95% CI) p value 
2 IL18R1 rs3771166 102352654 GENO 0.79 (0.71-0.88) 1.93x10(-5) GENO 0.71 (0.57-0.87) 0.001 0.77 (0.70-0.85) 1.24x10(-7) 
5 C5orf56 rs11745587 131824821 GENO 1.30 (1.17-1.45) 2.09x10(-6) GENO 1.13 (0.92-1.39) 0.25 1.26 (1.15-1.39) 2.13x10(-6) 
6 CD83 rs9382936 14173097 GENO 1.31 (1.17-1.48) 5.61x10(-6) GENO 1.00 (0.79-1.25) 0.98 1.24 (1.12-1.38) 5.68x10(-5) 
7 PRPS1L1 rs12699949 18010787 GENO 0.77 (0.69-0.87) 1.19x10(-5) GENO 0.89 (0.72-1.10) 0.27 0.80 (0.72-0.88) 1.19x10(-5) 
13 Intergenic rs2496764 84477159 GENO 1.34 (1.18-1.52) 7.86x10(-6) GENO 0.99 (0.78-1.27) 0.96 1.26 (1.12-1.41) 8.03x10(-5) 
17 ERBB2 rs1810132 35119531 GENO 1.28 (1.14-1.43) 1.73x10(-5) GENO 1.07 (0.86-1.32) 0.56 1.23 (1.11-1.36) 4.54x10(-5) 
5 Imputed SNPs in regions above with a lower p value than the genotyped SNP 
2 IL18R1 rs9807989 102337632 0.91 0.76 (0.67-0.85) 5.20x10(-6) 0.91 0.72 (0.58-0.89) 0.003 0.75 (0.68-0.83) 5.59x10(-8) 
7 PRPS1L1 rs12699948 18010735 0.92 0.75 (0.66-0.85) 4.84x10(-6) 0.93 0.92 (0.74-1.15) 0.46 0.79 (0.71-0.88) 1.44x10(-5) 
13 Intergenic rs9547037 84476839 0.90 1.38 (1.20-1.58) 6.60x10(-6) 0.90 1.00 (0.78-1.29) 0.97 1.28 (1.13-1.44) 8.01x10(-5) 
17 STARD3 rs9972882 35061224 0.98 1.32 (1.17-1.49) 5.17x10(-6) 0.99 1.07 (0.85-1.34) 0.55 1.26 (1.13-1.40) 1.64x10(-5) 
2 SNPs with p>10(-5) responsible for secondary peaks in regions with known asthma genes 
2 IL1R1 rs13035227 102130269 0.96 1.36 (1.16-1.58) 8.91x10(-5) GENO 1.53 (1.17-1.99) 0.002 1.40 (1.22-1.59) 6.69x10(-7) 
5 IL13 rs847 132024568 0.86 1.35 (1.17-1.55) 4.05x10(-5) 0.94 1.12 (0.88-1.43) 0.37 1.29 (1.14-1.45) 6.43x10(-5) 
12 SNPs from new regions identified by imputation with p<10(-5) and r2imp=0.7 (includes 2 secondary peaks in previously identified 17q12-21 locus) 
2 Intergenic chr2:211694960 211694960 0.70 1.76 (1.40-2.21) 1.27x10(-6) 0.78 1.11 (0.73-1.70) 0.62 1.59 (1.30-1.94) 6.80x10(-6) 
5 FLJ37543 rs7715669 60972053 GENO 0.74 (0.65-0.84) 5.92x10(-6) GENO 0.93 (0.74-1.18) 0.56 0.78 (0.69-0.87) 2.29x10(-5) 
5 NDFIP1 rs6867913 141426164 0.99 0.72 (0.63-0.82) 1.74x10(-6) 0.97 0.90 (0.69-1.15) 0.39 0.75 (0.67-0.85) 3.82x10(-6) 
6 GCLC rs9395865 53415653 GENO 0.76 (0.67-0.85) 5.27x10(-6) GENO 1.15 (0.93-1.42) 0.19 0.84 (0.76-0.93) 9.27x10(-4) 
6 Intergenic rs6922932 73384242 0.78 0.70 (0.60-0.82) 7.36x10(-6) 0.83 1.02 (0.79-1.31) 0.88 0.78 (0.68-0.89) 1.99x10(-4) 
8 DUSP4 rs650230 29322727 0.78 1.37 (1.19-1.57) 6.40x10(-6) 0.76 1.04 (0.83-1.30) 0.73 1.27 (1.13-1.42) 5.74x10(-5) 
9 ACO1 rs10970976 32423526 0.98 0.76 (0.67-0.86) 9.14x10(-6) 0.96 0.84 (0.67-1.05) 0.13 0.78 (0.70-0.86) 3.69x10(-6) 
11 OR52E4 rs4453217 5883859 0.87 1.43 (1.25-1.64) 2.82x10(-7) 0.88 0.94 (0.72-1.22) 0.63 1.31 (1.16-1.48) 1.50x10(-5) 
11 ETS1 rs7125574 127866404 0.93 1.34 (1.18-1.51) 5.28x10(-6) 0.93 0.92 (0.73-1.16) 0.49 1.23 (1.10-1.37) 2.13x10(-4) 
17 STAC2 rs9897185 34642935 GENO 1.31 (1.16-1.47) 1.19x10(-5) GENO 0.95 (0.75-1.19) 0.64 1.22 (1.10-1.35) 2.50x10(-4) 
17 ORMDL3 rs4794820 35342870 0.94 0.76 (0.68-0.85) 1.52x10(-6) 0.93 0.72 (0.59-0.89) 0.002 0.75 (0.69-0.83) 1.03x10(-8) 
19 ZNF665 rs16984547 58373854 GENO 1.53 (1.30-1.82) 5.45x10(-7) GENO 1.06 (0.76-1.49) 0.74 1.43 (1.23-1.66) 3.54x10(-6) 
IL18R1: interleukin 18 receptor 1; C5orf56: chromosome 5 open reading frame 56; CD83: CD83 molecule; PRPS1L1: phosphoribosyl pyrophosphate synthetase 1-like 1; ERBB2: v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2; STARD3: StAR-related lipid transfer (START) domain containing 3; IL1R1: interleukin 1 receptor-like 1; IL13: interleukin 13; NDFIP1: Nedd4 family interacting protein 1; GCLC: glutamate-
cysteine ligase, catalytic subunit; DUSP4: dual specificity phosphatase 4; ACO1: aconitase 1, soluble; OR52E4: olfactory receptor, family 52, subfamily E, member 4; ETS1: v-ets erythroblastosis virus E26 oncogene 
homolog 1 (avian) ; STAC2: SH3 and cysteine rich domain 2; ORMDL3: ORM1-like protein 3: ZNF665: zinc finger protein 665. 
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5.4.6 Evaluation of GABRIEL Loci 
All SNPs reported in the GABRIEL study for genome-wide significance and suggestive 
evidence for association with mild-to-moderate asthma were tested to assess the degree of 
association with severe asthma in the AUGOSA study. As expected, at least some evidence for 
association (p with the majority of these loci was seen, apart from rs11071559 on 
chromosome 15q22 (p=0.159) and rs2284033 on chromosome 22q12 (p=0.105) [Table 5.6]. 
Due to reduced coverage on the Illumina genotyping platform, no proxy SNP in LD was 
identified within the HLA-DQ locus.  The highest significance SNPs in the AUGOSA study 
within GABRIEL identified loci (reported SNP ±500kb) were also identified [Table 5.7]. 
Region plots based on these SNPs are shown in Figures 5.12 to 5.14 (genome-wide 
significance) and Figures 5.15 to 5.16 (suggestive evidence). 
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Table 5.6 - Association results using genotyped data in AUGOSA of SNPs identified with significant or suggestive evidence of effects on the risk of asthma by the 
GABRIEL Consortium. Odds ratios (ORs) were calculated by designating alternative alleles (Alt) as effect alleles. Ref denotes reference allele, Alt alternative allele and CI 
confidence interval. We were unable to test for association with the HLA-DQ locus due to reduced coverage on the Illumina genotyping platform and no proxy SNP in LD 
was identified. The SNP in closest proximity was rs2187668 (32,713,862bp), p=0.26. * Opposite coding allele. 
 AUGOSA (1026 cases, 3,345 controls) GABRIEL (10,365 cases 16,110 controls) 
Chromosome Gene SNP Position Ref Alt OR (95% CI) P value Ref Alt OR (95% CI) p value 
Genome-ZLGHVLJQLILFDQWORFLS[(-8)) in the GABRIEL study 
2 IL18R1 rs3771166 102352654 G A 0.79 (0.71-0.88) 1.93x10(-5) G A 0.87 (0.83-0.91) 3.40x10(-9) 
6 HLA-DQ rs9273349 32733847 - - - - T C 1.18 (1.13-1.24) 7.00x10(-14) 
9 IL33 rs1342326 6180076 T C 1.18 (1.03-1.35) 0.018 T C 1.20 (1.13-1.28) 9.20x10(-10) 
15 SMAD3 rs744910 65233839 A G 1.21 (1.09-1.35) 2.88x10(-4) G A 0.89 (0.86-0.92)* 3.90x10(-9) 
17 GSDMB rs2305480 35315722 G A 0.80 (0.72-0.89) 5.56x10(-5) G A 0.85 (0.81-0.90) 9.60x10(-8) 
17 GSDMA rs3894194 35375519 G A 1.25 (1.12-1.39) 4.39x10(-5) G A 1.17 (1.11-1.23) 4.60x10(-9) 
22 IL2RB rs2284033 35863980 G A 0.92 (0.82-1.02) 0.105 G A 0.89 (0.86-0.93) 1.20x10(-8) 
Suggestive loci S[(-7)) in the GABRIEL study 
5 SLC22A5 rs2073643 131751187 C T 1.15 (1.04-1.28) 0.009 T C 0.90 (0.87-0.94)* 2.20x10(-7) 
5 IL13 rs1295686 132023742 C T 1.29 (1.14-1.47) 9.30x10(-5) T C 0.87 (0.83-0.92)* 1.40x10(-7) 
15 RORA rs11071559 58857280 C T 0.89 (0.76-1.05) 0.159 C T 0.85 (0.80-0.90) 1.10x10(-7) 
IL18R1: interleukin 18 receptor 1; IL33:interleukin 33; SMAD3: SMAD family member 3; GSDMB: gasdermin B; GSDMA: gasdermin A; IL2RB: inerleukin 2 receptor, beta; SLC22A5: solute 
carrier family 22 (organic cation/carnitine transporter), member 5; IL13: interkeuin 13; RORA: RAR-related orphan receptor A. 
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Table 5.7 - Highest significance SNPs in AUGOSA within GABRIEL identified loci. 
Genotyped SNPs are shown in bold, imputed SNPs are shown in non-bold. 
Chromosome Gene GABRIEL 
SNP 
AUGOSA top SNP in 
region (±500kb) 
OR (95% CI) p value 
Genome-ZLGHVLJQLILFDQWORFLS[(-8)) in the GABRIEL study 
2 IL18R1 rs3771166 rs9807989 0.76 (0.67-0.85) 5.20x10(-6) 
6 HLA-DQ rs9273349 rs9281776 1.72 (1.34-2.22) 2.18x10(-5) 
9 IL33 rs1342326 rs394879 0.74 (0.64-0.86) 5.01x10(-5) 
15 SMAD3 rs744910 chr15:65161322 1.66 (1.30-2.11) 4.61x10(-5) 
17 GSDMB rs2305480 rs4794820 0.76 (0.68-0.85) 1.52x10(-6) 
17 GSDMA rs3894194 rs4794820 0.76 (0.68-0.85) 1.52x10(-6) 
22 IL2RB rs2284033 rs8140025 1.17 (1.06-1.30) 0.003 
Suggestive loci S[(-7)) in the GABRIEL study 
5 SLC22A5 rs2073643 rs11745587 1.30 (1.17-1.45) 2.09x10(-6) 
5 IL13 rs1295686 rs847 1.35 (1.17-1.55) 4.05x10(-5) 
15 RORA rs11071559 rs7173451 0.85 (0.76-0.95) 0.004 
IL18R1: interleukin 18 receptor 1; IL33:interleukin 33; SMAD3: SMAD family member 3; GSDMB: 
gasdermin B; GSDMA: gasdermin A; IL2RB: inerleukin 2 receptor, beta; SLC22A5: solute carrier family 
22 (organic cation/carnitine transporter), member 5; IL13: interkeuin 13; RORA: RAR-related orphan 
receptor A. 
 145 
 
Figure 5.12- Region plots in the AUGOSA study for 9807989 and rs9281776 in genome-
wide significant ORFL S[(-8)) identified by the GABRIEL study. Statistical 
significance of each SNP on the ±log10 scale is shown as a function of chromosome position 
(NCBI build 36). The reported SNP in GABRIEL is shown by the arrow. The correlation (r2) 
of each of the surrounding SNPs to the sentinel SNP in AUGOSA is shown by their colour (see 
key). Fine scale recombination rate is plotted in blue. 
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Figure 5.13 - Region plots in the AUGOSA study for rs394879 and chr15:65161322 in 
genome-ZLGH VLJQLILFDQW ORFL S.2x10(-8)) identified by the GABRIEL study. Statistical 
significance of each SNP on the ±log10 scale is shown as a function of chromosome position 
(NCBI build 36). The reported SNP in GABRIEL is shown by the arrow. The correlation (r2) 
of each of the surrounding SNPs to the sentinel SNP in AUGOSA is shown by their colour (see 
key). Fine scale recombination rate is plotted in blue. 
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Figure 5.14 - Region plots in the AUGOSA study for rs4794820 and rs8140025 in genome-
ZLGH VLJQLILFDQW ORFL S[(-8)) identified by the GABRIEL study. Statistical 
significance of each SNP on the ±log10 scale is shown as a function of chromosome position 
(NCBI build 36). The reported SNP in GABRIEL is shown by the arrow. The correlation (r2) 
of each of the surrounding SNPs to the sentinel SNP in AUGOSA is shown by their colour (see 
key). Fine scale recombination rate is plotted in blue. 
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Figure 5.15 - Region plots in the AUGOSA study for rs11745587 and rs847 in suggestive 
loci (p[(-7)) identified by the GABRIEL study. Statistical significance of each SNP on 
the ±log10 scale is shown as a function of chromosome position (NCBI build 36). The reported 
SNP in GABRIEL is shown by the arrow. The correlation (r2) of each of the surrounding SNPs 
to the sentinel SNP in AUGOSA is shown by their colour (see key). Fine scale recombination 
rate is plotted in blue. 
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Figure 5.16 - Region plots in the AUGOSA study for rs7173451 in suggestive loci 
S[(-7)) identified by the GABRIEL study. Statistical significance of each SNP on the    
±log10 scale is shown as a function of chromosome position (NCBI build 36). The reported 
SNP in GABRIEL is shown by the arrow. The correlation (r2) of each of the surrounding SNPs 
to the sentinel SNP in AUGOSA is shown by their colour (see key). Fine scale recombination 
rate is plotted in blue. 
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5.5 Discussion 
 
This Chapter presents results from the largest severe asthma GWA study conducted to date in a 
cohort of 933 cases defined by GINA step 3 or above for severity and 3,346 controls without 
history of asthma or wheeze in order to determine if there are common genetic polymorphisms 
contributing to susceptibility to severe asthma. 
 
Overall, no novel SNPs meeting genome-wide significance were identified. Further analysis of 
the results for polymorphisms just below this threshold was carried out to look for regions 
which did not meet standard genome-wide significance but had supporting evidence with at 
least one additional SNP with p<5x10(-5) within 500kb. Using this criterion, we identified six 
loci with suggestive evidence for association. Two of these loci, chromosomes 2q12 
(p=1.93x10(-6)) and 17q12-21 (p=1.73x10(-5)) implicating the IL1RL1/IL18R1 and 
ORMDL3/GSDMB loci respectively were convincingly replicated in the AAGC cohort 
(p=0.001 on 2q12, p=0.002 on 17q12-21). These loci have been previously reported by GWA 
studies for association with mild-to-moderate asthma (Moffatt et al. 2007; Gudbjartsson et al. 
2009; Moffatt et al. 2010). The same SNP, rs3771166 on chromosome 2q12 locus was reported 
by the GABRIEL Consortium showing the same direction of effect for association with the 
minor allele as that seen in AUGOSA severe asthma subjects. The strongest signal on     
17q12-21 in this study was with rs1810132: this SNP is in strong linkage disequilibrium 
(r2=0.97) with rs2305480 reported by GABRIEL. Recently, an evaluation of four previously 
associated genes (ORMDL3, PDE4D, DENND1B, and IL1RL1) was carried out by the AAGC 
study in their total asthma cohort (986 cases, 1,846 controls) and also confirmed association of 
variants within ORMDL3 and IL1RL1 (Ferreira et al. 2011). 
 
A previous GWA study in which the main phenotype was blood eosinophil counts identified 
additional evidence for an association with asthma for SNPs in IL1RL1 and IL33 (Gudbjartsson 
et al. 2009). The same SNP, rs3771166 on chromosome 2q12 locus as reported by the 
GABRIEL consortium showing the same direction of effect for association with the minor 
allele was identified within AUGOSA. A stronger protective effect size was observed for this 
 151 
polymorphism within the AUGOSA severe asthma cohort (OR=0.79, 95% CI 0.71-0.88) 
compared to that shown in the GABRIEL study (OR=0.87, 95% CI 0.83-0.91) (Moffatt et al. 
2010). 
 
The linkage disequilibrium (LD) block on 2q12 contains three additional genes: IL18R1, 
interleukin 18 receptor accessory protein (IL18RAP), and solute carrier family 9 
(sodium/hydrogen exchanger), member 4 (SLC9A4). Additional SNPs within these genes have 
been previously associated with asthma, atopic dHUPDWLWLV &URKQ¶V GLVHDVH DQG &RHOLDF¶V
disease (Shimizu et al. 2005; Hunt and al. 2008; Reijmerink et al. 2008; Zhernakova et al. 
2008; Zhu et al. 2008). The rs3771166 SNP reported by the GABRIEL study is in high LD 
with other IL1RL1 SNPs showing significant association with asthma but lies within the 
IL18R1 gene. These findings, along with associated tagging SNPs within the region in LD with 
rs1420101: rs1974675 (r2=0.27, p=0.025) and rs10206753 (r2=0.96, p=0.00057) in the 
deCODE study, show that it is unclear which of these are the causative genes driving the 
observed association signals (Gudbjartsson et al. 2009). 
 
With current data and the two distinct peaks seen in the region, it has not been possible to 
dissect the association as to whether the signal in this study lies within the IL1RL1 or the 
IL18R1 gene. However, both genes are plausible biological candidates which may play 
important roles in the inflammatory cascade in the pathway to asthma pathogenesis (Fukao et 
al. 2000; Schmitz et al. 2005). IL1RL1 and IL18R1 code for receptors expressed within the 
respiratory epithelium targeted by the IL33 and IL18 cytokines respectively. IL33 drives the 
production of Th2 cytokines such as IL4, IL5, and IL13 following epithelial damage (Schmitz 
et al. 2005; Carriere et al. 2007). IL18 acts in synergy with IL12 tR LQGXFH ,)1ȖSURGXFWLRQ
and promote Th1 responses (Fukao et al. 2000). 
 
Associations with asthma and SNPs located on chromosome 17q12-21 have been reported and 
replicated across multiple study populations (Van Den Berg et al. 2001; Moffatt et al. 2007; 
Galanter et al. 2008; Moffatt et al. 2010). Despite this, the region on 17q12-21 harbours a 
number of genes of currently poorly understood function. In combination with the difficult 
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linkage disequilibrium structure in this locus, it is difficult to determine which genetic variants 
are causal. Furthermore, this signal may be specific to childhood-onset disease (Moffatt et al. 
2007; Moffatt et al. 2010). However, the culmination of findings suggests that the strongest 
candidates within this locus are ORMDL3 and GSDMB. The role of these genes in severe 
asthma has also been previously reported (Halapi et al. 2010). The transmembrane ORMDL3 
protein may have functional roles in regulation of endoplasmic reticulum-mediated calcium 
signalling and protein folding, in turn causing inflammation (Cantero-Recasens et al. 2010). It 
has also been suggested to be involved in cell proliferation, signal transduction and apoptosis 
through regulation of a component of cell membranes termed sphingolipids and their 
metabolism (Zheng et al. 2006; Breslow et al. 2010). GSDMB has been shown to be highly 
expressed in T cells and at low levels in the foetal lung and bronchial epithelium (Su et al. 
2004). 
 
An additional four loci demonstrating suggestive evidence of association with severe asthma 
are reported in this Chapter. Reported SNPs lie within intronic and regulatory regions of 
candidate genes suggesting potential functions via alternative splicing and transcriptional 
regulation. The most significant result on chromosome 6p23 implicates CD83, the gene 
encoding the CD83 antigen expressed on dendritic cells and which may play a role in immune 
modulation in the airways (Van Den Berg et al. 2001). The identified SNP is approximately 
53kb upstream from the coding region of CD83. The SNP on chromosome 5q31 lies within the 
¶875RIC5orf56, but it is approximately 100kb downstream of the IL4 and IL13 genes as 
well as RAD50, a region previously reported for suggestive association with severe asthma by 
the TENOR study (Li et al. 2010). However, the region plots and results from imputation 
suggest that these may be two independent signals (r2=0.03). The remaining two regions 
downstream of PRPS1L1 on 7p21 and the intergenic region on 13q31 are potentially novel 
with unknown function and warrant further study. A single previous study reported a rare 
variant (MAF=0.044, p=7.3x10(-5)) associated with rheumatoid arthritis within PRPS1L1 
(Morris et al. 2009). Although none of these loci were replicated in the AAGC cohort, all SNPs 
apart from that within the intergenic region on 13q31 showed the same direction of effect for 
the minor allele as found within AUGOSA. 
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No published study has yet analysed imputed genotypes using data released from the 1000 
Genomes Project. Results from this analysis have provided strong support for all six 
association signals identified using genotyped data. A total of five imputed SNPs within 
identified regions had lower p values than genotyped SNPs on 2q12.1, 6p23, 7p21.1, 13q31.1, 
and 17q12-21 as well as three SNPs causing secondary peaks within 2q12.1, 5q31.1, and 
17q12-21, regions known to contain asthma associated genes. Although, these shadow signals 
may have been synthesised through imputation, these findings may also suggest that further 
fine mapping is required within each locus to identify the causative variants. Again, results in 
the AAGC cohort did not replicate these findings but showed consistent SNP effects. Results 
from imputation also identified 12 SNPs meeting statistical significance in new regions with 
reasonable supporting evidence (p<10(-5), r2imp>0.7) on 2q34, 5q12.1, 5q31.3, 6p12.1, 6q13, 
8p21.1, 9p21.1, 11p15.4, 11q24.3, and 19q13.41. Similarly, the functional implications of 
these SNPs are unclear as they do not lie in coding regions resulting in amino acid changes. 
However, the 19q13 locus has previously been shown to be associated with atopy (Holloway et 
al. 2010). 
 
Replication results were more variable for these regions showing inconsistent effects 
suggesting that there are overall, low supporting evidence for these regions. However, power 
calculations demonstrated that this smaller replication cohort of 231 cases and 1,345 controls 
would have had relatively low power to detect modest effects of SNPs within these regions. 
Meta-analysis of SNP results between the AUGOSA and AAGC cohorts found nominal 
statistical significance for all SNPs followed up S. P values were similar to that in the 
AUGOSA cohort and were most likely to have been driven by the initial signals from the 
GWA study. 
 
In addition, the contribution of additional previously identified asthma susceptibility loci was 
assessed in patients with severe disease reported by the recent GABRIEL study (Moffatt et al. 
2010). Since this GWA study is currently the largest published association study investigating 
the genetic determinants of asthma, with sufficient statistical power to identify common 
genetic variants contributing to asthma susceptibility, this second analysis aimed to determine 
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if these signals also contribute to disease susceptibility in this severe asthma cohort. It is 
important to note that although individuals used in the AUGOSA analyses are a subset of the 
total case subjects used in GABRIEL, they only constitute a relatively small proportion 
(8.94%). Therefore, an association signal specific for mild-to-moderate asthma would be 
unlikely to originate only from and be confounded by the group of severe asthmatics alone, 
thereby validating this approach. 
 
For genome-wide significant results when compared to mild-to-moderate asthma from 
GABRIEL, effect sizes for the alternative allele are greater in this cohort of severe asthmatics 
for rs3771166 on chromosome 2q12: the observed OR for the protective allele was 0.79 
compared to 0.87 in GABRIEL, for rs2305480 on chromosome 17q12-21: the observed OR for 
the protective allele was 0.80 for compared to 0.85, for rs3894194 on chromosome 17q12-21: 
the OR for the risk allele was 1.25 compared to 1.17. Further to this, this study has confirmed 
weaker association with IL33 and SMAD3 chromosomes 9p24 (p=1.80x10(-2)) and 15q22 
(p=2.88x10(-4)). The more distal signal seen in AUGOSA in the 9q24 region may indicate 
different regulatory control of the IL33 gene in severe compared to mild-to-moderate asthma. 
 
The explanations behind the increased effect size of risk alleles in severe asthma are potentially 
two-fold. The most likely explanation is that the contribution of genetic effects driven by 
variation in these genes is greater in more severe patients. However, it is possible that in 
populations with milder subjects, misclassification of cases and controls may result in an 
underestimate of true effect sizes. Furthermore, differences in population sizes used in analyses 
may also reflect our varying ability to determine robust effect sizes. 
 
Although the current study has been the largest effort so far to determine genetic determinants 
of severe asthma, the numbers of subjects used is still a limitation in being able to generate 
enough statistical power to detect all variants with modest effects. Whilst these results suggest 
that it is probable to exclude major effects being driven by a single gene as a risk for severe 
asthma, this data based primarily on genotyped SNPs suggests that there may be a number of 
loci which may be specific for severe asthma but with relatively small overall contributions to 
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the risk of developing severe disease. The obvious solution to resolving this issue is to 
undertake additional replication studies in severe asthma populations, but these populations by 
their very definition are hard to recruit: the current study included subjects recruited from eight 
major centres in the UK and hence obtaining a suitable replication population to take this work 
forward will require additional international efforts to establish suitably large populations with 
severe disease. The only other existing cohort of severe asthmatic subjects is the TENOR study 
with relatively few individuals (n=473) (Li et al. 2010). 
 
In summary, results presented in this Chapter provide evidence to support a potentially 
enhanced role for known genetic risk factors for asthma, for example, polymorphisms in the 
IL1RL1/IL18R1 and ORMDL3/GSDMB loci in the development of severe disease. These have 
highlighted the importance of candidate genes both in pathways initiating Th2 inflammation in 
response to epithelial damage as well as in down-regulation of airway inflammation and 
remodelling in determining asthma susceptibility irrespective of severity. A number of novel 
loci have been identified which may be specific to the development of severe as opposed to 
milder forms of asthma, but these require further analyses in addition to testing in severe 
asthmatics compared to individuals with mild-to-moderate disease as opposed to the controls 
used in the analyses reported herein. 
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Chapter 6 
Evaluation of the Relative Contribution of Previously 
Reported Candidate Loci in Severe Asthma 
 
6.1 Introduction 
 
As summarised in Chapter 1, a large number of candidate genes have been previously reported 
in the literature to determine susceptibility to asthma defined using multiple approaches. These 
have been identified through a number of methods including linkage and positional cloning, 
candidate gene association and recently, genome-wide association. Replicated findings have 
been seen for a number of candidate genes for example, toll-like receptor (TLR2) (4q32) (Qian 
et al. ; Eder et al. 2004; Bjornvold et al. 2009; Smit et al. 2009), IL18 (11q22.2-q22.3) (Higa et 
al. 2003; Imboden et al. 2006; Lee et al. 2006; Lachheb et al. 2008; Zhu et al. 2008), and 
IFNG (12q14) (Nakao et al. 2001; Nagarkatti et al. 2002; Wang et al. 2006; Kumar and Ghosh 
2008) which are involved in the inflammatory pathways and immune regulation.  
 
The results shown for many of these candidate genes suggest that they may play a real role in 
asthma susceptibility and may explain some of the missing heritability component not 
identified by GWA studies. However, the growing number of genetic association studies 
carried out in addition to limited consistency mean that it is still difficult to interpret these 
findings. Reasons for this include publication and study bias towards positive associations, 
inadequate power from individual studies due to sample size or phenotyping, genetic 
heterogeneity between independent study populations, and inadequate correction for multiple 
testing resulting in both type I and II errors (see Chapter 1: Section 1.4.1). Using data from 
larger, genome-wide association studies may increase power to detect marginal effects of 
previously identified candidate genes. To date, a select number of studies have used this 
approach in complex diseases including asthma (Gabriel et al. 2002; Feulner et al. 2009; 
Rogers et al. 2009; Wu et al. 2010). 
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Given the results of the GWA study described in Chapter 5, it seems that there is unlikely to be 
a select small number of novel susceptibility genes with major effects that are responsible for 
determining severe asthma specifically. However, it is pertinent to note that the current 
genotyping platforms used do not have complete, uniform coverage across the genome. This 
means that there may be additional loci that have not been adequately tested in poorly covered 
intervals as well as rare SNPs and structural variations such as copy number variants (CNVs) 
(Barrett and Cardon 2006; Barrett et al. 2008). The GABRIEL Consortium study observed 
genome-wide significance between asthma and SNPs within previously reported loci and genes 
including IL18R1, HLA-DQ, IL33, and chromosome 17q12-21, the latter specific to childhood-
onset disease (Moffatt et al. 2010). The contribution of these loci to severe disease were 
assessed in AUGOSA, but a large number of widely replicated genes and loci were not 
evaluated directly using the approach outlined in Chapter 5, such as IL4R (16p12.1-p11.2), 
TGFB (19q13.1), and ADAM33 (20p13) described in detail in Chapter 1: Section 1.3 (Ober and 
Hoffjan 2006). 
 
6.2 Aim 
 
The aim of this Chapter was to evaluate within the AUGOSA severe asthma cohort the 
contribution of candidate genes previously identified in the literature for association with mild-
to-moderate asthma. 
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6.3 Methods 
 
6.3.1 Literature Search 
A comprehensive, systematic review of previously published literature in asthma genetics was 
carried out updated to the 1st January 2011. An inclusive criterion was used to evaluate results 
from all studies in asthma (atopic, non-atopic, aspirin-induced, occupational, severe and 
unspecified) regardless of age-of-onset (childhood or adult) and population ancestry (all 
populations included). Reported loci (genes, SNPs, and microsatellite markers) were recorded 
for showing positive association in candidate gene studies (nominally defined) and only 
conventional genome-wide significance in GWA studies (p<5x10(-8)) or GWL studies 
(LOD. 
 
Using PubMed, a search was conducted within the following search string limited to humans 
and publications in English: 
³DVWKPD´ AND ³DVVRFLDWLRQ´ AND ³613´ 25 ³SRO\PRUSKLVP´ 25 ³YDULDQW´ 25
³JHQH´25³JHQHWLF´25³JHQRP´ 
Results were summarised in a table in MS Excel using the following variables: 
Gene, SNP or microsatellite marker, location, effect & baseline alleles, effect size, 
significance, study design, reference, associated phenotypes, study population (ethnicity, age, 
sample size), any other notes. 
 
In order to accurately summarise supporting evidence for individual genes and avoid 
duplication of identified candidate genes reported under different names or symbols in the 
literature, all gene names were standardised using the HUGO Gene Symbol online database 
(www.genenames.org). Genes identified on sex chromosomes were excluded. 
 
6.3.2 Defining Loci Co-ordinates 
Gene co-ordinates corresponding to the transcriptional start and end sites for each gene were 
ascertained using the USCS Gene tracks dataset on the USCS Gene tables genome browser 
(http://genome.ucsc.edu/cgi-bin/hgTables) and selecting genome: Human, assembly: Mar 2006 
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(NCBI36/hg18). For most Gene and Gene Prediction tracks, any individual gene will have one 
or more associated transcripts. Therefore, the canonical transcript was selected for each gene to 
include the longest or most 5' reaching transcript. 
 
Identified microsatellite names were searched using the NCBI UniSTS search engine 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=unists) to identify the reference sequence co-
ordinates. 
 
Regions were defined by ±10kb of identified gene co-ordinates, SNP positions and 
microsatellite co-ordinates to allow a margin for error in gene co-ordinate positions and in 
order not to miss out any SNPs with significant associations just upstream or downstream of 
each gene. This also helped to include any additional SNPs in LD from which the true signal 
may be originating. 
 
Three lists of regions were compiled to carry out three different analyses: 1) to evaluate all 
identified regions, 2) to exclude results from GWA studies, and 3) to evaluate loci reported by 
candidate gene studies and GWL studies supported by three or more publications only. 
 
6.3.3 Region Evaluation 
Each list of regions was evaluated by extracting results from GWA testing for all genotyped 
SNPs within the region in the AUGOSA study (see Chapter 5 for details). These were 
identified using a script written in R version 2.12.1. 
 
Co-ordinates in a number of identified regions overlapped, therefore duplicate SNPs within 
each extracted results files were removed. For the second and third analyses involving 
exclusion of identified regions, both SNPs within defined region co-ordinates and additional 
SNPs in LD with r2>0.3 lying outside the ±10kb criteria were excluded. The test inflation 
VWDWLVWLF ȜZDVFDOFXODWHG IRUHDFKOLVWRI Uegions (see Chapter 2: Section 2.4.3). Manhattan 
and Quantile-Quantile (Q-Q) plots were then generated (see Chapter 2: Section 2.3.2). 
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6.3.4 Region and SNP Analyses 
The threshold significance level was determined for each analysis using both the Bonferroni 
corrected p value at the 5% significance level assuming that each SNP remains an independent 
test and a MeffLi corrected p value taking into account the extent of LD between tested SNPs 
(see Chapter 2: Section 2.4.8). MeffLi variables indicating the number of effective independent 
variables were calculated using SNPSpD. Relevant data columns were extracted using R 
version 2.12.1 to create .pre and .map SNPSpD input files for SNPs extracted from all three 
sets of analyses. The .pre file contained the results per individual created using the data.txt file; 
the columns of this file contained the following information: Family ID (0=unknown), 
Individual ID, Paternal ID (0=unknown), Maternal ID (0=unknown), Sex (1=male, 2=female, 
 XQNQRZQ *HQRW\SHB « *HQRW\pe_n. SNPSpD was run using the following command 
line in UNIX: 
./SNPSpD.sh region_lookup_results 
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6.4 Results 
 
6.4.1 Systematic Literature Review 
As of 1st January 2011, the systematic literature search identified a total of 1,830 papers. A 
total of 303 papers met criteria for inclusion in this study [Table 6.1]. Studies in over 19 
populations were recorded, shown in Figure 6.1. Results from 1,527 papers were not recorded 
for the following reasons: 
 227 Negative reported results only 
 24 Severity analyses within asthmatic cases only 
 36 Haplotype-based analyses only 
 10 Meta-analyses of previous publications 
 1 Candidate gene look-up 
 1,229 Irrelevant or reviews 
 
 
Figure 6.1 - Recorded papers categorised by study population. Other includes Colombian 
(0.36%), Greek (0.36%), Malay (0.36%), Puerto-Rican (0.36%), Thai (0.36%), Venezuelan 
(0.36%), Hutterite (0.73%), Egyptian (1.09%), and Iranian (1.09%). 
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Table 6.1 - Recorded papers categorised by study design, phenotype, European or non-
European ancestry, and age of participants. Results were recorded from 303 papers 
identified for reporting positive association in candidate gene studies (nominally defined) and 
only conventional genome-wide significance in GWA studies (p<5x10(-8)) or GWL studies 
/2' 
 
6.4.2 Identified Genes 
From all recorded papers, a total of 170 genes were identified and stratified by the number of 
supporting publications. Stratifying by the type of variation studied, 269 papers reported SNP 
associations only, 32 reported insertion/deletion polymorphisms (indels) and two reported copy 
number variations (CNVs). Three genes on sex chromosomes reported by two papers were 
excluded; these were TLR8, TIMP1, and CYSLTR1. In addition, two SNPs and six 
microsatellites were also reported resulting in a total of 175 loci (±10kb) for the look-up. A 
table showing the full list of identified loci, transcriptional start and end co-ordinates, defined 
regions co-ordinates, and the number of supporting references for the locus is provided in 
Appendix 6. 
 
 All 
populations 
European 
ancestry 
Non-European 
ancestry 
Study design Case-control association 293 142 151 
GWA 6 3 3 
GWL 4 1 3 
Cohort Adult 150 66 84 
Children 79 36 43 
Both 40 30 10 
Unspecified 34 14 20 
Asthma 
phenotype 
Atopic 57 19 38 
Non-atopic 5 3 2 
Aspirin-induced 10 0 10 
Occupational 4 3 1 
Severe 4 3 1 
Asthma unspecified 223 118 105 
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6.4.3 Loci Evaluation Results 
Three sets of analyses were carried out to evaluate 1) all 175 identified loci, 2) 159 loci 
excluding results from GWA studies, and 3) 33 loci reported by candidate gene studies and 
GWL studies supported by three or more publications. Results for each set of analyses are 
listed below detailing the numbers of tested SNPs across identified loci, defined significances, 
and test LQIODWLRQ VWDWLVWLFV Ȝ 0DQKDWWDQ DQG 4-Q plots comparing all results are shown in 
Figure 6.1. 
 
6.4.3.1 All Identified Loci 
A total of 3,738 unique genotyped SNPs were tested within 175 identified loci (167 genes, two 
SNPs, six microsatellite regions). 7KHWHVWLQIODWLRQVWDWLVWLFȜIRUWKLVDQDO\VLVZDV7KH
defined levels of statistical significance described above were p=1.34x10(-5) as determined by 
the Bonferroni correction and p=2.37x10(-5) as determined by the MeffLi correction.  
 
Two SNPs met Bonferroni corrected significance: rs1837253 within thymic stromal 
lymhopoietin (TSLP) on 5q22.1 (p=5.52x10(-6)) and rs3771166 within interleukin 18 receptor 1 
(IL18R1) on 2p12.1 (p=1.93x10(-5)). An additional four SNPs met MeffLi defined significance: 
rs10192157 (p=2.34x10(-5)), rs10204137 (p=2.37x10(-5)), rs10206753 (p=2.49x10(-5)) all within 
IL1RL1/IL18R1 on 2p12.1, and rs2243204 within IL13 on 5q31.1 (p=5.71x10(-5)) [Table 6.2]. 
SNP rs3771166 (IL18R1) is the same SNP as reported by the GABRIEL study and examined in 
Chapter 5 tagged by the additional 3 SNPs (r2=0.966). SNP rs2243204 is in weak LD with the 
IL13 SNP rs1295686 reported by the GABRIEL study (r2=0.464). The next 10 genes 
containing SNPs just below defined statistical significance are listed in Table 6.3. 
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Figure 6.1 ± Results of look-up analyses for A) all 175 identified loci, B) 159 loci excluding results from GWA studies, and C) 33 loci reported by candidate gene 
studies and GWL studies supported by three or more publications only. Q-Q plots of observed versus expected ±log10 p values for all tested SNPs. Manhattan plots of     
±log10 p values for tested SNPs plotted against genomic position. * No SNPs on chromosomes 18 and 21 were tested for A) and B), only SNPs on chromosomes 1, 2, 4-7, 11, 
12, 14, 16, 17, 19, and 20 were tested for C). 
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6.4.3.2 Loci Excluding Results from GWA Studies  
A total of 2,800 unique genotyped SNPs identified within 159 loci (152 genes, one SNP, six 
microsatellites) remained after eliminating results from GWA studies. A further 159 SNPs in 
remaining loci tagging SNPs (r2>0.3) in eliminated regions were removed leaving 2,641 SNPs 
IRU DQDO\VLV 7KH WHVW LQIODWLRQ VWDWLVWLF Ȝ IRU WKLV DQDO\VLV ZDV  7KH GHILQHG OHYHOV RI
statistical significance described above were p=1.89x10(-5) as determined by the Bonferroni 
correction and p=3.17x10(-5) as determined by the MeffLi correction. 
 
No SNPs met Bonferroni corrected significance. However, rs1837253 (p=5.52x10(-6)) within 
TSLP and two SNPs within IL1RL1:  rs10204137 (p=2.37x10(-5)), rs10206753 (p=2.49x10(-5)) 
met MeffLi defined significance. All SNPs were also identified by the first set of analyses in 
all loci [Table 6.2]. 
 
6.4.3.3 Replicated Loci Excluding Results IURP *:$6WXGLHV &DQGLGDWH
Gene and GWL studies) 
A total of 323 unique genotyped SNPs were identified within 33 loci (33 genes) with three or 
more references from the list of regions tested in the second set of analyses. A further 29 SNPs 
in the 33 loci tagging SNPs (r2>0.3) in eliminated loci were removed leaving 294 SNPs for 
DQDO\VLV 7KH WHVW LQIODWLRQ VWDWLVWLF Ȝ IRU WKLV DQDO\VLV ZDV  7KH GHILQHG OHYHOV RI
statistical significance described above were p=1.70x10(-4) as determined by the Bonferroni 
correction and p=2.78x10(-4) as determined by the MeffLi correction. 
 
No SNPs met Bonferroni corrected significance or MeffLi defined significance following this 
analysis. The most statistically significant SNP was rs3917254 (p=4.35x10(-4)), also contained 
within IL1RL1 but not in LD with any of the above identified SNPs in the same locus 
(r2=0.003) [Table 6.2]. 
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Table 6.2 ±Results of statistically significant SNPs from look-up analyses for 1) all 175 identified loci and 2) 159 loci excluding results from GWA studies. Ref 
denotes reference allele; effect refers to the minor allele. 
Chromosome Gene SNP Position Ref Effect OR (95% CI) p value 
1) All identified loci 
2 IL1RL1 rs10192157 102334788 G A 0.79 (0.71-0.88) 2.34x10(-5) 
2 IL1RL1 rs10204137 102334644 A G 0.79 (0.71-0.88) 2.37x10(-5) 
2 IL1RL1 rs10206753 102334794 A G 0.79 (0.71-0.88) 2.49x10(-5) 
2 IL18R1 rs3771166 102352654 G A 0.79 (0.71-0.88) 1.93x10(-5) 
5 TSLP rs1837253 110429771 G A 0.75 (0.66-0.85) 5.52x10(-6) 
5 IL13 rs2243204 132027393 G A 1.48 (1.24-1.78) 5.71x10(-5) 
2) Loci excluding results from GWA studies 
2 IL1RL1 rs10204137 102334644 A G 0.79 (0.71-0.88) 2.37x10(-5) 
2 IL1RL1 rs10206753 102334794 A G 0.79 (0.71-0.88) 2.49x10(-5) 
5 TSLP rs1837253 110429771 G A 0.75 (0.66-0.85) 5.52x10(-6) 
IL1RL1: interleukin 1 receptor-like 1; IL18R1: interleukin 18 receptor 1; TSLP: thymic stromal lymphopoietin; IL13: interleukin 13.   
 
Table 6.3 ± Pivotal SNPs in top 10 genes just below statistical significance in analysis of all identified loci. Ref denotes reference allele; effect refers to the minor allele. 
Chromosome Gene SNP Position Ref Effect OR (95% CI) p value 
3 MYLK rs1343700 125054444 A G 1.25 (1.12-1.39) 3.20x10(-5) 
5 IRF1 rs2548993 131836768 A G 1.25 (1.11-1.40) 1.46x10(-4) 
5 RAD50 rs17772583 131981409 A G 0.81 (0.71-0.92) 8.67x10(-4) 
6 BTNL2 rs3817963 32476065 A G 1.25 (1.12-1.39) 2.86x10(-4) 
7 NPSR1 rs425990 34668324 A G 1.21 (1.09-1.34) 5.79x10(-4) 
9 PTPRD rs7873669 9876403 A C 1.75 (0.64-0.87) 2.13x10(-4) 
15 SMAD3 rs744910 65233839 A G 1.22 (1.10-1.35) 2.88x10(-4) 
17 ZPBP2 rs11557467 35282160 A C 1.24 (1.12-1.38) 7.18x10(-5) 
17 GSDMB rs2290400 35319766 G A 1.25 (1.12-1.39) 5.05x10(-5) 
17 ORMDL3 rs7216389 35323475 G A 1.24 (1.12-1.38) 5.73x10(-5) 
MYLK: myosin light chain kinase; IRF1: interferon regulatory factor 1; RAD50: DNA repair protein RAD50; BTNL2: butyrophilin-like 2 (MHC class II associated); NPSR1: neuropeptide 
S receptor 1; PTPRD: protein tyrosine phosphatase, receptor type, D; SMAD3: SMAD family member 3; ZPBP2: zona pellucida binding protein 2; GSDMB: gardermin B; ORMDL3: interleukin 
13. 
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6.4.4 Examination for Region Support 
Supporting evidence within the region for identified loci containing significant SNPs was 
assessed. Both the chromosome 2p12.1 and 5q31.1 loci were reported by the GABRIEL study 
and evaluated previously in the AUGOSA study (see Chapter 5 for details).  Low supporting 
evidence is seen for the TSLP locus and this was confirmed by no other SNPs within this locus 
reaching p<5x10(-3) within results for all regions tested [Figure 6.3]. 
 
 
Figure 6.3 - Region plots for rs1837253 (TSLP, 5q22.1). Statistical significance of each SNP 
on the ±log10 scale is shown as a function of chromosome position (NCBI build 36). The 
sentinel SNP is shown in blue and the correlation (r2) of each of the surrounding SNPs to the 
sentinel SNP is shown by their colour (see key). Fine scale recombination rate is plotted in 
blue. 
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6.4.5 Previously Reported SNPs within the 2q12 Locus 
The strongest candidate gene which has not been previously identified by GWA studies was 
IL1RL1 on 2q12. All six papers in the literature reporting positive association to the 2q12 locus 
were reviewed to evaluate consistency of findings across studies and further analysis was 
carried out to test association of reported SNPs in the AUGOSA study [Table 6.4]. The 
variable number tandem repeat (VNTR) polymorphism reported by Settin et al. and Zeyrek et 
al. was not tested; both rs447713 and rs3087271 reported by Pattaro et al. were not typed on 
the AUGOSA genotyping platforms. All reported SNPs were also significantly associated with 
severe asthma within AUGOSA (1.93x10(-5)<p<1.98x10(-3)) apart from rs1041973 reported by 
Wu et al (p=0.236) showing the same direction of effect for the tested alllele. 
 169 
Table 6.4 - Association results in AUGOSA of positively associated SNPs reported on chromosome 2q12. Odds ratios (ORs) were calculated by designating alternative 
alleles (Alt) as effect alleles. Ref denotes reference allele. All six papers in the previous literature reporting positive association to the chromosome 2q12 locus were reviewed 
to evaluate consistency of findings across studies and results for published SNPs within the AUGOSA cohort. 
Study Polymorphism 
Reference Sample size Ethnicity Age Gene SNP Position Ref Alt OR (95% CI) p value 
Gudbjartsson et al. 
2009 
7,996 cases, 
44,890 controls 
9 European, 1 East 
Asian sets 
Adult IL1RL1 rs1420101 102324148 G A 1.16 (1.11-1.21) 5.50x10(-12) 
AUGOSA G A 1.22 (1.10-1.36) 1.77x10(-4) 
Settin et al. 2008 69 cases, 
98 controls 
Egyptian Children IL1R1 VNTR Intron 2 240bp 410bp 7.5 (3.4-14) <0.05 
AUGOSA Not tested 
Zeyrek et al. 2008 328 cases, 
246 controls 
Turkish Children IL1R1 VNTR Intron 2 410bp 595bp 0.44 (0.22-0.85) 0.008 
AUGOSA Not tested 
Pattaro et al. 2006 25 cases, 
526 controls 
European Adult IL1R1 rs447713 1135067560 A G Unknown 0.0013 
AUGOSA Not typed 
Pattaro et al. 2006 25 cases, 
526 controls 
European Adult IL1R1 rs3087271 115075088 A C Unknown 0.0227 
AUGOSA Not typed 
Wu et al. 2010 492 case trios Mexican Children IL1RL1 rs13431828 102321085 C T 0.45 (0.29-0.70) 2.00x10(-4) 
AUGOSA G A 0.77 (0.65-0.91) 1.98x10(-3) 
Wu et al. 2010 492 case trios Mexican Children IL1RL1 rs1041973 102321900 C A 0.58 (0.43-0.78) 3.50x10(-4) 
AUGOSA C A 0.93 (0.81-1.05) 0.236 
Moffatt et al. 2010 10,365 cases, 
16,110 controls 
European Adult IL18R1 rs3771166 102352654 G A 0.87 (0.83-0.91) 3.40x10(-9) 
AUGOSA G A 0.79 (0.71-0.88) 1.93x10(-5) 
IL1RL1: interleukin 1 receptor-like 1; IL1R1 : interleukin 1 receptor 1 ; IL18R1 : interleukin 18 receptor 1. 
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6.4 Discussion 
 
The aim of this chapter was to assess the contribution of genetic variants previously reported to 
be associated with asthma irrespective of diagnosis criteria in the AUGOSA severe asthma 
cohort. A comprehensive literature review was undertaken in order to identify relevant gene 
regions for analysis. 
 
Assessments for significant loci were conducted using an appropriate significance threshold 
taking into account the true independency of the genomic regions examined. This is the first 
study to comprehensively evaluate the role of previously associated asthma genes in a severe 
asthma cohort. Firstly, genes forming the largest contribution to the severe asthma phenotype 
from all reported results were determined. A total of six SNPs met defined significance 
threshold tagging three distinct loci: IL1RL1/IL18R1 on chromosome 2p12.1 (p=1.93x10(-5)), 
TSLP on chromosome 5q22.1 (p=5.52x10(-6)), and IL13 on chromosome 5q31.1      
(p=5.71x10(-5)). 
 
Assuming that genes identified using the GWA approach are accepted as true determinants of 
susceptibility to severe asthma within this cohort, the next aim was to ascertain how much of 
the remaining variation seen can be explained by other identified genes with much more 
modest effects. Excluding all genes identified through GWA approaches and all tagging SNPs, 
the IL1RL1 (p=2.37x10(-5)), and TSLP (p=5.52x10(-6)) loci remained significant following the 
second set of analyses. 
 
Finally, analyses were undertaken to reduce the number of regions tested by only focusing on 
positively replicated genes supported by three or more independent papers. This aimed to 
evaluate the impact of publication bias in previous literature. No SNPs reached statistical 
significance; however, the IL1RL1 loci showed highest significance just below the defined 
threshold (p=4.35x10(-4)). This suggests that although results of candidate genes reported may 
be influenced by bias towards reporting positive associations, there is still substantial evidence 
to support identified loci by results from these analyses. Limiting analyses to widely replicated 
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results may be liable to miss a number of potentially important loci. The inflation test statistics 
resulting from these analyses were high: in alOUHJLRQVȜ H[FOXGLQJ*:$LGHQWLILHGORFL
Ȝ UHSOLFDWHGUHPDLQLQJORFLȜ +RZHYHUWKHRYHUDOOWHVWVWDWLVWLFIRUWKH*:$VWXG\
GHVFULEHGLQ&KDSWHULVORZȜ 7KLVSURYLGHVVWURQJHYLGHQFHWRVXJJHVWFRQWULEXWLRQV
from multiple genes in addition to those identified using GWA approaches. 
 
The chromosome 2p12.1 and 5q31.1 loci have already been discussed earlier in this thesis in 
Chapter 5, results from this Chapter emphasise the potential importance of these loci in 
determining genetic susceptibility to severe asthma. Taken together, the findings from the 
GWA studies in GABRIEL and AUGOSA as well as this candidate gene look-up, the signal 
for the IL1RL1 locus appears to show the strongest evidence for association with both mild-to-
moderate and severe asthma. All previously published SNPs which showed positive 
association on chromosome 2q12 were reviewed to evaluate consistency of findings across 
studies and within the AUGOSA cohort. All SNPs reported showed the same direction of 
effect and except for rs1041973 reported by Wu et al were also significantly associated with 
severe asthma within AUGOSA (Pattaro et al. 2006; Settin et al. 2008; Zeyrek et al. 2008; 
Gudbjartsson et al. 2009; Moffatt et al. 2010; Wu et al. 2010).  
 
Low supporting evidence was suggested for the TSLP locus. The TSLP gene has only been 
reported by one candidate gene association paper involving 5,565 individuals from four 
independent asthma studies (He et al. 2009). The GABRIEL study also reported suggestive 
association with severe asthma for the same SNP, rs1837253 within TSLP and showed the 
same direction of effect for the minor allele as identified in this Chapter (p=4.85x10(-6), 
OR=0.75 in the AUGOSA analyses; p=3x10(-6), OR=0.56 reported in the GABRIEL Study). 
However, the association result in the GABRIEL Study was only present in the 290 severe 
asthma subjects recruited by the GABRIEL Consortium and not replicated in the 637 core 
AUGOSA severe asthma subjects. 
 
The TSLP gene encodes an IL7-like cytokine and plays an important role in the maturation of 
T cell populations through activation of antigen presenting cells (Park et al. 2000; Ziegler and 
 172 
Liu 2006). This gene was originally studied due to its function as a biologically plausible 
candidate in immunomodulation of the Th2 phenotype and allergic airway inflammation 
(Headley et al. 2009). High expression of TSLP has been shown in airway epithelial cells with 
increased Th2 attracting chemokines and disease severity (Ying et al. 2005). This hypothesis 
has also been supported by work carried out in murine models testing both asthma and allergic 
phenotypes (Yoo et al. 2005; Zhou et al. 2005). Furthermore, TSLP has been shown to act in 
synergy with IL33 in upregulation of immune-mediated allergic sensitisation (Allakhverdi et 
al. 2007; Guo et al. 2009; Matsuda et al. 2010). 
 
Although not reaching genome-wide significance, another 5q22 SNP, rs2416257 (p=1.2x10(-4)) 
within the WD repeat domain 36 (WDR36) gene in the same LD block as TSLP was studied in 
the deCODE GWA study of eosinophil numbers (Gudbjartsson et al. 2009). WDR36 encodes a 
T-cell activation protein which is co-regulated with the T-cell growth factor, IL2. This SNP 
was shown to be highly associated with atopic asthma (p=4.2x10(-6)) but not with non-atopic 
asthma (p=0.78). These results as well as sub-phenotype analyses carried out for atopic asthma, 
airway hyper-responsiveness and atopy defined by SPT in the original candidate gene paper 
reporting this gene suggest that it may predominantly play a role in allergic disease and thus be 
a determinant of atopy rather than asthma. There has been evidence from functional studies to 
support the role of gene as being specific to both traits (Mao et al. 2004). 
 
Evidence to suggest that over-expression of TSLP may be sex-specific and vary across 
individual cohorts has also been published (Taneda et al. 2001; Kowalewska et al. 2007). 
Therefore, the fact that results were not replicated between the two severe asthma cohorts 
studied in the GABRIEL study should not be evidence to dismiss a potential role for this locus. 
Severe asthma has been shown to be more prevalent in adult females compared to males 
(Wenzel 2005). Furthermore, criteria for selection of subjects by GABRIEL were based on the 
ATS and ERS definitions for severe asthma and in addition, partially recruited from a 
childhood clinic. Therefore, these individuals may have more of an atopic phenotype compared 
to those recruited by the core AUGOSA cohort and may be a reason for the inconsistent result. 
The reason to explain why this locus was not identified by the main GABRIEL GWA study for 
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mild-to-moderate asthma but has shown significant association with severe disease may be the 
increased inflammatory environment in severe asthmatic airways.  
 
A recent meta-analysis of North-American asthma GWA studies in European American, 
African-American or African-Caribbean, and Latino ancestry populations (n=5,416 with 
replication in an additional 12,649 individuals) confirmed association of 17p21, near IL1RL1, 
TSLP, and IL33 across the three ethnic groups (Torgerson et al. 2011). In addition, a new locus 
at PYHIN1 was identified specific to individuals of African descent (p=3.9x10(-9)). This study 
suggests contributions to asthma susceptibility from loci which are robust to differences in 
ancestry detectable using sufficiently large sample sizes as well as ancestry-specific 
associations.  
 
This study population consisted of individuals with severe disease of European ancestry only. 
Many of the genes identified from previous studies may have effects specific to different forms 
of asthma and in different ethnic populations. Furthermore, underlying differences in allele 
frequencies may mean that although a variant is important in disease susceptibility across a 
number of populations, a study carried out in one, in which the variant is rare, will require a 
much greater sample size in order to generate enough statistical power to observe an effect. 
Under the assumption that many of the genes responsible for mild-to-moderate asthma are also 
involved in determining severe disease suggested by results from Chapter 5, a lack of 
replication for many candidate regions is potentially a reflection that much of the previously 
reported association came from studies with small sample sizes and inadequate gene coverage 
across the different genotyping arrays used. The Q-Q plots suggest that genes identified by 
GWA approaches have been able to explain some of the more extreme deviations from the line 
i.e. a small number of loci with large effects such as 2q12, 5q31, and 17q12-21. Positive results 
from previously reported candidate genes studies may actually be tagging the GWA signals 
seen at a later date. 
 
However despite this, there is still evidence to suggest the role of multiple additional loci with 
smaller effects seen by the deviation of a large number of SNPs lower down even after 
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removing tests for GWA reported hits. For example, the most suggestive gene identified just 
below statistical significance encodes for the myosin light chain kinase (MYLK) on 3q21.1. 
Several linkage studies have previously reported this region (Dizier et al. 2000; Lee et al. 
2000; Blumenthal et al. 2004; Kurz et al. 2005). Functional studies have shown increased 
levels of both smooth muscle and non-muscle myosin light chain kinase in asthma, which may 
result from functional alterations in airway smooth muscle (Benayoun et al. 2003).  This gene 
was listed as a candidate for evaluation because a single study had reported association with 
severe asthma and a variant within MYLK in the African-American population (Flores et al. 
2007). The SNP identified had not been genotyped in European individuals in the same study. 
The association signal seen in AUGOSA (p=5.21x10(-3)) may provide some supporting 
evidence for this gene and help to explain some of the more severe symptoms observed in 
asthma patients of African-American ancestry (Barnes et al. 2007). 
 
A potential weakness in the approach used is that publications reporting negative associations 
only were not included in these analyses. Using only studies with positive results weights the 
literature gathered towards unconfirmed associations. Comparing the relative numbers of 
positive and negative studies would help to evaluate the empirical evidence for identified loci 
to better put p value thresholds into context. Assessing studies reporting negative association 
could also help to determine the conditions in which a locus may confer susceptibility as 
contributing genetic loci are likely to vary between different sub types of asthma, levels of 
severity, and populations differing in age and ancestry. 
 
Currently, few other published studies have used this approach to apply GWA to evaluate 
previously reported candidate genes to such a detailed extent (Rogers et al. 2009; Moffatt et al. 
2010). The most extensive so far is a study in the Mexican population (492 families), which 
tested association of 237 candidate genes with childhood-onset asthma showing the most 
significant results for tumour growth factor, beta 1 (TGFB1) (p=3x10(-4)), IL1RL1 (p=2x10(-4)), 
IL18R1 (p=9×10(-3)), and DPP10 (p=8x10(-4)) (Wu et al. 2010). In other diseases, a study of 
$O]KHLPHU¶V 'LVHDVH  FDVHV  FRQWUROV FRQILUPHG DVVRFLDWLRQ ZLWK *:$ VLJQDOV DV
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well as identified evidence based on nominal significance for contributions from candidate 
genes reported by case-control studies (Feulner et al. 2009). 
 
There is limited power within the AUGOSA study to detect variants with small effects 
especially those with a low minor allele frequency (MAF). In determining statistical 
significance, the corrections taken for multiple testing are likely to have been over-
conservative. Under the hypothesis that there is a single gene or locus contributing to 
susceptibility to disease, SNPs would have met statistical significance defined using the 
Bonferroni correction. If degrees of linkage disequilibrium between SNPs are taken into 
consideration, then sufficient SNPs to explain a larger proportion of heritability would have 
met the MeffLi corrected significance threshold. However, current statistical corrections for 
multiple testing need to be re-evaluated to adequately take into consideration contributions 
from multiple genes. For example, if there were 30 loci expected to be associated with disease, 
a matched 30-fold correction would need to be taken. 
 
In summary, these results provide evidence to support contributions from multiple loci with 
small effects in the development of severe asthma in combination to a select number of loci 
meeting or approaching genome-wide significance. Further functional work is needed to help 
to distinguish pathways involved in the onset of this complex disease. In addition, fine 
mapping and re-sequencing of these loci will provide value to try and identify rare and/or 
intermediate variants which may also be contributing to the disease phenotype. 
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Chapter 7 
Molecular Characterisation of the Gene Promoter 
Regions of IL1RL1 and IL33 
 
7.1 Introduction 
 
Two recent large scale genome-wide association (GWA) studies have been carried out 
identifying common polymorphisms in the IL1RL1 and IL33 genes determining asthma 
(Gudbjartsson et al. 2009; Moffatt et al. 2010). Firstly, the deCODE Icelandic GWA study 
identified chromosomes 2q12 and 9p24 for genome-wide significant association with blood 
eosinophil counts and also asthma. The reported SNPs, rs1420101 is located within IL1RL1 
(2q12) and rs393928 is 32kb upstream of IL33 (9p24) (Gudbjartsson et al. 2009). Secondly, the 
GABRIEL study also reported asthma association of SNPs within these loci: rs3771166 within 
the IL18R1 gene in high linkage disequilibrium (LD) with other SNPs showing significant 
association within IL1RL1 as well as rs1342326 flanking IL33 approximately 52kb upstream 
(Moffatt et al. 2010). 
 
A number of candidate gene studies have identified polymorphisms in IL1RL1 and IL33 to be 
associated with atopic diseases including asthma: a three SNP haplotype within IL1RL1 (OR 
1.77) (Reijmerink et al. 2008) and atopic dermatitis: distal promoter -26,999 G/A (OR 1.86) 
(Shimizu et al. 2005). The distal promoter SNP -26,999 G/A was also shown to be associated 
with asthma severity with an increased severity score 10.1 compared to 9.3 based on a score 
ranging from 5 to 15 (5 to 7 mild, 8 to 11 moderate, 12 to 15 severe) (Castano et al. 2009). 
 
In addition to genetic links made between the IL1RL1 and IL33 genes with asthma and related 
traits, there has been accumulating evidence to suggest important roles for these genes in 
inflammatory disease pathogenesis by biological studies. The IL1RL1 (also known as ST2) 
receptor exists both as a transmembrane receptor and in a soluble form measurable in serum 
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(Kakkar and Lee 2008). IL1RL1 is targeted by its natural ligand IL33, a cytokine within the 
IL1 superfamily (Schmitz et al. 2005). The contribution of IL1RL1-IL33 signalling in 
eosinophil-mediated inflammation has been shown through both direct effects on eosinophil 
maturation, survival, and activation as well as indirect recruitment and regulation of Th2 
cytokines including IL4, IL5, and IL13 in inflamed tissues (Carriere et al. 2007; Cherry et al. 
2008). Higher serum IL33 levels were detected in patients with Japanese cedar pollinosis, a 
disease of allergic rhinitis and allergic conjunctivitis resulting from exposure to Japanese cedar 
pollen (Sakashita et al. 2008). Furthmore, there is evidence to suggest increased levels of 
expression of both the soluble form of the IL1RL1 receptor and IL33 in more severe asthma. 
Serum IL1RL1 levels during asthma exacerbations were shown to be statistically correlated 
with percent predicted peak expiratory flow (r2=0.634, p=0.004) (Oshikawa et al. 2001). Using 
bronchial biopsies from asthma patients, IL33 mRNA expression was found to be significantly 
higher compared to controls, particularly in subjects with severe disease (p=0.024 in moderate 
asthma, p=0.002 in severe asthma) (Préfontaine et al. 2009). 
 
Effects of the distal promoter region SNP, -26,999 G/A in increasing transcriptional activity of 
IL1RL1 has been shown to induce preferential activation of the Th2 response using reporter 
gene assays to measure different levels of the IL1RL1 protein and total IgE concentrations 
(Shimizu et al. 2005).  However, given the low effect sizes detected (OR <2) and common 
frequency in the population of associated polymophisms, for example, for rs1921622 (MAF 
0.42), rs1861246 (MAF 0.24), and rs1921622 (MAF 0.42) reported within IL1RL1 (Reijmerink 
et al. 2008), the functionalities of reported SNPs are still unclear. Using findings from these 
studies, it seems likely that SNPs within both IL1RL1 and IL33 may influence transcription of 
these genes and subsequent levels of protein expression. A recent study in a Dutch childhood 
cohort found multiple SNPs in IL1RL1 associated with increased serum levels of soluble 
IL1RL1 receptor as well as blood eosinophil counts and asthma (Savenije et al. 2011). 
 
A previous study investigating alternative splicing of the IL1RL1 gene demonstrated two 
variants with distinct non-coding primary exons and a common exon 2 containing the 
transcriptional start site (TSS). This was carried out in a  human leukaemic cell line (UT7) and 
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a human fibroblastic cell line (TM12) in which promoter usage varied (Iwahana et al. 1999). 
Expression of IL33 mRNA in epithelial cells has been shown to be positively regulated by 
inflammatory stimuli such as TNF, which may be provoked through interaction with 
environmental allergens (Kato and Schleimer 2007; Smith 2010). Additional information on 
transcriptional regulatory control in airway cells will also help to understand factors which may 
alter gene expression in asthma. Therefore, molecular characterisation of these genes will help 
to infer the potential function of SNPs both identified in the previous literature and by work 
described in the earlier Chapters of this thesis. 
 
7.2 Aim 
 
The aim of this Chapter was to investigate sequence upstream of the IL1RL1 and IL33 genes, 
E\FKDUDFWHULVLQJWKH¶875HVWDEOLVKWUDQVFULSWLRQVWDUWVLWHV, and identify putative promoter 
locations. 
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7.3 Methods 
 
7.3.1 Real-Time Quantitative PCR 
Taqman® real-time quantitative PCR was used to quantify levels of IL1RL1 and IL33 relative 
mRNA expression in a representative cell and tissue panel consisting of lung tissue, human 
airway smooth muscle (HASM), human bronchial epithelial cells (HBEC), peripheral blood 
mononuclear cells (PBMC), human bronchial epithelial cell line (BEAS-2B), human mast cell 
line (HMC-1) and human acute monocytic leukaemia cell line (THP-1) (see Chapter 2: Section 
2.5). 
 
Taqman® is based on the fluorescence emitted by a target gene specific fluorogenic probe. The 
probe is designed to be flanked by twR3&5SULPHUVDQGLVODEHOOHGZLWKD¶UHSRUWHUDQGD¶
quencher dye. As the two dyes are in close proximity with each other, the quencher dye is able 
WROLPLWWKHIOXRUHVFHQFHHPLWWHGE\WKHUHSRUWHUG\H'XULQJWKH3&5H[WHQVLRQSKDVHWKH¶
nuclease activity of the Taq DNA polymerase cleaves the probe resulting in separation of the 
¶ DQG ¶ G\HV WKHUHIRUH HPLWWLQJ IOXRUHVFHQFH 7KH IOXRUHVFHQFH HPLVVLRQ GHWHFWHG XVLQJ D
laser light distributed on thin-walled reaction tubes with optical fibres are then directed to a 
spectrograph with a charge-coupled device camera. 
 
An assay previously designed and optimised to test expression of IL1RL1 and IL33 by Jane 
Fox, Division of Therapeutics and Molecular Medicine was used. Primers (Invitrogen) and 
probes dual ODEHOOHG ZLWK ¶ )$0 DQG ¶ TAMRA dyes (Applied Biosystems) had been 
designed by Beacon designer 7 (Stratagene) (Appendix 2). Universal PCR Master Mix 
(Applied Biosystems. Cat. No. 1275) and Pre-Developed Assay Reagents were used in assays. 
 
Each sample was run in triplicate using 900nM forward and reverse primers and 250nM probe 
using a MX3005 qPCR system (Stratagene). RT negative and template negative controls were 
analysed in parallel. A standard protocol was used to detect amplification (50°C for 2 minutes; 
95°C for 10 minutes; 40 cycles: 95°C for 15 seconds, 60°C for 60 seconds; 4°C pause). 
Quantification of the target gene expression was monitored using MxPro QPCR software and 
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calculated using the Comparative method with measures of the number of threshold cycles (Ct) 
DWZKLFKDPSOLILFDWLRQILUVWEHFRPHVH[SRQHQWLDOǻ&W &WRIWDUJHWJHQH± Ct of housekeeping 
gene, obtaining a final value via 2-ǻ&W. Hypoxanthine ribosyltransferase (HPRT) was used as the 
endogenous housekeeping gene for data normalisation as this had been shown by Jane Fox to 
have the most uniform expression between cDNA samples compared to other tested 
housekeeping genes 18S, and GAPDH. Two repeats were performed per experiment and the 
results averaged. 
 
5DSLG$PSOLILFDWLRQRI¶F'1$(QGV¶5$&( 
Heterogeneous transcriptional start sites and the promoter regions of the IL1RL1 and IL33 
JHQHVZHUHFKDUDFWHULVHGXVLQJ¶5DSLG$PSOLILFDWLRQRIF'1$HQGV¶5$&(>Figure 7.1]. 
¶5$&( ZDV SHUIRUPHG XVLQJ WKH *HQH5DFHU .LW ,QYLWURJHn. Cat. No. L1502-01). 
Resulting PCR products were cloned into pCR® 4-TOPO® vectors using the TOPO TA 
Cloning® Kit for Sequencing (Invitrogen. Cat. No. K4575-01). Plasmid DNA was isolated 
using the QIAprep® Spin Miniprep Kit (Qiagen. Cat. No. 27104). 
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Figure 7.1- 3ULQFLSOHVRI¶5$&( A) RNA dephosphorylation. B) Removing the mRNA cap 
structure. C) Ligating the RNA Oligo to decapped mRNA. D) Reverse transcribing mRNA. E) 
Amplification of cDNA ends. 
 
7.3.2.1 Synthesis of RACE-Ready cDNA 
Total RNA was treaWHGZLWKFDOILQWHVWLQDOSKRVSKDWDVH&,3WRUHPRYH¶SKRVSKDWHV&,3KDV
no effect on full-length, capped mRNA and therefore eliminated truncated mRNA and non-
mRNA from subsequent ligation wiWK WKH *HQH5DFHU 51$ 2OLJR >)LJXUH  $@. 
Desphosphorylated RNA was treated with tobacco acid pyrophosphatase (TAP) to remove the 
¶FDSVWUXFWXUHIURPLQWDFWIXOO-OHQJWKP51$OHDYLQJD¶SKRVSKDWHUHTXLUHGIRUOLJDWLRQWR
WKH*HQH5DFHU51$2OLJRXVLQg T4 RNA ligase [Figure 7.1 B, C]. This provided a known 
primiQJVLWHIRUWKH*HQH5DFHU3&5SULPHUVDIWHUWUDQVFULSWLRQRIP51$LQWRF'1$7KH
OLJDWHGP51$ZDVUHYHUVHWUDQVFULEHGXVLQJ6XSHU6FULSW,,,57DQGWKH*HQH5DFHU2OLJR
dT Primer to create RACE-ready first-strand cDNA with knoZQ SULPLQJ VLWHV DW WKH ¶ HQd 
[Figure 7.1 D]. 
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RNA Dephosphorylation 
In addition to test RNA, a HeLa RNA positive control was provided in the kit. Each reaction 
was set up on ice in a 1.5ml sterile microcentrifuge tube using: 
RNA    ȝJ 
10x CIP Buffer   ȝO 
51DVH2XW8ȝO  ȝO 
DEPC water   to 10ȝO 
Reagents were mixed gently by pipetting and vortexed briefly before being centrifuged and 
incubated at 50°C for 1 hour. Each reaction was then centrifuged briefly and placed on ice. 
  
RNA Precipitation 
90ȝO RI '(3& ZDWHUDQG ȝO SKHQROFKORURIRUP ZDV DGGHG Wo each reaction and vortexed 
vigorously for 30 seconds before centrifugation at maximum speed in a microcentrifuge for 5 
minutes at room temperature. The top, aqueous phase was transferred to a new microcentrifuge 
tube. Subsequently, 2ȝO PJPO PXVVHO JO\FRJHQ WR DLG SUHFLSLWDWLRQ ȝO 0 VRGLXP
DFHWDWH S+  DQG ȝO  HWKDQRO ZHUH DGGHG YRUWH[HG, and frozen on dry ice for 10 
minutes. Centrifugation at maximum speed in a microcentrifuge was carried out for 20 minutes 
at 4°C to pellet the RNA. A pipette was used to carefully remove the supernatant. Then, ȝO
70% ethanol was added, the tube inverted several times and vortexed briefly before repeated 
centrifugation for 20 minutes and removal of the resulting supernatant. The pellet was air-dried 
for 1 to PLQXWHVDWURRPWHPSHUDWXUHEHIRUHUHVXVSHQVLRQLQȝO'(3&ZDWHU 
 
Removing the mRNA Cap Structure 
Each reaction was set up on ice in a 1.5ml sterile microcentrifuge tube using: 
Dephosphorylated RNA  ȝO 
10x TAP Buffer   ȝO 
51DVH2XW8ȝO  ȝO 
TAP (0.5U/ȝO   1ȝO 
Reagents were mixed gently by pipetting and vortexed briefly before being centrifuged and 
incubated at 37°C for 1 hour. Each reaction was then centrifuged briefly and placed on ice. The 
samples were then precipitated and resuspended in 7ȝO'(3&ZDWHUDVEHIRUH 
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Ligating the RNA Oligo to Decapped mRNA 
ȝO RI GHSKRVSKRU\ODWHG GHFDSSHG 51$ ZDV DGGHG WR D WXEH FRQWDLQLQJ O\RSKLOLVHG
*HQH5DFHU 51$ 2OLJR ȝJ, mixed gently to resuspend the Oligo and centrifuged 
before incubation at 65°C for 5 minutes to relax the RNA secondary structure. The reaction 
was placed on ice, centrifuged briefly, and the following reagents added and mixed gently 
before brief centrifugation and incubation at 37°C for 1 hour: 
10x Ligase Buffer  ȝO 
10mM ATP   ȝO 
51DVH2XW8ȝO  ȝO 
T4 RNA ligase (5U/ȝl)  1ȝl 
7KHWXEHVZHUHUHWXUQHGWRLFHDQGSUHFLSLWDWHGDVEHIRUHZLWKUHVXVSHQVLRQLQȝORI'(3&
water. 
 
Reverse Transcribing mRNA 
7KHIROORZLQJUHDJHQWVZHUHDGGHGWRȝO of ligated RNA: 
ȝ02OLJRG7SULPHUV  ȝO 
G173PL[ȝ0HDFK  ȝO 
DEPC water   ȝO 
The reaction was incubated at 65°C for 5 minutes to remove any RNA secondary structure, 
placed on ice for at least 1 minute and centrifuged briefly before adding: 
5x First Strand Buffer  ȝO 
51DVH2XW8ȝO  ȝO 
6XSHUVFULSW,,,578ȝl) 1ȝl 
This was mixed well, centrifuged briefly, and incubated at 50°C for 50 minutes. Subsequent 
incubation at 70°C for 15 minutes was carried out to inactivate the reaction prior to chilling on 
LFH IRUPLQXWHVDQGEULHIFHQWULIXJDWLRQȝORI 51DVH +8ZDVDGGHGDQGLQFXEDWHGDW
37°C for 20 minutes to digest away the RNA template before repeated centrifugation. 
Synthesised RACE-ready cDNA was stored at -20°C for use as templates in RACE PCR 
reactions. 
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7.3.2.2 PCR Primer Design for RACE 
Gene-specific primers were designed using NCBI sequences taking the following parameters 
into consideration: primer length 23bp to 25bp, 50% to 70% GC, annealing temperature >70°C 
given by 4(G+C)+2(A+T),  *& UHVLGXHV LQ WKH ODVW  EDVHV DW WKH ¶ HQG QR VHOI-
complementary sequences within the primer or complementary to kit primers, especially at the 
¶HQG*HQH-specific nested primers were designed to have similar annealing temperatures to 
the *HQH5DFHUQHVWHGSULPHUDQGGLVWDQWHQRXJK IURP WKHRULJLQDOJHQH-specific primer in 
order to distinguish the products of the original and nested PCRs by size. Known SNPs in 
coding sequences were identified and avoided during primer design. 3ULPHUV IRU ¶ RACE 
were designed in exon 3 for IL1RL1 common to both published transcripts. Designed primers 
for IL33 were in exon 4 common to published transcripts 1 and 2 only. This was due to 
transcript 3 of IL33 being documented online on 10th December 2010, after RACE experiments 
had already been carried out. IL1RL1 and IL33 SULPHUV XVHG IRU ¶ 5$&( DUH OLVWHG LQ
Appendix 2. 
 
7.3.2.3 Amplification of cDNA Ends 
The first-strand cDNA was amplified using a reverse gene-specific primer and the 
*HQH5DFHU ¶ 3ULPHU KRPRORJRXV WR WKH *HQH5DFHU 51$ 2OLJR 2QO\ FRPSOHWHO\
UHYHUVH WUDQVFULEHG P51$ ZLWK WKH *HQH5DFHU 51$ 2OLJR OLJDWHG WR WKH ¶ HQG ZDV
amplified using PCR and subsequent nested PCR. Platinum® Taq DNA Polymerase High 
Fidelity results in single A-overhangs to WKH ¶ HQGV RI 3&5 SURGXFWV WR DOORZ VXEVHTXHQW
ligation with linearised vectors containing siQJOHRYHUKDQJLQJ¶7UHVLGXHV>)LJXUH(@. 
 
7ZR3&5UHDFWLRQVZHUHSHUIRUPHGWRLQFUHDVHSURGXFWVSHFLILFLW\WKHVHFRQGQHVWHGXVLQJȝO
of the first reaction as the template and with primers nested inside those used for the first 
amplification. Negative controls using the gene-specific primers were set up to check for 
background binding and amplification in test samples as well as a template negative to check 
IRUSXULW\RIUHDJHQWVDQGSURFHGXUDOFRQWDPLQDWLRQ3RVLWLYHFRQWUROSULPHUVIRUȕ-actin were 
tested on the HeLa control sample. 
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ȝOUHDFWLRQVZHUHVHWXSIRUHDFKUHDFWLRQF\FOLQJSDUDPHWHUV 
First PCR (94ͼC for 2mins; 5 cycles at 94ͼC for 1min, 72ͼC for 2mins; 5 cycles at 94ͼC for 
1min, 70ͼC for 2mins; 20 cycles at 94ͼC for 1min, 68ͼC for 2.5mins; 68ͼC for 10mins; 4ͼC 
hold) 
*HQH5DFHU¶3ULPHU     ȝO 
Reverse gene-specific primer    ȝO 
RACE-ready cDNA     ȝO 
10x High Fidelity PCR Buffer    ȝO 
dNTPs (10mM each)     ȝO 
3ODWLQXP7DT'1$SRO\PHUDVH+LJK)LGHOLW\8ȝO ȝO 
MgSO4 50mM      ȝO 
Sterile water      ȝO 
Nested PCR (94ͼC for 2mins; 25 cycles at 94ͼC for 1min, 65ͼC for 30secs, 68ͼC for 2mins; 
68ͼC for 10mins; 4ͼC hold). 
 
7.3.2.4 LiJDWLRQDQG7UDQVIRUPDWLRQRI¶5$&(3&53URGXFWV 
¶ 5$&( 3&5 SURGXFWV ZHUH SXULILHG DQG FORQHG LQWR S&5® 4-TOPO® vectors containing 
flanking sequences recognised by sequencing primers M13R [Figure 7.2]. Topoisomerase I 
enzyme from Vaccinia virus covalently bound to the vector ligates T-overhangs present on the 
cut vector to A-overhangs on the PCR product. The constructs produced by the cloning 
reaction were transformed into One Shot® Chemically Competent TOP10 E. coli. Ligation of a 
PCR product disrupts expression of the lethal E. coli gene, ccdB permitting growth of only 
positive recombinants upon transformation. 
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Figure 7.2 ± pCR®4-TOPO vector map taken from the TOPO TA Cloning® Kit for 
Sequencing manual showing the sequence surrounding multiple cloning sites. M13 reverse 
primers were used for sequencing the insert and EcoRI sites (underlined) used to excise the 
PCR product inserts from the vector. 
 
ȝORIWKH3&5SURGXFWZDVDGGHGWRȝO6DOWVROXWLRQDQGȝO7232® vector, mixed gently 
before incubation for 5 minutes at room temperature, DQGSODFHGRQLFHȝORIWhe reaction was 
added into a vial of thawed TOP10 cells and gently mixed with the pipette tip. Cells were left 
on ice for 5 minutes prior to heat-shock in a hot block for 30 seconds at 42°C and then 
LPPHGLDWHO\WUDQVIHUUHGWRLFH62&PHGLXPȝOZDVDGGHGWRHQVXUHHYHQVSUHDGLQJDQG
the tube placed horizontally at 37ͼC to shake at 200rpm for 1 hour. The broth and cells were 
then plated onto pre-ZDUPHGȝJPODPSLFLOOLQVHOHFWLYHDJDUSODWHVDWYROXPHVRIȝODQG
ȝOWRREWDLQDUDQJHRIFRORQ\GHQVLWLHVDQGLQFXEDWHGDWͼC overnight. Single colonies 
obtained were picked into 4ml /% EURWKV FRQWDLQLQJ DPSLFLOOLQ DW ȝJPO DQG DJDLQ
incubated at 37ͼC overnight with shaking at 200rpm. 
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7.3.2.4 Purification of Plasmid DNA from LB Broth 
Plasmid DNA was isolated using the QIAprep Spin Miniprep kit (Qiagen. Cat. No. 27104). 
This procedure is based on alkaline lysis of bacterial cells followed by adsorption of DNA onto 
silica in the presence of high salt before washing and eluting the resulting plasmid DNA. A 
restriction enzyme recognises a specific sequence of DNA (approximately 4bp to 6bp) and 
cleaves the DNA at this point. Digestion using EcoRI restriction enzyme was performed on the 
DNA prepared to check the presence of inserts. 
 
DNA Plasmid Preparation 
1.5ml of prepared broths was transferred to 1.5ml eppendorf tubes and centrifuged at 
13,000rpm for 5 minutes to pellet the cells. The supernatant was discarded and tubes inverted 
RQWR SDSHU WRZHO WR GUDLQ &HOOV ZHUH YRUWH[HG DQG UHVXVSHQGHG LQ ȝO %XIIHU 3 ZLWK
51DVH $ PJPO DGGHG WR JLYH D ILQDO FRQFHQWUDWLRQ RI ȝJPO ȝO Buffer P2 was 
added and tubes gently inverted 4 to WLPHVWRO\VHFHOOVȝO%XIIHU1ZDVDGGHGZLWKLQ
minutes to avoid DNA denaturing which would result in a restriction enzyme-resistant open 
circular form of the plasmid. The tubes were gently inverted 4 to 6 times to neutralise the 
mixture and precipitate proteins, chromosomal DNA, cellular debris, and SDS before 
centrifugation at 13,000rpm for 10 minutes. The resulting supernatant was transferred to a 
QIAprep column placed in a collection tube and spun for 30 seconds. The flow-through was 
discarded after centrifugation for 45 seconds with consecutive washes of 0.5ml Buffer PB and 
0.75ml Buffer PE. The flow-through was again discarded and columns centrifuged for 2 
minutes to dry and transferred to a FOHDQ PO HSSHQGRUI WXEH ȝO RI VWHULOH ZDWHU ZDV
carefully added directly onto the column membrane, left to rest for 1 minute before 
centrifugation for 1 minute to elute the plasmid DNA before storing at -20°C. 
 
Restriction Endonuclease Digestion of DNA to Identify PCR Inserts 
The following reaction per plasmid sample was set up, gently vortexed, and centrifuged before 
incubation at 37϶C for 2 hours: 
EcoRI enzyme    ȝO 
10x EcoRI Buffer   ȝO 
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Plasmid product from miniprep  ȝO 
3ȝOZDVUXQ with 6x loading dye for agarose gel electrophoresis using 1.5% agarose gel. 
 
7.3.2.5 Sequencing and Analysis of Inserts 
'1$REWDLQHGIURP¶5$&(FORQHPLQLSUHSVZDVVHTXHQFHGXVLQJYHFWRUSULPHU05VHH
Chapter 2: Section 2.2.4). Sequence data was analysed by comparison with reference contigs to 
identify individual exons, splice borders, and primers. Only sequences bearing the GeneRacer 
¶SULPHUVZHUHDFFHSWHGDVWUXHWUDQVFULSWV 
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7.3.3 Sequence Data Analysis 
Transcription start sites were identified, putative promoter regions were analysed for 
transcription factor binding sites, and protein prediction carried out for novel transcripts 
detected (see Chapter 2: Section 2.3.1). Transcription factors known to be important in asthma 
including Nuclear factor-ț% 1F-ț% DFWLYDWRU SURWHLQ-1 (AP-1), CAAT/Enhancer binding 
proteins (C/EBP), signal transduction-activated transcription factors (STAT), cyclic AMP 
response element binding protein (CREB), CREB binding protein (CBP), Glucocorticoid 
receptors (GRs), and nuclear factor of activated T-cells (NF-AT) were mapped (Barnes and 
Adcock 1998). Four online databases were used to search for promoter factor binding sites, 
those reported by two or more databases were identified (see Chapter 2: Section 2.3.1). 
Locations of SNPs reported for genome-wide association were determined in relation to 
characterised gene structures. All transcript information was based on Genome Build Ch37.1 
and data from earlier builds converted accordingly using the Convert utility on the UCSC 
Genome Browser annotation tracks page. 
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7.4 Results 
 
7.4.1 Defining Genomic Arrangements 
Previously reported transcripts for IL1RL1 and IL33 documented online in NCBI databases 
were used to build maps of expected gene structures. Two published transcripts have been 
reported for IL1RL1 with six exons in common. Variant 1 (NM_016232.4) encodes the longest 
isoform 1 FRPSRVHG RI  H[RQV 9DULDQW  10B GLIIHUV LQ WKH ¶ DQG ¶ 875V
compared to variant 1 resulting in a distinct isoform 2 with a shorter C-terminus [Figure 7.3]. 
A third variant (NM_173459.1) has previously been reported for IL1RL1 containing a new 
exon compared to variant 1, which leads to a protein with a different C-terminus localising on 
the plasma membrane of cells (Tominaga et al. 1999; Tago et al. 2001). This transcript was 
however permanently supressed on NCBI because it was weakly supported by other studies. 
Three known transcripts have been reported for IL33 with the same N- and C- termini but 
differing in length. Variant 1 (NM_033439.3) encodes the longest isoform composed of 8 
exons. Variant 2 (NM_001199640.1) encodes a shorter isoform which does not contain exon 5 
of variant 1. Variant 3 further lacks exons 3 and 4 resulting in the shortest isoform [Figure 7.4]. 
 
Asthma associated SNPs responsible for the signals reported in IL1RL1 and IL33 genes by the 
deCODE and GABRIEL studies were mapped in relation to published structures (Gudbjartsson 
et al. 2009; Moffatt et al. 2010). All GWA tested SNPs genotyped in the AUGOSA severe 
asthma study for each gene were plotted and r2 identified with reported SNPs: rs1420101 
(IL1RL1) and rs3939286 (IL33) by the deCODE study, rs1342326 (IL33) by the GABRIEL 
study [Figures 7.3 and 7.4]. 
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Figure 7.3 - Schematic representation of the transcript arrangements obtained from published sequences for IL1RL1. A) Published Transcript 1 (NM_016232.4). B) 
Published Transcript 2 (NM_003856.2). C) Exon and intron sizes (bp). Established exons are colour coded, translational start (ATG) and stop codon (TAG) sites are shown. 
Asthma associated SNP, rs1420101 reported by deCODE and r2 values with genotyped SNPs (in black) in the AUGOSA study are marked. Amino acid changes resulting 
IURP613VLQFRGLQJUHJLRQVDUHGHWDLOHG3ULPHUVIRU¶5$&(ZHUHGHVLJQHGLQFRPPRQH[RQ\HOORZ 
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Figure 7.4 - Schematic representation of the transcript arrangements obtained from published sequences for IL33. A) Published Transcript 1 (NM_033439.3). B) 
Published Transcript 2 (NM_001199640.1). C) Published Transcript 3 (NM_001199641.1). D) Exon and intron sizes (bp). Established exons are colour coded, translational 
start (ATG) and stop codon (TAG) sites are shown. No LD was found between genotyped SNPs (in black) in the AUGOSA study and rs3939286 reported by deCODE, r2 
values with rs1342326 reported by GABRIEL are shown. PULPHUVIRU¶5$&(ZHUHGHVLJQHGLQH[RQFRPPRQWRWUDQVFULSWVDQGSXUSOH 
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7.4.2 Quantitative Gene Expression 
 
Relative levels of mRNA expression of IL1RL1 and IL33 were averaged from two repeat 
experiments using Taqman® quantitative PCR [Figure 7.5]. All RT and template negative 
controls were free of contamination. Both mRNA transcripts were expressed in lung tissue; 
levels of IL1RL1 mRNA were most abundant in HMC-1 and of IL33 in HASM cell templates. 
Low quantities of IL1RL1 and IL33 were detected in HBEC templates (IL1RL1 in one donor, 
IL33 in two donors). Lung tissue (donor 1) and HASM cell (donor 3) samples were selected as 
WHPSODWHV IRUFDUU\LQJRXW¶5$&(IRU IL1RL1. Lung tissue (donor 1) and HMC-1 samples 
were chosen for IL33 [Figure 7.3]. 
 
 
Figure 7.5 ± Relative mRNA expression of IL1RL1 and IL33 using Taqman® quantitative 
PCR expression. Mean fold difference (%) and standard error of the mean (SEM) of two 
separate experiments carried out in triplicate, data was normalised to Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) housekeeping gene, compared to lung. 
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7.4.3 IL1RL1 and IL33 7UDQVFULSWV'HWHFWHG8VLQJ¶5$&( 
 
7.4.3.1 Primary and Nested PCR Reactions 
¶5$&(ZDVSHUIRUPHGRQF'1$WHPSODWHVV\QWKHVLVHGXVLQJROLJR'7SULPHUUHDFtions on 
total RNA (IL1RL1 in lung tissue and HMC-1, IL33 in lung tissue and HASM). 
Electrophoresis gel pictures showing the products of the first and second nested PCR reactions 
are shown in Figures 7.6 and 7.7 for IL1RL1 and IL33 respectively. 
 
 
Figure 7.6 - ¶5$&(3&5UHDFWLRQVIRUIL1RL1 in lung and HMC-1 visualised using 2% 
agarose gel electrophoresis. A) PCR reactions performed on 1st strand RACE cDNA from 
lung and HMC-1 total RNA. B) Nested PCR reactions performed on products shown in gel 
picture A. Products seen indicate a single main transcript in lung, two main with multiple 
minor transcripts in human mast cell line (HMC-1). Primer negative (in lung and HMC-1) as 
well as template negative controls were free from contamination. An immortalised HeLa cell 
line (HELA) was used as the positive control. 
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Figure 7.7 - ¶ 5$&( 3&5UHDFWLRQV IRU IL33 in lung and HASM visualised using 2% 
agarose gel electrophoresis. A) PCR reactions performed on 1st strand RACE cDNA from 
lung and HASM total RNA. B) Nested PCR reactions performed on products shown in gel 
picture A. Products seen indicate a single main transcript in lung and in human airway smooth 
muscle (HASM). Primer negative (in lung and HASM) as well as template negative controls 
were free from contamination. An immortalised HeLa cell line (HELA) was used as the 
positive control. 
 
7.4.3.2 Detected Transcripts 
A total of 48 clones were obtained for each gene in each test template. Gel pictures following 
EcoRI plasmid digestion to check for the presence of inserts prior to sequencing are shown in 
$SSHQGL[)ROORZLQJVHTXHQFLQJWKHSUHVHQFHRIWKH*HQH5DFHU¶SULPHUVHTXHQFHVDQGWKH
gene specific primers were verified prior to studying the transcript sequences. 
 
For IL1RL1, a total of 60 clones were successfully sequenced: lung (n=21) and HMC-1 (n=39). 
The vast majority (95%) of clones in lung were reported transcript variant 2 (NM_003856.2), a 
single clone confirmed the presence of transcript variant 1 (NM_016232.4). Transcript 1 was 
confirmed by 49% of clones in HMC-1 and transcript 2 was also detected as well as three 
novel transcripts in this mast cell line, each identified through multiple clones [Figure 7.8]. For 
IL33, a total of 46 clones were successfully sequenced: lung (n=23) and HASM (n=23). All 
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FORQHVPDWFKHGWKHFRPPRQ¶VHTXHQFHRIUHSRUWHGWUDQVFULSWVDQG, which can be detected 
using the primers designed [Figure 7.9]. 
 
 
Figure 7.8 - Schematic representation of the IL1RL1 transcript arrangements obtained 
from 5¶5$&( A) Transcript 1 refers to published transcript 1 (NM_016232.4). B) Transcript 
2 to published transcript 2 (NM_003856.2). C) Novel transcript 3. D) Novel transcript 4. E) 
Novel transcript 5. F) Exon and intron length (bp). ATG sites are marked. 
A 
B 
C 
D 
E 
¶5$&(7UDQVFULSW 
Lung, not present 
HMC-1, n=8/39 clones (21%) 
¶5$&(7UDQVFULSW 
Lung, n=1/21 clones (5%) 
HMC-1, n=23/39 clones (59%) 
¶5$&(7UDQVFULSW 
Lung, n=20/21 clones (95%) 
HMC-1, n=3/39 clones (8%) 
¶5$&(7UDQVFULSW 
Lung, not present 
HMC-1, n=3/39 clones (8%) 
ATG 
ATG 
ATG 
ATG 
ATG 
¶5$&(7UDQVFULSW 
Lung, not present 
HMC-1, n=2/39 clones (5%) 
F Exon length (bp) 
Intron length (bp) 
122 81 215 211 140 
304 777 1,283 507 
92 
(23,808) 
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Figure 7.9 - Schematic representation of the IL33 WUDQVFULSW DUUDQJHPHQWV REWDLQHG IURP ¶5$&( A) Single transcript detected matching published transcript 1 
(NM_033439.3), 2 (NM_001199640.1), and 3 (NM_001199641.1). ATG sites, asthma associated SNPs, rs3939286 reported by deCODE and rs1342326 reported by 
GABRIEL are marked. 
 
Exon length (bp) 
Intron length (bp) 
78 104 129 130 
25,818 534 8,688 
¶5$&(7UDQVFULSW1 
Lung, n=23/23 clones (100%) 
HASM, n=23/23 clones (100%) 
ATG rs3939286 rs1342326 A 
B 
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7.4.3.3 Consensus Splice Sites for Novel Exons 
Novel exons were identified in IL1RL1 WUDQVFULSWVDQGGHWHFWHGE\¶5$&(6HTXHQFHV
surrounding each splice site obeyed the GT-AG rule and showed high levels of concordance 
with the consensus splice site sequences for the donor site and acceptor sites (Breathnach et al. 
1978; Zhang 1998): 
In genomic DNA 
Exon               Exon 
CAGGTAAGT          //              CCCCCCCCCCCNCAGG 
A          G             TTTTTTTTTTT    T      A 
Splice donor site    Splice acceptor site 
 
In cDNA 
CAGG 
A      A 
Branch point 
 
This provided further confidence that the exon arrangements GHWHUPLQHGE\¶5$&(ZHUHQRW
artefacts [Table 7.1]. 
 
Table 7.1 - Sequences around splice borders of novel exons in IL1RL1 RACE transcripts 
show agreement with consensus splice sequences. Intronic sequence is shown in subscript. 
Green = mismatch to consensus, red = matches consensus, black = surrounding sequence. 
 Donor site Branch point Acceptor site 
Transcript 3 
Exon 1-2 AATGAGGGTAAGTG AATGAGGʜGTAAACA TTTGCAGGTAAACA 
Transcript 4 
Exon 1-2 AATGAGGGTAAGTG AATGAGGʜGCATAAG CTTCCAGGCATAAG 
Exon 2-3 TGCAGAGGTTTGGA TGCAGAGʜATATAGG AGTTGAGATATAGG 
Transcript 5 
Exon 1-2 AATGAGGGTAAGTG AATGAGGʜGCATAAG CTTCCAGGCATAAG 
Exon 2-3 TGCAGAGGTTTGGA TGCAGAGʜATATAGG AGTTGAGATATAGG 
Exon 3-4 TGTTTAGGTGAGGA TGTTTAGʜATATAGG AGTTGAGATATAGG 
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7.4.3.3 Analysis of Transcriptional Start Sites 
Multiple transcriptional start sites (TSSs) were identfied for both genes. For IL1RL1, the TSSs 
for exons were spread over regions of 105bp on transcript 1 and 99bp on transcript 2; a 
potential TATA box site was found in transcript 1 approximately 22bp to 27bp upstream of a 
cluster of TSS sites [Figure 7.10]. Detected novel transcripts 3, 4, and 5 share the same exon 1 
as transcript 1. Combining clones for lung and HMC-1, the TSSs for transcript 1 clustered at 
one main site, accounting for 41% of clones and resulting in a 98bp length exon 1. Three main 
sites were seen for transcript 2 resulting in exon 1 with lengths 38bp, 80bp, and 81bp 
collectively accounting for 52% of clones, the TSS coding for the 81bp exon 1 is reported in 
the literature. 
 
 
Figure 7.10 ± Transcription start sites (TSSs) for IL1RL1 transcripts REWDLQHG IURP ¶
RACE. Combining clones for lung and HMC-1, the TSSs for transcript 1 clustered at one main 
site (red), no clones with the same TSS as reported in the literature were seen (white). Three 
main sites were seen for transcript 2 (orange), the first being the reported TSS. A potential 
TATA box site is shown in the blue box. 
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Combining IL33 clones for lung and HASM, the TSSs clustered at one main site, accounting 
for 58% of clones and resulting in a 42bp length exon 1. No clones with exactly the same TSS 
as reported in the literature were seen. The TSSs for exons were spread over a 67bp region 
[Figure 7.11]. 
 
 
Figure 7.11 ± Transcription start sites (TSSs) for IL33 transcripts REWDLQHG IURP ¶
RACE. Combining clones for lung and HASM, the TSSs clustered at one main site (red), no 
clones with the same TSS as reported in the literature were seen (white). 
 
7.4.4 IL1RL1 Open Reading Frame Analysis 
7KH ¶ 875V FUHDWHG E\ WKH QRYHO IL1RL1 transcript variants detected by ¶ RACE were 
examined to identify any open reading frames (ORFs) present which may potentially result in 
different protein coding or have regulatory effects on downstream gene expression. 
Information from the UniProtKB/Swiss-Prot online database show that the longer transcript 1 
codes for the transmembrane (NP_057316.3) and the shorter transcript 2 codes for the soluble 
(NP_057316.3) forms of the IL1RL1 receptor protein respectively. 
 
Protein prediction for the 3 novel transcripts detected in HMC-1 was carried out using 
EMBOSS Transeq (EMBL-EBI), in-frame amino acid sequences for each transcript are 
detailed in Appendix 8. Transcript 4 lacks exon 2 which contains the published ATG site, the 
resulting ATG for this transcript may lie within exon 3 coding for a truncated protein with a 
loss of 117 amino acids. Transcripts 3 and 5 contain additional exons but are likely to have the 
same ATG site and subsequently code for the same protein as transcript 1. 
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7.4.5 Promoter Binding Sites 
7KHVHTXHQFHVNEXSVWUHDPRI WKHPRVW¶766IRU IL1RL1 and IL33 were used to identify 
putative promoter binding sites [Figure 7.12]. Multiple promoter binding sites were identified 
across all IL1RL1 and IL33 transcripWVZLWKFRQVHQVXV IURPRQOLQHGDWDEDVHV IRU Nuclear 
factor-ț% (NF-ț% DFWLYDWRU SURWHLQ-1 (AP-1), CAAT/Enhancer binding proteins (C/EBP), 
signal transduction-activated transcription factors (STAT), cyclic AMP response element 
binding protein (CREB), CREB binding protein (CBP), and nuclear factor of activated T-cells 
(NF-AT) were analysed (Barnes and Adcock 1998). C/EBP and CREB binding sites were not 
identified for IL1RL1 transcript 2. 
 
 
Figure 7.12 Promoter binding site analyses (2kb). 7KHVHTXHQFHVXSVWUHDPRI WKHPRVW¶
TSS were used to identify putative promoter binding sites for all transcripts of IL1RL1 and 
IL33. Transcription factors (AP-1   , C/EBP   , CREB   , GR   , CBP   , GATA    ) are 
positioned on the scale relative to the distance from the first exon. 
 
IL33 All Transcripts 
IL1RL1 Transcripts 1, 3, 4, 5 
IL1RL1 Transcript 2 
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7.5 Discussion 
 
7KLV&KDSWHUGHVFULEHVZRUNFDUULHGRXWXVLQJD¶5$&(DSSURDFKWRDPSOLI\WKHH[WUHPH¶
ends of mRNA transcripts of IL1RL1 from lung tissue and a human mast cell line (HMC-1), as 
well as IL33 from lung tissue and human airway smooth muscle (HASM) cells. IL1RL1 
(IL1RL1) and IL33 (IL33) have been recognised to exert an important role in the development 
of inflammation and airway hyperresponsiveness in asthma by both genetic association and 
functional studies (Schmitz et al. 2005; Reijmerink et al. 2008; Ali et al. 2009; Gudbjartsson et 
al. 2009; Moffatt et al. 2010). However, the transcriptional regulatory mechanisms operating 
on their expression in human airway cells and tissues are poorly understood. Furthermore, the 
effects of identified polymorphic variation within these genes are still to be determined. The 
presence of previously published transcripts were confirmed in tested templates as well as three 
novel IL1RL1 transcripts with a potentially alternative open reading frame. Results were 
analysed to establish the positions of the transcription start sites (TSSs) and multiple locations 
for transcription factor binding were found in the putative promoter regions of these genes. 
 
Both the IL1RL1 and IL33 genes were found to be expressed across templates in a 
representative airway cells and tissues panel with higher levels of IL1RL1 expression 
particularly in HMC-1 inflammatory cells and IL33 preferentially expressed in structural cells 
such as HASM and HBECs. This supports findings from previous studies showing abundant 
IL33 mRNA expression in multiple tissue related cells types including endothelial cells, 
smooth muscle, and mucosal epithelial cells (Schmitz et al. 2005; Moussion et al. 2008). 
Expression of IL1RL1 was reported previously to be predominantly by cells involved in 
allergic inflammation such as mature mast cells (Gächter et al. 1998; Moritz et al. 1998; 
Allakhverdi et al. 2007). Injury to epithelial cells may increase the product of IL33 cytokines, 
which in turn result in recruitment of IL1RL1 to the affected site. 5HVXOWVIURP¶5$&(KDYH 
confirmed the presence of the two published transcripts for IL1RL1 and the three published 
transcripts for IL33. Two variant forms of the IL1RL1 receptor protein are known to exist, a 
transmembrane form and a soluble form coded by the longer transcript 1 and shorter trancript 2 
respectively. A third variant encoding a truncated membrane-bound form of the receptor 
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protein has also previously been published but weakly supported (Tominaga et al. 1999; Tago 
et al. 2001). Findings from this Chapter have also detected the presence of three novel IL1RL1 
transcripts closely related to published transcript 1, one of which potentially codes for a shorter 
¶HQGRIWKHtransmembrane form of the receptor. 
 
7KH ¶ 875V RI GHWHFWHG WUDQVFULSWV IRU HDFK JHQH GLIIHU EHFDXVH RI WKH YDULDWLRQ LQ WKH ¶
terminal exons. It is therefore possible that regulation at the transcript level differs between the 
splice variants observed by potentially introducing or removing regulatory elements or by 
causing the gene to be expressed from an alternative promoter. All TSSs are more widespread 
for IL1RL1 over an 105bp region on transcript 1 and a 99bp region on transcript 2 compared to 
IL33 over a 67bp region for all transcripts. A potential TATA box was identified for IL1RL1 
transcript 1. A range of TSSs over a large area could be due to fewer clones produced from the 
experiment reducing the likelihood of identifying definite clusters or due to artefacts of 
degredation. Alternatively, multiple locations for TSSs could also suggest that gene expression 
is differentially regulated by the use of alternate promoters and has cell-specific expression 
patterns (Smale 1997). This is indicative of the ability of RNA polymerase II to initiate mRNA 
synthesis over a region of sequences. The TATA box motif is important in establishing the 
position of the transcriptional initiation of RNA polymerase II. Genes without TATA boxes are 
reported to show greater variation in TSS intiation positions (Smale 1997). 
 
These results provides evidence to suggest that IL33 transcriptional regulation is dependent on 
fewer controlling mechanisms than IL1RL1 and therefore, potentially under tighter regulation. 
This may help to explain the functional roles of these genes in asthma. Structural changes in 
the airway following tissue injury may increase production of IL33 cytokines and 
transmembrane forms of the IL1RL1 receptor (Oshikawa et al. 2001; Smith 2010). During 
exacerbations and the induction of the inflammatory cascade, soluble IL1RL1 receptors may be 
upregulated via the recruitment of inflammatory cells such as mast cells to act as a decoy 
receptor (Allakhverdi et al. 2007). 
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Multiple promoter binding sites for transcription factors reported to be important in asthma 
were identified in the 2kb ¶ UHJLRQ XSVWUHDP RI HDFK JHQH LQFOXGLQJ $3-1, C/EBP, CREB, 
GR, CBP, and GATA (Barnes and Adcock 1998). Altered gene function may occur not only 
due to coding region variability but also due to polymorphic variation within the promoter. 
Promoter polymorphisms might result in altered expression levels of an otherwise normal 
protein potentially resulting in a modified behaviour of gene-product dependent pathways.  
 
Previous studies have proposed ways in which differing promoter usage and alternative 
splicing in IL1RL1 and IL33 may be involved in determining asthma susceptibility (Iwahana et 
al. 1999; Kato and Schleimer 2007; Smith 2010). The use of both proximal and distal 
promoters with multiple TSSs in other cells types has also been shown (Iwahana et al. 1999). 
The SNPs reported for association with asthma identified by the deCODE Icelandic and the 
GABRIEL GWA studies were mapped relative to identified transcripts for IL1RL1 and IL33. 
The signal generated by the SNP reported by deCODE, rs1420101 within intron 5 of IL1RL1 
could, through taggLQJ RI PRUH ¶ FDXVDWLYH SRO\PRUSKLVPV EH GULYHQ E\ GLIIHUHQWLDO
expression of the different receptor splice variants resulting in production of different levels of 
the IL1RL1 receptor protein in cases compared to controls (Schmitz et al. 2005). Intronic SNPs 
may also influence either the transcriptional activity or the splicing efficiency of the genes, or 
alter the expression of alternative transcripts (Manolio et al. 2009). Association with IL33 
SNPs may be due to effects on promoter binding sites therefore determining levels of 
transcription. Both SNPs flanking IL33 reported by the deCODE Icelandic and GABRIEL 
VWXGLHV DUH ¶ RI WKH FRGLQJ UHJLRQs: rs13423626 being 32kb upstream (deCODE) and 
rs3939286 being 52kb upstream (GABRIEL) of the identified TSSs; these could be tagging 
polymorphisms within distal promoters positioned more closely to the gene coding regions. 
 
Difficulty in determining the functionality of these SNPs is also in part due to the strong LD 
structure of the 2q12 locus making it uncertain where the true causative origin of the 
association signal lies (see Chapter 5 Discussion). Mapping of genotyped SNPs tested for 
association in the AUGOSA GWA study described in Chapter 5 across the IL1RL1 and IL33 
transcript regions has shown that coverage using current genotyping platforms is still relatively 
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low. Furthermore, it is likely that these detected polymorphisms are tagging rare variants 
within the identified locus through synthetic associations that have not been able to be detected 
by current GWA approaches (Dickson et al. 2010). These questions will only be able to be 
addressed by advances in next-generation sequencing, which have made re-sequencing 
candidate genes more affordable to identify rare variants within hypothesised or previously 
identified loci. This approach was used in Chapter 8 to further study the IL1RL1 and IL33 
susceptibility loci on chromosome 2q12 and 9p24.1 respectively. 
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Chapter 8 
Re-sequencing to Identify Rare Variants within the 
Chromosome 2q12 and 9p24.1 Loci 
 
8.1 Introduction 
 
Substantial evidence for the role of the chromosome 2q12 and 9p24.1 regions in asthma has 
been found. However, effect sizes for identified polymorphisms remain small and it has been 
difficult to determine which genes the association signals are originating from. Although 
associations of polymorphisms within 2q12 in particular and asthma have been widely 
replicated, few direct SNP associations have been reproduced (Reijmerink et al. 2008; Ali et 
al. 2009; Gudbjartsson et al. 2009; Reijmerink et al. 2010; Wu et al. 2010). This loose region-
based replication as well as the work described in this thesis and the wider literature suggests 
that there may be multiple signals in the relevant regions containing IL1RL1/IL18R1, and IL33 
(Savenije et al. 2011). In addition, identified SNPs may be tagging other polymorphisms in 
nearby genes or rare variants. Furthermore, an individual may be predisposed to disease as a 
result of individual variants with functional effects or multiple variants within a gene having a 
deleterious effect in synergy. 
 
As explained in Chapter 1 and shown by results from Chapter 5 to 7, due to small effect sizes, 
it is unlikely that common variants assayed using current SNP genotyping platforms will 
explain all the heritability still to be identified in asthma and there is increasing interest in the 
contribution of rare variants (Maher 2008; Moffatt et al. 2010). The common disease, rare 
variant hypothesis proposes that multiple rare genetic polymorphisms, each with relatively 
high penetrance, form major contributions to common disease susceptibility (Bodmer and 
Bonilla 2008). Population-level processes such as mutation, selection, and random genetic drift 
are likely to have acted against common variants favouring the existence of multiple rare 
variations contributing to disease arising from recent population growth (Pritchard 2001; 
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Coventry et al. 2010). Rare and potentially functionally significant polymorphisms have also 
been shown to occur naturally in many genes affecting complex, multi-factorial traits 
(Crawford et al. 2004; Schork et al. 2008). 
 
Data released from the August 2010 pilot of the 1000 Genomes Project has made available an 
online database of eight million previously unknown SNPs illustrating the fact that potentially 
a large proportion of the effects of specific polymorphisms on disease risk still remain to be 
identified. These less frequent variants have also been proposed as more likely to be functional 
than predominantly common variations tested using most genome-wide SNP genotyping 
platforms (Gorlov et al. 2008). Findings from some previous studies in the literature have 
shown that rare variants are likely to have larger effect sizes with an OR between 2 and 5 
filling the effect gap of detected heritable variants between linkage and association studies 
(Bodmer and Bonilla 2008) (see Chapter 1, Section 1.4). 
 
Recent advances in next-generation sequencing (NGS) have allowed affordable re-sequencing 
of candidate genes to test for association of previously unidentified rare variants with disease. 
This approach will help to determine the relationship of common and rare polymorphisms and 
identify the location of causative polymorphisms; this approach has recently being used to 
identify low frequency variants determining high plasma triglyceride levels (Johansen et al. 
2010). Studies in other complex diseases have observed frequency differences between cases 
and controls in rare SNPs identified through sequencing of coding regions in candidate genes 
and loci (Cohen et al. 2004; Fearnhead et al. 2004; Ji et al. 2008). Although this has been to a 
certain extent subject to publication bias, these findings indicate that multiple rare variants may 
be associated with susceptibility to complex disease. 
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8.2 Aim 
 
The aim of this Chapter was to carry out re-sequencing of the chromosome 2q12 and 9q24.1 
loci in 200 severe asthma cases and 200 general population controls to identify whether an 
excess of variants contribute to the determination of developing severe asthma as well as 
establish if unique variants exist in the asthma and control populations. 
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8.3 Methods 
 
8.3.1 Study Populations 
A total of 200 severe asthma cases and 200 controls were used in re-sequencing. Case subjects 
consisted of 200 individuals from the AUGOSA study. A subset of general population controls 
was selected from the Nottingham Gedling cohort to be non-asthmatic, non-wheeze, and non-
atopic controls. Details of study recruitment and phenotyping are described in Chapter 2: 
Sections 2.1 and 2.2. Selection of individual samples were made based on the highest yields of 
DNA available in order to maximise the success of the sequencing reaction (minimum required 
concentration 50ng/ul) whilst attempting to approximately sex-match the case and control 
groups. Control individuals were chosen to be slightly older in order to provide further 
assurance of their non-asthmatic status. Using these criteria, the resulting samples were made 
up of cases in which 69.4% were female with an average age of 48.1 years (SD 14.9) and 
controls in which 73.0% were female with an average age of 56.7 years (SD 13.0). 
 
8.3.2 Region Selection 
For both the chromosome 2q12 and 9p24.1 loci, regions were defined to include the entire 
association signal from genotyped data by either the most distal SNP with ±log10 p value >2.5 
on either side of the sentinel SNP, or by the co-ordinates of the IL1RL1/IL18R1 and IL33 genes 
(±10kb), whichever was furthest from the sentinel SNP. All co-ordinates were converted from 
NCBI Build 36.1 to Genome Reference Consortium GRCh37 using the UCSC Batch Convertor 
tool and the Lift Genome Annotations tool. 
 
8.3.3 The 1000 Genomes Project 
Sequencing and genotyping efforts carried out by the 1000 Genomes projects are currently 
underway and data is being updated and deposited online continuously. The latest data releases 
were analysed using the Variant Call Format (VCF) version 4.0 files uploaded online 
(http://www.1000genomes.org/) for genotype and indel data as well as the browser for 
sequence data. The full project genotype release (16 December 2010) and indel release (16 
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February 2011) was available at the time of analysis. This resource was used to evaluate new 
variants currently identified for the IL1RL1 and IL33 regions of interested intervals, defined by 
chromosome 2: 102,738,158-103,208,945bp and chromosome 9: 5,924,967-6,267,982bp 
respectively based on NCBI Build 37.1 co-ordinates. Sequence data was assessed using the 
online browser (December 2010). Genotype and indel data containing calls based on 629 
individuals was extracted from the EBI FTP site (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/) 
using the following commands using tabix in UNIX: 
tabix -h 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20100804/ALL.2of4intersectoin.201
00804.genotypes.vcf.gz 
2:102738158-103208945 
9:5924967-6267982 
 
8.3.4 Re-sequencing Design 
All technical stages of re-sequencing in terms of library preparation and target enrichment, 
cluster generation and sequencing, base calling and data processing were carried out by 
SourceBioscience (Nottingham, UK). Paired-end sequencing using 100bp reads for cases and 
controls were run on tZRVHSDUDWHODQHVLQDVLQJOHIORZFHOOXVLQJWKH,OOXPLQD+L6HT
Systems pipeline designed by Illumina (San Diego, USA). 
 
Due to the cost implications of generating individual level data, a degree of multiplexing was 
carried out by splitting cases and controls into three randomly assigned pools of 66, 66, and 68 
individuals. Concentrations of each sample were determined using an Agilent BioAnalyzer 
prior to pooling in order to ensure that each sample contributed the same quantity of DNA for 
sequencing. DNA samples within each pool were sheared in order to carry out target sequence 
enrichment using 120bp oligos (baits). These were designed using web-based design tool 
eArray (http://earray.chem.agilent.com) for use in the Agilent SureSelect Custom Capture kit 
(x10 reactions) with capture size range of 500kb to 1.5Mb. Biotinylated RNA baits hybridise to 
regions of interest on fragmented DNA, which allow these to be selected out using streptavidin 
coated magnetic beads for focused amplification prior to cluster generation and sequencing 
(Mamanova et al. 2010). Indexing was then carried out by bar-coding each pool of samples 
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using unique adaptor sequences prior to library preparation and subsequent sequencing 
(Harismendy and Frazer 2009). 
 
Illumina sequencing uses automated cluster generation using cBot followed by sequencing-by-
synthesis reversible terminator technology (Shendure and Ji 2008; Metzker 2010). Genomic 
DNA is randomly fragmented and bound to two unique adaptor oligo-nucleotides at either ends 
with resulting fragments of approximately size 150bp to 200bp. This allows hybridisation to a 
lawn of oligo-nucleotides corresponding to the sequences of ligated adapters immobilized on 
WKHVXUIDFHRIIORZFHOOFKDQQHOV)ROORZLQJ¶H[WHQVion from hybridised adaptors, the original 
templates are denatured leaving copies immobilised onto the flow cell surface. The free, distal 
ends of these fragments bind to complementary oligos nearby. Solid phase bridge amplification 
is then carried out to synthesis dense clusters of double stranded fragments (approximately 
2,000) in order to produce stronger fluorescence signals [Figure 8.1]. The reverse strand is then 
removed to increase the efficiency of sequencing, carried out using labelled reversible 
nucleotide terminators, primers, and DNA polymerase. Emitted fluorescence from each cluster 
is captured following laser excitation and bases identified sequentially. 
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Figure 8.1 ± Solid phase bridge amplification and cluster formation prior to Illumina 
sequencing. A) Adaptor bound DNA fragments hybridise to ligated adaptors on the flow cell 
surface. B) Original templates are denatured to leave immobiOLVHG FRSLHV IROORZLQJ ¶
extension. C) Free, distal ends bind to complimentary copies for bridge amplification. D) 
Dense template clusters are generated by repeated extension and denaturation. 
 
As mentioned above, the regions defined for re-sequencing were chromosome 2: 102,738,158-
103,208,945bp (343,015bp size) and chromosome 9: 5,924,967-6,267,982bp (470,787bp size) 
based on Genome Reference Consortium GRCh37 co-ordinates. The total region size 
sequenced in a single lane was therefore 53.7Mb (813,802bp x66). According to Illumina 
product specifications, approximately 10GB of data for each lane of sequencing with 60% on-
target efficiency is expected using the HiSeq2000 Systems pipeline. Therefore, the estimated 
average coverage per individual was 37-fold calculated (10GB data/3 pools/54MB region x 
0.60 efficiency). 
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8.4 Results 
 
8.4.1 Region Selection 
A total region of 814kb covering association signals in the IL1RL1/IL18R1 and IL33 regions 
was identified for re-sequencing [Table 8.1]. For IL33, which did not show significant regions 
of association in AUGOSA, the region was extended to include the complete IL33 gene 
(+10kb) which was intersected by the cut off defined by the association region [Figures 8.2 and 
8.3]. 
 
Table 8.1 ± Re-sequencing regions on 2q12 and 9p24.1 based on Genome Reference 
Consortium GRCh37. 
Target Region 
Chromosome Gene Start (bp) End (bp) Length 
2q12 IL1RL1/IL18R1 102,738,158 103,208,945 470,787bp 
9p24.1 IL33 5,924,967 6,267,982 343,015bp 
   TOTAL 813.802kb 
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Figure 8.2 ± Annotated regional plots for the sentinel SNPs on 2q12 (rs3771166) and 
9p24.1 (rs1342326) used to define regions for re-sequencing. Defined regions are shown by 
the square brackets. 
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8.4.2 Results from the 1000 Genomes Project 
Data from the latest releases from the 1000 Genomes Project were analysed for chromosome 
2q12 and 9p24.1 regions defined for re-sequencing. Polymorphisms not previously published 
and not tested in the AUGOSA GWA study within IL1RL1, IL18R1, and IL33 plus 2kb 
upstream of all three genes identified in the CEU population (n=60 at low coverage x2 to x6, 
n=3 from a trio family) are summaried in Table 8.2. Results from the 1000 Genomes Project 
from sequencing at low coverage have identified 21 novel SNPs (MAF <1%: 17 SNPs, <2%: 2 
SNPs, <3%: 2 SNPs) in IL1RL1, 12 novel SNPs (all MAF <1%) in IL18R1, and three novel 
SNPs (all MAF <1%) in IL33. A single synonymous SNP in IL1RL1 was identified; all 
UHPDLQLQJ613VZHUHLQWKH¶875¶875DQGLQWURQLFUHJLRQV6HTXHQFLQJRIDWULRIDPLO\
has identified four indels in IL1RL1, nine indels in IL18R1, and a SNP and three indels in IL33 
[Table 8.2]. 
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Table 8.2 ± New variants in IL1RL1, IL18R1, and IL33 identified by the 1000 Genomes 
Project from sequencing CEU populations at low coverage and a trio family not present 
on the genotyping platforms used in the AUGOSA study. Ref and alt denotes reference and 
alternate alleles respectively. Positions are based on Genome Reference Consortium GRCh37. 
* Called in the trio family only. 
Chr Gene Position (bp) Variation Ref/alt Function MAF 
2q12 IL1RL1 102929183 SNP G/A ¶875 0.008 
102930603 SNP C/A ¶875 0.017 
102930605 Indel T/TAGC ¶875 Tri o * 
102931322 SNP G/A ¶875 0.025 
102931527 SNP A/G ¶875 0.008 
102931622 SNP G/T ¶875 0.008 
102931763 Indel A/AC ¶875 Tri o * 
102935208 SNP G/A ¶875 0.008 
102935998 SNP T/G ¶875 0.008 
102939614 SNP A/G ¶875 0.008 
102940755 SNP T/C ¶875 0.017 
102949305 Indel C/CA ¶875 Tri o * 
102949645 SNP A/T ¶875 0.025 
102949652 SNP T/C ¶875 0.008 
102949848 SNP G/A ¶875 0.008 
102951053 Indel G/GA ¶875 Tri o * 
102952845 SNP A/G 5¶875 0.009 
102952902 SNP T/C ¶875 0.007 
102954495 SNP A/G Intronic 0.008 
102954751 SNP C/T Synonymous: Leu [L] 0.002 
102957731 SNP G/T Intronic 0.008 
102958648 SNP C/T Intronic 0.004 
102960262 SNP A/G Intronic 0.008 
102960632 SNP A/G Intronic 0.004 
102964745 SNP T/A Intronic 0.002 
2q12 IL18R1 102980480 SNP T/C Intronic 0.008 
102980590 SNP A/C Intronic 0.005 
102985646 Indel G/GC Intronic Tri o * 
102986971 SNP A/G Intronic 0.009 
102987503 Indel C/CT Intronic Tri o * 
102988409 SNP A/G Intronic 0.008 
102989060 Indel C/T Intronic Tri o * 
102989580 SNP C/T Intronic 0.008 
102990071 Indel T/TA Intronic Tri o * 
102991422 SNP T/C Intronic 0.004 
102993385 SNP C/A Intronic 0.008 
102996624 Indel C/CACTG Intronic Tri o * 
102997129 Indel C/CACTG Intronic Tri o * 
103001628 SNP G/A Intronic 0.008 
103003973 SNP T/G Intronic 0.007 
103004251 SNP A/G Intronic 0.008 
103006399 SNP G/A Intronic 0.001 
103007692 Indel G/GC Intronic Tri o * 
103009730 Indel G/GA Intronic Tri o * 
103010547 SNP T/C Intronic 0.008 
103013388 Indel T/TG Intronic Tri o * 
9q24.1 IL33 6242273 SNP T/G Intronic 0.002 
6242785 SNP T/G Intronic 0.001 
6244171 SNP C/A Intronic 0.008 
6249037 SNP C/T Intronic 0.004 
6252040 SNP A/C Intronic Tri o * 
6252056 Indel C/CA Intronic Tri o * 
6252330 Indel T/TAA Intronic Tri o * 
6257936 Indel T/TCTA ¶875 Tri o * 
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8.4.3 Bait Design for Target Enrichment 
Bait groups for each region were designed using paired-end oligos with 120bp length centred 
to give even distribution across the target region using eArray. The allowed overlap outside of 
the defined region was restricted to 20bp and a 5x tiling frequency was used. Standard repeat 
masked regions based on the UCSC RepeatMasker track were avoided. The resulting baits for 
each region were downloaded as a .zip file containing a .summary file describing the design 
and results, a .fate file listing the number of baits generated per target region, a .bed file 
mapping the bait positions, and a .tdt file detailing each bait sequence and targeted position. 
 
A total of 8,886 oligos (8,705 in normal regions, 181 in regions with high GC content) were 
designed for chromosome 2q12. A total of 4,503 oligos (4,448 in normal regions, 55 in regions 
with high GC content) were designed for chromosome 9q24.1. The .bed files were uploaded 
using the UCSC Genome Browser for visualisation and analysed with the .fate file showing 
that successful bait coverage across each region [Figure 8.4]. High GC baits (>60%) were 
identified using Microsoft Excel in order to enrich for GC rich regions through inclusion of 
these baits to normal GC baits in a ratio of 4:1 in the final library. 
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Figure 8.3 ± Baits (RNA oligo probes) designed to cover A) the IL1RL1/IL18R1 region on 
2p12 and B) the IL33 region on 9p24.1 visualised using UCSC Genome Browser. 
A 
B 
 219 
8.4.4 Variants Identified by Re-sequencing 
Results of re-sequencing were provided by SourceBioscience following base calling. In 
collaboration with Dr. N G Shrine, reads from sequencing were aligned and compared to the 
reference genome. SNP and indel variant detection was then carried out using Syzygy software 
(http://www.broadinstitute.org/software/syzygy/) by scanning each genomic position to 
LGHQWLI\ SRVLWLRQV DW ZKLFK GLIIHUHQFHV EHWZHHQ UHDG DQG UHIHUHQFH RFFXU LQ µVLJQLILFDQW¶
amounts. 
 
Indications of quality were given for variants called, this is a stringent threshold based on 
whether or not there is concordance between the number of alleles counted on the plus strand 
DQGWKHQXPEHUFRXQWHGRQWKHQHJDWLYHVWUDQG$)LVKHU¶VH[DFWWHVWZDVXVHGWRFRPSDUHLI
the proportion of non-reference to reference alleles is the same between the plus and negative 
strands and a variant was classed as high quality if p>0.1 and low if p<0.1. This was not used 
to further filter the data as some low quality variants may have been real as evidenced by 
mapping to an rs code from dbSNP. A total of 9,560 variants were called across all pools, of 
which 4,851 were high quality. In the total regions sequenced, 30.5% of known SNPs 
documented on dbSNP and the 1000 Genomes project was identified overall (1,596 out of 
4,488 SNPs on 2q12, 1,760 out of 6,504 SNPs on 9p24.1). This was expected as the average 
MAF of SNPs which were not identified was 0.02. In addition, the list of known SNPs was 
compiled across multiple populations and therefore numerous SNPs may not be in Caucasian 
populations.  
 
Excluding called SNPs mapped to known variants documented by dbSNP and the 1000 
Genomes Project, using a filter of low quality scores corresponding to p<0.1 error, 48.9% of all 
SNPs called across all pools would have been removed [Table 8.3]. However, all of these 
4,666 low quality SNPs were observed in all six pools indicating that these were likely to have 
been real. Therefore, putative variants for comparison of cases and controls were not filtered 
using quality thresholds in individual pools. This was chosen in order to not to remove 
potentially real variants through quality threshold bias especially those which may have been 
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very rare whilst ensuring some confidence that they were not artefact as demonstrated by 
reproducibility across independent pools. 
 
Multiple SNPs and indels were detected in both the chromosome 2 and 9 regions re-sequenced. 
The distribution of these variants between the cases and controls are listed in Table 8.3 and 
grouped by level of confidence using the quality threshold in Table 8.4. For all variants called, 
71.9% (4,080 out of 5,676) on 2q12 and 77.3% (3,004 out of 3,884) on 9p24.1 were novel to 
our samples. Novel SNPs within these regions were not present on the genotyping platforms 
used in the AUGOSA study and therefore had not been tested for association in Chapter 5. All 
replicated variants were compared and both cases and controls were found to carry multiple 
variants unique to each affection status group. 
 
Table 8.3 ± Numbers of variants detected by re-sequencing on 2q12 and 9p24.1. Novel 
SNPs did not match to a rs ID in dbSNP or variant documented by the 1000 Genomes Project 
(all populations). High quality denotes p<0.1 and low quality GHQRWHVS!XVLQJD)LVKHU¶V
exact test to compare concordance of base calling between strands. 
Region 2q12 9p24.1 
Total variants detected 
Controls Pool 1 5,466 (2,658 High quality) 3,690 (1,789 High quality) 
Pool 2 5,506 (2,698 High quality) 3,759 (1,858 High quality) 
Pool 3 5,477 (2,669 High quality) 3,718 (1,817 High quality) 
Cases Pool 4 5,360 (2,552 High quality) 3,620 (1,719 High quality) 
Pool 5 5,399 (2,591 High quality) 3,648 (1,747 High quality) 
Pool 6 5,416 (2,608 High quality) 3,706 (1,805 High quality) 
Variants replicated across pools 
Common to all pools (controls and cases) 5,580 (2,772 High quality) 3,806 (1,905 High quality) 
Unique to controls (pools 1, 2, and 3) 68 (68 High quality) 58 (58 High quality) 
Unique to cases (pools 4, 5, and 6) 28 (28 High quality) 20 (20 High quality) 
Total 5,676 (2,868 High quality) 3,884 (1,983 High quality) 
 
Table 8.4 ± Numbers of novel variants detected by re-sequencing on 2q12 and 9p24.1. 
Multiple variants unique to each pool of controls and cases were detected. 
Region 2q12 9p24.1 
Novel variants replicated across pools 
Common to all pools (controls and cases) 4,019 (1,235 High quality) 2,952 (1,070 High quality) 
Unique to controls (pools 1, 2, and 3) 42 (42 High quality) 39 (39 High quality) 
Unique to cases (pools 4, 5, and 6) 19 (19 High quality) 13 (13 High quality) 
Total 4,080 (1,296 High quality) 3,004 (1,122 High quality) 
 
Prediction of functional changes implicated by identified SNPs was carried out using FANS 
version 1.7 (Liu et al. 2008). The majority of novel variants did not lie within the IL1RL1, 
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IL18R1, and IL33 genes. However, IL1RL1 was found to carry three exonic SNPs with 
potential functional changes within both controls and cases in additional to multiple SNPs 
unique to controls and to cases. A single indel which may cause a change in the open reading 
frame of IL18R1 was also detected. All remaining variants within these candidate genes were 
intronic [Table 8.5]. 
 
Table 8.5 ± High quality novel variants detected by re-sequencing within candidate genes: 
IL1RL1, IL18R1, and IL33. Ref and alt denotes reference and alternate alleles respectively. 
Positions are based on Genome Reference Consortium GRCh37. 
Gene Position Function Ref Alt 
Common to all pools (controls and cases) 
IL1RL1 102955425 Non-synonymous: mis-sense 
(conservative change) 
C T 
102965608 Non-synonymous: mis-sense 
(protein domain abolished) 
G A 
102968231 Non-synonymous: mis-sense 
(conservative change) 
G T 
A further 75 intronic variants (and 6 variants within 2kb upstream) are not listed 
IL18R1 103013389 Open reading frame change G Deletion  
A further 80 variants (and 1 SNP within 2kb upstream) are not listed 
IL33 71 intronic variants are not listed 
Unique to controls (pools 1, 2, and 3) 
IL1RL1 102939726 Intronic T Insertion 
102939727 Intronic A G 
102939729 Intronic A G 
102939731 Intronic A G 
102939754 Intronic G A 
102939801 Intronic T Deletion 
102943140 Intronic A Deletion 
102945241 Intronic G A 
102946684 Intronic G A 
102946867 Intronic G T 
102946954 Intronic A Deletion 
IL18R1 None detected 
IL33 None detected 
Unique to cases (pools 4, 5, and 6) 
IL1RL1 102945127 Intronic G A 
102947242 Intronic G A 
IL18R1 None detected 
IL33 None detected 
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8.5 Discussion 
 
This Chapter describes work carried out to test whether the relative abundance of variants 
within the group of cases compared to the group of controls determines susceptibility to severe 
asthma within two regions identified by GWA studies on chromosomes 2q12 and 9q24.1. 
These were re-sequenced in two separate pools consisting of 200 severe asthma cases and 200 
general population controls to identify the variants present and establish whether different 
variants exist between cases and controls. 
 
The high depth of coverage from re-sequencing (estimate average of 37-fold) was powered to 
detect rare variants. Using pooled data, multiple SNP and indel variants were found in both the 
group of cases and the group of controls. Variants replicated across independent pools unique 
to each affection status group were identified: 42 in controls and 19 in cases on 2q12, 39 in 
controls and 13 in cases on 9p24.1. The increased allelic heterogeneity observed in the loci of 
interest seen provides further evidence to support the common disease, rare variant hypothesis 
in asthma (Pritchard 2001). The functional implications of these variants remains unclear as the 
majority of did not lie within the coding regions of the candidate genes IL1RL1, IL18R1, and 
IL33. This supports the observation that it is difficult to identify the causal variants responsible 
for the association signals detected by GWA studies. All SNPs within gene regions were found 
to be intronic. This challenges the hypothesis that rare and low frequency variants are more 
likely to have significantly functional effects such as those resulting in protein changes (Gorlov 
et al. 2008). 
 
A relatively larger number of unique SNPs were called in controls compared to cases on both 
2q12 and 9q24.1. Differences in the collective risk of harbouring rare SNPs detected between 
the controls and the severe asthma cases would support the familial cluster of disease seen in 
asthma. Theoretical calculations suggest that under the assumption of the existence of only a 
few predisposing variations with low penetrance as opposed to multiple rare variants with 
additive effects, complex diseases influenced by rare variants are unlikely to show familial 
clustering (Bodmer and Bonilla 2008). Variants detected by high depth re-sequencing may be 
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individually rare but sufficiently common in aggregate to contribute to the variation seen in 
common diseases. 
 
This study has only been able to identify the collective abundance of variants within each pool 
in order to compare the total group of cases and controls. The hypothesis under test is based on 
the assumption that all the SNPs within these loci have similar effects in determining disease. 
Due to the limitations in study design and implementation, additional, in-depth inferences 
about the implications of SNPs identified cannot be drawn from these preliminary data. Cost 
and logistical implications meant that individual level sequencing could not be undertaken in 
the current study. Pooled sequencing is a more cost-effective approach to study rare variants in 
large populations by reducing the costs of both sample preparation and sequencing (Sham et al. 
2002). However, as costs come down, individual level re-sequencing will become more 
affordable and may provide additional insight. 
 
Allele frequency generation using pooled sequencing has been a commonly used and validated 
approach, particularly in GWA studies (Kwok et al. 1994; Taillon-Miller et al.). Careful 
quantification of of individual DNA samples and accurate combining was carried out to 
provide accurate allele calling. However, a limitiation to the pooling approach is the difficulty 
in ensuring absolute equimolar representation of samples. Therefore, due to uncertainties in the 
pooling accuracy and sequencing read quality, rare alleles are often difficult to detect in pooled 
sequencing and allele frequency estimates may be incorrect by around 5% (Marth et al. 2001). 
As a result, allele frequency data generated using this approach may not be accurate and so 
were not assessed for identified SNPs in the current study. Therefore, it has not been possible 
to study association of any individual SNPs to generate allele frequency data or determine 
effects in disease. Furthermore, in pooled samples, very rare variants such as a single 
heterozygote SNP in one individual may have an allele frequency which falls below 
sequencing error rates. As a result, some true variants may not have been detected. 
 
Any single SNP may be present in individuals in isolation or in distinct combinations with 
other SNPs in different people. Sequencing studies are currently underpowered to assess SNPs 
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in rare variant association analyses using single-point tests; as a result, methods have been 
developed to combine information across multiple variant sites, described for example in a 
review by Asimit and Zeggini (Asimit and Zeggini 2010). However, these require SNP 
frequency data and therefore have not been used in analyses described in this Chapter. Several 
locus-based statistical methods exist including the collapsing method which compares the load 
of rare variants between cases and controls, as well as the allele-matching method which takes 
into account the direction of effect of alleles in the tested gene by comparing the number of 
shared alleles between cases and controls. Recently, a novel approach to test for the presence 
of mixed effects across a set of rare variants has also been proposed (Neale et al. 2011). This 
could allow detection of both risk and protective variants in the same genes or pathways in 
determining disease. 
 
The findings presented here add weight to the hypothesis that rare variation explains some of 
the genetic heritability still to be identified in asthma. The functions of identified variants are 
still unclear and inferences on how they relate to common variants detected by GWA 
approaches in the sequenced regions cannot be made from results presented in this Chapter. 
Further work will need to be conducted to determine the location of casual polymorphisms, 
resulting functional effects, and the relationship between common and rare variants. As the 
gold standard of GWA studies has been validation through replication, this provides a further 
challenge for the future in selecting appropriate individuals and populations for follow-up 
studies (Chanock et al. 2007). Validation of identified variants through genotyping for example 
will be required as well as individual level data to be able to assess the frequency of detected 
variants. Given the nature of looking for infrequent variation, measures to minimise bias and 
confounding need to be taken into account by considering factors such as adequate 
phenotyping and population stratification (Schork et al. 2009). Furthermore, appropriate 
methods for statistical analyses are still in development for testing these associations (Hoggart 
et al. 2008; Li and Leal 2008; Schork et al. 2008). 
 
Further advances to increase throughput and decrease costs in sequencing technologies are 
required in order to identify sufficient numbers of rare variants in large numbers of individuals 
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prior to testing associations with disease. These include developments in methods to improve 
target enrichment of selected regions, including enriching for DNA samples in multiplex pools 
at the same time (Johansson et al. 2011; Kenny et al. 2011; Singh et al. 2011). Current efforts 
from a number of large-scale sequencing projects may provide further insight into the impact 
of rare variants as well as provide usable reference data through assembling entire genomes of 
individuals at higher depth (1000 Genomes Project Consortium et al. 2010) 
(http://www.uk10k.org/). Furthermore, there may be additional low-frequency and rare 
polymorphisms in other regions identified across the genome such as the IL13 and TSLP loci as 
well as the chromosome 17q12-21 locus which may be important in the development of asthma 
(see Chapters 5 and 6). This calls for designs such as whole-genome or at a slightly reduced 
cost, whole-exome sequencing. 
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Chapter 9 
General Discussion 
 
A summary of positive associations identified using primary GWA studies in atopy and severe 
asthma is given in Table 9.1. The strength of association in the original discovery cohort and 
subsequent replication is detailed. 
 
Table 9.1 ± Summary of positive associations from primary GWA studies. Results shown 
for studied SNPs identified in the discovery GWA study cohort and replicated SNPs in 
subsequent follow-XSFRKRUWV5LVNPLQRUDOOHOHØ3URWHFWLYHPLQRUDOOHOH 
Phenotype Chr Gene SNP Discovery Replication 
Cohort p value Cohort p value 
Specific 
IgE 
8q12  Intergenic rs7835920 British 
1958 
Birth 
Cohort 
5.54x10(-7) +    
8q22  ANKRD46 rs7835153 4.50x10(-7) Ø 
10q26  Intergenic rs11244450 6.50x10(-6) + 
11q24  KIRREL3 rs4936003 4.20x10(-5) + ALSPAC 7.33x10(-4) + 
13q14  FNDC3A rs6561505 2.15x10(-9) +   
18q22  NETO1 rs10514054 2.54x10(-5) + 
20p13 Intergenic rs6082335 5.00x10(-5) + 
Severe 
asthma 
2q12.1  IL18R1  rs3771166 AUGOSA 1.93x10(-5) Ø AAGC Ø 
5q31.1  C5orf56  rs11745587 2.09x10(-6) +   
6p23  CD83  rs9382936 5.61x10(-6) + 
7p21.1  PRPS1L1  rs12699949 1.19x10(-5) Ø 
13q31.1  Intergenic  rs2496764 7.86x10(-6) + 
17q12-21  ERBB2 rs1810132 1.73x10(-5) + 
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9.1 Genetic Determinants of Atopy 
 
Genetic heritability to allergic disease has been long established (see Chapter 1: Section 1.3). 
However, it has been difficult to determine the contribution of individual genetic variants to 
disease. The first part of this thesis aimed to study atopy by using a genome-wide association 
(GWA) approach to identify novel atopy susceptibility loci and fine mapping of previously 
reported linkage signals through candidate region association. 
 
Overall, results from the GWA scan in the British 1958 Birth Cohort suggest that there is 
evidence for a large number of loci influencing risk of atopy defined using elevated specific 
IgE and/or positive skin prick test (SPT), each conferring a modest effect. A single SNP on 
chromosome 13q14 met genome-wide significance and a further six loci were identified using 
SNPs meeting nominal significance on chromosomes 8q12, 8q22, 10q26, 11q24, 18q22, and 
20p13. A combination of in silico replication, prospective genotyping, and combined analyses 
were used to replicate these findings. 
 
Subsequently, a more focused approach was used to test association of SNPs within 
chromosomes 3p22.1-q22.1 and 17p12-q24.3. These loci were identified through a meta-
analysis of genome-wide linkage studies (GSMA) as having significant linkage (p<4.17x10(-4)) 
with atopy in asthma-enriched families (Denham et al. 2008). Fine mapping was carried out to 
try and localise the causative signal before attempting replication of a single SNP on 
chromosome 17q21.31 using the same methodology as for the GWA scan. 
 
For the majority of assessed SNPs from the GWA scan, inconsistent replication was seen 
across the cohorts for both statistical significance and direction of effect of the minor allele. 
Although significant effect sizes were seen for some SNPs following combined analyses, they 
were most likely driven by the initial signals from the GWA scan. Results from replication of 
the SNP identified through fine mapping of reported linkage signals were inconsistent within 
tested populations in spite of findings from a second, recent GSMA also providing supporting 
evidence for chromosome 17q12-q24 (Bouzigon et al. 2010). 
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While it is not possible to confidently confirm any of the identified loci as being determinants 
of disease, some suggestive evidence for association can be concluded. For example in the 
GWA scan, although not all replication results were statistically significant, SNPs on 
chromosomes 8q12 and 20p13 showed a consistent effect for the minor allele across study 
cohorts. In addition, the SNP on chromosome 11q24 showed statistically significant replication 
of association with atopy across two independent cohorts using subjects of different ages and 
different definitions of atopy, both elevated specific IgE and positive SPT. It is possible that 
these loci contain susceptibility genes which influence risk of atopy. However, the function of 
genes implicated by significant SNPs identified (ANKRD46, KIRREL3, FNDC3A, and NETO1 
using GWA; KIF18B using fine mapping) are unknown and variable mRNA expression is seen 
across a range of cells and tissues involved in allergic disease including in the lung and skin 
(see Chapter 3: Section 3.4.8 and Chapter 4: Section 4.4.7). 
 
Association with SNPs within previously reported candidate genes such as FCER1A, IL13, and 
STAT6 has demonstrated the ability of the British 1958 Birth Cohort dataset used in being able 
to detect atopy susceptibility polymorphisms (Heinzmann et al. 2000). Despite some overlap in 
SNP association across markers of atopy analysed, genetic factors controlling allergen specific 
atopic responses via elevated specific IgE or positive SPT may be different to that of serum 
total IgE levels. With the exception of the IL13 and HLA regions, distinct variants may 
determine these traits specifically (Moffatt et al. 2010). This highlights the potential existence 
of both pleitropic genes determining the generalised allergic response as well as those unique 
to sensitisation. 
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9.2 Genetic Determinants of Severe Asthma 
 
The genetic architecture of asthma has been widely investigated with consistent replication of a 
number of loci and genes reported providing relatively strong evidence of their contributions to 
disease. These include ORMDL3 identified through GWA as well as IL4R (16p12.1-p11.2), 
TGFB (19q13.1), and ADAM33 (20p13) through positional cloning and candidate gene 
association (Ober and Hoffjan 2006; Moffatt et al. 2007). However, the majority of studies 
conducted to date have focused on mild-to-moderate disease. The second part of this thesis 
aimed to use GWA to establish if there are any novel variants determining severe asthma and 
to evaluate the contribution within severe forms of disease of previously identified genes for 
association with mild-to-moderate asthma. 
 
Results from GWA testing did not identify any SNPs meeting genome-wide statistical 
significance. However, six loci with suggestive evidence for association were identified just 
below this threshold; previously known loci on chromosomes 2q12.1 and 17q12-21 as well as 
potentially novel loci on chromosomes 5q31, 6p23, 7p21 containing C5orf56, CD83, PRPS1L1 
repectively, and an intergenic region on 13q31. Identified SNPs of interest were tested in a 
smaller cohort showing convincing replication for the 2q12.1 and 17q12-21 regions and 
consistent directions of effects for all loci apart from 13q31. These findings mean that there are 
unlikely to be major effects driven by common polymorphisms within a single or a few gene(s) 
on the risk of developing severe asthma. There may be a small number of additional loci which 
may be specific to this phenotype but with overall relatively small contributions. 
 
Association of susceptibility loci reported by the GABRIEL Consortium study for mild-to-
moderate asthma were confirmed for severe asthmatics with SNPs within IL18R1 (2q12.1), 
SLC22A5 and IL13 (5q31.1), HLA-DQ (6p21.32), IL33 (9p24.1), SMAD3 (15q22.33), and 
GSDMB and GSDMA (17q12-21). This reinforces the hypothesis that determinants of asthma 
are likely to come from the same genes regardless of severity of disease. Effect sizes for the 
alternative allele were greater within severe asthmatics compared to individuals with milder 
disease for the chromosomes 2q12.1 and 17q12-21 SNPs. This could be explained by the fact 
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that contribution of genetic effects driven by these polymorphisms may be greater in more 
severe disease. 
 
A large number of widely replicated findings from candidate gene studies had not been 
evaluated directly within the GWA scan such as TLR2 (4q32) (Qian et al. ; Eder et al. 2004; 
Bjornvold et al. 2009; Smit et al. 2009), IL18 (11q22.2-q22.3) (Higa et al. 2003; Imboden et 
al. 2006; Lee et al. 2006; Lachheb et al. 2008; Zhu et al. 2008), and IFNG (12q14) (Nakao et 
al. 2001; Nagarkatti et al. 2002; Wang et al. 2006; Kumar and Ghosh 2008). Therefore, a 
comprehensive literature review was undertaken in order to identify all previously reported 
genes and loci in order to evaluate whether polymorphisms within these regions contributed to 
disease risk in severe asthma. 
 
In this analysis, the extent of linkage disequilibrium between tested SNPs was taken into 
account and significant association was found for SNPs within 3 distinct loci implicating 
IL1RL1/IL18R1 (2p12.1), TSLP (5q22.1), and IL13 (5q31.1). The IL1RL1 and TSLP genes 
remained significant even when all reported genes identified through GWA approaches for 
asthma were excluded. High test inflation statistics from assessing only loci identified through 
FDQGLGDWHJHQHDVVRFLDWLRQVȜ ZHUHVHHQLQVSLWHRIDQRYHUDOOORZWHVWLQIODWLRQVWDWLVWLF
IURPWKHLQLWLDOVHYHUHDVWKPD*:$VWXG\Ȝ 7KLVSURYLGHVVWURQJHYLGHQFHWR suggest 
that there are contributions from multiple genes with more modest effects in determining 
disease in addition to those identified using GWA approaches. 
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9.3 Chromosomes 2q12 and 9p24 as Asthma Susceptibility Loci 
 
Substantial evidence for polymorphisms within chromosomes 2q12 and 9p24 as contributing to 
asthma have been reported by both GWA and candidate gene association studies (Gabriel et al. 
2002; Shimizu et al. 2005; Reijmerink et al. 2008; Castano et al. 2009; Gudbjartsson et al. 
2009). Work carried out in this thesis for severe asthma has yielded strong support for the 2q12 
locus and provided further suggestive evidence for 9p24. Identified genetic variants for 
association are common SNPs (MAF >5%) with unknown function. Therefore, these loci were 
IXUWKHUH[DPLQHGWKURXJKPROHFXODUFKDUDFWHULVDWLRQRIWKH¶JHQHUHJLRQVRIIL1RL1 and IL33 
as well as next-generation re-sequencing of the region bearing the GWA signals seen. 
 
The IL1RL1 receptor and its natural ligand, the IL33 cytokine have been recognised to exert 
important roles in the development of airway hyperresponsiveness in asthma. IL1RL1-IL33 
signalling is thought to result in eosinophil-mediated inflammation via direct effects on 
eosinophils and indirect control of Th2 cytokines including IL4, IL5, and IL13 in inflamed 
tissues (Carriere et al. 2007; Cherry et al. 2008). Airway and immune cells and tissues likely to 
be important in asthma exhibit mRNA expression of both the IL1RL1 and IL33 genes, with 
increased levels of IL1RL1 particularly in HMC-1 inflammatory cells and IL33 preferentially 
in structural cells such as HASM and HBEC (see Chapter 7: Section 7.4.2).  
 
5HVXOWVIURP¶5$&(KDYHLGHQWLILHGPXOtiple splice variants in both genes and a potentially 
novel open reading frame (ORF) in IL1RL1 coding for a shorter form of the membrane-bound 
receptor. Multiple promoter binding sites for transcription factors with important roles in 
airway disease including AP-1, C/EBP, CREB, GR, CBP, and GATA were identified in the 
2kb region upstream of the gene transcription start sites (TSSs) (Barnes and Adcock 1998). 
 
The reported SNP implicating IL1RL1 by the deCODE Icelandic GWA study is contained 
within an intronic region (Gudbjartsson et al. 2009). This SNP could be in LD with PRUH¶
causative polymorphisms and therefore be driving the association signal through differential 
expression between IL1RL1 splice variants, and by inference production of different levels of 
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the IL1RL1 receptor protein in cases compared to controls. Asthma associated SNPs in IL33 
are upstream of the established TSSs suggesting that these signals may be due to effects on 
transcription factor binding sites therefore determining levels of transcription varying between 
cases and controls. 
 
These findings suggest that repeated airway injury in asthma resulting in structural changes 
may increase the production of IL33 cytokines and membrane-bound forms of the IL1RL1 
receptor. During exacerbations and the induction of the inflammatory cascade, decoy soluble 
IL1RL1 receptors may be upregulated via the recruitment of inflammatory cells such as mast 
cells. This supports previously published functional work showing increased levels of 
expression of both the soluble form of the IL1RL1 receptor and IL33 in more severe asthma 
(Oshikawa et al. 2001; Préfontaine et al. 2009)7KHUROHRI,/DVDQHQGRJHQRXVµGDQJHU¶
VLJQDO RU µDODUPLQ¶ UHOHDVHG from dead or dying cells following injury due to trauma or 
infection has also been proposed (Moussion et al. 2008). IL33 either acting alone or with other 
mediators such as TSLP may be an important activator of initiator and effector cells 
responsible for innate immunity such as mast cells (Allakhverdi et al. 2007). 
 
Results from re-sequencing of the chromosome 2q12 and 9p24.1 regions identified multiple 
variants detected by re-sequencing in homogenised pools of cases compared to controls. Both 
cases and controls were found to carry unique variants. Carrying severe asthma specific 
variants may have implications in determining disease susceptibility. The majority of these 
variants did not lie with the coding regions of IL1RL1, IL18R1, and IL33 genes and were not 
common SNPs detected by GWA signals. These findings provide support for the common 
disease, rare variant hypothesis and warrant further work before the function of these variants 
and relation to previously identified SNPs can be determined. 
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9.4 Strengths and Weaknesses in Study Design 
 
This thesis presents the first use of GWA approaches to identify genetic determinants of both 
the atopy per se and severe asthma phenotypes. Study cohorts used in analyses were the largest 
accessible at the given time. The AUGOSA cohort is the largest collection of individuals with 
severe asthma established to date; the only other existing cohort to study this phenotype is the 
TENOR study with relatively low numbers of recruited subjects (Li et al. 2010). 
 
The total numbers of individuals in the initial GWA scans are relatively low for both atopy 
(1,083 cases, 2,070 controls) and severe asthma analyses (933 cases, 3,346 controls) compared 
to recently published GWA studies, for example on lung function (20,288 individuals) (Repapi 
et al. 2010) and mild-to-moderate asthma (10,365 cases, 16,110 controls) (Moffatt et al. 2010). 
However, attempts to increase study power were made by increasing the number of controls 
due to the difficulty encountered in recruiting defined cases. Severe asthma is an extreme 
phenotype therefore increasing statistical power due to expected augmentations in effect sizes 
of identified polymorphisms during case-control comparisons. Furthermore, combined 
analyses were carried out using multiple cohorts to increase the total n numbers for association 
testing following efforts to replicate identified signals. However, this method may not have 
been optimal in the absence of large effect sizes as pooled calculations when combining all 
individuals with potentially large amounts of heterogeneity may have prevented accurate signal 
identification. 
 
Despite limiting the regions studied for fine mapping of linkage signals for atopy, the power to 
find linkage produced by a single or even a few gene(s) in specific chromosomal regions may 
have been low given that it is likely that a large number of genes are likely to be involved in 
the development of atopy, each conferring a modest effect. As explained in Chapter 4, the 
approach taken to localise the susceptibility loci was probably unsuccessful due to the 
problems in effect size replication, limitations in study power, and analysis of individual 
cohorts in stages. Additionally, fine mapping for individual genes may have been inappropriate 
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if the significant signals seen were due to several genes in combination in close proximity 
within the entire region. 
 
The over-conservative nature of commonly used corrections for multiple testing to determine 
genome-wide significance such as the Bonferroni correction was taken into account through 
the use of nominal significance and the MeffLi correction. An inclusive approach was taken to 
identify significantly associated loci in the consideration that each SNP does not undergo a 
truly independent test due to linkage disequilibrium (LD), joint effects through epistasis, and 
strong evidence to suggest the existence of multiple polymorphisms with modest effects. 
Nevertheless, this thesis has highlighted the need for more appropriate methods to assess 
statistical significance, particularly when the a priori hypothesis is based on a large number of 
contributing polymorphisms to disease. 
 
Difficulty in identifying robust signals with confidence due to limited consistency in 
replication in terms of both statistical significance and effect size may have resulted due to a 
number of different factors. Attempts at replicating initially significant signals in subsequent 
cohorts with much smaller sample sizes inevitably leads to a type of ascertainment bias known 
DVµZLQQHU¶VFXUVHELDV¶7KHRYHUHVWLPDWLRQRIWKHJHQHWLFHIIHFWLQWKHGLVFRYHU\FRKRUWZLOO
require much larger follow-up studies in order to generate enough power to adequately 
replicate signals with unbiased effect sizes. This is likely to have occurred in both the atopy 
and severe asthma GWA scans, particularly given the modest effects of expected variants. 
 
Confounding through varying degrees of phenotypic heterogeneity between studies can also be 
used to explain these difficulties encountered as demonstrated by the meta-analysis of serum 
total IgE levels in atopy analyses. This would have occurred through recruitment of individuals 
with differences such as in age, population demographics, subtle population stratification, and 
accuracy in case-control definition. In atopy analyses, high correlation of results between 
specific IgE, positive SPT, and serum total IgE levels were seen. Furthermore, good 
representation of an atopic state was expected from a core test panel of three allergens in the 
initial study i.e. house dust mite (Der p 1), mixed grass pollen, and cat fur (Perkin et al. 2006). 
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However, this is based on the assumption that the genetic factors underlying sensitivity to, for 
example, house dust mite is the same as that to cat fur. Therefore, it may not have been 
appropriate to group these allergens together in phenotype defintion. The use of different 
antigen panels and measures to define atopy between studies may have caused complications 
as the relationship between these specific traits is still uncertain and there is still some risk of 
some cases being classed as controls in the absence of a more extensive panel. In severe 
asthma analyses, some patients with milder forms of disease may have been misclassified as 
severe cases leading to an underestimation of effects. Furthermore, currently no uniform 
definition of asthma severity has yet been established, differences in methods used across 
studies such as the ATS, ERS, and GINA criteria are also likely to have contributed to the 
difficulty in replicating findings. 
 
Variable SNP coverage across the genome in genotyping arrays in different study cohorts may 
have been another contributing factor, particularly when fine mapping signals. Imputation is 
generally accepted as a good surrogate as shown by both imputation against a selected group 
genotyped SNPs in the ALSPAC cohort and against genome-wide data generated by the 1000 
Genomes Project. Although study cohorts were genotyped reasonably densely using the 
highest coverage platforms at the time, this is still limiting in many regions, exemplified by 
mapping of genotyped SNPs in AUGOSA surrounding the IL1RL1 and IL33 genes. This has 
made it difficult to determine the location of the causative polymorphisms and is currently 
inadequate in identifying rare variants. In the absence of denser genotyping, imputation has 
helped to inform interpretation of association signal strength, maximise replication data, and 
guide pinpointing of causative variants through detection of new peaks in identified regions. 
However, this statistical approach is driven by LD with pre-existing signals and is thus 
automatically biased to providing further supporting evidence for these regions. 
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9.5 Future Work 
 
Hundreds of GWA studies carried out in common diseases have led to the identification of 
many statistically compelling and biologically plausible variations (Manolio et al. 2008). 
However in general, greater than 90% of the expected heritable component of a disease 
remains unexplained after extensive GWAS interrogation (Maher 2008). Current 
methodologies to reliably identify causative genetic factors contributing to disease require 
greater refinement in both study power and design. Atopy and asthma are both collections of 
symptoms with varying levels of inflammation, reversibility, exacerbations, severity, and 
degrees of treatment response. Overall, there is a large amount of evidence to suggest that 
genetic variation determining the loosely defined phenotypes of atopy and severe asthma are 
likely to come from multiple polymorphisms with modest effects. These polymorphisms are 
probable to be a combination of common, intermediate, and rare SNPs as well as other forms 
of structural variation such as indels and CNVs. Effects on disease are also expected to be 
exerted through multiple interacting gene pathways with a number of environmental influences 
that may differ between populations and epigenetic influences. 
 
Improvements in individual recruitment, phenotyping, and genotyping will help to reduce 
confounding through heterogeneity across studies. Large-scale, international collaborations 
will drive efforts to generate cohorts with sufficient statistical power. Advances in genotyping 
technology will help to increase SNP coverage and address the role of rare and intermediate 
variants both in focused regions as well as genome-wide through whole exome sequencing. 
More detailed fine mapping techniques will then be needed to localise identified loci and 
confirm causative variants. Further work to elucidate the function of variants found will also be 
required to confirm their roles in disease pathogenesis. These could include functional genomic 
approaches such as targeting transcription and mapping expression by using microarrays for 
specific genes or expression quantitative trait loci (eQTL) mapping studies, for example. This 
will help to distinguish biological pathways whilst testing for interactions in gene pathways 
and with other environmental risk factors predisposing to disease using new analytical methods 
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such as genome-wide interaction studies (GWIS) (Murcray et al. 2009; Manning et al. 2011; 
Ober and Vercelli 2011). 
 
The low predictive power of risk loci identified by GWAS, with a typical genotype relative 
risk of only 1.1 to 1.5 has been somewhat disappointing for the genetic community. However,  
what has been identified as a problem in estimating heritability using these variants may 
simply be more a reflection of the difficulty in being able to fully describe the architecture of 
phenotypic variation. Heritability does not equate to genetic contributions but rather the ratio 
of the genetic to the total phenotypic variance in a population (Visscher et al. 2008). Findings 
from current studies may reflect the complex interactions between different genetic and 
environmental factors (Manolio et al. 2008). These factors will be different in individual 
patients and hence be determined by different patterns of genetic contributions. Identification 
of specific variants may not be effective in predicting individual susceptibility risks but may 
substantially explain the burden of disease in the general population (Moffatt et al. 2010).  
 
Furthermore, genetic approaches to these complex diseases has provided the opportunity to 
identify previously unrecognised biological pathways in disease pathophysiology (Hirschhorn 
2009). GWA studies indicated that asthma and chronic obstructive pulmonary disease (COPD) 
may share common genetic factors influencing lung development (Postma et al. 2011). In other 
diseases, examples include the complement pathway in patients with age-related macular 
degeneration and the IL23 DVVRFLDWHGSDWKZD\V LQ&URKQ¶VGLVHDVH (Klein et al. 2005; Lettre 
and Rioux 2008). The value of this research is to question our understanding of disease 
mechanisms in parallel with identifying pathways important in causing certain symptoms and 
disease outcomes in order to lead us to better targeted therapies in the future. Combining 
information on genetic variations from individuals with clinical factors may increase the 
sensitivity and specificitiy of predictions in disease aetiology, in particular in identifying sub-
phenotypes and response to treatment (Wu et al. 2010). Further incorporation of other 
influences such as environmental interactions, for example, with levels of allergen exposure 
could also help to provide further opportunities for preventative medicine.  
 
 238 
Appendices 
LIST OF APPENDICES .................................................................................................. 238 
 
APPENDIX 1 
URLS FOR ONLINE RESOURCES ...................................................................................... 239 
 
APPENDIX 2 
PCR PRIMERS AND CONDITIONS ..................................................................................... 240 
 
APPENDIX 3 
ASSOCIATION RESULTS FOR STUDIED ATOPY SNPS IDENTIFIED THROUGH GWA .............. 241 
 
APPENDIX 4 
LD STRUCTURE ON CHROMOSOMES 3P22.1-Q22 AND 17P12-Q24. .................................... 244 
 
APPENMDIX 5 
REGION PLOTS FOR ELIMINATED LOCI FOLLOWING GENOTYPE ANALYSES AND NEW REGIONS 
IDENTIFIED THROUGH IMPUTATION ANALYSES ................................................................ 249 
 
APPENDIX 6 
IDENTIFIED CANDIDATE LOCI FROM PREVIOUS LITERATURE AND CORRESPONDING REGION 
CO-ORDINATES............................................................................................................... 257 
 
APPENDIX 7 
GEL ELETRCTROPHORESIS OF IL1RL1 AND IL33 CLONES ................................................. 269 
 
APPENDIX 8 
IN-FRAME AMINO ACID SEQUENCES ............................................................................... 270 
 239 
Appendix 1 URLs for Online Resources 
 
NCBI (The National Centre for Biotechnology Information) public database 
http://www.ncbi.nlm.nih.gov/ 
dbSNP: SNP database provided by NCBI 
http://www.ncbi.nlm.nih.gov/projects/SNP 
 Nucleotide: sequence database provided by NCBI 
 http://www.ncbi.nlm.nih.gov/nuccore 
Entrez Gene: gene database provided by NCBI 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene 
BLAST sequence alignment tool provided by NCBI 
http://blast.ncbi.nlm.nih.gov/BLAST.cgi 
 The International HapMap Project provided by NCBI 
 http://hapmap.ncbi.nlm.nih.gov/ 
UCSC Genome Browser 
http://genome.ucsc.edu/ 
Ensembl Genome Browser public database 
http://www.ensembl.org/index/html 
The 1000 Genomes Project Browser 
http://browser.1000genomes.org/index.html 
SNAP pairwise LD program (Broad Institute) 
http://www.broadinstitute.org/mpg/snap/ldsearch.php 
EMBOSS Transeq Nucleotide to protein sequence converter (EMBL-EBI) 
http://www.ebi.ac.uk/Tools/emboss/transeq/ 
UniProtKB/Swiss-Prot Protein database 
http://www.uniprot.org/ 
TOPO2 Transmembrane protein display program (UCSF) 
http://www.sacs.ucsf.edu/TOPO-run/wtopo.pl 
PCR Primer Stats sequence analysis tool 
http://www.ualberta.ca/~stothard/javascript/pcr_primer_stats.html 
WWW Signal Scan TFD, WWW Signal Scan TRANSFAC 
http://www-bimas.cit.nih.gov/molbio/signal/ 
Transcription Element Search System (TESS) 
http://www.cbil.upenn.edu/cgi-bin/tess/tess 
TFSEARCH 
http://www.cbrc.jp/research/db/TFSEARCH.html
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Appendix 2 PCR Primers and Conditions 
 
Standard PCR 
Target gene No. of bases Primer name Primer sequence Position Product length Annealing temp. No. of cycles 
ANKRD46 20 ANKRD46-EP-F753 ¶-GACCATGCAAACAGCTGAGA-¶ Exon 5 302bp Û& 40 
20 ANKRD46-EP-R1054 ¶-AACAAACATTGGAAGCCAGG-¶ Exon 6 
KIRREL3 20 KIRREL3-EP-F200 ¶-GAGGCACAAAGAGACCGAAG-¶ Exon 1 300bp Û& 40 
20 KIRREL3-EP-R499 ¶-TTGGCCTTCATTCATTCTCC-¶ Exon 2/Exon 3 
FNDC3A 20 FNDC3A-EP-F786 ¶-GGAGATGTAGATGCTCACTC-¶ Exon 5/Exon 6 563bp Û& 40 
21 FNDC3A-EP-R1349 ¶-CTGGACTTTTGCATGGTAATC-¶ Exon 9/Exon 10 
NETO1 20 NETO1-EP-F94 ¶-CATTCAGAGATGCTGGCAGA-¶ Exon 1 366bp Û& 40 
21 NETO1-EP-R459 ¶-TTGTCCACAGAAACGTCCAA-¶ Exon 4 
NETO1 20 NETO1-EP-F121 ¶-CCTAAGGTTGTAGCAAGTTT-¶ Exon 1/Exon 2 203bp Û& 40 
19 NETO1-EP-R323 ¶-CGGCTTCTATGATGTAGAT-¶ Exon 3/Exon 4 
KIF18B 20 KIF18B- EP-F1163 ¶-GCTGAAGAGCAATGTGACCA-¶ Exon 7/Exon 8 331bp Û& 40 
20 KIF18B-EP-R1493 ¶-GGACTGCTCCTGGTCTGAAG-¶ Exon 10 
GAPDH 24 GAPDH-control-F152 ¶&&$&&&$7**&$$$77&&$7**&$-¶ Exon 2 600bp Û& 40 
24 GAPDH-control-R749 ¶-TCTAGACGGCAGGTCAGGTCCACC-¶ Exon 6 
Taqman® PCR 
Target gene Forward primer Reverse primer Probe Product length Exons targeted Cat. No./scale 
IL1RL1 ¶-CAAACAAAAGTATTCCCACT 
CAGG-¶ 
¶-ACATTCGCATATCCAGTCC 
TATTG-¶ 
¶-TCGTGTGTTTGCCTCAGGCCA 
ACT-¶ 
148bp 3/4 at 
492bp to 376bp 
PB-DD101-
004 (40nmol) 
IL33 ¶-TAGGAGAGAAACCACCAAAA 
GG-¶ 
¶-ATATACCAAAGGCAAAGCA 
CTC-¶ 
¶-CATCTGGTACTCGCTGCCTGT 
CAACA-¶ 
117bp 2/3 at 
197bp to 313bp 
PB-DD101-
004 (40nmol) 
¶5$&(3&5 
Target gene No. of bases Primer name Primer sequence Position PCR 
IL1RL1 27 IL1RL1-5'RACEa-R531 ¶-CAGGTATAAATACCAGAATCAGCAACT-¶ Exon 3 Primary 
26 ST2-5'RACEb-R481 ¶- TGGCCTGAGGCAAACACACGATTTCT-¶ Exon 3 Nested 
IL33 25 IL33-5'RACEa-R295 ¶-CACTCCACAGTAGACTGCTGTTGAC-¶ Exon 4 Primary 
26 IL33-5'RACEb-R269  ¶-GGCAGCGAGTACCAGATGTCTTTTGT-¶ Exon 4 Nested 
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Appendix 3 Association Results for Studied Atopy SNPs 
Identified through GWA 
 
Association results between studied SNPs detailing per-allele p values and effect sizes 
measured using OR for dichotomised traits: elevated specific IgE and positive SPT; Beta Trend 
coefficient for continuous trait: serum total IgE.  Data for serum total IgE corrected for sex, 
sample collection differences at age 44-45yrs in B58C; uncorrected in ALSPAC, Nottingham 
Gedling, and Southampton. Effect sizes presented for the minor (2nd) allele. 
 
(i) Chr 8 (59,471,286 bp) 
 
(ii) Chr 8 (101,642,996 bp) ± ANKRD46 
 
 
 
 
SNP Phenotype Cohort N Effect (95% CI) p value 
Case Control 
rs7835920 Elevated 
specific IgE 
B58C 1,083 2,770 1.33 (1.19-1.49) 5.54x10(-7) 
µ$&¶ Southampton 292 376 1.14 (0.89-1.46) 0.302 
 Positive SPT ALSPAC 281 1,042 1.10 (0.90-1.36) 0.349 
 Gedling 385 822 1.21 (0.99-1.47) 0.060 
 Southampton 377 291 1.09 (0.85-1.40) 0.495 
 Serum total 
IgE 
B58C 3,873 1.13 (1.06-1.22) 5.79x10(-4) 
 ALSPAC 1,423 1.02 (0.95-1.11) 0.552 
 Gedling 1,117 1.13 (0.97-1.32) 0.129 
 Southampton 663 1.38 (0.92-2.07) 0.119 
 Combined Specific IgE 1,375 3,146 1.29 (1.17-1.43) 8.20x10(-7) 
 Positive SPT 1,043 2,155 1.10 (0.98-1.24) 0.114 
 Total IgE 1,780 1.19 (0.90-1.57) 0.236 
SNP Phenotype Cohort N Effect (95% CI) p value 
Case Control 
rs7835153 Elevated 
specific IgE 
B58C 1,082 2,759 0.77 (0.70-0.85) 4.50x10(-7) 
µ$*¶ Southampton 290 380 1.17 (0.94-1.45) 0.171 
 Positive SPT ALSPAC 282 1,036 0.86 (0.72-1.05) 0.132 
 Gedling 390 828 0.98 (0.83-1.16) 0.819 
 Southampton 377 293 1.17 (0.94-1.45) 0.172 
 Serum total 
IgE 
B58C 3,873 0.88 (0.82-0.93) 3.47x10(-5) 
 ALSPAC 1,423 1.03 (0.96-1.10) 0.451 
 Gedling 1,129 0.98 (0.86-1.13) 0.823 
 Southampton 665 1.18 (0.82-1.69) 0.376 
 Combined Specific IgE 1,372 3,139 0.83 (0.76-0.91) 7.00x10(-5) 
 Positive SPT 1,049 2,157 0.99 (0.89-1.10) 0.817 
 Total IgE 1,794 1.05 (0.82-1.34) 0.718 
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(iii) Chr 10 (126,026,768 bp) 
 
(iv) Chr 11 (126,258,841 bp) ± KIRREL3 
 
(v) Chr 13 (48,651,730 bp) ± FNDC3A 
 
 
SNP Phenotype Cohort N Effect (95% CI) p value 
Case Control 
rs11244450 Elevated 
specific IgE 
B58C 1,079 2,763 1.46 (1.24-1.72) 6.50x10(-6) 
µ*$¶ Southampton 291 374 0.83 (0.57-1.21) 0.332 
 Positive SPT ALSPAC 242 1,042 0.67 (0.45-1.00) 0.045 
 Gedling 382 826 0.95 (0.71-1.27) 0.733 
 Southampton 376 289 0.75 (0.52-1.08) 0.120 
 Serum total 
IgE 
B58C 3,873 1.23 (1.10-1.37) 2.14x10(-4) 
 ALSPAC 1,423 1.01 (0.89-1.15) 0.889 
 Gedling 1,120 0.84 (0.67-1.05) 0.131 
 Southampton 660 0.95 (0.51-1.77) 0.872 
 Combined Specific IgE 1,370 3,137 1.33 (1.14-1.55) 2.08x10(-4) 
 Positive SPT 1,040 2,157 0.87 (0.72-1.05) 0.142 
 Total IgE 1,780 0.86 (0.57-1.31) 0.486 
SNP Phenotype Cohort N Effect (95% CI) p value 
Case Control 
rs4936003 Elevated 
specific IgE 
B58C 1,073 2,754 1.27 (1.13-1.43) 4.20x10(-5) 
µ$*¶ Southampton 295 381 0.89 (0.69-1.13) 0.332 
 Positive SPT ALSPAC 282 1,042 1.43 (1.16-1.76) 7.33x10(-4) 
 Gedling 386 826 0.90 (0.74-1.11) 0.321 
 Southampton 382 294 1.05 (0.82-1.34) 0.685 
 Serum total 
IgE 
B58C 3,873 1.08 (1.00-1.16) 0.054 
 ALSPAC 1,423 1.03 (0.95-1.12) 0.477 
 Gedling 1,125 0.99 (0.84-1.16) 0.864 
 Southampton 671 0.91 (0.61-1.35) 0.628 
 Combined Specific IgE 1,368 3,135 1.20 (1.09-1.34) 4.36x10(-4) 
 Positive SPT 1,050 2,162 1.13 (1.00-1.27) 0.052 
 Total IgE 1,769 1.19 (0.90-1.58) 0.229 
SNP Phenotype Cohort N Effect (95% CI) p value 
Case Control 
rs6561505 Elevated 
specific IgE 
B58C 1,081 2,768 1.67 (1.41-1.98) 2.15x10(-9) 
µ*$¶ Southampton 288 370 0.85 (0.55-1.30) 0.442 
 Positive SPT ALSPAC 242 1,042 1.33 (0.97-1.83) 0.078 
 Gedling 394 825 1.24 (0.92-1.67) 0.158 
 Southampton 371 286 0.79 (0.52-1.20) 0.273 
 Serum total 
IgE 
B58C 3,873 1.26 (1.12-1.41) 7.75x10(-5) 
 ALSPAC 1,423 0.99 (0.88-1.12) 0.870 
 Gedling 1,167 1.03 (0.80-1.32) 0.835 
 Southampton 675 0.94 (0.47-1.90) 0.863 
 Combined Specific IgE 1,369 3,138 1.49 (1.28-1.75) 5.45x10(-7) 
 Positive SPT 1,007 2.,153 1.10 (0.91-1.33) 0.305 
 Total IgE 1,842 0.81 (0.52-1.26) 0.344 
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(vi) Chr 18 (68,532,581 bp) 
 
(vii) Chr 20 (2,114,427 bp) 
SNP Phenotype Cohort N Effect (95% CI) p value 
Case Control 
rs10514054 Elevated 
specific IgE 
B58C 1,082 2,770 1.37 (1.18-1.59) 2.54x10(-5) 
µ&$¶ Southampton 290 377 0.79 (0.56-1.11) 0.169 
 Positive SPT ALSPAC 282 1,041 1.29 (0.98-1.69) 0.069 
 Gedling 385 831 0.89 (0.68-1.16) 0.381 
 Southampton 377 290 0.91 (0.65-1.28) 0.599 
 Serum total 
IgE 
B58C 3,873 1.14 (1.04-1.26) 6.52x10(-3) 
 ALSPAC 1,423 1.09 (0.98-1.21) 0.128 
 Gedling 1,126 1.16 (0.93-1.44) 0.190 
 Southampton 662 0.53 (0.30-0.94) 0.030 
 Combined Specific IgE 1,372 3,147 1.25 (1.09-1.43) 1.32x10(-3) 
 Positive SPT 1,044 2,162 1.01 (0.86-1.19) 0.901 
 Total IgE 1,782 0.87 (0.59-1.29) 0.484 
SNP Phenotype Cohort N Effect (95% CI) p value 
Case Control 
rs6082335 Elevated 
specific IgE 
B58C 1,076 2,741 1.24 (1.12-1.37) 5.00x10(-5) 
µ*$¶ Southampton 290 376 1.22 (0.96-1.51) 0.104 
 Positive SPT ALSPAC 242 1,042 1.03 (0.85-1.24) 0.795 
 Gedling 385 826 1.00 (0.84-1.20) 0.973 
 Southampton 375 291 1.12 (0.90-1.41) 0.309 
 Serum total 
IgE 
B58C 3,873 1.07 (1.00-1.14) 0.044 
 ALSPAC 1,423 1.00 (0.93-1.08) 0.961 
 Gedling 1,123 1.07 (0.93-1.23) 0.344 
 Southampton 662 1.25 (1.16-1.67) 0.434 
 Combined Specific IgE 1,366 3,117 1.22 (1.11-1.34) 2.78x10(-5) 
 Positive SPT 1,003 2,159 1.02 (0.92-1.14) 0.714 
 Total IgE 1,785 0.97 (0.76-1.25) 0.828 
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Appendix 4 LD Structure on Chromosomes 3p22.1-q22 and 
17p12-q24.3 
 
The following /'SORWVVKRZWKHSRVLWLRQVRI613VPHHWLQJVWDWLVWLFDOVLJQLILFDQFHS
for association with atopy in the British 1958 Birth Cohort. This analysis tested association of 
SNPs genotyped on both the Illumina HumanHap550 and the Affymetrix Human Mapping 
.613SODWIRUPVLQDVXEVHWRILQGLYLGXDOVZLWKHOHYDWHGVSHFLILF,J(N8A/L. 
This informed selection of regions for fine mapping prior to identifying SNPs to take forward 
for in silico replication and prospective genotyping. 
 
SNPs identified on chromosome 3p22.1-q22 are shown in Figures A4.1 and A4.2. SNPs 
identified on chromosome 17p12-q24.3 are shown in Figures A4.3 and A4.4.  
SNPs genotyped on each platform are colour coded as below: 
* Ilumina HumanHap550 
* Affymetrix Human Mapping 500K 
* Both SNP platforms 
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Figure A4.1 - SNPs identified on chromosome 3p22.1-q22 meeting statistical significance 
S IRU DVVRFLDWLRQ ZLWK DWRS\ LQ D VXEVHW RI WKH %ULWLVK  %LUWK &RKRUW
(45,000kb to 67,200kb). 
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Figure A4.2 - SNPs identified on chromosome 3p22.1-q22 meeting statistical significance 
S IRU DVVRFLDWLRQ ZLWK DWRS\ LQ D VXEVHW RI WKH British 1958 Birth Cohort 
(86,800kb to 119,000kb). 
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Figure A4.3 - SNPs identified on chromosome 17p12-q24.3 meeting statistical significance 
S IRU DVVRFLDWLRQ ZLWK DWRS\ LQ D VXEVHW RI WKH %ULWLVK  %LUWK &RKRUW
(12,800kb to 50,600kb). 
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Figure A4.4 - SNPs identified on chromosome 17p12-q24.3 meeting statistical significance 
S IRU DVVRFLDWLRQ ZLWK DWRS\ LQ D VXEVHW RI WKH %ULWLVK  %LUWK &RKRUW
(52,900kb to 554,400kb). 
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Appendix 5 Region Plots for Eliminated Loci following 
Genotype Analyses and New Regions Identified through 
Imputation Analyses 
 
The following region plots show the statistical significance of each SNP on the ±log10 scale as 
a function of chromosome position (NCBI build 36). The sentinel SNP is shown in blue and in 
Figure 5.1A also flagged by the arrow. The correlation (r2) of each of the surrounding SNPs to 
the sentinel SNP is shown by their colour (see key). Fine scale recombination rate is plotted in 
blue. 
 
Two SNPs meeting statistical significance following GWA testing of genotyped SNPs: 
rs9395865 on 6p12.1 (p=5.27x10(-6)) and rs10500656 on 11p15.4 (p=1.87x10(-5)) were found to 
have low supporting evidence in the region. Based on the region plots shown in Figure A5.1, 
these loci were not taken forward for replication analyses.  
 
Results from imputation identified 12 SNPs meeting statistical significance in new regions 
with reasonable supporting evidence (p<10(-5), r2imp >0.7). Two of these SNPs, rs4794820 and 
rs9897185 produced secondary peaks in the previously identified 17q12-21 region. The region 
plot for rs9897185 is shown in Chapter 5: Figure 5.6. Region plots showing supporting 
evidence from surrounding SNPs for the remaining 11 new regions are shown in Figures A5.2 
to A5.7. 
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Figure A5.1 - Region plots for rs9395865 and rs10500656 with low supporting evidence 
from surrounding SNPs. 
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Figure A5.2 - Region plots for chr2:211694960 and rs7715669 in new regions identified by 
imputation with p<10(-5) and r2imp=0.7. Note chr2:211694960 is intergenic. 
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Figure A5.3 - Region plots for rs6867913 and rs9395865 in new regions identified by 
imputation with p<10(-5) and r2imp=0.7. 
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Figure A5.4 - Region plots for rs6922932 andrs650230 in new regions identified by 
imputation with p<10(-5) and r2imp=0.7. Note rs6922932 is intergenic. 
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Figure A5.5 - Region plots for rs10970976 and rs4453217 in new regions identified by 
imputation with p<10(-5) and r2imp=0.7. 
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Figure A5.6 - Region plots for rs7125574 and rs4794820 in new regions identified by 
imputation with p<10(-5) and r2imp=0.7. 
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Figure A5.6 - Region plots rs16984547 in a new region identified by imputation with 
p<10(-5) and r2imp=0.7. 
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Appendix 6 Identified Candidate Loci from Previous Literature 
and Corresponding Region Co-ordinates 
 
The full list of identified loci previously reported in the literature and corresponding region co-
ordinates used to extract SNP results for the evaluation of candidate loci are listed in Table A6. 
A total of 1,830 papers were reviewed identifying 171 genes, two SNPs and six microsatellites 
from 303 recorded papers. Region co-ordinates (±10kb) were based on the position of 
transcriptional start and end sites of genes, location of SNPs and sequence-tagged sites (STS) 
start and end positions of microsatellites. The relevant references specific to this table are listed 
in the following pages. 
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Genes 
Chromosome Gene Transcriptional  References Region  Positive 
references Start End Start End 
1p31.2 PTGER3 71190702 71286079 Kim et al. 2007; Park et al. 2010 71180702 71296079 2 
1p33-p32 TGFBR3 91920574 92124243 Kim et al. 2010 91910574 92134243 1 
1p21 S1PR1 101474892 101479664 Sun et al. 2010 101464892 101489664 1 
1p13.3 GSTM1 110031964 110037890 Ivaschenko et al. 2002; Brasch-Andersen et al. 2004; Hanene et al. 2007; Mak et al. 2007; Islam et al. 2009 110021964 110047890 5 
1p13.2 CHIA 111635006 111664708 Bierbaum et al. 2005; Chatterjee et al. 2008  111625006 111674708 2 
1q21.3 FLG 150541274 150564303 Muller et al. 2009 150531274 150574303 1 
1q22 DAP3 153925497 153974943 Hirota et al. 2004 153915497 153984943 1 
1q21-q22 DARC 157441824 157442914 Vergara et al. 2008 157431824 157452914 1 
1q25.2-q25.3 PTGS2 184907591 184916179 Szczeklik et al. 2004; Chan et al. 2007; Kormann et al. 2008 184897591 184926179 3 
1q31.3 DENND1B 195788007 196011179 Sleiman et al. 2010 195778007 196021179 1 
1q32.1 CHI3L1 201414681 201422545 Ober et al. 2008; Rathcke et al. 2009 201404681 201432545 2 
1q31-q32 IL10 205007570 205012462 Hang et al. 2003; Chatterjee et al. 2005; Wjst 2005; Zedan et al. 2008 204997570 205022462 4 
1q41-q42 PARP1 224615014 224662424 Tezcan et al. 2009 224605014 224672424 1 
1q44 NLRP3 245646097 245679029 Hitomi et al. 2009 245636097 245689029 1 
2q11.2 INPP4A 98427844 98564716 Sharma et al. 2008 98417844 98574716 1 
2q12 IL1R1 102136832 102162766 Pattaro et al. 2006; Settin et al. 2008; Zeyrek et al. 2008 102126832 102172766 3 
2q12 IL1RL1 102294393 102334929 Gudbjartsson et al. 2009; Wu et al. 2009; Moffatt et al. 2010 102284393 102344929 3 
2q12 IL18R1 102345524 102381649 Wu et al. 2009; Moffatt et al. 2010 102335524 102391649 2 
2q14 IL1B 113303807 113310827 Zeyrek et al. 2008 113293807 113320827 1 
2q14.2 IL1RN 113601608 113608064 Mao et al. 2000; Gohlke et al. 2004 113591608 113618064 2 
2q14.1 DPP10 115636201 116318406 Wu et al. 2009; Zhou et al. 2009 115626201 116328406 2 
2q22.1 HNMT 138438277 138490404 Yan et al. 2000 138428277 138500404 1 
2q31.3 PDE11A 178196222 178645728 DeWan et al. 2010 178186222 178655728 1 
2q33 CTLA4 204440753 204446928 Howard et al. 2002; Schubert et al. 2006 204430753 204456928 2 
3p26-p24 IL5RA 3086420 3127031 Cheong et al. 2005 3076420 3137031 1 
3p25 PPARG 12368000 12450855 Oh et al. 2009 12358000 12460855 1 
3p21.3 CX3CR1 39279988 39296531 Tremblay et al. 2006 39269988 39306531 1 
3p21.3 CCR3 46258691 46283166 Fukunaga et al. 2001; Al-Abdulhadi and Al-Rabia 2009 46248691 46293166 2 
3p21 CCR2 46370238 46377429 Mak et al. 2007 46360238 46387429 1 
3p21 CCR5 46386636 46392701 Hall et al. 1999; McGinnis et al. 2002; Srivastava et al. 2003; Berce et al. 2008 46376636 46402701 4 
3p21.3 TLR9 52230137 52235219 Lazarus et al. 2003; Lachheb et al. 2008 52220137 52245219 2 
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3p21.1 IL17RB 53855616 53874867 Jung et al. 2009 53845616 53884867 1 
3q21 CD86 123256910 123322673 Wu et al. 2007 123246910 123332673 1 
3q21 MYLK 124813832 125085839 Flores et al. 2007 124803832 125095839 1 
3q21 TF 134947489 134980325 Isada et al. 2010 134937489 134990325 1 
4p14 TLR10 38450646 38460984 Lazarus et al. 2004 38440646 38470984 1 
4p14 TLR1 38474270 38482807 Kormann et al. 2008 38464270 38492807 1 
4p16.1 TLR6 38504802 38507553 Tantisira et al. 2004; Hoffjan et al. 2005; Kormann et al. 2008 38494802 38517553 3 
4q12 PDGFRA 54790020 54859169 Wu et al. 2006 54780020 54869169 1 
4q13.3 MUC7 71372524 71383303 Kirkbride et al. 2001 71362524 71393303 1 
4q13-q21 IL8 74825138 74828297 Heinzmann et al. 2004 74815138 74838297 1 
4q23 ADH5 100211152 100228954 Corydon et al. 2007; Wu et al. 2007 100201152 100238954 2 
4q26-q27 IL2 123592075 123597100 Christensen et al. 2006; Trajkov et al. 2008; Sekigawa et al. 2009 123582075 123607100 3 
4q31 IL15 142777203 142874062 Bierbaum et al. 2006 142767203 142884062 1 
4q32 TLR2 154824890 154846692 Eder et al. 2004; Bjornvold et al. 2009; Smit et al. 2009; Qian et al. 2010 154814890 154856692 4 
5q35 ADAMTS12 33563043 33927881 Kurz et al. 2006 33553043 33937881 1 
5p13 IL7R 35892747 35912680 Kurz et al. 2006 35882747 35922680 1 
5p13.1 PTGER4 40715788 40729594 Kurz et al. 2006; Kim et al. 2007; Park et al. 2007 40705788 40739594 3 
5q12 PDE4D 58300622 59225378 Himes et al. 2009 58290622 59235378 1 
5q22.1 TSLP 110435288 110441621 He et al. 2009 110425288 110451621 1 
5q22.2 WDR36 110455768 110494099 Gudbjartsson et al. 2009 110445768 110504099 1 
5q23-q31 IRF1 131846683 131854326 Nakao et al. 2001; Wang et al. 2006 131836683 131864326 2 
5q23-q31 RAD50 131920528 132007494 Li et al. 2010 131910528 132017494 1 
5q31 IL13 132021763 132024700 Heinzmann et al. 2000; Howard et al. 2001; Heinzmann et al. 2003; Park et al. 2004; Xi et al. 2004; 
Hosseini-Farahabadi et al. 2007; Black et al. 2009; Bottema et al. 2010; Li et al. 2010; Undarmaa et al. 
2010; Wu et al. 2010 
132011763 132034700 11 
5q23-q31 IL4 132037271 132046267 Noguchi et al. 1998; Chouchane et al. 1999; Beghe et al. 2003; Child et al. 2003; Nagarkatti et al. 2004; 
Wilson et al. 2004; Gervaziev et al. 2006; Schubert et al. 2006; Hosseini-Farahabadi et al. 2007; Kamali-
Sarvestani et al. 2007; Trajkov et al. 2008; Amirzargar et al. 2009  
132027271 132056267 13 
5q22-q32 CD14 139991500 139993439 Sharma et al. 2004; Zambelli-Weiner et al. 2005; Lachheb et al. 2008; Wang et al. 2009 139981500 140003439 4 
5q32 SCGB3A2 147238466 147241946 Niimi et al. 2002 147228466 147251946 1 
5q31-q32 SPINK5 147423727 147497118 Kabesch et al. 2004; Liu et al. 2009 147413727 147507118 2 
5q31-q32 ADRB2 148186348 148188381 Hopes et al. 1998; Santillan et al. 2003; Thakkinstian et al. 2005; Szczepankiewicz et al. 2009 148176348 148198381 4 
5q32 CSF1R 149413050 149473128 Shin et al. 2010 149403050 149483128 1 
5q31-q32 SLC6A7 149549712 149570828 Kim et al. 2010 149539712 149580828 1 
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5q33.3 TIMD4 156278947 156322844 Cai et al. 2009 156268947 156332844 1 
5q33.2 HAVCR1 156389108 156418065 Chae et al. 2003; Chae et al. 2003; Chae et al. 2004; Gao et al. 2005 156379108 156428065 4 
5q34 CYFIP2 156625668 156755184 Noguchi et al. 2005 156615668 156765184 1 
5q31.1-q33.1 IL12B 158674368 158690059 Randolph et al. 2004; Wjst et al. 2006 158664368 158700059 2 
6p24.3 LY86 6533932 6600215 Lee et al. 2008 6523932 6610215 1 
6p24.1 EDN1 12398514 12405413 Immervoll et al. 2001; Zhu et al. 2008 12388514 12415413 2 
6p21.3 MICA 31479349 31491069 Hui et al. 2006 31469349 31501069 1 
6p21.3 LTA 31648071 31650077 Moffatt and Cookson 1997; Albuquerque et al. 1998; Mak et al. 2007; Huang et al. 2008 31638071 31660077 4 
6p21.3 TNF 31651328 31654091 Moffatt and Cookson 1997; Albuquerque et al. 1998; Chagani et al. 1999; Winchester et al. 2000; Fan and 
Jung 2002; Di Somma et al. 2003; Shin et al. 2004; Gupta et al. 2005; Li et al. 2006; Schubert et al. 2006; 
Sharma et al. 2006; Munthe-Kaas et al. 2007; Castro-Giner et al. 2008; Kumar et al. 2008; Kumar et al. 
2008; Trajkov et al. 2008; Zedan et al. 2008; Jimenez-Morales et al. 2009; Puthothu et al. 2009; Undarmaa 
et al. 2010 
31641328 31664091 20 
6p21.3 BTNL2 32470490 32482878 Li et al. 2010 32460490 32492878 1 
6p21.3 HLA-DRA 32515624 32520802 Li et al. 2010 32505624 32530802 1 
6p21.3 HLA-DRB1 32628467 32635757 Soriano et al. 1997; Lara-Marquez et al. 1999; Cho et al. 2000; Horne et al. 2000; Di Somma et al. 2003; 
Torio et al. 2003; Parapanissiou et al. 2005; Juhn et al. 2007; Munthe-Kaas et al. 2007; Li et al. 2010 
32618467 32645757 10 
6p21.3 HLA-DQA1 32713160 32719407 Mapp et al. 2000; Gao et al. 2003; Parapanissiou et al. 2005; Li et al. 2010; Moffatt et al. 2010 32703160 32729407 5 
6p21.3 HLA-DQB1 32735634 32742444 Balboni et al. 1996; Horne et al. 2000; Mapp et al. 2000; Gao et al. 2003; Torio et al. 2003; Movahedi et 
al. 2008; Li et al. 2010; Moffatt et al. 2010 
32725634 32752444 8 
6p21.3 TAP1 32920963 32929726 Ismail et al. 1997 32910963 32939726 1 
6p21.3 HLA-DPB1 33151737 33162954 Caraballo et al. 1991; Choi et al. 2004 33141737 33172954 2 
6p12 VEGFA 43845930 43862201 Sharma et al. 2009 43835930 43872201 1 
6p12 IL17F 52209442 52217257 Hizawa et al. 2006, 602 52199442 52227257 2 
6p12.2 GSTA1 52764346 52776616 Polimanti et al. 2010 52754346 52786616 1 
6q21 FYN 112089177 112147958 Szczepankiewicz et al. 2008 112079177 112157958 1 
6q25 SOD2 160020138 160034343 Mak et al. 2006 160010138 160044343 1 
7p21-p15 IL6 22733322 22738145 Settin et al. 2008; Trajkov et al. 2008 22723322 22748145 2 
7p15-p14 NOD1 30430674 30484790 Weidinger et al. 2005 30420674 30494790 1 
7p14.3 NPSR1 34664421 34884469 Kormann et al. 2005; Hersh et al. 2007; Castro-Giner et al. 2009; Vergara et al. 2009 34654421 34894469 4 
7p14-p12 AOAH 36519132 36730678 Barnes et al. 2006 36509132 36740678 1 
7p14 TCRG 38245705 38262515 Walsh et al. 2010 38235705 38272515 1 
7q11.2 CCL26 75236777 75257000 Chae et al. 2004 75226777 75267000 1 
7q11.23 CCL24 75279049 75281028 Chae et al. 2004 75269049 75291028 1 
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7q21.3-q22 SERPINE1 100557098 100569262 Buckova et al. 2002 100547098 100579262 1 
7q36 NOS3 150319079 150342609 Lee et al. 2000; Yanamandra et al. 2005; Holla et al. 2006 150309079 150352609 3 
8p23.1 DEFB1 6715508 6722939 Levy et al. 2005 6705508 6732939 1 
8q22 NAT2 18293034 18303003 Nacak et al. 2002; Batra et al. 2006 18283034 18313003 2 
8p12-p11 IDO1 39890484 39905104 Sekigawa et al. 2009 39880484 39915104 1 
9p24.1 IL33 6231683 6247982 Gudbjartsson et al. 2009; Moffatt et al. 2010 6221683 6257982 2 
9p24.1-p23 PTPRD 8304245 10602505 Shyur et al. 2008 8294245 10612505 1 
9q31 IKBKAP 110669620 110736429 Takeoka et al. 2001 110659620 110746429 1 
9q32-q34 TNC 116822625 116920307 Matsuda et al. 2005 116812625 116930307 1 
9q34.2-q34.3 PTGDS 138990821 138996015 Noguchi et al. 2002 138980821 139006015 1 
10p13 MRC1 17891367 17993184 Hattori et al. 2009 17881367 18003184 1 
10q21 CTNNA3 67349730 69125955 Kim et al. 2009 67339730 69135955 1 
10q24 PLAU 75340895 75347261 Begin et al. 2007 75330895 75357261 1 
10q25.1 GSTO1 106004667 106021203 Polimanti et al. 2010 105994667 106031203 1 
11q12-q13.1 MS4A3 59580676 59595164 Adra et al. 1999 59570676 59605164 1 
11q12-q13 MS4A2 59612712 59622592 Shirakawa et al. 1994; Adra et al. 1999; Palmer et al. 1999; Cui et al. 2003; Sharma et al. 2004; Zhang et 
al. 2004; Sharma and Ghosh 2009; Wang et al. 2009 
59602712 59632592 8 
11q12-q13.3 GPR44 60374973 60380020 Huang et al. 2004; Wang et al. 2009 60364973 60390020 2 
11q11-qter SCGB1A1 61943098 61947243 Laing et al. 2000; Sharma and Ghosh 2004; Candelaria et al. 2005 61933098 61957243 3 
11q12-q13 CHRM1 62432726 62445588 Maeda et al. 2006 62422726 62455588 1 
11q12.3 SLC22A10 62814005 62835822 Adra et al. 1999 62804005 62845822 1 
11q13-qter GSTP1 67107861 67110699 Fryer et al. 2000; Child et al. 2003; Aynacioglu et al. 2004; Lee et al. 2005; Hanene et al. 2007; Kamada et 
al. 2007; Li et al. 2008; Islam et al. 2009 
67097861 67120699 8 
11q13 CTTN 69922259 69960338 Ma et al. 2008 69912259 69970338 1 
11q22.2-q22.3 IL18 111519185 111540050 Higa et al. 2003; Imboden et al. 2006; Lachheb et al. 2008; Lee et al. 2008; Zhu et al. 2008 111509185 111550050 5 
12p13 SLC6A12 169510 193632 Pasaje et al. 2010 159510 203632 1 
12p13.31 LPCAT3 6955607 6996103 Srivastava et al. 1985 6945607 7006103 1 
12q12-q14 VDR 46521586 46585081 Poon et al. 2004; Raby et al. 2004; Wjst et al. 2006; Saadi et al. 2009 46511586 46595081 4 
12q13.2 STAT2 55021648 55040176 Hsieh et al. 2009 55011648 55050176 1 
12q13 STAT6 55775459 55791428 Chae et al. 2003 55765459 55801428 1 
12q14 IFNG 66834816 66839788 Nakao et al. 2001; Nagarkatti et al. 2002; Wang et al. 2006; Kumar and Ghosh 2008 66824816 66849788 4 
12q22 LTA4H 94918741 94953496 Holloway et al. 2008; Via et al. 2010 94908741 94963496 2 
12q14-qter NOS1 116135361 116283965 Grasemann et al. 1999; Gao et al. 2000; Grasemann et al. 2000; Shao et al. 2004; Martinez et al. 2007 116125361 116293965 5 
12q24.33 SFRS8 130761587 130850235 Eder et al. 2006 130751587 130860235 1 
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13q12 ALOX5AP 30207668 30236556 Holloway et al. 2008; Via et al. 2010 30197668 30246556 2 
13q14.2 CYSLTR2 48178953 48181499 Pillai et al. 2004 48168953 48191499 1 
13q14.11 PHF11 48967801 49001118 Zhang et al. 2003; Gao et al. 2009 48957801 49011118 2 
14q24-q31 RNASE3 20429401 20430347 Munthe-Kaas et al. 2007 20419401 20440347 1 
14 CMA1 24044551 24047311 Sharma et al. 2005; Hossny et al. 2008 24034551 24057311 2 
14q22.1 PTGDR 51804180 51813192 Oguma et al. 2004; Sanz et al. 2006; Zhu et al. 2007 51794180 51823192 3 
14q22 PTGER2 51850862 51865072 Kim et al. 2007; Park et al. 2007 51840862 51875072 2 
14q24.1 ARG2 67156331 67188189 Salam et al. 2009; Vonk et al. 2010 67146331 67198189 2 
15q21-q22 SMAD3 65145248 65274587 Moffatt et al. 2010 65135248 65284587 1 
15q26.3 IL16 79276273 79392157 Burkart et al. 2006; Hosseini-Farahabadi et al. 2007 79266273 79402157 2 
16p13.13 SOCS1 11255774 11257540 Harada et al. 2007 11245774 11267540 1 
16p13.1 ABCC1 15950934 16144431 Kedda et al. 2004 15940934 16154431 1 
16p12.1-p11.2 IL4R 27232751 27283600 Ober et al. 2000; Takabayashi et al. 2000; Risma et al. 2002; Beghe et al. 2003; Zhang et al. 2007; Zhang 
et al. 2007; Lv et al. 2009; Berce and Potocnik 2010; Undarmaa et al. 2010 
27222751 27293600 9 
16p11 IL27 28418183 28425656 Chae et al. 2007 28408183 28435656 1 
16q12 NOD2 49288550 49324488 Weidinger et al. 2005; Wjst 2005 49278550 49334488 2 
16q12-q22 NQO1 68300804 68318034 Li et al. 2009 68290804 68328034 1 
16q24 CYBA 87237197 87244958 Izakovicova Holla et al. 2009 87227197 87254958 1 
17p13.3 PAFAH1B1 2443672 2535659 Kruse et al. 2000; Ito et al. 2002 2433672 2545659 2 
17p13.3 TRPV1 3415489 3447085 Zhang et al. 2010 3405489 3457085 1 
17q11.2-q21.1 CCL2 29606408 29608333 Chelbi et al. 2008 29596408 29618333 1 
17q21.1-q21.2 CCL11 29636799 29639312 Batra et al. 2007 29626799 29649312 1 
17q11.2-q12 CCL5 31222608 31231490 Fryer et al. 2000; Yao et al. 2003; Al-Abdulhadi et al. 2005; Lachheb et al. 2007 31212608 31241490 4 
17q21.1 ZPBP2 35277980 35287675 Madore et al. 2008 35267980 35297675 1 
17q21.2 GSDMB 35314373 35328429 Moffatt et al. 2010 35304373 35338429 1 
17q21.2 GSDML 35314373 35328429 Madore et al. 2008; Wu et al. 2009 35304373 35338429 2 
17q21 ORMDL3 35330821 35337380 Moffatt et al. 2007; Brown et al. 2008; Galanter et al. 2008; Madore et al. 2008; Li et al. 2009; Wu et al. 
2009, Halapi et al. 2010; Moffatt et al. 2010 
35320821 35347380 8 
17q21.32 ITGB3 42686206 42745076 Weiss et al. 2005 42676206 42755076 1 
17q21.2 TBX21 43165608 43178484 Raby et al. 2006; Suttner et al. 2009; Undarmaa et al. 2010 43155608 43188484 3 
17q21.33 TAC4 45270669 45280378 Klassert et al. 2010 45260669 45290378 1 
17q21.3-q23 MPO 53702215 53713295 Polonikov et al. 2009 53692215 53723295 1 
17q23 ACE 58908165 58928711 Benessiano et al. 1997; Urhan et al. 2004 58898165 58938711 2 
19p13.3 TBXA2R 3545503 3557658 Unoki et al. 2000; Leung et al. 2002; Kim et al. 2007; Undarmaa et al. 2010 3535503 3567658 4 
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19p13.3-p13.2 C3 6628845 6671662 Hasegawa et al. 2004; Inoue et al. 2008 6618845 6681662 2 
19p13.3-p13.2 ICAM1 10242516 10258291 Puthothu et al. 2006 10232516 10268291 1 
19p13.1 PTGER1 14444277 14447174 Park et al. 2010 14434277 14457174 1 
19p13.1 IL12RB1 18031370 18058742 Wjst 2005 18021370 18068742 1 
19q13.1 TGFB1 46528490 46551656 Pulleyn et al. 2001; Cakebread et al. 2004; Nagpal et al. 2005; Mak et al. 2006; Hatsushika et al. 2007; 
Salam et al. 2007; Lv et al. 2009; Wu et al. 2009; Zhang et al. 2010 
46518490 46561656 9 
19q13 PLAUR 48844571 48866342 Barton et al. 2009 48834571 48876342 1 
19q13.3 PTGIR 51815564 51820194 Kim et al. 2007 51805564 51830194 1 
19q13.33-
q13.41 
SIGLEC8 56646062 56653520 Gao et al. 2010 56636062 56663520 1 
19q13.4 CACNG6 59187353 59207732 Lee et al. 2010 59177353 59217732 1 
20p13 ADAM33 3596619 3610738 Van Eerdewegh et al. 2002; Howard et al. 2003; Werner et al. 2004; Hirota et al. 2006; Noguchi et al. 
2006; Sakagami et al. 2007; Su et al. 2008; Thongngarm et al. 2008; Zhang et al. 2009; Undarmaa et al. 
2010 
3586619 3620738 10 
20q12-q13 MMP9 44070953 44078607 Nakashima et al. 2006 44060953 44088607 1 
22q11.23 MIF 22566564 22567409 Wu et al. 2009 22556564 22577409 1 
22q11.23 GSTT1 22706138 22714284 Fan and Jung 2002; Brasch-Andersen et al. 2004; Babusikova et al. 2009 22696138 22724284 3 
22q13 IL2RB 35851825 35875908 Moffatt et al. 2010 35841825 35885908 1 
 
SNPs 
Chromosome Marker Position References Region Start Region End Evidence 
9q21.31 rs2378383 81229182 (Hancock et al. 2009) 81219182 81239182 1 
2q14 D2S308 SNP 261056 (Allen et al. 2003) 251056 271056 1 
 
 
 
Microsatellites 
Chromosome Marker STS start STS end References Region Start Region End Evidence 
5q13 D5S2498 87363565 87363812 Teerlink et al. 2009 87353565 87373812 1 
11q13 D11S1337 67888234 67888517 Huang et al. 2003 67878234 67898517 1 
14q24 D14S588 69290039 69290158 Hakonarson et al. 2002 69280039 69300158 1 
14q24 D14S603 69593706 69593828 Hakonarson et al. 2002 69583706 69603828 1 
5q31-33 D5S820 156054978 156055188 Yokouchi et al. 2000 156044978 156065188 1 
5q31-33 D5S1471 166809050 166809216 Yokouchi et al. 2000 166799050 166819216 1 
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Appendix 7 Gel Eletrctrophoresis of IL1RL1 and IL33 Clones 
 
Gel electrophoresis images showing clone inserts following EcoR1 plasmid digestion for 
IL1RL1 [Figure A7.1] and IL33 [Figure A7.2] PCR inserts. 
 
 
Figure A7.1 ± 1% gel electrophoresis showing clone inserts following plasmid digestion 
using EcoR1 for IL1RL1. Inserts in lung and human mast cell line (HMC-1) are shown in the 
top and bottom rows respectively. 1kb DNA ladders are shown on the left and right extremes. 
Inserts were roughly the same size in lung, multiple insert sizes can be seen in HMC-1. 
 
 
Figure A7.2 ± 1% gel electrophoresis showing clone inserts following plasmid digestion 
using EcoR1 for IL33. Inserts in lung and human airway smooth muscle (HASM) are shown 
in the top and bottom rows respectively. All inserts were roughly the same size in both 
templates. 
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Appendix 8 In-Frame Amino Acid Sequences for IL1RL1 
 
In frame amino acid sequences were delineated for the five transcripts identified for IL1RL1 
IURP ¶ 5$&( DVVXPLQJ FRQVHUYDWLRQ RI WKH UHPDLQLQJ SXEOLVKHG ¶ VHTXHQFHV DFURVV DOO
detected transcripts. Transcripts 1 and 2 correspond to published transcripts NM_016232.4 and 
NM_003856.2 respectively. Transcripts 3, 4 and 5 are novel. The amino acid sequence coded 
by the open reading frame is in green, potential methyanine site are highlighted in red with the 
most likely site in yellow. 
 
Transcript 1 (codes for the transmembrane form of the IL1RL1 receptor NP_057316.3) 
5'3' 
KRGWLLYLVKL-SCKRNWLSEL-NCGQKVEEERTQVQPNEVEI-ATLPNSVLKSITNCLM 
CGDLHCRMPVTHLE-SQQRVTNTCS-LINRMGFWILAILTILMYSTAAKFSKQSWGLENE 
ALIVRCPRQGKPSYTVDWYYSQTNKSIPTQERNRVFASGQLLKFLPAAVADSGIYTCIVR 
SPTFNRTGYANVTIYKKQSDCNVPDYLMYSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKN 
CQALQGSRYRAHKSFLVIDNVMTEDAGDYTCKFIHNENGANYSVTATRSFTVKDEQGFSL 
FPVIGAPAQNEIKEVEIGKNANLTCSACFGKGTQFLAAVLWQLNGTKITDFGEPRIQQEE 
GQNQSFSNGLACLDMVLRIADVKEEDLLLQYDCLALNLHGLRRHTVRLSRKNPIDHHSIY 
CIIAVCSVFLMLINVLVIILKMFWIEATLLWRDIAKPYKTRNDGKLYDAYVVYPRNYKSS 
TDGASRVEHFVHQILPDVLENKCGYTLCIYGRDMLPGEDVVTAVETNIRKSRRHIFILTP 
QITHNKEFAYEQEVALHCALIQNDAKVILIEMEALSELDMLQAEALQDSLQHLMKVQGTI 
KWREDHIANKRSLNSKFWKHVRYQMPVPSKIPRKASSLTPLAAQKQ-CLL-CAKASEFEA 
FLTSPSWLMPLH-SVRSRNIKGIQA 
 
Transcript 2 (codes for the soluble form of the IL1RL1 receptor NP_003847.2) 
5'3' Frame 3 
GGTYKDWKLFLAPSLTPSSSPLSFSLVEI-ATLPNSVLKSITNCLMCGDLHCRMPVTHLE 
-SQQRVTNTCS-LINRMGFWILAILTILMYSTAAKFSKQSWGLENEALIVRCPRQGKPSY 
TVDWYYSQTNKSIPTQERNRVFASGQLLKFLPAAVADSGIYTCIVRSPTFNRTGYANVTI 
YKKQSDCNVPDYLMYSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKNCQALQGSRYRAHKS 
FLVIDNVMTEDAGDYTCKFIHNENGANYSVTATRSFTVKDEQGFSLFPVIGAPAQNEIKE 
VEIGKNANLTCSACFGKGTQFLAAVLWQLNGTKITDFGEPRIQQEEGQNQSFSNGLACLD 
MVLRIADVKEEDLLLQYDCLALNLHGLRRHTVRLSRKNPSKECF-DFDHLNFL-QV-AEW 
SVVPRDPSRQWEWPVP-NVLLFFGMLFAV-SL-TVPVCWELLCCLNCSSSPTPSYRWFV- 
NTQLLLWSSLFSNFMNSLCVTVCERKCTNNRKLNVFFCALL-LALHVVSMVRSIPFSGHN 
EHSFC-RGW-SEQKGEVSNYCHFSEKILGATL--DIC-AILALI-RNT-DWVIYMKRGLI 
GSQFCRLYGKHGGICFWGHLRSFTHGRRQSKGRHFTQ-KQERERGATLKQPDLMRSHSLL 
QGQHQRDGAKPFMMNSPP-SNHLPPGSTSNTGDYHSA-DLGRNTDPNHTTHIIIVKLCKV 
FKVHGTHGKSGSSAHFFIASVIHHVIQVPRIPGSLSWPSVCSIHTFQVLL-HPVCIIALV 
TLPYLNLFDSLLNTTASSMRAGTSSLPSLGP-CNTWQLASAQLNIC-LNK-MHNQKKKKK 
KKKKKK 
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7UDQVFULSWUHVXOWVLQDVKRUWHUSURWHLQWUXQFDWHGDWWKH¶HQG with a loss of 117 amino acids) 
5'3' 
KRGWLLYLVKL-SCKRNWLSEL-NCGQKVEEERTQVQPNEGKQSWGLENEALIVRCPRQG 
KPSYTVDWYYSQTNKSIPTQERNRVFASGQLLKFLPAAVADSGIYTCIVRSPTFNRTGYA 
NVTIYKKQSDCNVPDYLMYSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKNCQALQGSRYR 
AHKSFLVIDNVMTEDAGDYTCKFIHNENGANYSVTATRSFTVKDEQGFSLFPVIGAPAQN 
EIKEVEIGKNANLTCSACFGKGTQFLAAVLWQLNGTKITDFGEPRIQQEEGQNQSFSNGL 
ACLDMVLRIADVKEEDLLLQYDCLALNLHGLRRHTVRLSRKNPIDHHSIYCIIAVCSVFL 
MLINVLVIILKMFWIEATLLWRDIAKPYKTRNDGKLYDAYVVYPRNYKSSTDGASRVEHF 
VHQILPDVLENKCGYTLCIYGRDMLPGEDVVTAVETNIRKSRRHIFILTPQITHNKEFAY 
EQEVALHCALIQNDAKVILIEMEALSELDMLQAEALQDSLQHLMKVQGTIKWREDHIANK 
RSLNSKFWKHVRYQMPVPSKIPRKASSLTPLAAQKQ-CLL-CAKASEFEAFLTSPSWLMP 
LH-SVRSRNIKGIQA 
 
Transcript 4 (results in the transmembrane form of the IL1RL1 receptor NP_057316.3) 
5'3' Frame 3 
REAGCCI--SYKAVREIGFLSCETVGRKLRKKELKYNPMRA-GNRRHVSVWL-QFSY-IL 
RPNYSHAIVPEYHCGHNHLILAIPCRVEI-ATLPNSVLKSITNCLMCGDLHCRMPVTHLE 
-SQQRVTNTCS-LINRMGFWILAILTILMYSTAAKFSKQSWGLENEALIVRCPRQGKPSY 
TVDWYYSQTNKSIPTQERNRVFASGQLLKFLPAAVADSGIYTCIVRSPTFNRTGYANVTI 
YKKQSDCNVPDYLMYSTVSGSEKNSKIYCPTIDLYNWTAPLEWFKNCQALQGSRYRAHKS 
FLVIDNVMTEDAGDYTCKFIHNENGANYSVTATRSFTVKDEQGFSLFPVIGAPAQNEIKE 
VEIGKNANLTCSACFGKGTQFLAAVLWQLNGTKITDFGEPRIQQEEGQNQSFSNGLACLD 
MVLRIADVKEEDLLLQYDCLALNLHGLRRHTVRLSRKNPIDHHSIYCIIAVCSVFLMLIN 
VLVIILKMFWIEATLLWRDIAKPYKTRNDGKLYDAYVVYPRNYKSSTDGASRVEHFVHQI 
LPDVLENKCGYTLCIYGRDMLPGEDVVTAVETNIRKSRRHIFILTPQITHNKEFAYEQEV 
ALHCALIQNDAKVILIEMEALSELDMLQAEALQDSLQHLMKVQGTIKWREDHIANKRSLN 
SKFWKHVRYQMPVPSKIPRKASSLTPLAAQKQ-CLL-CAKASEFEAFLTSPSWLMPLH-S 
VRSRNIKGIQA 
 
Transcript 5 (results in the transmembrane form of the IL1RL1 receptor NP_057316.3) 
5'3' Frame 1 
KERLAVVFSKAIKL-EKLAF-VVKLWAES-GRKNSSTTQ-GHKEIGGMFLSGYNSSPTRS 
-GQTIHMPLFLNTIVGIII-FWLFHAEICCCDC-LECYGIPSRIWDSLCS-MRCLVEI-A 
TLPNSVLKSITNCLMCGDLHCRMPVTHLE-SQQRVTNTCS-LINRMGFWILAILTILMYS 
TAAKFSKQSWGLENEALIVRCPRQGKPSYTVDWYYSQTNKSIPTQERNRVFASGQLLKFL 
PAAVADSGIYTCIVRSPTFNRTGYANVTIYKKQSDCNVPDYLMYSTVSGSEKNSKIYCPT 
IDLYNWTAPLEWFKNCQALQGSRYRAHKSFLVIDNVMTEDAGDYTCKFIHNENGANYSVT 
ATRSFTVKDEQGFSLFPVIGAPAQNEIKEVEIGKNANLTCSACFGKGTQFLAAVLWQLNG 
TKITDFGEPRIQQEEGQNQSFSNGLACLDMVLRIADVKEEDLLLQYDCLALNLHGLRRHT 
VRLSRKNPIDHHSIYCIIAVCSVFLMLINVLVIILKMFWIEATLLWRDIAKPYKTRNDGK 
LYDAYVVYPRNYKSSTDGASRVEHFVHQILPDVLENKCGYTLCIYGRDMLPGEDVVTAVE 
TNIRKSRRHIFILTPQITHNKEFAYEQEVALHCALIQNDAKVILIEMEALSELDMLQAEA 
LQDSLQHLMKVQGTIKWREDHIANKRSLNSKFWKHVRYQMPVPSKIPRKASSLTPLAAQK 
Q-CLL-CAKASEFEAFLTSPSWLMPLH-SVRSRNIKGIQA 
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